{
  "cells": [
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "0YZHOrHlB8al"
      },
      "source": []
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "SDupn_cW0m21",
        "outputId": "c38e76cb-11de-45df-f302-8e389ed417c2"
      },
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "\u001b[2K     \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m50.4/50.4 kB\u001b[0m \u001b[31m779.3 kB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m1.0/1.0 MB\u001b[0m \u001b[31m17.5 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m2.3/2.3 MB\u001b[0m \u001b[31m51.0 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m52.0/52.0 kB\u001b[0m \u001b[31m2.7 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m207.2/207.2 kB\u001b[0m \u001b[31m11.0 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m15.6/15.6 MB\u001b[0m \u001b[31m56.6 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m294.6/294.6 kB\u001b[0m \u001b[31m15.7 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m232.6/232.6 kB\u001b[0m \u001b[31m11.1 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m139.8/139.8 kB\u001b[0m \u001b[31m7.5 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m396.4/396.4 kB\u001b[0m \u001b[31m18.3 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m290.5/290.5 kB\u001b[0m \u001b[31m16.2 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m373.5/373.5 kB\u001b[0m \u001b[31m17.0 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m1.1/1.1 MB\u001b[0m \u001b[31m36.4 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m76.4/76.4 kB\u001b[0m \u001b[31m4.3 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m77.9/77.9 kB\u001b[0m \u001b[31m3.9 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m318.9/318.9 kB\u001b[0m \u001b[31m17.4 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m49.3/49.3 kB\u001b[0m \u001b[31m2.6 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m141.9/141.9 kB\u001b[0m \u001b[31m7.8 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m2.3/2.3 MB\u001b[0m \u001b[31m57.2 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m58.3/58.3 kB\u001b[0m \u001b[31m2.5 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25h"
          ]
        }
      ],
      "source": [
        "%pip install --upgrade --quiet langchain langchain-community langchain-openai langchain-experimental yfiles-jupyter-graphs neo4j PyPDF2 json-repair"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "QvJmsik62OwP"
      },
      "outputs": [],
      "source": [
        "from neo4j import GraphDatabase\n",
        "import os\n",
        "from langchain_community.graphs import Neo4jGraph\n",
        "import PyPDF2\n",
        "from langchain.docstore.document import Document\n",
        "from langchain_openai import ChatOpenAI\n",
        "from langchain_experimental.graph_transformers import LLMGraphTransformer\n",
        "from langchain.text_splitter import TokenTextSplitter\n",
        "from langchain.graphs import Neo4jGraph\n",
        "from langchain.vectorstores.neo4j_vector import Neo4jVector\n",
        "from langchain.embeddings.openai import OpenAIEmbeddings\n",
        "from langchain.chains import RetrievalQA\n",
        "from langchain.chat_models import ChatOpenAI\n",
        "#import streamlit as st"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "H9QQ8oza2PlZ"
      },
      "outputs": [],
      "source": [
        "NEO4J_URI=\"neo4j+s://########.databases.neo4j.io:7687\"\n",
        "NEO4J_USERNAME=\"neo4j\"\n",
        "NEO4J_PASSWORD=\"#######################\""
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "mIsK8Jzr7F9y"
      },
      "outputs": [],
      "source": [
        "os.environ['OPENAI_API_KEY'] = '###########################'\n",
        "OPENAI_API_KEY = os.getenv('OPENAI_API_KEY')"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "2vido7sAyVE5"
      },
      "outputs": [],
      "source": [
        "os.environ[\"OPENAI_API_KEY\"] = OPENAI_API_KEY\n",
        "os.environ[\"NEO4J_URI\"] = NEO4J_URI\n",
        "os.environ[\"NEO4J_USERNAME\"] = NEO4J_USERNAME\n",
        "os.environ[\"NEO4J_PASSWORD\"] = NEO4J_PASSWORD\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "vqd6JIoq2R0E"
      },
      "outputs": [],
      "source": [
        "graph = Neo4jGraph()\n",
        "driver = GraphDatabase.driver(\n",
        "    os.environ[\"NEO4J_URI\"],\n",
        "    auth=(os.environ[\"NEO4J_USERNAME\"], os.environ[\"NEO4J_PASSWORD\"])\n",
        ")\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "VxHM83cJ2kqN"
      },
      "outputs": [],
      "source": [
        "graph = Neo4jGraph()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "vnvROI6l2v21"
      },
      "outputs": [],
      "source": [
        "# Define the file paths for your 4 PDFs\n",
        "pdf_files = [\n",
        "    '/content/Paper1.pdf',  # Replace with the path to your first PDF\n",
        "    '/content/Paper2.pdf',  # Replace with the path to your second PDF\n",
        "    '/content/Paper3.pdf',  # Replace with the path to your third PDF\n",
        "    '/content/Paper4.pdf'   # Replace with the path to your fourth PDF\n",
        "]"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "4n5Ls8dKyQba"
      },
      "outputs": [],
      "source": [
        "# Initialize a list to hold all the documents\n",
        "all_documents = []\n",
        "\n",
        "# Loop through each PDF file\n",
        "for file_path in pdf_files:\n",
        "    pdf_reader = PyPDF2.PdfReader(open(file_path, \"rb\"))\n",
        "\n",
        "    # Extract text from each page of the PDF and create Document objects\n",
        "    for page_num in range(len(pdf_reader.pages)):\n",
        "        page = pdf_reader.pages[page_num]\n",
        "        text = page.extract_text()\n",
        "        all_documents.append(Document(page_content=text))\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "biO5xpJs2yiw",
        "outputId": "c31f6248-4abc-4634-d13b-1d7748074080"
      },
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "Citation: Weaver, D.F. Thirty Risk\n",
            "Factors for Alzheimer’s Disease\n",
            "Unified by a Common\n",
            "Neuroimmune–Neuroinflammation\n",
            "Mechanism. Brain Sci. 2024 ,14, 41.\n",
            "https://doi.org/10.3390/brainsci\n",
            "14010041\n",
            "Academic Editors: Junhui Wang,\n",
            "Hongxing Wang and Jing Sun\n",
            "Received: 29 November 2023\n",
            "Revised: 27 December 2023\n",
            "Accepted: 30 December 2023\n",
            "Published: 31 December 2023\n",
            "Copyright: ©2023 by the author.\n",
            "Licensee MDPI, Basel, Switzerland.\n",
            "This article is an open access article\n",
            "distributed under the terms and\n",
            "conditions of the Creative Commons\n",
            "Attribution (CC BY) license (https://\n",
            "creativecommons.org/licenses/by/\n",
            "4.0/).\n",
            "brain sciences \n",
            "Review\n",
            "Thirty Risk Factors for Alzheimer’s Disease Unified by a\n",
            "Common Neuroimmune–Neuroinflammation Mechanism\n",
            "Donald F. Weaver\n",
            "Krembil Research Institute, University Health Network, Departments of Medicine, Chemistry, Pharmaceutical\n",
            "Sciences, University of Toronto, Toronto, ON M5T 0S8, Canada; donald.weaver@uhnresearch.ca\n",
            "Abstract: One of the major obstacles confronting the formulation of a mechanistic understanding for\n",
            "Alzheimer’s disease (AD) is its immense complexity—a complexity that traverses the full structural\n",
            "and phenomenological spectrum, including molecular, macromolecular, cellular, neurological and\n",
            "behavioural processes. This complexity is reflected by the equally complex diversity of risk factors\n",
            "associated with AD. However, more than merely mirroring disease complexity, risk factors also\n",
            "provide fundamental insights into the aetiology and pathogenesis of AD as a neurodegenerative\n",
            "disorder since they are central to disease initiation and subsequent propagation. Based on a systematic\n",
            "literature assessment, this review identified 30 risk factors for AD and then extended the analysis to\n",
            "further identify neuroinflammation as a unifying mechanism present in all 30 risk factors. Although\n",
            "other mechanisms (e.g., vasculopathy, proteopathy) were present in multiple risk factors, dysfunction\n",
            "of the neuroimmune–neuroinflammation axis was uniquely central to all 30 identified risk factors.\n",
            "Though the nature of the neuroinflammatory involvement varied, the activation of microglia and\n",
            "the release of pro-inflammatory cytokines were a common pathway shared by all risk factors. This\n",
            "observation provides further evidence for the importance of immunopathic mechanisms in the\n",
            "aetiopathogenesis of AD.\n",
            "Keywords: Alzheimer’s disease; dementia; neurodegeneration; neuroinflammation; neuroimmune;\n",
            "microglia; cytokine\n",
            "1. Introduction\n",
            "The brain is the human body’s most complex and convoluted organ, and neurode-\n",
            "generative disorders such as Alzheimer’s disease (AD) are arguably amongst the most\n",
            "complex diseases of the brain. One of the major hurdles encountered when formulating a\n",
            "mechanistic understanding with which to facilitate management strategies for AD is its\n",
            "immense complexity—a complexity that traverses the full structural and phenomenological\n",
            "spectrum, including molecular, macromolecular, cellular, behavioural and neurological\n",
            "processes [ 1,2]. AD risk factors are excellent examples of this immense complexity; these\n",
            "risk factors include such bewilderingly diverse conditions as medical diseases (diabetes),\n",
            "psychiatric disorders (depression), personal injuries (head trauma), societal factors (social\n",
            "isolation) and environmental issues (air pollution).\n",
            "To identify a harmonizing mechanistic explanation with which to unify the many and\n",
            "varied risk factors for AD, a comprehensive literature review was initially completed (in\n",
            "PubMed, Web of Science, Scopus and Google Scholar databases including publications\n",
            "dating up to November 2023) and identified 30 “risk” factors for AD, employing a broad\n",
            "definition of “risk factor”: some are modifiable risk factors connected in a causative manner\n",
            "with AD (e.g., smoking, alcohol abuse, obesity); others are concomitant disorders occurring\n",
            "as co-morbidities (e.g., glaucoma; people with glaucoma are at risk for also developing AD);\n",
            "others are bidirectional risk factors (e.g., chronic pain causes neuroinflammation, which\n",
            "is a risk factor for AD, yet the neuroinflammation is a positive feedback risk factor for\n",
            "continuing pain). This comprehensive list of 30 risk factors includes the 12 modifiable risk\n",
            "Brain Sci. 2024 ,14, 41. https://doi.org/10.3390/brainsci14010041 https://www.mdpi.com/journal/brainsci\n"
          ]
        }
      ],
      "source": [
        "# Check the first document\n",
        "print(all_documents[0].page_content)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "nB4w7wjP20eo",
        "outputId": "57d8c110-69c6-4120-f0b7-0a243da9a50a"
      },
      "outputs": [
        {
          "name": "stderr",
          "output_type": "stream",
          "text": [
            "<ipython-input-14-0826f6001701>:3: LangChainDeprecationWarning: The class `ChatOpenAI` was deprecated in LangChain 0.0.10 and will be removed in 1.0. An updated version of the class exists in the langchain-openai package and should be used instead. To use it run `pip install -U langchain-openai` and import as `from langchain_openai import ChatOpenAI`.\n",
            "  llm=ChatOpenAI(temperature=0, model_name=\"gpt-3.5-turbo-0125\")\n"
          ]
        }
      ],
      "source": [
        "text_splitter = TokenTextSplitter(chunk_size=512, chunk_overlap=24)\n",
        "documents = text_splitter.split_documents(all_documents)\n",
        "llm=ChatOpenAI(temperature=0, model_name=\"gpt-3.5-turbo-0125\")\n",
        "llm_transformer = LLMGraphTransformer(llm=llm)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "FJyWSYy-22md"
      },
      "outputs": [],
      "source": [
        "#graph_documents = llm_transformer.convert_to_graph_documents(documents)\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "xupR308L5bGf",
        "outputId": "4e96e7f3-dc65-4823-c0a9-46a6e5a27cc8"
      },
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "[{'nodes': [{'id': 'tau containing neurofibrillary tangles', 'type': 'Finding', 'properties': {}}, {'id': 'age at onset of Alzheimer disease', 'type': 'Characteristic', 'properties': {}}, {'id': 'amyloid plaques', 'type': 'Finding', 'properties': {}}, {'id': 'dementia', 'type': 'Condition', 'properties': {}}, {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, {'id': 'Apo lipoprotein E', 'type': 'Gene', 'properties': {}}], 'relationships': [{'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'dementia', 'type': 'Condition', 'properties': {}}, 'type': 'IS_CAUSE_OF', 'properties': {}}, {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'amyloid plaques', 'type': 'Finding', 'properties': {}}, 'type': 'HAS_PATHOLOGIC_FINDINGS', 'properties': {}}, {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'tau containing neurofibrillary tangles', 'type': 'Finding', 'properties': {}}, 'type': 'HAS_PATHOLOGIC_FINDINGS', 'properties': {}}, {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'Apo lipoprotein E', 'type': 'Gene', 'properties': {}}, 'type': 'HAS_GENETIC_RISK_FACTOR', 'properties': {}}, {'source': {'id': 'Apo lipoprotein E', 'type': 'Gene', 'properties': {}}, 'target': {'id': 'age at onset of Alzheimer disease', 'type': 'Characteristic', 'properties': {}}, 'type': 'INFLUENCES', 'properties': {}}, {'source': {'id': 'Apo lipoprotein E', 'type': 'Gene', 'properties': {}}, 'target': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'type': 'INFLUENCES', 'properties': {}}], 'source': {'id': None, 'metadata': {}, 'page_content': 'Genetic aspects of Alzheimer disease\\nThomas D. Bird, MD\\nAlzheimer disease is the most common cause of dementia and represents a major public health problem. The\\nneuropathologic findings of amyloid- /H9252plaques and tau containing neurofibrillary tangles represent important\\nmolecular clues to the underlying pathogenesis. Genetic factors are well recognized, but complicated. Three rare\\nforms of autosomal-dominant early-onset familial Alzheimer disease have been identified and are associated with\\nmutations in amyloid precursor protein, presenilin 1, and presenilin 2 genes. The more common late-onset form\\nof Alzheimer disease is assumed to be polygenic/multifactorial. However, thus far the only clearly identified genetic\\nrisk factor for Alzheimer disease is Apo lipoprotein E. The /H92804 allele of Apo lipoprotein E influences age at onset of\\nAlzheimer disease, but is neither necessary nor sufficient for the disease. The search continues for the discovery\\nof additional genetic influences. Genet Med 2008:10(4):231–239.\\nKey Words: Alzheimer, dementia, amyloid, neurogenetics\\nTable of Contents\\nOverview ................................................................................................................. 231\\nClinical manifestations of Alzheimer disease ............................................... 231\\nEstablishing the diagnosis of Alzheimer disease ......................................... 231\\nDifferential diagnosis of Alzheimer disease .................................................. 232\\nPrevalence of Alzheimer disease .................................................................... 232\\nCauses .................................................................................................................... 232\\nEnvironmental causes ...................................................................................... 233\\nHeritable causes ................................................................................................ .233\\nChromosomal ................................................................................................. 233\\nDown syndrome ......................................................................................... 233\\nSingle gene ................................................................................................ 233\\nLate-onset familial Alzheimer disease ................................................... 233\\nEarly onset familial Alzheimer disease ...................................................... 233\\nUnknown cause ................................................................................................. 234\\nEvaluation Strategy ............................................................................................... 234\\nFamily history ..................................................................................................... 234\\nMolecular genetic testing ................................................................................ 234\\nLate-onset familial AD .................................................................................. 234\\nEarly-onset familial AD ................................................................................. 235\\nGenetic Counseling ............................................................................................... 235\\nMode of inheritance .......................................................................................... 235\\nRisk to family members–late-onset nonfamilial Alzheimer disease .......... 235Risk to family members–early-onset familial Alzheimer disease .............. 235\\nRelated genetic counseling issue ................................................................... 235\\nUse of APOE genotyp', 'type': 'Document'}}, {'nodes': [{'id': 'dementia', 'type': 'Symptom', 'properties': {}}, {'id': 'hallucinations', 'type': 'Symptom', 'properties': {}}, {'id': 'memory failure', 'type': 'Symptom', 'properties': {}}, {'id': 'withdrawal', 'type': 'Symptom', 'properties': {}}, {'id': 'language disturbance', 'type': 'Symptom', 'properties': {}}, {'id': 'seizures', 'type': 'Symptom', 'properties': {}}, {'id': 'confusion', 'type': 'Symptom', 'properties': {}}, {'id': 'Parkinsonian features', 'type': 'Symptom', 'properties': {}}, {'id': 'poor judgment', 'type': 'Symptom', 'properties': {}}, {'id': 'agitation', 'type': 'Symptom', 'properties': {}}, {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}], 'relationships': [{'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'dementia', 'type': 'Symptom', 'properties': {}}, 'type': 'HAS_MANIFESTATION', 'properties': {}}, {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'memory failure', 'type': 'Symptom', 'properties': {}}, 'type': 'HAS_MANIFESTATION', 'properties': {}}, {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'confusion', 'type': 'Symptom', 'properties': {}}, 'type': 'HAS_MANIFESTATION', 'properties': {}}, {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'poor judgment', 'type': 'Symptom', 'properties': {}}, 'type': 'HAS_MANIFESTATION', 'properties': {}}, {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'language disturbance', 'type': 'Symptom', 'properties': {}}, 'type': 'HAS_MANIFESTATION', 'properties': {}}, {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'agitation', 'type': 'Symptom', 'properties': {}}, 'type': 'HAS_MANIFESTATION', 'properties': {}}, {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'withdrawal', 'type': 'Symptom', 'properties': {}}, 'type': 'HAS_MANIFESTATION', 'properties': {}}, {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'hallucinations', 'type': 'Symptom', 'properties': {}}, 'type': 'HAS_MANIFESTATION', 'properties': {}}, {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'seizures', 'type': 'Symptom', 'properties': {}}, 'type': 'HAS_MANIFESTATION', 'properties': {}}, {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'Parkinsonian features', 'type': 'Symptom', 'properties': {}}, 'type': 'HAS_MANIFESTATION', 'properties': {}}], 'source': {'id': None, 'metadata': {}, 'page_content': '-onset familial Alzheimer disease .............. 235\\nRelated genetic counseling issue ................................................................... 235\\nUse of APOE genotyping for predictive testing ......................................... 235\\nDown syndrome ............................................................................................. 236\\nTesting of at-risk asymptomatic EOAD family members ............................. 236\\nTesting of at-risk asymptomatic adults ...................................................... 236\\nTesting of at-risk individuals during childhood ......................................... 236\\nPrenatal testing ................................................................................................. 236\\nPreimplantation genetic diagnosis ................................................................. 236\\nManagement .......................................................................................................... 236\\nTreatment of manifestations ........................................................................... 236\\nTherapies under investigation ......................................................................... 236\\nOther ................................................................................................................... 236\\nGenetics clinics ............................................................................................. 236\\nSupport groups .............................................................................................. 236\\nSummary ................................................................................................................. .237\\nDisease characteristics .................................................................................... 237\\nDiagnosis/testing ............................................................................................. 237\\nManagement ...................................................................................................... 237\\nGenetic counseling ........................................................................................... 237\\nResources .............................................................................................................. 237\\nClinical manifestations of Alzheimer disease\\nThe clinical manifestation of Alzheimer disease (AD) is de-\\nmentia that typically begins with subtle and poorly recognized\\nfailure of memory and slowly becomes more severe and, even-\\ntually, incapacitating. Other common findings include confu-\\nsion, poor judgment, language disturbance, agitation, with-\\ndrawal, and hallucinations. Occasionally, seizures, Parkinsonianfeatures, increased muscle tone, myoclonus, incontinence, and\\nmutism occur.1\\nDeath usually results from general inanition, malnutrition,\\nand pneumonia. The typical clinical duration of the disease is\\n8–10 years, with a range from 1 to 25 years.\\nEstablishing the diagnosis of Alzheimer disease\\nEstablishing the diagnosis of Alzheimer disease relies on\\nclinical-neuropathologic assessment.1Neuropathologic find-\\nings on autopsy examination remain the gold standard for di-\\nagnosis of AD. The clinical diagnosis of AD (before autopsy\\nconfirmation) is correct about 80–90% of the time.2\\n●Clinical signs: slowly progressive dementia\\n●Neuroimaging: gross cerebral cortical atrophy3\\n●Neuropathologic findings: microscopic extracellular amy-\\nloid-/H9252(A/H9252)-amyloid neuritic plaques, intraneuronal neu-From the University of Washington', 'type': 'Document'}}, {'nodes': [{'id': 'Thomas D. Bird', 'type': 'Person', 'properties': {}}, {'id': 'VA Puget Sound Health Care System', 'type': 'Organization', 'properties': {}}, {'id': 'University of Washington', 'type': 'Organization', 'properties': {}}, {'id': 'Athena Diagnostics, Inc.', 'type': 'Company', 'properties': {}}], 'relationships': [{'source': {'id': 'Thomas D. Bird', 'type': 'Person', 'properties': {}}, 'target': {'id': 'University of Washington', 'type': 'Organization', 'properties': {}}, 'type': 'WORKS_FOR', 'properties': {}}, {'source': {'id': 'Thomas D. Bird', 'type': 'Person', 'properties': {}}, 'target': {'id': 'VA Puget Sound Health Care System', 'type': 'Organization', 'properties': {}}, 'type': 'WORKS_FOR', 'properties': {}}, {'source': {'id': 'Thomas D. Bird', 'type': 'Person', 'properties': {}}, 'target': {'id': 'Athena Diagnostics, Inc.', 'type': 'Company', 'properties': {}}, 'type': 'RECEIVES', 'properties': {}}], 'source': {'id': None, 'metadata': {}, 'page_content': 'H9252)-amyloid neuritic plaques, intraneuronal neu-From the University of Washington, Geriatric Research Education and Clinical Center, VA\\nPuget Sound Health Care System, Seattle, Washington.\\nThomas D. Bird, MD, University of Washington, Geriatric Research Education and Clinical\\nCenter, VA Puget Sound Health Care System, Seattle, Washington. E-mail: tomnroz@\\nu.washington.edu.\\nDisclosure: Dr. Bird receives licensing fees from Athena Diagnostics, Inc.\\nSubmitted for publication January 11, 2008.\\nAccepted for publication January 29, 2008.\\nDOI: 10.1097/GIM.0b013e31816b64dcApril 2008 /H18528Vol. 10 /H18528No. 4\\nGenetics inMedicine\\ncollaborative review\\nGenetics INMedicine 231', 'type': 'Document'}}, {'nodes': [{'id': 'United States', 'type': 'Country', 'properties': {}}, {'id': 'frontotemporal dementia', 'type': 'Disease', 'properties': {}}, {'id': 'North America', 'type': 'Region', 'properties': {}}, {'id': 'Parkinson disease', 'type': 'Disease', 'properties': {}}, {'id': 'diffuse Lewy body disease', 'type': 'Disease', 'properties': {}}, {'id': 'depression', 'type': 'Condition', 'properties': {}}, {'id': 'rofibrillary tangles', 'type': 'Pathological Feature', 'properties': {}}, {'id': 'Creutzfeldt-Jakob disease', 'type': 'Disease', 'properties': {}}, {'id': 'chronic drug intoxication', 'type': 'Condition', 'properties': {}}, {'id': 'thyroid disease', 'type': 'Condition', 'properties': {}}, {'id': 'CADASIL', 'type': 'Disease', 'properties': {}}, {'id': 'normal-pressure hydrocephalus', 'type': 'Condition', 'properties': {}}, {'id': 'Europe', 'type': 'Region', 'properties': {}}, {'id': 'Picks disease', 'type': 'Disease', 'properties': {}}, {'id': 'central nervous system angitis', 'type': 'Condition', 'properties': {}}, {'id': 'amyloid angiopathy', 'type': 'Pathological Feature', 'properties': {}}, {'id': 'vitamin deficiencies', 'type': 'Condition', 'properties': {}}, {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}], 'relationships': [{'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'rofibrillary tangles', 'type': 'Pathological Feature', 'properties': {}}, 'type': 'ASSOCIATED_WITH', 'properties': {}}, {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'amyloid angiopathy', 'type': 'Pathological Feature', 'properties': {}}, 'type': 'ASSOCIATED_WITH', 'properties': {}}, {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'depression', 'type': 'Condition', 'properties': {}}, 'type': 'DIFFERENTIAL_DIAGNOSIS', 'properties': {}}, {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'chronic drug intoxication', 'type': 'Condition', 'properties': {}}, 'type': 'DIFFERENTIAL_DIAGNOSIS', 'properties': {}}, {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'thyroid disease', 'type': 'Condition', 'properties': {}}, 'type': 'DIFFERENTIAL_DIAGNOSIS', 'properties': {}}, {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'vitamin deficiencies', 'type': 'Condition', 'properties': {}}, 'type': 'DIFFERENTIAL_DIAGNOSIS', 'properties': {}}, {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'central nervous system angitis', 'type': 'Condition', 'properties': {}}, 'type': 'DIFFERENTIAL_DIAGNOSIS', 'properties': {}}, {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'normal-pressure hydrocephalus', 'type': 'Condition', 'properties': {}}, 'type': 'DIFFERENTIAL_DIAGNOSIS', 'properties': {}}, {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'frontotemporal dementia', 'type': 'Disease', 'properties': {}}, 'type': 'DIFFERENTIAL_DIAGNOSIS', 'properties': {}}, {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'Picks disease', 'type': 'Disease', 'properties': {}}, 'type': 'DIFFERENTIAL_DIAGNOSIS', 'properties': {}}, {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'Parkinson disease', 'type': 'Disease', 'properties': {}}, 'type': 'DIFFERENTIAL_DIAGNOSIS', 'properties': {}}, {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'diffuse Lewy body disease', 'type': 'Disease', 'properties': {}}, 'type': 'DIFFERENTIAL_DIAGNOSIS', 'properties': {}}, {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'Creutzfeldt-Jakob disease', 'type': 'Disease', 'properties': {}}, 'type': 'DIFFERENTIAL_DIAGNOSIS', 'properties': {}}, {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'CADASIL', 'type': 'Disease', 'properties': {}}, 'type': 'DIFFERENTIAL_DIAGNOSIS', 'properties': {}}, {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'North America', 'type': 'Region', 'properties': {}}, 'type': 'PREVALENCE', 'properties': {}}, {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'Europe', 'type': 'Region', 'properties': {}}, 'type': 'PREVALENCE', 'properties': {}}, {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'United States', 'type': 'Country', 'properties': {}}, 'type': 'PREVALENCE', 'properties': {}}], 'source': {'id': None, 'metadata': {}, 'page_content': 'rofibrillary tangles, and amyloid angiopathy at postmor-\\ntem examination (Figs. 1 and 2). The plaques should stain\\npositively with A /H9252-amyloid antibodies and negative for\\nprion antibodies, which are diagnostic of prion diseases.\\nThe numbers of plaques and tangles must exceed those\\nfound in age-matched controls without dementia. Guide-\\nlines for the quantitative assessment of these changes ex-ist.4,5Aggregation of alpha-synuclein in the form of Lewy\\nbodies may also be found in neurons in the amygdala.6\\nDifferential diagnosis of Alzheimer disease\\nDifferential diagnosis of AD includes other causes of de-\\nmentia, especially treatable forms of cognitive decline, such as\\ndepression, chronic drug intoxication, chronic central nervous\\nsystem infection, thyroid disease, vitamin deficiencies (espe-\\ncially B12 and thiamine), central nervous system angitis, and\\nnormal-pressure hydrocephalus.1\\nOther degenerative disorders associated with dementia, such as\\nfrontotemporal dementia, including frontotemporal dementia\\nwith parkinsonism-17, Picks disease, Parkinson disease, diffuse\\nLewy body disease, Creutzfeldt-Jakob disease, and cerebral auto-\\nsomal dominant arteriopathy with subcortical infarcts and leu-\\nkoencephalopathy (CADASIL), may also be confused with AD.7\\nComputerized tomography and magnetic resonance imag-\\ning are valuable for identifying some of these other causes of\\ndementia, including neoplasms, normal-pressure hydroceph-\\nalus, frontotemporal dementia, and cerebral vascular disease.\\nPrevalence of Alzheimer disease\\nAD is the most common cause of dementia in North Amer-\\nica and Europe, with an estimate of 4 million affected individ-\\nuals in the United States.\\nThe prevalence of AD increases with age. Mild memory loss\\nis often called mild cognitive impairment. In many persons\\nmild cognitive impairment is considered an early stage of AD.\\nThe incidence of AD rises from 2.8 per 1000 person years in\\nthe 65–69 years age group to 56.1 per 1000 person years in the\\nolder than 90-year age group.8Approximately 10% of persons\\nolder than 70 years have significant memory loss and more\\nthan half of these individuals have AD', 'type': 'Document'}}, {'nodes': [{'id': 'Unknown (includes genetic/environment interactions)', 'type': 'Cause', 'properties': {}}, {'id': 'late-onset familial AD', 'type': 'Condition', 'properties': {}}, {'id': 'Early-onset familial AD (AD1, AD3, AD4)', 'type': 'Cause', 'properties': {}}, {'id': 'Alzheimer disease', 'type': 'Condition', 'properties': {}}, {'id': 'Alzheimer brain', 'type': 'Condition', 'properties': {}}, {'id': 'marked diffuse cortical atrophy', 'type': 'Characteristic', 'properties': {}}, {'id': 'early-onset AD', 'type': 'Condition', 'properties': {}}, {'id': 'Late-onset familial (AD2)', 'type': 'Cause', 'properties': {}}, {'id': 'persons older than 85 years', 'type': 'Person', 'properties': {}}, {'id': 'AD', 'type': 'Condition', 'properties': {}}, {'id': 'persons older than 70 years', 'type': 'Person', 'properties': {}}, {'id': 'familial', 'type': 'Characteristic', 'properties': {}}, {'id': 'onset before age 60-65 years', 'type': 'Characteristic', 'properties': {}}, {'id': 'autosomal-dominant manner', 'type': 'Characteristic', 'properties': {}}, {'id': 'significant memory loss', 'type': 'Condition', 'properties': {}}, {'id': 'Familial', 'type': 'Cause', 'properties': {}}, {'id': 'early onset', 'type': 'Characteristic', 'properties': {}}, {'id': 'neuritic plaque', 'type': 'Characteristic', 'properties': {}}, {'id': 'onset after age 60-65 years', 'type': 'Characteristic', 'properties': {}}, {'id': 'dementia', 'type': 'Condition', 'properties': {}}, {'id': 'ventricular enlargement', 'type': 'Characteristic', 'properties': {}}, {'id': 'neurofibrillary tangles', 'type': 'Characteristic', 'properties': {}}, {'id': 'early-onset familial AD', 'type': 'Condition', 'properties': {}}, {'id': 'Chromosomal (Down syndrome)', 'type': 'Cause', 'properties': {}}], 'relationships': [{'source': {'id': 'persons older than 70 years', 'type': 'Person', 'properties': {}}, 'target': {'id': 'significant memory loss', 'type': 'Condition', 'properties': {}}, 'type': 'HAS', 'properties': {}}, {'source': {'id': 'persons older than 70 years', 'type': 'Person', 'properties': {}}, 'target': {'id': 'AD', 'type': 'Condition', 'properties': {}}, 'type': 'HAS', 'properties': {}}, {'source': {'id': 'persons older than 85 years', 'type': 'Person', 'properties': {}}, 'target': {'id': 'dementia', 'type': 'Condition', 'properties': {}}, 'type': 'HAS', 'properties': {}}, {'source': {'id': 'AD', 'type': 'Condition', 'properties': {}}, 'target': {'id': 'early onset', 'type': 'Characteristic', 'properties': {}}, 'type': 'IS', 'properties': {}}, {'source': {'id': 'early-onset AD', 'type': 'Condition', 'properties': {}}, 'target': {'id': 'familial', 'type': 'Characteristic', 'properties': {}}, 'type': 'IS', 'properties': {}}, {'source': {'id': 'early-onset AD', 'type': 'Condition', 'properties': {}}, 'target': {'id': 'autosomal-dominant manner', 'type': 'Characteristic', 'properties': {}}, 'type': 'IS', 'properties': {}}, {'source': {'id': 'early-onset familial AD', 'type': 'Condition', 'properties': {}}, 'target': {'id': 'onset before age 60-65 years', 'type': 'Characteristic', 'properties': {}}, 'type': 'IS', 'properties': {}}, {'source': {'id': 'late-onset familial AD', 'type': 'Condition', 'properties': {}}, 'target': {'id': 'onset after age 60-65 years', 'type': 'Characteristic', 'properties': {}}, 'type': 'IS', 'properties': {}}, {'source': {'id': 'Alzheimer brain', 'type': 'Condition', 'properties': {}}, 'target': {'id': 'marked diffuse cortical atrophy', 'type': 'Characteristic', 'properties': {}}, 'type': 'SHOWS', 'properties': {}}, {'source': {'id': 'Alzheimer brain', 'type': 'Condition', 'properties': {}}, 'target': {'id': 'ventricular enlargement', 'type': 'Characteristic', 'properties': {}}, 'type': 'SHOWS', 'properties': {}}, {'source': {'id': 'Alzheimer disease', 'type': 'Condition', 'properties': {}}, 'target': {'id': 'neuritic plaque', 'type': 'Characteristic', 'properties': {}}, 'type': 'SHOWS', 'properties': {}}, {'source': {'id': 'Alzheimer disease', 'type': 'Condition', 'properties': {}}, 'target': {'id': 'neurofibrillary tangles', 'type': 'Characteristic', 'properties': {}}, 'type': 'SHOWS', 'properties': {}}, {'source': {'id': 'Alzheimer disease', 'type': 'Condition', 'properties': {}}, 'target': {'id': 'Chromosomal (Down syndrome)', 'type': 'Cause', 'properties': {}}, 'type': 'CAUSED_BY', 'properties': {}}, {'source': {'id': 'Alzheimer disease', 'type': 'Condition', 'properties': {}}, 'target': {'id': 'Familial', 'type': 'Cause', 'properties': {}}, 'type': 'CAUSED_BY', 'properties': {}}, {'source': {'id': 'Alzheimer disease', 'type': 'Condition', 'properties': {}}, 'target': {'id': 'Late-onset familial (AD2)', 'type': 'Cause', 'properties': {}}, 'type': 'CAUSED_BY', 'properties': {}}, {'source': {'id': 'Alzheimer disease', 'type': 'Condition', 'properties': {}}, 'target': {'id': 'Early-onset familial AD (AD1, AD3, AD4)', 'type': 'Cause', 'properties': {}}, 'type': 'CAUSED_BY', 'properties': {}}, {'source': {'id': 'Alzheimer disease', 'type': 'Condition', 'properties': {}}, 'target': {'id': 'Unknown (includes genetic/environment interactions)', 'type': 'Cause', 'properties': {}}, 'type': 'CAUSED_BY', 'properties': {}}], 'source': {'id': None, 'metadata': {}, 'page_content': 'roximately 10% of persons\\nolder than 70 years have significant memory loss and more\\nthan half of these individuals have AD. An estimated 25–45%\\nof persons older than 85 years have dementia.\\nCAUSES\\nAbout 1–6% of all AD is early onset (before age 60–65\\nyears) and about 60% of early-onset AD is familial, with 13%\\nseeming to be inherited in an autosomal-dominant manner\\n(Table 1).9,10\\nThe distinction between early-onset familial AD (EOFAD,\\nonset before age 60–65 years) and late-onset familial AD (on-\\nset after age 60–65 years) is somewhat arbitrary. Early-onset\\ncases can occur in families with generally late-onset disease.11\\nFig. 1. Normal adult brain (top) compared with Alzheimer brain (bottom) showing\\nmarked diffuse cortical atrophy and ventricular enlargement.\\nFig. 2. Microscopic neuropathology of Alzheimer disease showing a neuritic plaque\\n(lower left hand corner) and neurofibrillary tangles (upper right hand corner).Table 1\\nCauses of Alzheimer disease\\nCause % of cases\\nChromosomal (Down syndrome) /H110211\\nFamilial /H1101125\\nLate-onset familial (AD2) 15–25\\nEarly-onset familial AD (AD1, AD3, AD4) /H110212\\nUnknown (includes genetic/environment interactions) /H1101175Bird\\n232 Genetics INMedicine', 'type': 'Document'}}, {'nodes': [{'id': 'Familial cases', 'type': 'Cases', 'properties': {}}, {'id': 'persons with Down syndrome', 'type': 'Individuals', 'properties': {}}, {'id': 'polymorphism in the APP gene', 'type': 'Polymorphism', 'properties': {}}, {'id': 'pathogenesis of AD', 'type': 'Disease', 'properties': {}}, {'id': 'familial', 'type': 'Type', 'properties': {}}, {'id': 'brain', 'type': 'Organ', 'properties': {}}, {'id': 'Apo E genotype', 'type': 'Genotype', 'properties': {}}, {'id': '25% of AD', 'type': 'Percentage', 'properties': {}}, {'id': 'APP gene', 'type': 'Gene', 'properties': {}}, {'id': 'Twin studies', 'type': 'Study', 'properties': {}}, {'id': 'AD', 'type': 'Disease', 'properties': {}}, {'id': 'Aβ deposition', 'type': 'Deposition', 'properties': {}}, {'id': 'unknown environmental factors', 'type': 'Factor', 'properties': {}}, {'id': 'environmental agents', 'type': 'Agent', 'properties': {}}, {'id': 'research on the molecular and genetic basis of AD', 'type': 'Research', 'properties': {}}, {'id': 'genes and environment', 'type': 'Factor', 'properties': {}}, {'id': 'mothers younger than 35 years', 'type': 'Mothers', 'properties': {}}, {'id': 'Down syndrome', 'type': 'Chromosomal Condition', 'properties': {}}, {'id': 'age of onset of dementia', 'type': 'Onset Age', 'properties': {}}, {'id': 'chromosome 21', 'type': 'Chromosome', 'properties': {}}, {'id': 'clinical evidence of cognitive decline', 'type': 'Evidence', 'properties': {}}, {'id': '78-year-old woman', 'type': 'Individual', 'properties': {}}, {'id': 'onset age', 'type': 'Onset Age', 'properties': {}}, {'id': 'Rosenberg, Sleegers, van Duijn, Nussbaum, Ellis, Goedert, Spillantini, Roses, Saunders', 'type': 'Researchers', 'properties': {}}, {'id': 'unexplained increased risk for AD', 'type': 'Risk', 'properties': {}}, {'id': 'neuropathologic hallmarks of AD', 'type': 'Hallmarks', 'properties': {}}, {'id': 'predisposing genetic background', 'type': 'Background', 'properties': {}}, {'id': 'family history or by molecular genetic testing', 'type': 'Criteria', 'properties': {}}], 'relationships': [{'source': {'id': 'environmental agents', 'type': 'Agent', 'properties': {}}, 'target': {'id': 'pathogenesis of AD', 'type': 'Disease', 'properties': {}}, 'type': 'INVOLVED_IN', 'properties': {}}, {'source': {'id': 'unknown environmental factors', 'type': 'Factor', 'properties': {}}, 'target': {'id': 'predisposing genetic background', 'type': 'Background', 'properties': {}}, 'type': 'ACTING_ON', 'properties': {}}, {'source': {'id': 'Twin studies', 'type': 'Study', 'properties': {}}, 'target': {'id': 'genes and environment', 'type': 'Factor', 'properties': {}}, 'type': 'IMPLICATED', 'properties': {}}, {'source': {'id': 'Down syndrome', 'type': 'Chromosomal Condition', 'properties': {}}, 'target': {'id': 'neuropathologic hallmarks of AD', 'type': 'Hallmarks', 'properties': {}}, 'type': 'DEVELOP', 'properties': {}}, {'source': {'id': 'persons with Down syndrome', 'type': 'Individuals', 'properties': {}}, 'target': {'id': 'clinical evidence of cognitive decline', 'type': 'Evidence', 'properties': {}}, 'type': 'SHOW', 'properties': {}}, {'source': {'id': 'APP gene', 'type': 'Gene', 'properties': {}}, 'target': {'id': 'chromosome 21', 'type': 'Chromosome', 'properties': {}}, 'type': 'OVEREXPRESSION_ON', 'properties': {}}, {'source': {'id': 'Aβ deposition', 'type': 'Deposition', 'properties': {}}, 'target': {'id': 'brain', 'type': 'Organ', 'properties': {}}, 'type': 'BEGIN_IN', 'properties': {}}, {'source': {'id': '78-year-old woman', 'type': 'Individual', 'properties': {}}, 'target': {'id': 'AD', 'type': 'Disease', 'properties': {}}, 'type': 'NOTED', 'properties': {}}, {'source': {'id': 'Apo E genotype', 'type': 'Genotype', 'properties': {}}, 'target': {'id': 'age of onset of dementia', 'type': 'Onset Age', 'properties': {}}, 'type': 'ASSOCIATED_WITH', 'properties': {}}, {'source': {'id': 'polymorphism in the APP gene', 'type': 'Polymorphism', 'properties': {}}, 'target': {'id': 'onset age', 'type': 'Onset Age', 'properties': {}}, 'type': 'ASSOCIATED_WITH', 'properties': {}}, {'source': {'id': 'mothers younger than 35 years', 'type': 'Mothers', 'properties': {}}, 'target': {'id': 'unexplained increased risk for AD', 'type': 'Risk', 'properties': {}}, 'type': 'FOUND', 'properties': {}}, {'source': {'id': '25% of AD', 'type': 'Percentage', 'properties': {}}, 'target': {'id': 'familial', 'type': 'Type', 'properties': {}}, 'type': 'IS', 'properties': {}}, {'source': {'id': 'Familial cases', 'type': 'Cases', 'properties': {}}, 'target': {'id': 'family history or by molecular genetic testing', 'type': 'Criteria', 'properties': {}}, 'type': 'DISTINGUISHED_BY', 'properties': {}}, {'source': {'id': 'research on the molecular and genetic basis of AD', 'type': 'Research', 'properties': {}}, 'target': {'id': 'Rosenberg, Sleegers, van Duijn, Nussbaum, Ellis, Goedert, Spillantini, Roses, Saunders', 'type': 'Researchers', 'properties': {}}, 'type': 'SUMMARIZED_BY', 'properties': {}}], 'source': {'id': None, 'metadata': {}, 'page_content': 'Environmental causes\\nNo environmental agents (e.g., head trauma, viruses, toxins,\\nlow education level) have been proven to be directly involved\\nin the pathogenesis of AD. It is often speculated that late-onset\\nAD is the result of unknown environmental factors acting on a\\npredisposing genetic background.12Twin studies have impli-\\ncated both genes and environment.13\\nHeritable causes\\nChromosomal\\nDown syndrome. Essentially, all persons with Down syndrome\\n(DS) (trisomy 21) develop the neuropathologic hallmarks of\\nAD after 40 years. More than half of individuals with DS also\\nshow, if carefully observed or tested, clinical evidence of cog-\\nnitive decline.14The presumed reason for this association is the\\nlifelong overexpression of the APP gene on chromosome 21\\nencoding the amyloid precursor protein and the resultant\\noverproduction of /H9252-amyloid in the brains of persons who are\\ntrisomic for this gene.\\nThe A /H9252deposition in the brain may begin in the first decade\\nof life in persons with DS.15AD was not noted clinically or\\npathologically in a 78-year-old woman with partial trisomy 21,\\nwho did not have an extra copy of the APP gene.16Two studies\\nhave found no association of Apo E genotype with age of onset\\nof dementia in DS,17,18but one study did find an association of\\nonset age with a polymorphism in the APP gene.18Schupf et\\nal.19found an unexplained increased risk for AD in mothers\\nyounger than 35 years, who gave birth to children with DS.\\nSingle gene. About 25% of AD is familial (i.e., two or more\\nfamily members have AD). Familial cases seem to have the\\nsame clinical and pathologic phenotypes as nonfamilial cases\\n(i.e., an individual with AD and no known family history of\\nAD)20,21and are thus distinguished only by family history or by\\nmolecular genetic testing. A large volume of research on the\\nmolecular and genetic basis of AD has been summarized by\\nRosenberg,22Sleegers and van Duijn,23Nussbaum and Ellis,24\\nGoedert and Spillantini,25and Roses and Saunders.26\\nLate-onset familial Alzheimer disease', 'type': 'Document'}}, {'nodes': [{'id': 'amyloid precursor protein (APP) trafficking', 'type': 'Process', 'properties': {}}, {'id': 'late-onset AD', 'type': 'Disease', 'properties': {}}, {'id': 'markers', 'type': 'Marker', 'properties': {}}, {'id': 'families', 'type': 'Group', 'properties': {}}, {'id': 'multiple susceptibility genes', 'type': 'Gene', 'properties': {}}, {'id': 'GST02', 'type': 'Gene', 'properties': {}}, {'id': 'chromosome 12', 'type': 'Chromosome', 'properties': {}}, {'id': 'chromosome 10', 'type': 'Chromosome', 'properties': {}}, {'id': 'GAB2', 'type': 'Gene', 'properties': {}}, {'id': 'age of onset', 'type': 'Characteristic', 'properties': {}}, {'id': 'EOFAD', 'type': 'Disease', 'properties': {}}, {'id': 'before age 65 years', 'type': 'Age', 'properties': {}}, {'id': 'A2M', 'type': 'Gene', 'properties': {}}, {'id': 'usually in the 40s or early 50s', 'type': 'Age', 'properties': {}}, {'id': 'late-onset familial Alzheimer disease', 'type': 'Disease', 'properties': {}}, {'id': 'SORL1', 'type': 'Gene', 'properties': {}}, {'id': 'GST01', 'type': 'Gene', 'properties': {}}, {'id': 'APOE e4 allele', 'type': 'Gene', 'properties': {}}], 'relationships': [{'source': {'id': 'late-onset familial Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'multiple susceptibility genes', 'type': 'Gene', 'properties': {}}, 'type': 'INVOLVES', 'properties': {}}, {'source': {'id': 'APOE e4 allele', 'type': 'Gene', 'properties': {}}, 'target': {'id': 'age of onset', 'type': 'Characteristic', 'properties': {}}, 'type': 'AFFECTS', 'properties': {}}, {'source': {'id': 'SORL1', 'type': 'Gene', 'properties': {}}, 'target': {'id': 'amyloid precursor protein (APP) trafficking', 'type': 'Process', 'properties': {}}, 'type': 'INVOLVED_WITH', 'properties': {}}, {'source': {'id': 'A2M', 'type': 'Gene', 'properties': {}}, 'target': {'id': 'chromosome 12', 'type': 'Chromosome', 'properties': {}}, 'type': 'LOCATED_ON', 'properties': {}}, {'source': {'id': 'GST01', 'type': 'Gene', 'properties': {}}, 'target': {'id': 'chromosome 10', 'type': 'Chromosome', 'properties': {}}, 'type': 'LOCATED_ON', 'properties': {}}, {'source': {'id': 'GST02', 'type': 'Gene', 'properties': {}}, 'target': {'id': 'chromosome 10', 'type': 'Chromosome', 'properties': {}}, 'type': 'LOCATED_ON', 'properties': {}}, {'source': {'id': 'GAB2', 'type': 'Gene', 'properties': {}}, 'target': {'id': 'APOE e4 allele', 'type': 'Gene', 'properties': {}}, 'type': 'INTERACTS_WITH', 'properties': {}}, {'source': {'id': 'late-onset AD', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'markers', 'type': 'Marker', 'properties': {}}, 'type': 'LINKED_TO', 'properties': {}}, {'source': {'id': 'EOFAD', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'families', 'type': 'Group', 'properties': {}}, 'type': 'REFERS_TO', 'properties': {}}, {'source': {'id': 'EOFAD', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'families', 'type': 'Group', 'properties': {}}, 'type': 'OCCURS_IN', 'properties': {}}, {'source': {'id': 'EOFAD', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'before age 65 years', 'type': 'Age', 'properties': {}}, 'type': 'HAS_MEAN_AGE_OF_ONSET', 'properties': {}}, {'source': {'id': 'EOFAD', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'usually in the 40s or early 50s', 'type': 'Age', 'properties': {}}, 'type': 'HAS_MEAN_AGE_OF_ONSET', 'properties': {}}], 'source': {'id': None, 'metadata': {}, 'page_content': 'Goedert and Spillantini,25and Roses and Saunders.26\\nLate-onset familial Alzheimer disease. Many families have mul-\\ntiple affected members, most or all of whom have onset of\\ndementia after age 60 or 65 years (Table 2). Disease duration is\\ntypically 8–10 years, but ranges from 2 to 25 years. Investiga-\\ntions have supported the concept that late-onset AD is a com-\\nplex disorder that may involve multiple susceptibility genes\\n(reviewed and summarized by Kamboh,27Bertram and\\nTanzi,28Serretti et al.,29and Roses and Saunders26). Bertram et\\nal.30have performed a meta-analysis on these data. The follow-\\ning information are currently available:●Well-documented association of late-onset familial AD\\n(FAD) with the APOE e4 allele. The APOE e4 allele, by\\nunknown mechanisms, seems to affect age of onset by\\nshifting the onset toward an earlier age.31,32\\n●Several other potential genes are under investigation:\\n●SORL1 on chromosome 11q23, a protein involved with\\namyloid precursor protein (APP) trafficking33\\n●A2M on chromosome 1234–37\\n●GST01 andGST02 on chromosome 1038\\n●GAB2 on chromosome 11q14 interacting with the\\nAPOE e4 allele39\\n●Several other potential loci are under investigation on the\\nfollowing chromosomes:\\n●1240–43\\n●1044–48\\n●2q, 9p, and 15q49,50\\n●19p1351\\n●7q3652\\n●9q22 ( UBQLN1 )53–56\\n●Studies of late-onset AD in a genetically isolated Dutch\\npopulation have suggested linkage of AD to markers on\\nchromosome 1q22, 3q23, 10q22, and 11q25.57\\nEarly -onset familial Alzheimer disease\\n●Clinical features: EOFAD refers to families in which mul-\\ntiple cases of AD occur with the mean age of onset usually\\nbefore age 65 years, although some studies have used age\\n60 or 70 years. Age of onset is usually in the 40s or early\\n50s, although onset in the 30s and early 60s has been re-\\nported. Campion et al.10', 'type': 'Document'}}, {'nodes': [{'id': '19q13.2', 'type': 'Genomic Locus', 'properties': {}}, {'id': 'APP', 'type': 'Gene', 'properties': {}}, {'id': 'nonfamilial AD', 'type': 'Disease', 'properties': {}}, {'id': 'Presenilin 2 (PS2)', 'type': 'Gene', 'properties': {}}, {'id': 'alpha- and gamma-secretases', 'type': 'Enzyme', 'properties': {}}, {'id': 'gamma-secretase complex', 'type': 'Protein Complex', 'properties': {}}, {'id': 'early-onset AD', 'type': 'Disease', 'properties': {}}, {'id': '41.2 per 100,000 persons', 'type': 'Statistic', 'properties': {}}, {'id': 'autosomal-dominant inheritance', 'type': 'Characteristic', 'properties': {}}, {'id': 'positive family history', 'type': 'Characteristic', 'properties': {}}, {'id': 'Apolipoprotein E', 'type': 'Protein', 'properties': {}}, {'id': 'APP, Presenilin 1 (PS1), Presenilin 2 (PS2)', 'type': 'Gene', 'properties': {}}, {'id': 'Presenilin 1 (PS1)', 'type': 'Gene', 'properties': {}}, {'id': 'AD1, AD3, and AD4', 'type': 'Subtype', 'properties': {}}, {'id': 'extracellular amyloid plaque', 'type': 'Structure', 'properties': {}}, {'id': 'EOFAD', 'type': 'Disease', 'properties': {}}, {'id': 'A beta-peptide', 'type': 'Protein', 'properties': {}}, {'id': 'APOE', 'type': 'Gene', 'properties': {}}], 'relationships': [{'source': {'id': 'early-onset AD', 'type': 'Disease', 'properties': {}}, 'target': {'id': '41.2 per 100,000 persons', 'type': 'Statistic', 'properties': {}}, 'type': 'HAS_PREVALENCE', 'properties': {}}, {'source': {'id': 'early-onset AD', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'positive family history', 'type': 'Characteristic', 'properties': {}}, 'type': 'HAS_FAMILY_HISTORY', 'properties': {}}, {'source': {'id': 'early-onset AD', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'autosomal-dominant inheritance', 'type': 'Characteristic', 'properties': {}}, 'type': 'HAS_INHERITANCE_CRITERIA', 'properties': {}}, {'source': {'id': 'EOFAD', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'nonfamilial AD', 'type': 'Disease', 'properties': {}}, 'type': 'SIMILAR_TO', 'properties': {}}, {'source': {'id': 'EOFAD', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'AD1, AD3, and AD4', 'type': 'Subtype', 'properties': {}}, 'type': 'HAS_GENETIC_SUBTYPES', 'properties': {}}, {'source': {'id': 'EOFAD', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'APP, Presenilin 1 (PS1), Presenilin 2 (PS2)', 'type': 'Gene', 'properties': {}}, 'type': 'HAS_CAUSATIVE_GENES', 'properties': {}}, {'source': {'id': 'APP', 'type': 'Gene', 'properties': {}}, 'target': {'id': 'alpha- and gamma-secretases', 'type': 'Enzyme', 'properties': {}}, 'type': 'CLEAVED_BY', 'properties': {}}, {'source': {'id': 'APP', 'type': 'Gene', 'properties': {}}, 'target': {'id': 'A beta-peptide', 'type': 'Protein', 'properties': {}}, 'type': 'FORMS', 'properties': {}}, {'source': {'id': 'A beta-peptide', 'type': 'Protein', 'properties': {}}, 'target': {'id': 'extracellular amyloid plaque', 'type': 'Structure', 'properties': {}}, 'type': 'PRIMARY_COMPONENT_OF', 'properties': {}}, {'source': {'id': 'Presenilin 1 (PS1)', 'type': 'Gene', 'properties': {}}, 'target': {'id': 'gamma-secretase complex', 'type': 'Protein Complex', 'properties': {}}, 'type': 'PART_OF', 'properties': {}}, {'source': {'id': 'Presenilin 2 (PS2)', 'type': 'Gene', 'properties': {}}, 'target': {'id': 'Presenilin 1 (PS1)', 'type': 'Gene', 'properties': {}}, 'type': 'CLOSE_HOMOLOG_OF', 'properties': {}}, {'source': {'id': 'APOE', 'type': 'Gene', 'properties': {}}, 'target': {'id': '19q13.2', 'type': 'Genomic Locus', 'properties': {}}, 'type': 'LOCATED_AT', 'properties': {}}, {'source': {'id': 'APOE', 'type': 'Gene', 'properties': {}}, 'target': {'id': 'Apolipoprotein E', 'type': 'Protein', 'properties': {}}, 'type': 'ENCODES', 'properties': {}}], 'source': {'id': None, 'metadata': {}, 'page_content': ', although onset in the 30s and early 60s has been re-\\nported. Campion et al.10found a prevalence of early-onset\\nAD in the general population of 41.2 per 100,000 persons\\nat risk (ages 40–59 years). Sixty-one percent of these in-\\ndividuals with early-onset AD had a positive family history,\\nand 13% met stringent criteria for autosomal-dominant in-\\nheritance (i.e., affected individuals in three generations).\\nEOFAD cannot be clinically distinguished from nonfamilial\\nAD except on the basis of family history and age of onset. The\\ndementia phenotype is similar to that of late-onset AD,\\nsometimes with a long prodrome.58–60\\n●Molecular genetics: At least three subtypes of EOFAD (AD1,\\nAD3, and AD4) have been identified based on the causative\\ngene. The relative proportion of each subtype and the caus-\\native genes are summarized in Table 3.10,61–63 The APP is\\ncleaved by alpha- and gamma-secretases to form the A beta-\\npeptide, which is the primary component of the extracellular\\namyloid plaque deposited in AD (Fig. 3). Presenilin 1 (PS1)\\nis part of the gamma-secretase complex (and PS2 is a close\\nhomolog of PS1). Thus, the three primary genes associated\\nwith EOFAD are all related to APP and A beta-amyloid mo-\\nlecular biology. It is likely that other genes will be identified as\\na cause of EOFAD because kindreds with autosomal-domi-\\nnant FAD with no known mutations in presenilin 1\\n(PSEN1 ),PSEN2 ,o rAPPhave been described.63,64Table 2\\nLate-onset familial Alzheimer’s disease: molecular genetics\\nLocus\\nnameGene\\nsymbolChromosomal\\nlocusProtein\\nnameTest\\navailability\\nAD2 APOE 19q13.2 ApolipoproteinE ClinicalGenetic aspects of Alzheimer disease\\nApril 2008 /H18528Vol. 10 /H18528No. 4 233', 'type': 'Document'}}, {'nodes': [{'id': 'late-onset FAD', 'type': 'Disease', 'properties': {}}, {'id': 'head trauma', 'type': 'Factor', 'properties': {}}, {'id': 'late-onset AD', 'type': 'Disease', 'properties': {}}, {'id': 'late-onset familial AD', 'type': 'Disease', 'properties': {}}, {'id': 'APOE allele e4', 'type': 'Gene', 'properties': {}}, {'id': 'EOFAD', 'type': 'Disease', 'properties': {}}, {'id': 'viruses', 'type': 'Factor', 'properties': {}}, {'id': 'aging', 'type': 'Factor', 'properties': {}}, {'id': 'nonfamilial AD', 'type': 'Disease', 'properties': {}}, {'id': 'after age 60–65 years', 'type': 'Characteristic', 'properties': {}}, {'id': 'e4/e4 genotype', 'type': 'Genotype', 'properties': {}}, {'id': 'AD', 'type': 'Disease', 'properties': {}}, {'id': 'genetic predisposition', 'type': 'Factor', 'properties': {}}, {'id': 'multiple cases of AD', 'type': 'Disease', 'properties': {}}, {'id': 'APOE e4', 'type': 'Gene', 'properties': {}}, {'id': 'positive family history of dementia', 'type': 'Factor', 'properties': {}}, {'id': 'APOE e4 allele', 'type': 'Gene', 'properties': {}}, {'id': 'toxins', 'type': 'Factor', 'properties': {}}, {'id': 'exposure to environmental agents', 'type': 'Factor', 'properties': {}}, {'id': 'before age 60–65 years', 'type': 'Characteristic', 'properties': {}}], 'relationships': [{'source': {'id': 'nonfamilial AD', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'AD', 'type': 'Disease', 'properties': {}}, 'type': 'MEETS_DIAGNOSTIC_CRITERIA', 'properties': {}}, {'source': {'id': 'nonfamilial AD', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'aging', 'type': 'Factor', 'properties': {}}, 'type': 'RESULTS_FROM', 'properties': {}}, {'source': {'id': 'nonfamilial AD', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'genetic predisposition', 'type': 'Factor', 'properties': {}}, 'type': 'RESULTS_FROM', 'properties': {}}, {'source': {'id': 'nonfamilial AD', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'exposure to environmental agents', 'type': 'Factor', 'properties': {}}, 'type': 'RESULTS_FROM', 'properties': {}}, {'source': {'id': 'nonfamilial AD', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'head trauma', 'type': 'Factor', 'properties': {}}, 'type': 'RESULTS_FROM', 'properties': {}}, {'source': {'id': 'nonfamilial AD', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'viruses', 'type': 'Factor', 'properties': {}}, 'type': 'RESULTS_FROM', 'properties': {}}, {'source': {'id': 'nonfamilial AD', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'toxins', 'type': 'Factor', 'properties': {}}, 'type': 'RESULTS_FROM', 'properties': {}}, {'source': {'id': 'EOFAD', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'multiple cases of AD', 'type': 'Disease', 'properties': {}}, 'type': 'DIAGNOSED_IN_FAMILIES_WITH', 'properties': {}}, {'source': {'id': 'EOFAD', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'before age 60–65 years', 'type': 'Characteristic', 'properties': {}}, 'type': 'MEAN_AGE_OF_ONSET', 'properties': {}}, {'source': {'id': 'late-onset FAD', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'multiple cases of AD', 'type': 'Disease', 'properties': {}}, 'type': 'DIAGNOSED_IN_FAMILIES_WITH', 'properties': {}}, {'source': {'id': 'late-onset FAD', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'after age 60–65 years', 'type': 'Characteristic', 'properties': {}}, 'type': 'MEAN_AGE_OF_ONSET', 'properties': {}}, {'source': {'id': 'APOE allele e4', 'type': 'Gene', 'properties': {}}, 'target': {'id': 'late-onset AD', 'type': 'Disease', 'properties': {}}, 'type': 'ASSOCIATED_WITH', 'properties': {}}, {'source': {'id': 'APOE e4', 'type': 'Gene', 'properties': {}}, 'target': {'id': 'late-onset AD', 'type': 'Disease', 'properties': {}}, 'type': 'ASSOCIATED_WITH', 'properties': {}}, {'source': {'id': 'APOE e4', 'type': 'Gene', 'properties': {}}, 'target': {'id': 'positive family history of dementia', 'type': 'Factor', 'properties': {}}, 'type': 'ASSOCIATED_WITH', 'properties': {}}, {'source': {'id': 'APOE e4 allele', 'type': 'Gene', 'properties': {}}, 'target': {'id': 'late-onset familial AD', 'type': 'Disease', 'properties': {}}, 'type': 'ASSOCIATED_WITH', 'properties': {}}, {'source': {'id': 'APOE e4 allele', 'type': 'Gene', 'properties': {}}, 'target': {'id': 'e4/e4 genotype', 'type': 'Genotype', 'properties': {}}, 'type': 'ASSOCIATED_WITH', 'properties': {}}], 'source': {'id': None, 'metadata': {}, 'page_content': 'Unknown causes\\nIndividuals with nonfamilial AD meet the diagnostic criteria\\nfor AD and have a negative family history. Onset can be any-\\ntime in adulthood. The exact pathogenesis of the disease is\\nunknown. A common hypothesis is that nonfamilial AD is\\nmultifactorial and results from a combination of aging, genetic\\npredisposition, and exposure to one or more environmental\\nagents, such as head trauma, viruses, and/or toxins65although\\nno environmental agents have been proven to be directly in-\\nvolved in the pathogenesis of AD.EVALUATION STRATEGY\\nFamily history\\nA three-generation family history with close attention to the\\nhistory of individuals with dementia should be obtained. For each\\naffected individual, the age of onset of dementia should be noted.\\nGenerally, individuals with onset before age 65 years are consid-\\nered to have early-onset AD and those with onset after age 65 years\\nare considered to have late-onset AD. Medical records of affected\\nfamily members, including reports of neuroimaging studies and\\nautopsy examinations, should be obtained.\\n●The diagnosis of EOFAD is made in families with multiple\\ncases of AD in which the mean age of onset is before age\\n60–65 years.\\n●The diagnosis of late-onset FAD is made in families with\\nmultiple cases of AD in which the mean age of onset is\\nafter age 60–65 years.\\nMolecular genetic testing\\nLate-onset familial AD\\nThe association of one or two copies of the APOE allele e4\\n(i.e., genotypes e2/e4, e3/e4, e4/e4) with late-onset AD is well\\ndocumented (Table 4).32,66,67\\n●The association between APOE e4 and AD is greatest\\nwhen the individual has a positive family history of de-\\nmentia. The last column of Table 4 largely represents late-\\nonset familial AD.\\n●The strongest association between the APOE e4 allele and\\nAD, relative to the normal control population, is with the\\ne4/e4 genotype. That genotype occurs in about 1% of the\\nnormal control population and in nearly 19% of the fa-\\nmilial AD population.\\n●In individuals who have the clinical diagnosis of AD, the\\nprobability that AD is the correct diagnosis is increased', 'type': 'Document'}}, {'nodes': [{'id': 'APOE e4/e4 genotype', 'type': 'Genotype', 'properties': {}}, {'id': 'Individuals with AD', 'type': 'Population', 'properties': {}}, {'id': 'APP', 'type': 'Protein', 'properties': {}}, {'id': 'PSEN2', 'type': 'Gene', 'properties': {}}, {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, {'id': 'Individuals with AD and positive family history of dementia', 'type': 'Population', 'properties': {}}, {'id': 'APOE e4 allele', 'type': 'Genotype', 'properties': {}}, {'id': 'Early-onset familial Alzheimer disease (EOFAD)', 'type': 'Disease', 'properties': {}}, {'id': 'APP gene', 'type': 'Gene', 'properties': {}}, {'id': 'AD', 'type': 'Disease', 'properties': {}}, {'id': 'APOE genotype', 'type': 'Genotype', 'properties': {}}, {'id': 'Rare Alzheimer disease', 'type': 'Disease', 'properties': {}}, {'id': '1q31-q42', 'type': 'Chromosomal locus', 'properties': {}}, {'id': 'Normal controls', 'type': 'Population', 'properties': {}}, {'id': 'Caribbean Hispanics', 'type': 'Ethnicity', 'properties': {}}, {'id': '14q24.3', 'type': 'Chromosomal locus', 'properties': {}}, {'id': 'Breitner et al.', 'type': 'Person', 'properties': {}}, {'id': 'PSEN1', 'type': 'Gene', 'properties': {}}, {'id': 'Amyloid beta A4 protein', 'type': 'Protein', 'properties': {}}, {'id': 'African-Americans', 'type': 'Ethnicity', 'properties': {}}, {'id': '21q21', 'type': 'Chromosomal locus', 'properties': {}}, {'id': 'lifetime risks for developing AD', 'type': 'Disease', 'properties': {}}], 'relationships': [{'source': {'id': 'AD', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'APOE e4/e4 genotype', 'type': 'Genotype', 'properties': {}}, 'type': 'ASSOCIATED_WITH', 'properties': {}}, {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'APOE e4 allele', 'type': 'Genotype', 'properties': {}}, 'type': 'ASSOCIATED_WITH', 'properties': {}}, {'source': {'id': 'APOE e4 allele', 'type': 'Genotype', 'properties': {}}, 'target': {'id': 'AD', 'type': 'Disease', 'properties': {}}, 'type': 'NOT_SPECIFIC_FOR', 'properties': {}}, {'source': {'id': 'APOE e4 allele', 'type': 'Genotype', 'properties': {}}, 'target': {'id': 'AD', 'type': 'Disease', 'properties': {}}, 'type': 'NOT_RULE_OUT', 'properties': {}}, {'source': {'id': 'Breitner et al.', 'type': 'Person', 'properties': {}}, 'target': {'id': 'lifetime risks for developing AD', 'type': 'Disease', 'properties': {}}, 'type': 'ESTIMATED', 'properties': {}}, {'source': {'id': 'APOE genotype', 'type': 'Genotype', 'properties': {}}, 'target': {'id': 'African-Americans', 'type': 'Ethnicity', 'properties': {}}, 'type': 'FOUND_IN', 'properties': {}}, {'source': {'id': 'APOE genotype', 'type': 'Genotype', 'properties': {}}, 'target': {'id': 'Caribbean Hispanics', 'type': 'Ethnicity', 'properties': {}}, 'type': 'FOUND_IN', 'properties': {}}, {'source': {'id': 'APP gene', 'type': 'Gene', 'properties': {}}, 'target': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'type': 'INVOLVED_IN', 'properties': {}}, {'source': {'id': 'PSEN1', 'type': 'Gene', 'properties': {}}, 'target': {'id': 'Early-onset familial Alzheimer disease (EOFAD)', 'type': 'Disease', 'properties': {}}, 'type': 'CAUSES', 'properties': {}}, {'source': {'id': 'APP', 'type': 'Protein', 'properties': {}}, 'target': {'id': 'Amyloid beta A4 protein', 'type': 'Protein', 'properties': {}}, 'type': 'PRODUCES', 'properties': {}}, {'source': {'id': 'PSEN1', 'type': 'Gene', 'properties': {}}, 'target': {'id': '14q24.3', 'type': 'Chromosomal locus', 'properties': {}}, 'type': 'LOCATED_AT', 'properties': {}}, {'source': {'id': 'APP', 'type': 'Protein', 'properties': {}}, 'target': {'id': '21q21', 'type': 'Chromosomal locus', 'properties': {}}, 'type': 'LOCATED_AT', 'properties': {}}, {'source': {'id': 'PSEN2', 'type': 'Gene', 'properties': {}}, 'target': {'id': 'Rare Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'type': 'CAUSES', 'properties': {}}, {'source': {'id': 'PSEN2', 'type': 'Gene', 'properties': {}}, 'target': {'id': '1q31-q42', 'type': 'Chromosomal locus', 'properties': {}}, 'type': 'LOCATED_AT', 'properties': {}}, {'source': {'id': 'APOE genotype', 'type': 'Genotype', 'properties': {}}, 'target': {'id': 'Normal controls', 'type': 'Population', 'properties': {}}, 'type': 'FOUND_IN', 'properties': {}}, {'source': {'id': 'APOE genotype', 'type': 'Genotype', 'properties': {}}, 'target': {'id': 'Individuals with AD', 'type': 'Population', 'properties': {}}, 'type': 'FOUND_IN', 'properties': {}}, {'source': {'id': 'APOE genotype', 'type': 'Genotype', 'properties': {}}, 'target': {'id': 'Individuals with AD and positive family history of dementia', 'type': 'Population', 'properties': {}}, 'type': 'FOUND_IN', 'properties': {}}], 'source': {'id': None, 'metadata': {}, 'page_content': '●In individuals who have the clinical diagnosis of AD, the\\nprobability that AD is the correct diagnosis is increased to\\nabout 97% in the presence of the APOE e4/e4 genotype.68\\n●The increased risk of AD associated with one APOE e4\\nallele or two APOE e4 alleles is also found in African-\\nAmericans69and Caribbean Hispanics.70\\n●Approximately 42% of persons with AD do not have an\\nAPOE e4 allele. Thus, APOE genotyping is not specific for\\nAD. The absence of an APOE e4 allele does not rule out\\nthe diagnosis of AD2.\\n●Breitner et al.71have estimated lifetime risks for devel-\\noping AD based on gender and APOE genotype (see\\nTesting of At-risk Asymptomatic Individuals under\\nGenetic Counseling).\\nFig. 3. Molecular aspects of the APP gene and protein showing the sites of cleavage by\\n/H9251,/H9252, and /H9253secretases, production of the A /H9252peptide (upper right), and sites of several\\ndisease causing mutations (bottom line).Table 3\\nEarly-onset familial Alzheimer disease (EOFAD): molecular genetics\\nLocus name Proportion of EOFAD Gene symbol Chromosomal locus Protein name Test availability\\nAD3 20–70% PSEN1 14q24.3 Presenilin-1 Clinical\\nAD1 10–15% APP 21q21 Amyloid beta A4 protein Clinical\\nAD4 Rare PSEN2 1q31-q42 Presenilin-2 Clinical\\nTable 4\\nPercent of APOE genotypes in controls and individuals with AD\\nAPOE\\ngenotypeNormal controls\\n(n/H11005304)All individuals\\nwith AD\\n(n/H11005233)Individuals with AD\\nand positive family\\nhistory of dementiaa\\n(n/H1100585)\\ne2/e2 1.3% 0% 0%\\ne2/e3 12.5% 3.4% 3.5%\\ne2/e4 4.9% 4.3% 8.2%\\ne3/e3 59.9% 38.2% 23.5%\\ne3/e4 20.7% 41.2% 45.9%\\ne4/', 'type': 'Document'}}, {'nodes': [{'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, {'id': 'e4', 'type': 'Genotype', 'properties': {}}, {'id': 'e3', 'type': 'Genotype', 'properties': {}}], 'relationships': [{'source': {'id': 'e3', 'type': 'Genotype', 'properties': {}}, 'target': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'type': 'TRANSMISSION', 'properties': {}}, {'source': {'id': 'e4', 'type': 'Genotype', 'properties': {}}, 'target': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'type': 'TRANSMISSION', 'properties': {}}, {'source': {'id': 'e4', 'type': 'Genotype', 'properties': {}}, 'target': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'type': 'TRANSMISSION', 'properties': {}}], 'source': {'id': None, 'metadata': {}, 'page_content': '5%\\ne3/e4 20.7% 41.2% 45.9%\\ne4/e4 0.7% 12.9% 18.8%\\nModified from Jarvik G, Larson EB, Goddard K, Schellenberg GD, et al. Influ-\\nence of apolipoprotein E genotype on the transmission of Alzheimer disease in\\na community-based sample. Am J Hum Genet 1996;58:191–200.\\naMost families would be considered to have late-onset familial AD.Bird\\n234 Genetics INMedicine', 'type': 'Document'}}, {'nodes': [{'id': 'autosomal-dominant manner', 'type': 'Concept', 'properties': {}}, {'id': 'EOFAD', 'type': 'Concept', 'properties': {}}, {'id': 'APOE e4 allele', 'type': 'Concept', 'properties': {}}, {'id': 'diagnosis of AD', 'type': 'Concept', 'properties': {}}, {'id': 'APOE genotyping', 'type': 'Concept', 'properties': {}}, {'id': 'molecular genetic testing', 'type': 'Concept', 'properties': {}}, {'id': 'APOE e2 allele', 'type': 'Concept', 'properties': {}}, {'id': 'AD3', 'type': 'Concept', 'properties': {}}, {'id': 'significant diagnostic use in identifying AD', 'type': 'Concept', 'properties': {}}, {'id': 'neuropathologic confirmation of AD', 'type': 'Concept', 'properties': {}}, {'id': 'AD1', 'type': 'Concept', 'properties': {}}, {'id': 'AD474', 'type': 'Concept', 'properties': {}}, {'id': 'AD', 'type': 'Concept', 'properties': {}}, {'id': 'risk for AD', 'type': 'Concept', 'properties': {}}], 'relationships': [{'source': {'id': 'APOE genotyping', 'type': 'Concept', 'properties': {}}, 'target': {'id': 'diagnosis of AD', 'type': 'Concept', 'properties': {}}, 'type': 'HAS_ADJUNCT_ROLE_IN', 'properties': {}}, {'source': {'id': 'APOE e4 allele', 'type': 'Concept', 'properties': {}}, 'target': {'id': 'neuropathologic confirmation of AD', 'type': 'Concept', 'properties': {}}, 'type': 'IS_ASSOCIATED_WITH', 'properties': {}}, {'source': {'id': 'APOE genotyping', 'type': 'Concept', 'properties': {}}, 'target': {'id': 'significant diagnostic use in identifying AD', 'type': 'Concept', 'properties': {}}, 'type': 'NOT_FOUND_TO_BE', 'properties': {}}, {'source': {'id': 'APOE e2 allele', 'type': 'Concept', 'properties': {}}, 'target': {'id': 'risk for AD', 'type': 'Concept', 'properties': {}}, 'type': 'HAS_PROTECTIVE_EFFECT_IN', 'properties': {}}, {'source': {'id': 'APOE e4 allele', 'type': 'Concept', 'properties': {}}, 'target': {'id': 'risk for AD', 'type': 'Concept', 'properties': {}}, 'type': 'IS_ASSOCIATED_WITH', 'properties': {}}, {'source': {'id': 'EOFAD', 'type': 'Concept', 'properties': {}}, 'target': {'id': 'AD3', 'type': 'Concept', 'properties': {}}, 'type': 'HAS_SUBTYPES', 'properties': {}}, {'source': {'id': 'EOFAD', 'type': 'Concept', 'properties': {}}, 'target': {'id': 'AD1', 'type': 'Concept', 'properties': {}}, 'type': 'HAS_SUBTYPES', 'properties': {}}, {'source': {'id': 'EOFAD', 'type': 'Concept', 'properties': {}}, 'target': {'id': 'AD474', 'type': 'Concept', 'properties': {}}, 'type': 'HAS_SUBTYPES', 'properties': {}}, {'source': {'id': 'EOFAD', 'type': 'Concept', 'properties': {}}, 'target': {'id': 'molecular genetic testing', 'type': 'Concept', 'properties': {}}, 'type': 'CAN_BE_DISTINGUISHED_BY', 'properties': {}}, {'source': {'id': 'EOFAD', 'type': 'Concept', 'properties': {}}, 'target': {'id': 'autosomal-dominant manner', 'type': 'Concept', 'properties': {}}, 'type': 'IS_INHERITED_IN', 'properties': {}}, {'source': {'id': 'AD', 'type': 'Concept', 'properties': {}}, 'target': {'id': 'AD', 'type': 'Concept', 'properties': {}}, 'type': 'IS_CONSIDERED_POLYGENIC_AND_MULTIFACTORIAL', 'properties': {}}, {'source': {'id': 'EOFAD', 'type': 'Concept', 'properties': {}}, 'target': {'id': 'autosomal-dominant manner', 'type': 'Concept', 'properties': {}}, 'type': 'IS_INHERITED_IN', 'properties': {}}, {'source': {'id': 'AD', 'type': 'Concept', 'properties': {}}, 'target': {'id': 'AD', 'type': 'Concept', 'properties': {}}, 'type': 'IS_CONSIDERED_POLYGENIC_AND_MULTIFACTORIAL', 'properties': {}}, {'source': {'id': 'AD', 'type': 'Concept', 'properties': {}}, 'target': {'id': 'AD', 'type': 'Concept', 'properties': {}}, 'type': 'IS_GENETICALLY_HETEROGENEOUS', 'properties': {}}], 'source': {'id': None, 'metadata': {}, 'page_content': 'The usefulness of APOE genotyping in clinical diagnosis and\\nrisk assessment remains unclear (Statements and Policies Re-\\ngarding Genetic Testing).\\n●Although the presence of one APOE e4 allele or two APOE\\ne4 alleles is neither necessary nor sufficient to establish a\\ndiagnosis of AD, APOE genotyping may have an adjunct\\nrole in the diagnosis of AD because a large proportion of\\nindividuals with one APOE e4 allele or two APOE e4 al-\\nleles who are demented have been found to have neuro-\\npathologic confirmation of AD at autopsy.2,66,72,73\\n●In contrast, APOE genotyping was not found to be of\\nsignificant diagnostic use in identifying AD in a commu-\\nnity-based sample with late-onset dementia.74\\nThere is some evidence that the APOE e2 allele may have a\\nprotective effect in regard to risk for AD (Table 4).\\nAnother way to look at this association between AD and an\\nAPOE e4 allele is with APOE e4 allele frequencies (Table 5).\\nEarly-onset familial AD\\nThe three known subtypes of EOFAD, called AD3, AD1, and\\nAD474,75can only be distinguished by molecular genetic testing\\n(Table 3). Genetic testing of individuals who are simplex cases\\n(i.e., a single occurrence of early-onset AD in a family) is con-\\ntroversial and should be undertaken in the context of formal\\ngenetic counseling.76A small proportion ( /H110215%) of such cases\\nwill have a mutation in PS1.\\nGENETIC COUNSELING\\nMode of inheritance\\nBecause AD is genetically heterogeneous, genetic counseling\\nof persons with AD and their family members must be tailored\\nto the information available for that family. AD is usually con-\\nsidered polygenic and multifactorial. EOFAD is inherited in an\\nautosomal-dominant manner.\\nRisk to family members—late-onset nonfamilial Alzheimer disease\\nGenetic counseling for people with nonfamilial AD and\\ntheir family members must be empiric and relatively nonspe-\\ncific. It should be pointed out that AD is common and that theoverall lifetime risk to any individual of developing dementia is\\napproximately 10–12%.\\nFirst-degree relatives of a person with AD have a cumulative\\n', 'type': 'Document'}}, {'nodes': [{'id': 'family members', 'type': 'Person', 'properties': {}}, {'id': 'parents', 'type': 'Person', 'properties': {}}, {'id': 'offspring', 'type': 'Person', 'properties': {}}, {'id': 'sibs', 'type': 'Person', 'properties': {}}, {'id': 'individuals', 'type': 'Person', 'properties': {}}, {'id': \"proband's parents\", 'type': 'Person', 'properties': {}}, {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}], 'relationships': [{'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'individuals', 'type': 'Person', 'properties': {}}, 'type': 'AFFECTS', 'properties': {}}, {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'family members', 'type': 'Person', 'properties': {}}, 'type': 'AFFECTS', 'properties': {}}, {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'parents', 'type': 'Person', 'properties': {}}, 'type': 'AFFECTS', 'properties': {}}, {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'offspring', 'type': 'Person', 'properties': {}}, 'type': 'AFFECTS', 'properties': {}}, {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'individuals', 'type': 'Person', 'properties': {}}, 'type': 'AFFECTS', 'properties': {}}, {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'family members', 'type': 'Person', 'properties': {}}, 'type': 'AFFECTS', 'properties': {}}, {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'parents', 'type': 'Person', 'properties': {}}, 'type': 'AFFECTS', 'properties': {}}, {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'offspring', 'type': 'Person', 'properties': {}}, 'type': 'AFFECTS', 'properties': {}}, {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'family members', 'type': 'Person', 'properties': {}}, 'type': 'AFFECTS', 'properties': {}}, {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'sibs', 'type': 'Person', 'properties': {}}, 'type': 'AFFECTS', 'properties': {}}, {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'target': {'id': \"proband's parents\", 'type': 'Person', 'properties': {}}, 'type': 'AFFECTS', 'properties': {}}], 'source': {'id': None, 'metadata': {}, 'page_content': ' of developing dementia is\\napproximately 10–12%.\\nFirst-degree relatives of a person with AD have a cumulative\\nlifetime risk of developing AD of about 15–30%, which is typ-\\nically reported as a 20–25% risk.77,78This risk is about 2.5 times\\nthat of the background risk ( /H1101127% vs. 10.4%).79,80\\nDisagreement exists as to whether the age of onset of the\\naffected person changes the risk to first-degree relatives. One\\nstudy found that early-onset AD increased the risk,78whereas\\nanother study did not.77\\nThe number of additional affected family members proba-\\nbly increases the risk to close relatives, but the magnitude of\\nthat increase is unclear unless the pattern in the family is char-\\nacteristic of autosomal-dominant inheritance. Having two,\\nthree, or more affected family members probably raises the risk\\nto other first-degree relatives in excess of that noted above for\\nnonfamilial cases, although the exact magnitude of the risk is\\nnot clear. Heston et al.81found a 35–45% risk of dementia in\\nindividuals who had a parent with AD and a sib with onset of\\nAD before age 70 years. Jayadev et al.82also report data sug-\\ngesting that offspring of parents with conjugal AD (i.e., both\\nparents affected) had an increased risk of dementia.\\nRisk to family members—early-onset familial Alzheimer disease\\nMany individuals diagnosed as having early-onset AD have\\nanother affected family member, although family history is\\nnegative 40% of the time.10Family history may be “negative”\\nbecause of early death of a parent, failure to recognize the dis-\\norder in family members, or, rarely, a de novo mutation. The\\nrisk to sibs depends upon the genetic status of the affected\\nproband’s parent. If one of the proband’s parents has a mutant\\nallele, then the risk to the sibs of inheriting the mutant allele is\\n50%. Individuals with EOFAD (and a mutation in APP,PS1,o r\\nPS2) have a 50% chance of transmitting the mutant allele to\\neach child. The risk to other family members depends upon the\\nstatus of the proband’s parents. If a parent', 'type': 'Document'}}, {'nodes': [{'id': 'APOE testing', 'type': 'Test', 'properties': {}}, {'id': 'developing AD', 'type': 'Event', 'properties': {}}, {'id': 'predictive testing', 'type': 'Purpose', 'properties': {}}, {'id': 'APOE e4/e4 genotype', 'type': 'Genotype', 'properties': {}}, {'id': 'developing AD by age 73 years', 'type': 'Event', 'properties': {}}, {'id': 'APOE e4 allele', 'type': 'Allele', 'properties': {}}, {'id': 'risk', 'type': 'Characteristic', 'properties': {}}, {'id': 'age of onset', 'type': 'Characteristic', 'properties': {}}, {'id': 'men', 'type': 'Person', 'properties': {}}, {'id': 'AD', 'type': 'Disease', 'properties': {}}, {'id': 'adjunct diagnostic test', 'type': 'Purpose', 'properties': {}}, {'id': 'women with an APOE e4/e4 genotype', 'type': 'Population', 'properties': {}}, {'id': 'APOE', 'type': 'Gene', 'properties': {}}], 'relationships': [{'source': {'id': 'APOE', 'type': 'Gene', 'properties': {}}, 'target': {'id': 'AD', 'type': 'Disease', 'properties': {}}, 'type': 'PREDICTS', 'properties': {}}, {'source': {'id': 'APOE e4/e4 genotype', 'type': 'Genotype', 'properties': {}}, 'target': {'id': 'developing AD', 'type': 'Event', 'properties': {}}, 'type': 'PREDICTS_RISK', 'properties': {}}, {'source': {'id': 'women with an APOE e4/e4 genotype', 'type': 'Population', 'properties': {}}, 'target': {'id': 'developing AD by age 73 years', 'type': 'Event', 'properties': {}}, 'type': 'HAVE_PROBABILITY', 'properties': {}}, {'source': {'id': 'men', 'type': 'Person', 'properties': {}}, 'target': {'id': 'developing AD', 'type': 'Event', 'properties': {}}, 'type': 'HAVE_RISK', 'properties': {}}, {'source': {'id': 'APOE e4 allele', 'type': 'Allele', 'properties': {}}, 'target': {'id': 'risk', 'type': 'Characteristic', 'properties': {}}, 'type': 'AFFECTS', 'properties': {}}, {'source': {'id': 'APOE e4 allele', 'type': 'Allele', 'properties': {}}, 'target': {'id': 'age of onset', 'type': 'Characteristic', 'properties': {}}, 'type': 'AFFECTS', 'properties': {}}, {'source': {'id': 'APOE testing', 'type': 'Test', 'properties': {}}, 'target': {'id': 'predictive testing', 'type': 'Purpose', 'properties': {}}, 'type': 'USED_FOR', 'properties': {}}, {'source': {'id': 'APOE testing', 'type': 'Test', 'properties': {}}, 'target': {'id': 'adjunct diagnostic test', 'type': 'Purpose', 'properties': {}}, 'type': 'USED_AS', 'properties': {}}], 'source': {'id': None, 'metadata': {}, 'page_content': '. The risk to other family members depends upon the\\nstatus of the proband’s parents. If a parent is found to be af-\\nfected, his or her family members are at risk.\\nRelated genetic counseling issues\\nUse of APOE genotyping for predictive testing\\nIn contrast to the use of APOE testing as an adjunct diagnos-\\ntic test in individuals with dementia, there is general agreement\\nthatAPOE testing has limited value used for predictive testing\\nfor AD in asymptomatic persons. Data suggest that a young\\nasymptomatic person with the APOE e4/e4 genotype may have\\nan approximately 30% lifetime risk of developing AD.83Fur-\\nther refinement of this risk reveals that women with an APOE\\ne4/e4 genotype have a 45% probability of developing AD by\\nage 73 years, whereas men have a 25% risk.71These risks are\\nlower—and the likely age of onset later—for persons with only\\noneAPOE e4 allele (peak age 87 years) or no APOE e4 allele\\n(peak age 95 years). These estimates are not generally consid-\\nered clinically useful; however, a research study to assess the\\npotential use of APOE testing in relatives of individuals with\\nlate-onset AD is under way.79,84Table 5\\nAPOE allele frequencies in controls and individuals with AD\\nAPOE\\nalleleNormal\\ncontrols\\n(n/H11005304)All individuals\\nwith AD\\n(n/H11005233)Individuals with AD\\nand positive family\\nhistory of dementiaa\\n(n/H1100585)\\ne2 9.0% 3.9% 5.9%\\ne3 76.5% 60.5% 48.2%\\ne4 13.7% 35.6% 45.9%\\nModified from Jarvik G, Larson EB, Goddard K, Schellenberg GD, et al. Influ-\\nence of apolipoprotein E genotype on the transmission of Alzheimer disease in\\na community-based sample. Am J Hum Genet 1996;58:191–200.\\naMost families would be considered to have late-onset familial AD.Genetic aspects of Alzheimer disease\\nApril 2008 /H18528Vol. 10 /H18528No. 4 235', 'type': 'Document'}}, {'nodes': [{'id': 'mutations in the PSEN1 gene', 'type': 'Genetic Mutation', 'properties': {}}, {'id': 'prenatal diagnosis', 'type': 'Medical Procedure', 'properties': {}}, {'id': 'prenatal testing', 'type': 'Medical Procedure', 'properties': {}}, {'id': 'increased risk for EOFAD', 'type': 'Condition', 'properties': {}}, {'id': 'fetal cells obtained by amniocentesis', 'type': 'Biological Sample', 'properties': {}}, {'id': 'chorionic villus sampling', 'type': 'Medical Procedure', 'properties': {}}, {'id': 'Down syndrome', 'type': 'Disease', 'properties': {}}, {'id': 'increased risk for AD', 'type': 'Condition', 'properties': {}}], 'relationships': [{'source': {'id': 'Down syndrome', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'increased risk for AD', 'type': 'Condition', 'properties': {}}, 'type': 'CAUSES', 'properties': {}}, {'source': {'id': 'mutations in the PSEN1 gene', 'type': 'Genetic Mutation', 'properties': {}}, 'target': {'id': 'increased risk for EOFAD', 'type': 'Condition', 'properties': {}}, 'type': 'CAUSES', 'properties': {}}, {'source': {'id': 'mutations in the PSEN1 gene', 'type': 'Genetic Mutation', 'properties': {}}, 'target': {'id': 'prenatal diagnosis', 'type': 'Medical Procedure', 'properties': {}}, 'type': 'CAUSES', 'properties': {}}, {'source': {'id': 'mutations in the PSEN1 gene', 'type': 'Genetic Mutation', 'properties': {}}, 'target': {'id': 'prenatal testing', 'type': 'Medical Procedure', 'properties': {}}, 'type': 'CAUSES', 'properties': {}}, {'source': {'id': 'mutations in the PSEN1 gene', 'type': 'Genetic Mutation', 'properties': {}}, 'target': {'id': 'fetal cells obtained by amniocentesis', 'type': 'Biological Sample', 'properties': {}}, 'type': 'CAUSES', 'properties': {}}, {'source': {'id': 'mutations in the PSEN1 gene', 'type': 'Genetic Mutation', 'properties': {}}, 'target': {'id': 'chorionic villus sampling', 'type': 'Medical Procedure', 'properties': {}}, 'type': 'CAUSES', 'properties': {}}], 'source': {'id': None, 'metadata': {}, 'page_content': 'Down syndrome\\nFamily members of persons with DS are not at increased risk\\nfor AD.\\nTesting of at-risk asymptomatic EOAD family members\\nTesting of at-risk asymptomatic adults\\nTesting of asymptomatic adults at risk for EOFAD caused by\\nmutations in the PSEN1 ,PSEN2 ,o rAPP gene is available clin-\\nically. Testing results for at-risk asymptomatic adults can only\\nbe interpreted after an affected family member’s disease-caus-\\ning mutation has been identified. It should be remembered\\nthat testing of asymptomatic at-risk individuals with nonspe-\\ncific or equivocal symptoms is predictive testing, not diagnos-\\ntic testing.\\nPreliminary results have shown that although relatively few\\nfamily members choose such testing, they usually cope well\\nwith the results, which can affect personal relationships and\\nemotional well-being.85However, significant depression after\\nsuch testing has been reported.86\\nTesting of at-risk individuals during childhood\\nConsensus holds that individuals at risk for adult-onset dis-\\norders should not have testing during childhood in the absence\\nof symptoms. The principal arguments against testing asymp-\\ntomatic individuals during childhood are that it removes their\\nchoice to know or not know this information, it raises the\\npossibility of stigmatization within the family and in other so-\\ncial settings, and it could have serious educational and career\\nimplications.\\nPrenatal testing\\nPrenatal diagnosis for pregnancies at increased risk for mu-\\ntations in the PSEN1 gene is possible by analysis of DNA ex-\\ntracted from fetal cells obtained by amniocentesis usually per-\\nformed at about 15–18 weeks’ gestation or chorionic villus\\nsampling at about 10 to 12 weeks’ gestation. The disease-caus-\\ning allele of an affected family member must be identified be-\\nfore prenatal testing can be performed.\\nNo laboratories offering molecular genetic testing for pre-\\nnatal diagnosis of EOFAD caused by APP orPSEN2 mutations\\nare listed in the GeneTests Laboratory Directory. However,\\nprenatal testing may be available for families in which the dis-\\nease-causing mutation has been identified.\\nRequests for prenatal diagnosis of adult-onset diseases are\\nuncommon. Differences in perspective may exist among med-\\nical', 'type': 'Document'}}, {'nodes': [{'id': 'beta-site cleaving enzyme (BACE) inhibitors', 'type': 'Drug', 'properties': {}}, {'id': 'pregnancy termination', 'type': 'Medical Procedure', 'properties': {}}, {'id': 'anti-inflammatory agents', 'type': 'Drug', 'properties': {}}, {'id': 'individuals', 'type': 'Person', 'properties': {}}, {'id': 'behavioral benefit', 'type': 'Medical Benefit', 'properties': {}}, {'id': 'Preimplantation genetic diagnosis', 'type': 'Medical Procedure', 'properties': {}}, {'id': 'statins', 'type': 'Drug', 'properties': {}}, {'id': 'cognitive benefit', 'type': 'Medical Benefit', 'properties': {}}, {'id': 'centers', 'type': 'Facility', 'properties': {}}, {'id': 'treatment', 'type': 'Medical Procedure', 'properties': {}}, {'id': 'families', 'type': 'Group', 'properties': {}}, {'id': 'Aricept®', 'type': 'Drug', 'properties': {}}, {'id': 'parents', 'type': 'Person', 'properties': {}}, {'id': 'over-the-counter medications', 'type': 'Medication', 'properties': {}}, {'id': 'Memantine', 'type': 'Drug', 'properties': {}}, {'id': 'ginkgo biloba', 'type': 'Herbal Supplement', 'properties': {}}, {'id': 'disease-causing mutation', 'type': 'Medical Condition', 'properties': {}}, {'id': 'moderate to severe AD', 'type': 'Medical Condition', 'properties': {}}, {'id': 'acetylcholinesterase', 'type': 'Biological Molecule', 'properties': {}}, {'id': 'estrogens', 'type': 'Drug', 'properties': {}}, {'id': 'Vitamins', 'type': 'Supplement', 'properties': {}}, {'id': 'Drugs', 'type': 'Medical Treatment', 'properties': {}}, {'id': 'tacrine', 'type': 'Drug', 'properties': {}}, {'id': 'brain cholinergic system', 'type': 'Biological System', 'properties': {}}, {'id': 'adult-onset diseases', 'type': 'Medical Condition', 'properties': {}}, {'id': 'Exelon®', 'type': 'Drug', 'properties': {}}, {'id': 'antioxidants', 'type': 'Drug', 'properties': {}}, {'id': 'care', 'type': 'Service', 'properties': {}}, {'id': 'galantamine', 'type': 'Drug', 'properties': {}}, {'id': 'cholinergic activity', 'type': 'Biological Activity', 'properties': {}}, {'id': 'assisted living arrangements', 'type': 'Service', 'properties': {}}, {'id': 'neurotransmitters', 'type': 'Biological Molecule', 'properties': {}}, {'id': 'nerve growth factors', 'type': 'Biological Molecule', 'properties': {}}, {'id': 'manifestations', 'type': 'Medical Condition', 'properties': {}}, {'id': 'depression', 'type': 'Medical Condition', 'properties': {}}, {'id': 'prenatal diagnosis', 'type': 'Medical Procedure', 'properties': {}}, {'id': 'Treatment trials', 'type': 'Medical Study', 'properties': {}}, {'id': 'biochemical basis', 'type': 'Medical Concept', 'properties': {}}, {'id': 'prenatal testing', 'type': 'Medical Procedure', 'properties': {}}, {'id': 'APP mutation', 'type': 'Medical Condition', 'properties': {}}, {'id': 'Antidepressant medication', 'type': 'Drug', 'properties': {}}, {'id': 'mother', 'type': 'Person', 'properties': {}}], 'relationships': [{'source': {'id': 'prenatal diagnosis', 'type': 'Medical Procedure', 'properties': {}}, 'target': {'id': 'adult-onset diseases', 'type': 'Medical Condition', 'properties': {}}, 'type': 'USED_FOR', 'properties': {}}, {'source': {'id': 'prenatal testing', 'type': 'Medical Procedure', 'properties': {}}, 'target': {'id': 'pregnancy termination', 'type': 'Medical Procedure', 'properties': {}}, 'type': 'USED_FOR', 'properties': {}}, {'source': {'id': 'centers', 'type': 'Facility', 'properties': {}}, 'target': {'id': 'prenatal testing', 'type': 'Medical Procedure', 'properties': {}}, 'type': 'PROVIDE_SERVICE', 'properties': {}}, {'source': {'id': 'parents', 'type': 'Person', 'properties': {}}, 'target': {'id': 'prenatal testing', 'type': 'Medical Procedure', 'properties': {}}, 'type': 'MAKE_DECISION', 'properties': {}}, {'source': {'id': 'Preimplantation genetic diagnosis', 'type': 'Medical Procedure', 'properties': {}}, 'target': {'id': 'families', 'type': 'Group', 'properties': {}}, 'type': 'AVAILABLE_FOR', 'properties': {}}, {'source': {'id': 'Preimplantation genetic diagnosis', 'type': 'Medical Procedure', 'properties': {}}, 'target': {'id': 'disease-causing mutation', 'type': 'Medical Condition', 'properties': {}}, 'type': 'AVAILABLE_FOR', 'properties': {}}, {'source': {'id': 'Preimplantation genetic diagnosis', 'type': 'Medical Procedure', 'properties': {}}, 'target': {'id': 'mother', 'type': 'Person', 'properties': {}}, 'type': 'AVAILABLE_FOR', 'properties': {}}, {'source': {'id': 'Preimplantation genetic diagnosis', 'type': 'Medical Procedure', 'properties': {}}, 'target': {'id': 'APP mutation', 'type': 'Medical Condition', 'properties': {}}, 'type': 'AVAILABLE_FOR', 'properties': {}}, {'source': {'id': 'treatment', 'type': 'Medical Procedure', 'properties': {}}, 'target': {'id': 'manifestations', 'type': 'Medical Condition', 'properties': {}}, 'type': 'USED_FOR', 'properties': {}}, {'source': {'id': 'individuals', 'type': 'Person', 'properties': {}}, 'target': {'id': 'assisted living arrangements', 'type': 'Service', 'properties': {}}, 'type': 'REQUIRE', 'properties': {}}, {'source': {'id': 'individuals', 'type': 'Person', 'properties': {}}, 'target': {'id': 'care', 'type': 'Service', 'properties': {}}, 'type': 'REQUIRE', 'properties': {}}, {'source': {'id': 'biochemical basis', 'type': 'Medical Concept', 'properties': {}}, 'target': {'id': 'brain cholinergic system', 'type': 'Biological System', 'properties': {}}, 'type': 'RELATED_TO', 'properties': {}}, {'source': {'id': 'biochemical basis', 'type': 'Medical Concept', 'properties': {}}, 'target': {'id': 'neurotransmitters', 'type': 'Biological Molecule', 'properties': {}}, 'type': 'RELATED_TO', 'properties': {}}, {'source': {'id': 'Drugs', 'type': 'Medical Treatment', 'properties': {}}, 'target': {'id': 'cholinergic activity', 'type': 'Biological Activity', 'properties': {}}, 'type': 'INCREASE', 'properties': {}}, {'source': {'id': 'Drugs', 'type': 'Medical Treatment', 'properties': {}}, 'target': {'id': 'acetylcholinesterase', 'type': 'Biological Molecule', 'properties': {}}, 'type': 'INHIBIT', 'properties': {}}, {'source': {'id': 'Drugs', 'type': 'Medical Treatment', 'properties': {}}, 'target': {'id': 'behavioral benefit', 'type': 'Medical Benefit', 'properties': {}}, 'type': 'PRODUCE', 'properties': {}}, {'source': {'id': 'Drugs', 'type': 'Medical Treatment', 'properties': {}}, 'target': {'id': 'cognitive benefit', 'type': 'Medical Benefit', 'properties': {}}, 'type': 'PRODUCE', 'properties': {}}, {'source': {'id': 'tacrine', 'type': 'Drug', 'properties': {}}, 'target': {'id': 'Aricept®', 'type': 'Drug', 'properties': {}}, 'type': 'SIMILAR_TO', 'properties': {}}, {'source': {'id': 'tacrine', 'type': 'Drug', 'properties': {}}, 'target': {'id': 'Exelon®', 'type': 'Drug', 'properties': {}}, 'type': 'SIMILAR_TO', 'properties': {}}, {'source': {'id': 'tacrine', 'type': 'Drug', 'properties': {}}, 'target': {'id': 'galantamine', 'type': 'Drug', 'properties': {}}, 'type': 'SIMILAR_TO', 'properties': {}}, {'source': {'id': 'Memantine', 'type': 'Drug', 'properties': {}}, 'target': {'id': 'moderate to severe AD', 'type': 'Medical Condition', 'properties': {}}, 'type': 'TREAT', 'properties': {}}, {'source': {'id': 'Antidepressant medication', 'type': 'Drug', 'properties': {}}, 'target': {'id': 'depression', 'type': 'Medical Condition', 'properties': {}}, 'type': 'IMPROVE', 'properties': {}}, {'source': {'id': 'Treatment trials', 'type': 'Medical Study', 'properties': {}}, 'target': {'id': 'anti-inflammatory agents', 'type': 'Drug', 'properties': {}}, 'type': 'EVALUATE', 'properties': {}}, {'source': {'id': 'Treatment trials', 'type': 'Medical Study', 'properties': {}}, 'target': {'id': 'estrogens', 'type': 'Drug', 'properties': {}}, 'type': 'EVALUATE', 'properties': {}}, {'source': {'id': 'Treatment trials', 'type': 'Medical Study', 'properties': {}}, 'target': {'id': 'nerve growth factors', 'type': 'Biological Molecule', 'properties': {}}, 'type': 'EVALUATE', 'properties': {}}, {'source': {'id': 'Treatment trials', 'type': 'Medical Study', 'properties': {}}, 'target': {'id': 'ginkgo biloba', 'type': 'Herbal Supplement', 'properties': {}}, 'type': 'EVALUATE', 'properties': {}}, {'source': {'id': 'Treatment trials', 'type': 'Medical Study', 'properties': {}}, 'target': {'id': 'statins', 'type': 'Drug', 'properties': {}}, 'type': 'EVALUATE', 'properties': {}}, {'source': {'id': 'Treatment trials', 'type': 'Medical Study', 'properties': {}}, 'target': {'id': 'beta-site cleaving enzyme (BACE) inhibitors', 'type': 'Drug', 'properties': {}}, 'type': 'EVALUATE', 'properties': {}}, {'source': {'id': 'Treatment trials', 'type': 'Medical Study', 'properties': {}}, 'target': {'id': 'antioxidants', 'type': 'Drug', 'properties': {}}, 'type': 'EVALUATE', 'properties': {}}, {'source': {'id': 'Vitamins', 'type': 'Supplement', 'properties': {}}, 'target': {'id': 'treatment', 'type': 'Medical Procedure', 'properties': {}}, 'type': 'USED_IN', 'properties': {}}, {'source': {'id': 'over-the-counter medications', 'type': 'Medication', 'properties': {}}, 'target': {'id': 'treatment', 'type': 'Medical Procedure', 'properties': {}}, 'type': 'USED_IN', 'properties': {}}], 'source': {'id': None, 'metadata': {}, 'page_content': ' for prenatal diagnosis of adult-onset diseases are\\nuncommon. Differences in perspective may exist among med-\\nical professionals and within families regarding the use of pre-\\nnatal testing, particularly if the testing is being considered for\\nthe purpose of pregnancy termination. Although most centers\\nwould consider decisions about prenatal testing to be the\\nchoice of the parents, careful discussion of these issues is ap-\\npropriate.\\nPreimplantation genetic diagnosis\\nPreimplantation genetic diagnosis may be available for fam-\\nilies in which the disease-causing mutation has been identified.Preimplantation diagnosis has been reported in a mother with\\nanAPP mutation.87,88\\nMANAGEMENT\\nTreatment of manifestations\\nThe mainstay of treatment for AD is necessarily supportive\\nand each symptom is managed on an individual basis.1In gen-\\neral, affected individuals eventually require assisted living ar-\\nrangements or care in a nursing home.\\nAlthough the exact biochemical basis of AD is not well un-\\nderstood, it is known that deficiencies of the brain cholinergic\\nsystem and of other neurotransmitters are present. Drugs that\\nincrease cholinergic activity by inhibiting acetylcholinesterase\\nproduce a modest but useful behavioral or cognitive benefit in\\nsome affected individuals. The first such drug was tacrine;\\nhowever, this agent is also hepatotoxic. Newer such drugs with\\nsimilar pharmacologic action, such as Aricept® (donepezil),89–91\\nExelon® (rivastigmine),92and galantamine,93–95 are not hepato-\\ntoxic.\\nMemantine, an NMDA receptor antagonist, has shown some\\neffectiveness in the treatment of moderate to severe AD.96–99\\nAntidepressant medication may improve associated de-\\npression.\\nTherapies under investigation\\nTreatment trials evaluating use of anti-inflammatory agents\\n(NSAIDs), estrogens, nerve growth factors, ginkgo biloba, st-\\natins, beta-site cleaving enzyme (BACE) inhibitors, and anti-\\noxidants are under way or recently reviewed.100–102\\nOther\\nVitamins and other over-the-counter medications have\\nbeen used in the treatment of AD.103\\nSome, but not all, reports suggest that affected individuals\\ntaking 3-hydroxy-3-methylglutaryl (HMG)-coen', 'type': 'Document'}}, {'nodes': [{'id': 'search for possible vaccination approach', 'type': 'Activity', 'properties': {}}, {'id': 'H9252-amyloid', 'type': 'Substance', 'properties': {}}, {'id': 'human trial', 'type': 'Clinical Trial', 'properties': {}}, {'id': 'AD mouse model', 'type': 'Animal Model', 'properties': {}}, {'id': 'Genetics clinics', 'type': 'Facility', 'properties': {}}, {'id': 'individuals and families', 'type': 'Group', 'properties': {}}, {'id': 'information', 'type': 'Activity', 'properties': {}}, {'id': 'few subjects', 'type': 'Person', 'properties': {}}, {'id': 'support', 'type': 'Activity', 'properties': {}}, {'id': 'individuals', 'type': 'Person', 'properties': {}}, {'id': 'symptomatic AD', 'type': 'Condition', 'properties': {}}, {'id': 'Support groups', 'type': 'Organization', 'properties': {}}, {'id': 'dementia', 'type': 'Condition', 'properties': {}}, {'id': 'treatment', 'type': 'Therapy', 'properties': {}}, {'id': 'AD pathology', 'type': 'Condition', 'properties': {}}, {'id': 'encephalitis', 'type': 'Condition', 'properties': {}}, {'id': '3-hydroxy-3-methylglutaryl (HMG)-coenzyme A reductase inhibitors', 'type': 'Medication', 'properties': {}}], 'relationships': [{'source': {'id': 'individuals', 'type': 'Person', 'properties': {}}, 'target': {'id': '3-hydroxy-3-methylglutaryl (HMG)-coenzyme A reductase inhibitors', 'type': 'Medication', 'properties': {}}, 'type': 'AFFECTED_BY', 'properties': {}}, {'source': {'id': 'individuals', 'type': 'Person', 'properties': {}}, 'target': {'id': 'dementia', 'type': 'Condition', 'properties': {}}, 'type': 'HAVE', 'properties': {}}, {'source': {'id': 'AD mouse model', 'type': 'Animal Model', 'properties': {}}, 'target': {'id': 'H9252-amyloid', 'type': 'Substance', 'properties': {}}, 'type': 'IMMUNIZED_WITH', 'properties': {}}, {'source': {'id': 'AD mouse model', 'type': 'Animal Model', 'properties': {}}, 'target': {'id': 'AD pathology', 'type': 'Condition', 'properties': {}}, 'type': 'ATTENUATED', 'properties': {}}, {'source': {'id': 'AD mouse model', 'type': 'Animal Model', 'properties': {}}, 'target': {'id': 'search for possible vaccination approach', 'type': 'Activity', 'properties': {}}, 'type': 'STIMULATED', 'properties': {}}, {'source': {'id': 'human trial', 'type': 'Clinical Trial', 'properties': {}}, 'target': {'id': 'encephalitis', 'type': 'Condition', 'properties': {}}, 'type': 'HALTED', 'properties': {}}, {'source': {'id': 'human trial', 'type': 'Clinical Trial', 'properties': {}}, 'target': {'id': 'few subjects', 'type': 'Person', 'properties': {}}, 'type': 'HALTED', 'properties': {}}, {'source': {'id': 'treatment', 'type': 'Therapy', 'properties': {}}, 'target': {'id': 'symptomatic AD', 'type': 'Condition', 'properties': {}}, 'type': 'NOT_PROVEN_BENEFICIAL_FOR', 'properties': {}}, {'source': {'id': 'Genetics clinics', 'type': 'Facility', 'properties': {}}, 'target': {'id': 'information', 'type': 'Activity', 'properties': {}}, 'type': 'PROVIDE', 'properties': {}}, {'source': {'id': 'Genetics clinics', 'type': 'Facility', 'properties': {}}, 'target': {'id': 'support', 'type': 'Activity', 'properties': {}}, 'type': 'PROVIDE', 'properties': {}}, {'source': {'id': 'Support groups', 'type': 'Organization', 'properties': {}}, 'target': {'id': 'individuals and families', 'type': 'Group', 'properties': {}}, 'type': 'ESTABLISHED_FOR', 'properties': {}}, {'source': {'id': 'Support groups', 'type': 'Organization', 'properties': {}}, 'target': {'id': 'information', 'type': 'Activity', 'properties': {}}, 'type': 'PROVIDE', 'properties': {}}, {'source': {'id': 'Support groups', 'type': 'Organization', 'properties': {}}, 'target': {'id': 'support', 'type': 'Activity', 'properties': {}}, 'type': 'PROVIDE', 'properties': {}}], 'source': {'id': None, 'metadata': {}, 'page_content': ' reports suggest that affected individuals\\ntaking 3-hydroxy-3-methylglutaryl (HMG)-coenzyme A re-\\nductase inhibitors for hypercholesteralemia have a reduced in-\\ncidence of dementia.104–106\\nImmunization of an AD mouse model with /H9252-amyloid has\\nattenuated the AD pathology and stimulated the search for a\\npossible vaccination approach to the treatment of human\\nAD.107A human trial of this approach was halted because of\\nencephalitis in a few subjects.108–110 Alternative approaches to\\nimmunization therapy have been proposed.111\\nThus far, treatment of symptomatic AD with estrogens has\\nnot proven beneficial.112,113\\nGenetics clinics\\nGenetics clinics are a source of information for individuals\\nand families regarding the natural history, treatment, mode of\\ninheritance, and genetic risks to other family members as well\\nas information about available consumer-oriented resources.\\nSupport groups\\nSupport groups have been established for individuals and\\nfamilies to provide information, support, and contact withBird\\n236 Genetics INMedicine', 'type': 'Document'}}, {'nodes': [{'id': 'hallucinations', 'type': 'Characteristic', 'properties': {}}, {'id': 'withdrawal', 'type': 'Characteristic', 'properties': {}}, {'id': 'language disturbance', 'type': 'Characteristic', 'properties': {}}, {'id': 'Neuropathologic findings', 'type': 'Assessment Method', 'properties': {}}, {'id': 'symptom management', 'type': 'Approach', 'properties': {}}, {'id': 'mutations', 'type': 'Cause', 'properties': {}}, {'id': 'familial', 'type': 'Genetic Component', 'properties': {}}, {'id': 'APOE genotyping', 'type': 'Assessment Method', 'properties': {}}, {'id': 'late-onset', 'type': 'Genetic Component', 'properties': {}}, {'id': 'clinical diagnosis', 'type': 'Assessment Method', 'properties': {}}, {'id': 'poor judgment', 'type': 'Characteristic', 'properties': {}}, {'id': 'drug therapy', 'type': 'Management', 'properties': {}}, {'id': 'PSEN2', 'type': 'Gene', 'properties': {}}, {'id': 'three genes', 'type': 'Genes', 'properties': {}}, {'id': 'mutism', 'type': 'Characteristic', 'properties': {}}, {'id': 'Molecular genetic testing', 'type': 'Testing Method', 'properties': {}}, {'id': '1 to 25 years', 'type': 'Duration', 'properties': {}}, {'id': 'Assisted living arrangements', 'type': 'Approach', 'properties': {}}, {'id': 'AD', 'type': 'Disease', 'properties': {}}, {'id': 'myoclonus', 'type': 'Characteristic', 'properties': {}}, {'id': 'early-onset', 'type': 'Genetic Component', 'properties': {}}, {'id': 'care in a nursing home', 'type': 'Approach', 'properties': {}}, {'id': 'death', 'type': 'Outcome', 'properties': {}}, {'id': 'dementia', 'type': 'Characteristic', 'properties': {}}, {'id': '8 to 10 years', 'type': 'Duration', 'properties': {}}, {'id': 'APP', 'type': 'Gene', 'properties': {}}, {'id': 'behavioral or cognitive benefit', 'type': 'Benefit', 'properties': {}}, {'id': 'seizures', 'type': 'Characteristic', 'properties': {}}, {'id': 'EOFAD', 'type': 'Form', 'properties': {}}, {'id': 'individual symptom management', 'type': 'Approach', 'properties': {}}, {'id': 'clinical laboratories', 'type': 'Facility', 'properties': {}}, {'id': 'cholinergic activity inhibitors', 'type': 'Drug', 'properties': {}}, {'id': 'clinical-neuropathologic assessment', 'type': 'Assessment Method', 'properties': {}}, {'id': 'Parkinsonian features', 'type': 'Characteristic', 'properties': {}}, {'id': 'PSEN1', 'type': 'Gene', 'properties': {}}, {'id': 'increased muscle tone', 'type': 'Characteristic', 'properties': {}}, {'id': 'agitation', 'type': 'Characteristic', 'properties': {}}, {'id': 'confusion', 'type': 'Characteristic', 'properties': {}}, {'id': 'APOE e4 allele', 'type': 'Assessment Method', 'properties': {}}, {'id': 'incontinence', 'type': 'Characteristic', 'properties': {}}, {'id': 'supportive treatment', 'type': 'Management', 'properties': {}}, {'id': 'drug therapy', 'type': 'Approach', 'properties': {}}], 'relationships': [{'source': {'id': 'AD', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'dementia', 'type': 'Characteristic', 'properties': {}}, 'type': 'CHARACTERIZED_BY', 'properties': {}}, {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'confusion', 'type': 'Characteristic', 'properties': {}}, 'type': 'CHARACTERIZED_BY', 'properties': {}}, {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'poor judgment', 'type': 'Characteristic', 'properties': {}}, 'type': 'CHARACTERIZED_BY', 'properties': {}}, {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'language disturbance', 'type': 'Characteristic', 'properties': {}}, 'type': 'CHARACTERIZED_BY', 'properties': {}}, {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'agitation', 'type': 'Characteristic', 'properties': {}}, 'type': 'CHARACTERIZED_BY', 'properties': {}}, {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'withdrawal', 'type': 'Characteristic', 'properties': {}}, 'type': 'CHARACTERIZED_BY', 'properties': {}}, {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'hallucinations', 'type': 'Characteristic', 'properties': {}}, 'type': 'CHARACTERIZED_BY', 'properties': {}}, {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'seizures', 'type': 'Characteristic', 'properties': {}}, 'type': 'CHARACTERIZED_BY', 'properties': {}}, {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'Parkinsonian features', 'type': 'Characteristic', 'properties': {}}, 'type': 'CHARACTERIZED_BY', 'properties': {}}, {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'increased muscle tone', 'type': 'Characteristic', 'properties': {}}, 'type': 'CHARACTERIZED_BY', 'properties': {}}, {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'myoclonus', 'type': 'Characteristic', 'properties': {}}, 'type': 'CHARACTERIZED_BY', 'properties': {}}, {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'incontinence', 'type': 'Characteristic', 'properties': {}}, 'type': 'CHARACTERIZED_BY', 'properties': {}}, {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'mutism', 'type': 'Characteristic', 'properties': {}}, 'type': 'CHARACTERIZED_BY', 'properties': {}}, {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'death', 'type': 'Outcome', 'properties': {}}, 'type': 'RESULTS_IN', 'properties': {}}, {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}}, 'target': {'id': '8 to 10 years', 'type': 'Duration', 'properties': {}}, 'type': 'HAS_DURATION', 'properties': {}}, {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}}, 'target': {'id': '1 to 25 years', 'type': 'Duration', 'properties': {}}, 'type': 'HAS_DURATION', 'properties': {}}, {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'familial', 'type': 'Genetic Component', 'properties': {}}, 'type': 'HAS_GENETIC_COMPONENT', 'properties': {}}, {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'late-onset', 'type': 'Genetic Component', 'properties': {}}, 'type': 'HAS_GENETIC_COMPONENT', 'properties': {}}, {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'early-onset', 'type': 'Genetic Component', 'properties': {}}, 'type': 'HAS_GENETIC_COMPONENT', 'properties': {}}, {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'clinical-neuropathologic assessment', 'type': 'Assessment Method', 'properties': {}}, 'type': 'RELIANT_ON', 'properties': {}}, {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'Neuropathologic findings', 'type': 'Assessment Method', 'properties': {}}, 'type': 'RELIANT_ON', 'properties': {}}, {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'clinical diagnosis', 'type': 'Assessment Method', 'properties': {}}, 'type': 'RELIANT_ON', 'properties': {}}, {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'APOE e4 allele', 'type': 'Assessment Method', 'properties': {}}, 'type': 'RELIANT_ON', 'properties': {}}, {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'APOE genotyping', 'type': 'Assessment Method', 'properties': {}}, 'type': 'RELIANT_ON', 'properties': {}}, {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'EOFAD', 'type': 'Form', 'properties': {}}, 'type': 'RECOGNIZES', 'properties': {}}, {'source': {'id': 'EOFAD', 'type': 'Form', 'properties': {}}, 'target': {'id': 'mutations', 'type': 'Cause', 'properties': {}}, 'type': 'CAUSED_BY', 'properties': {}}, {'source': {'id': 'EOFAD', 'type': 'Form', 'properties': {}}, 'target': {'id': 'APP', 'type': 'Gene', 'properties': {}}, 'type': 'CAUSED_BY', 'properties': {}}, {'source': {'id': 'EOFAD', 'type': 'Form', 'properties': {}}, 'target': {'id': 'PSEN1', 'type': 'Gene', 'properties': {}}, 'type': 'CAUSED_BY', 'properties': {}}, {'source': {'id': 'EOFAD', 'type': 'Form', 'properties': {}}, 'target': {'id': 'PSEN2', 'type': 'Gene', 'properties': {}}, 'type': 'CAUSED_BY', 'properties': {}}, {'source': {'id': 'EOFAD', 'type': 'Form', 'properties': {}}, 'target': {'id': 'three genes', 'type': 'Genes', 'properties': {}}, 'type': 'RECOGNIZES', 'properties': {}}, {'source': {'id': 'three genes', 'type': 'Genes', 'properties': {}}, 'target': {'id': 'Molecular genetic testing', 'type': 'Testing Method', 'properties': {}}, 'type': 'TESTED_BY', 'properties': {}}, {'source': {'id': 'Molecular genetic testing', 'type': 'Testing Method', 'properties': {}}, 'target': {'id': 'clinical laboratories', 'type': 'Facility', 'properties': {}}, 'type': 'AVAILABLE_IN', 'properties': {}}, {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'supportive treatment', 'type': 'Management', 'properties': {}}, 'type': 'MANAGED_BY', 'properties': {}}, {'source': {'id': 'supportive treatment', 'type': 'Management', 'properties': {}}, 'target': {'id': 'symptom management', 'type': 'Approach', 'properties': {}}, 'type': 'INVOLVES', 'properties': {}}, {'source': {'id': 'supportive treatment', 'type': 'Management', 'properties': {}}, 'target': {'id': 'individual symptom management', 'type': 'Approach', 'properties': {}}, 'type': 'INVOLVES', 'properties': {}}, {'source': {'id': 'supportive treatment', 'type': 'Management', 'properties': {}}, 'target': {'id': 'Assisted living arrangements', 'type': 'Approach', 'properties': {}}, 'type': 'INVOLVES', 'properties': {}}, {'source': {'id': 'supportive treatment', 'type': 'Management', 'properties': {}}, 'target': {'id': 'care in a nursing home', 'type': 'Approach', 'properties': {}}, 'type': 'INVOLVES', 'properties': {}}, {'source': {'id': 'supportive treatment', 'type': 'Management', 'properties': {}}, 'target': {'id': 'drug therapy', 'type': 'Approach', 'properties': {}}, 'type': 'INVOLVES', 'properties': {}}, {'source': {'id': 'drug therapy', 'type': 'Management', 'properties': {}}, 'target': {'id': 'cholinergic activity inhibitors', 'type': 'Drug', 'properties': {}}, 'type': 'UTILIZES', 'properties': {}}, {'source': {'id': 'cholinergic activity inhibitors', 'type': 'Drug', 'properties': {}}, 'target': {'id': 'behavioral or cognitive benefit', 'type': 'Benefit', 'properties': {}}, 'type': 'PRODUCES', 'properties': {}}], 'source': {'id': None, 'metadata': {}, 'page_content': 'other affected individuals. The Resources section may include\\ndisease-specific and/or umbrella support organizations.\\nSUMMARY\\nDisease characteristics\\nAD is characterized by dementia that typically begins with\\nsubtle and poorly recognized failure of memory and slowly\\nbecomes more severe and, eventually, incapacitating. Other\\ncommon findings include confusion, poor judgment, lan-\\nguage disturbance, agitation, withdrawal, and hallucinations.\\nOccasionally, seizures, Parkinsonian features, increased mus-\\ncle tone, myoclonus, incontinence, and mutism occur. Death\\nusually results from general inanition, malnutrition, and\\npneumonia. The typical clinical duration of the disease is 8 to\\n10 years, with a range from 1 to 25 years. About 25% of all AD\\nis familial (i.e., two or more persons in a family have AD) of\\nwhich about 95% is late-onset (after age 60–65 years) and 5%\\nis early-onset (before age 65 years).\\nDiagnosis/testing\\nEstablishing the diagnosis of AD relies upon clinical-neuro-\\npathologic assessment. Neuropathologic findings of extracel-\\nlular /H9252-amyloid plaques and intraneuronal neurofibrillary\\ntangles remain the gold standard for diagnosis. The clinical\\ndiagnosis of AD, based on signs of slowly progressive dementia\\nand findings of gross cerebral cortical atrophy on neuroimag-\\ning, is correct about 80–90% of the time. The association of the\\nAPOE e4 allele with AD is significant; however, APOE geno-\\ntyping is neither fully specific nor sensitive. APOE genotyping\\nmay have an adjunct role in the diagnosis of AD in symptom-\\natic individuals and a limited role at this time in predictive\\ntesting of asymptomatic individuals. Three forms of EOFAD\\ncaused by mutations in one of three genes ( APP,PSEN1 , and\\nPSEN2 ) are recognized. Molecular genetic testing of the three\\ngenes is available in clinical laboratories.\\nManagement\\nTreatment is supportive. Each symptom is managed on an\\nindividual basis. Assisted living arrangements or care in a nurs-\\ning home is usually necessary. Drugs that increase cholinergic\\nactivity by inhibiting acetylcholinesterase produce a modest\\nbut useful behavioral or cognitive benefit in some', 'type': 'Document'}}, {'nodes': [{'id': 'family members', 'type': 'Person', 'properties': {}}, {'id': 'Alzheimer Disease', 'type': 'Resource', 'properties': {}}, {'id': 'depression', 'type': 'Condition', 'properties': {}}, {'id': 'genetic counseling', 'type': 'Service', 'properties': {}}, {'id': 'AD', 'type': 'Disease', 'properties': {}}, {'id': 'activity', 'type': 'Activity', 'properties': {}}, {'id': 'EOFAD', 'type': 'Disease', 'properties': {}}, {'id': 'persons with AD', 'type': 'Person', 'properties': {}}, {'id': 'dementia', 'type': 'Condition', 'properties': {}}, {'id': 'acetylcholinesterase', 'type': 'Protein', 'properties': {}}, {'id': 'Antidepressant medication', 'type': 'Medication', 'properties': {}}, {'id': 'autosomal-dominant manner', 'type': 'Characteristic', 'properties': {}}], 'relationships': [{'source': {'id': 'acetylcholinesterase', 'type': 'Protein', 'properties': {}}, 'target': {'id': 'activity', 'type': 'Activity', 'properties': {}}, 'type': 'INHIBITS', 'properties': {}}, {'source': {'id': 'Antidepressant medication', 'type': 'Medication', 'properties': {}}, 'target': {'id': 'depression', 'type': 'Condition', 'properties': {}}, 'type': 'IMPROVES', 'properties': {}}, {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'genetic counseling', 'type': 'Service', 'properties': {}}, 'type': 'GENETICALLY_HETEROGENEOUS', 'properties': {}}, {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'persons with AD', 'type': 'Person', 'properties': {}}, 'type': 'GENETICALLY_HETEROGENEOUS', 'properties': {}}, {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'family members', 'type': 'Person', 'properties': {}}, 'type': 'GENETICALLY_HETEROGENEOUS', 'properties': {}}, {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'dementia', 'type': 'Condition', 'properties': {}}, 'type': 'GENETICALLY_HETEROGENEOUS', 'properties': {}}, {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'Alzheimer Disease', 'type': 'Resource', 'properties': {}}, 'type': 'GENETICALLY_HETEROGENEOUS', 'properties': {}}, {'source': {'id': 'EOFAD', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'autosomal-dominant manner', 'type': 'Characteristic', 'properties': {}}, 'type': 'INHERITED_IN', 'properties': {}}], 'source': {'id': None, 'metadata': {}, 'page_content': '\\nactivity by inhibiting acetylcholinesterase produce a modest\\nbut useful behavioral or cognitive benefit in some affected in-\\ndividuals. Antidepressant medication may improve associated\\ndepression. An NMDA receptor antagonist is also FDA ap-\\nproved.\\nGenetic counseling\\nBecause AD is genetically heterogeneous, genetic counseling\\nof persons with AD and their family members must be tailored\\nto the information available for that family. It should be\\npointed out that AD is common and that the overall lifetime\\nrisk for any individual of developing dementia is approxi-\\nmately 10–12%. Genetic counseling for people with nonfamil-\\nial AD and their family members must be empiric and rela-\\ntively nonspecific. First-degree relatives of a simplex case of AD(i.e., single occurrence in a family) have a cumulative lifetime\\nrisk of developing AD of about 15–30%, which is typically re-\\nported as a 20–25% risk. This risk is about 2.5 times that of the\\nbackground risk ( /H1101127% vs. 10.4%). In contrast, EOFAD with\\nmutations in APP,PS1orPS2is inherited in an autosomal-\\ndominant manner.\\nRESOURCES\\nAlzheimer’s Association National Headquarters, 225 North\\nMichigan Avenue Fl 17, Chicago, IL 60601-7633, Phone:\\n800-272-3900, 312-335-8700, Fax: 312-335-1110, E-mail:\\ninfo@alz.org, www.alz.org.\\nAlzheimer’s Disease Education and Referral Center, PO Box 8250,\\nSilver Spring, MD 20907-8250, Phone: 800-438-4380; 301-495-\\n3334, Fax: 301-495-3334, E-mail: adear@ alzheimers.org,\\nwww. alzheimers.org.\\nNational Library of Medicine Genetics Home Reference,\\nAlzheimer Disease.\\nNCBI Genes and Disease, Alzheimer Disease.\\nNational Institute on Aging, Building 31, Room 5C27, 31\\nCenter Drive MSC 2292, Bethesda, MD 20892, Phone:\\n301-496-1752, E-mail: karpf@nia.nih.gov, www.nia.nih', 'type': 'Document'}}, {'nodes': [{'id': 'ApoE and Alzheimer’s Disease', 'type': 'Topic', 'properties': {}}, {'id': 'Diagnostic challenges in dementia', 'type': 'Topic', 'properties': {}}, {'id': 'Alzheimer’s disease and primary dementias', 'type': 'Publication', 'properties': {}}, {'id': 'Kaye JA', 'type': 'Person', 'properties': {}}, {'id': 'National Institute on Aging/Alzheimer’s Association Working Group', 'type': 'Organization', 'properties': {}}, {'id': 'Post SG, Whitehouse PJ, Binstock RH, Bird TD', 'type': 'Person', 'properties': {}}, {'id': 'ethical, legal, and psychosocial implications of genetic testing in children and adolescents', 'type': 'Topic', 'properties': {}}, {'id': 'Apolipoprotein E genotyping in Alzheimer’s disease', 'type': 'Topic', 'properties': {}}, {'id': 'National Society of Genetic Counselors', 'type': 'Organization', 'properties': {}}, {'id': 'Veterans Affairs Research Funds and NIA/NIH Grant P50 AG 005136-22', 'type': 'Funding Source', 'properties': {}}, {'id': 'Mayeux R, Saunders AM, Shea S, Mirra S', 'type': 'Person', 'properties': {}}, {'id': 'Resolution on prenatal and childhood testing for adult-onset disorders', 'type': 'Policy', 'properties': {}}, {'id': 'This work', 'type': 'Work', 'properties': {}}, {'id': 'American College of Medical Genetics/American Society of Human Genetics Working Group', 'type': 'Organization', 'properties': {}}, {'id': 'Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer’s disease', 'type': 'Publication', 'properties': {}}, {'id': 'American Society of Human Genetics', 'type': 'Organization', 'properties': {}}, {'id': 'The clinical introduction of genetic testing for Alzheimer’s disease: an ethical perspective', 'type': 'Publication', 'properties': {}}, {'id': 'Bird TD, Miller BL', 'type': 'Person', 'properties': {}}], 'relationships': [{'source': {'id': 'American College of Medical Genetics/American Society of Human Genetics Working Group', 'type': 'Organization', 'properties': {}}, 'target': {'id': 'ApoE and Alzheimer’s Disease', 'type': 'Topic', 'properties': {}}, 'type': 'WORKED_ON', 'properties': {}}, {'source': {'id': 'American Society of Human Genetics', 'type': 'Organization', 'properties': {}}, 'target': {'id': 'ethical, legal, and psychosocial implications of genetic testing in children and adolescents', 'type': 'Topic', 'properties': {}}, 'type': 'WORKED_ON', 'properties': {}}, {'source': {'id': 'National Institute on Aging/Alzheimer’s Association Working Group', 'type': 'Organization', 'properties': {}}, 'target': {'id': 'Apolipoprotein E genotyping in Alzheimer’s disease', 'type': 'Topic', 'properties': {}}, 'type': 'WORKED_ON', 'properties': {}}, {'source': {'id': 'National Society of Genetic Counselors', 'type': 'Organization', 'properties': {}}, 'target': {'id': 'Resolution on prenatal and childhood testing for adult-onset disorders', 'type': 'Policy', 'properties': {}}, 'type': 'ISSUED', 'properties': {}}, {'source': {'id': 'Post SG, Whitehouse PJ, Binstock RH, Bird TD', 'type': 'Person', 'properties': {}}, 'target': {'id': 'The clinical introduction of genetic testing for Alzheimer’s disease: an ethical perspective', 'type': 'Publication', 'properties': {}}, 'type': 'WROTE', 'properties': {}}, {'source': {'id': 'Veterans Affairs Research Funds and NIA/NIH Grant P50 AG 005136-22', 'type': 'Funding Source', 'properties': {}}, 'target': {'id': 'This work', 'type': 'Work', 'properties': {}}, 'type': 'SUPPORTED', 'properties': {}}, {'source': {'id': 'Bird TD, Miller BL', 'type': 'Person', 'properties': {}}, 'target': {'id': 'Alzheimer’s disease and primary dementias', 'type': 'Publication', 'properties': {}}, 'type': 'WROTE', 'properties': {}}, {'source': {'id': 'Mayeux R, Saunders AM, Shea S, Mirra S', 'type': 'Person', 'properties': {}}, 'target': {'id': 'Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer’s disease', 'type': 'Publication', 'properties': {}}, 'type': 'MENTIONED_IN', 'properties': {}}, {'source': {'id': 'Kaye JA', 'type': 'Person', 'properties': {}}, 'target': {'id': 'Diagnostic challenges in dementia', 'type': 'Topic', 'properties': {}}, 'type': 'DISCUSSED', 'properties': {}}], 'source': {'id': None, 'metadata': {}, 'page_content': '496-1752, E-mail: karpf@nia.nih.gov, www.nia.nih.\\ngov.\\nPUBLISHED STATEMENTS AND POLICIES REGARDING GENETIC\\nTESTING\\n●American College of Medical Genetics/American Society of\\nHuman Genetics Working Group on ApoE and Alzheimer’s Dis-\\nease. Statement on use of apolipoprotein E testing for Alzhei-\\nmer’s disease. 1995.\\n●American Society of Human Genetics and American College of\\nMedical Genetics. Points to consider: ethical, legal, and psycho-\\nsocial implications of genetic testing in children and adolescents.\\n1995.\\n●National Institute on Aging/Alzheimer’s Association Working\\nGroup. Apolipoprotein E genotyping in Alzheimer’s disease.\\nLancet 1996;347:1091–1095.\\n●National Society of Genetic Counselors. Resolution on prenatal\\nand childhood testing for adult-onset disorders. 1995.\\n●Post SG, Whitehouse PJ, Binstock RH, Bird TD, et al. The clinical\\nintroduction of genetic testing for Alzheimer’s disease: an ethical\\nperspective. JAMA 1997;277:832–836.\\nACKNOWLEDGMENTS\\nThis work was supported by funding from Veterans Affairs\\nResearch Funds and NIA/NIH Grant P50 AG 005136-22.\\nReferences\\n1. Bird TD, Miller BL. Alzheimer’s disease and primary dementias. In: Kasper D,\\nFauci A, Branwald E, Longo DL, et al., editors. Harrison’s principles of internal\\nmedicine, 16th ed. New York: McGraw-Hill, 2005:2393–2406.\\n2. Mayeux R, Saunders AM, Shea S, Mirra S, et al. Utility of the apolipoprotein E\\ngenotype in the diagnosis of Alzheimer’s disease. Alzheimer’s Disease Centers Con-\\nsortium on Apolipoprotein E and Alzheimer’s Disease. N Engl J Med 1998;338:\\n506–511.\\n3. Kaye JA. Diagnostic challenges in dementia. Neurology 1998;51:45–52.Genetic aspects of Alzheimer disease\\nApril 2008 /H18528Vol. 10 /H18528No. 4 237', 'type': 'Document'}}, {'nodes': [{'id': 'Rumbaugh M', 'type': 'Person', 'properties': {}}, {'id': 'Borenstein AR', 'type': 'Person', 'properties': {}}, {'id': 'Brayne C', 'type': 'Person', 'properties': {}}, {'id': 'Braak E', 'type': 'Person', 'properties': {}}, {'id': 'Publication', 'type': 'Reynolds CA', 'properties': {}}, {'id': 'Early-onset Alzheimer disease in families with late-onset Alzheimer disease: a potential important subtype of familial Alzheimer disease', 'type': 'Publication', 'properties': {}}, {'id': 'Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum', 'type': 'Publication', 'properties': {}}, {'id': 'Neuropathological staging of Alzheimer-related changes', 'type': 'Publication', 'properties': {}}, {'id': 'Alzheimer’s disease and other dementias: a review', 'type': 'Publication', 'properties': {}}, {'id': 'Payami H', 'type': 'Person', 'properties': {}}, {'id': 'Dementia and Alzheimer disease incidence: a prospective cohort study', 'type': 'Publication', 'properties': {}}, {'id': 'Campion D', 'type': 'Person', 'properties': {}}, {'id': 'Hofman A', 'type': 'Person', 'properties': {}}, {'id': 'Early-life risk factors for Alzheimer disease', 'type': 'Publication', 'properties': {}}, {'id': 'National Institute on Aging-Reagan Working Group', 'type': 'Organization', 'properties': {}}, {'id': 'Braak H', 'type': 'Person', 'properties': {}}, {'id': 'Lee VM', 'type': 'Person', 'properties': {}}, {'id': 'Brickell KL', 'type': 'Person', 'properties': {}}, {'id': 'Lippa CF', 'type': 'Person', 'properties': {}}, {'id': 'Consensus recommendations for the postmortem diagnosis of Alzheimer’s disease', 'type': 'Publication', 'properties': {}}, {'id': 'Hannequin D', 'type': 'Person', 'properties': {}}, {'id': 'Publication', 'type': 'Fr', 'properties': {}}, {'id': 'Higdon R', 'type': 'Person', 'properties': {}}, {'id': 'Mortimer JA', 'type': 'Person', 'properties': {}}, {'id': 'Popescu A', 'type': 'Person', 'properties': {}}, {'id': 'Breteler MM', 'type': 'Person', 'properties': {}}, {'id': 'Steinbart EJ', 'type': 'Person', 'properties': {}}, {'id': 'Rogan S', 'type': 'Person', 'properties': {}}, {'id': 'McCormick WC', 'type': 'Person', 'properties': {}}, {'id': 'Frequency and distribution of Alzheimer’s disease in Europe: a collaborative study of 1980–1990 prevalence findings', 'type': 'Publication', 'properties': {}}, {'id': 'Copenhaver CI', 'type': 'Person', 'properties': {}}, {'id': 'Kukull WA', 'type': 'Person', 'properties': {}}, {'id': 'Dumanchin C', 'type': 'Person', 'properties': {}}, {'id': 'Rocca WA', 'type': 'Person', 'properties': {}}, {'id': 'Gatz M', 'type': 'Person', 'properties': {}}, {'id': 'Bowen JD', 'type': 'Person', 'properties': {}}, {'id': 'Trojanowski JQ', 'type': 'Person', 'properties': {}}, {'id': 'Dubois B', 'type': 'Person', 'properties': {}}, {'id': 'Lewy bodies in the amygdala: increase of alpha-synuclein aggregates in neurodegenerative diseases with tau-based inclusions', 'type': 'Publication', 'properties': {}}], 'relationships': [{'source': {'id': 'Braak H', 'type': 'Person', 'properties': {}}, 'target': {'id': 'Neuropathological staging of Alzheimer-related changes', 'type': 'Publication', 'properties': {}}, 'type': 'AUTHORED', 'properties': {}}, {'source': {'id': 'Braak E', 'type': 'Person', 'properties': {}}, 'target': {'id': 'Neuropathological staging of Alzheimer-related changes', 'type': 'Publication', 'properties': {}}, 'type': 'AUTHORED', 'properties': {}}, {'source': {'id': 'National Institute on Aging-Reagan Working Group', 'type': 'Organization', 'properties': {}}, 'target': {'id': 'Consensus recommendations for the postmortem diagnosis of Alzheimer’s disease', 'type': 'Publication', 'properties': {}}, 'type': 'PUBLISHED', 'properties': {}}, {'source': {'id': 'Popescu A', 'type': 'Person', 'properties': {}}, 'target': {'id': 'Lewy bodies in the amygdala: increase of alpha-synuclein aggregates in neurodegenerative diseases with tau-based inclusions', 'type': 'Publication', 'properties': {}}, 'type': 'AUTHORED', 'properties': {}}, {'source': {'id': 'Lippa CF', 'type': 'Person', 'properties': {}}, 'target': {'id': 'Lewy bodies in the amygdala: increase of alpha-synuclein aggregates in neurodegenerative diseases with tau-based inclusions', 'type': 'Publication', 'properties': {}}, 'type': 'CO_AUTHORED', 'properties': {}}, {'source': {'id': 'Lee VM', 'type': 'Person', 'properties': {}}, 'target': {'id': 'Lewy bodies in the amygdala: increase of alpha-synuclein aggregates in neurodegenerative diseases with tau-based inclusions', 'type': 'Publication', 'properties': {}}, 'type': 'CO_AUTHORED', 'properties': {}}, {'source': {'id': 'Trojanowski JQ', 'type': 'Person', 'properties': {}}, 'target': {'id': 'Lewy bodies in the amygdala: increase of alpha-synuclein aggregates in neurodegenerative diseases with tau-based inclusions', 'type': 'Publication', 'properties': {}}, 'type': 'CO_AUTHORED', 'properties': {}}, {'source': {'id': 'Rogan S', 'type': 'Person', 'properties': {}}, 'target': {'id': 'Alzheimer’s disease and other dementias: a review', 'type': 'Publication', 'properties': {}}, 'type': 'AUTHORED', 'properties': {}}, {'source': {'id': 'Lippa CF', 'type': 'Person', 'properties': {}}, 'target': {'id': 'Alzheimer’s disease and other dementias: a review', 'type': 'Publication', 'properties': {}}, 'type': 'CO_AUTHORED', 'properties': {}}, {'source': {'id': 'Kukull WA', 'type': 'Person', 'properties': {}}, 'target': {'id': 'Dementia and Alzheimer disease incidence: a prospective cohort study', 'type': 'Publication', 'properties': {}}, 'type': 'AUTHORED', 'properties': {}}, {'source': {'id': 'Higdon R', 'type': 'Person', 'properties': {}}, 'target': {'id': 'Dementia and Alzheimer disease incidence: a prospective cohort study', 'type': 'Publication', 'properties': {}}, 'type': 'CO_AUTHORED', 'properties': {}}, {'source': {'id': 'Bowen JD', 'type': 'Person', 'properties': {}}, 'target': {'id': 'Dementia and Alzheimer disease incidence: a prospective cohort study', 'type': 'Publication', 'properties': {}}, 'type': 'CO_AUTHORED', 'properties': {}}, {'source': {'id': 'McCormick WC', 'type': 'Person', 'properties': {}}, 'target': {'id': 'Dementia and Alzheimer disease incidence: a prospective cohort study', 'type': 'Publication', 'properties': {}}, 'type': 'CO_AUTHORED', 'properties': {}}, {'source': {'id': 'Rocca WA', 'type': 'Person', 'properties': {}}, 'target': {'id': 'Frequency and distribution of Alzheimer’s disease in Europe: a collaborative study of 1980–1990 prevalence findings', 'type': 'Publication', 'properties': {}}, 'type': 'AUTHORED', 'properties': {}}, {'source': {'id': 'Hofman A', 'type': 'Person', 'properties': {}}, 'target': {'id': 'Frequency and distribution of Alzheimer’s disease in Europe: a collaborative study of 1980–1990 prevalence findings', 'type': 'Publication', 'properties': {}}, 'type': 'CO_AUTHORED', 'properties': {}}, {'source': {'id': 'Brayne C', 'type': 'Person', 'properties': {}}, 'target': {'id': 'Frequency and distribution of Alzheimer’s disease in Europe: a collaborative study of 1980–1990 prevalence findings', 'type': 'Publication', 'properties': {}}, 'type': 'CO_AUTHORED', 'properties': {}}, {'source': {'id': 'Breteler MM', 'type': 'Person', 'properties': {}}, 'target': {'id': 'Frequency and distribution of Alzheimer’s disease in Europe: a collaborative study of 1980–1990 prevalence findings', 'type': 'Publication', 'properties': {}}, 'type': 'CO_AUTHORED', 'properties': {}}, {'source': {'id': 'Campion D', 'type': 'Person', 'properties': {}}, 'target': {'id': 'Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum', 'type': 'Publication', 'properties': {}}, 'type': 'AUTHORED', 'properties': {}}, {'source': {'id': 'Dumanchin C', 'type': 'Person', 'properties': {}}, 'target': {'id': 'Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum', 'type': 'Publication', 'properties': {}}, 'type': 'CO_AUTHORED', 'properties': {}}, {'source': {'id': 'Hannequin D', 'type': 'Person', 'properties': {}}, 'target': {'id': 'Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum', 'type': 'Publication', 'properties': {}}, 'type': 'CO_AUTHORED', 'properties': {}}, {'source': {'id': 'Dubois B', 'type': 'Person', 'properties': {}}, 'target': {'id': 'Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum', 'type': 'Publication', 'properties': {}}, 'type': 'CO_AUTHORED', 'properties': {}}, {'source': {'id': 'Brickell KL', 'type': 'Person', 'properties': {}}, 'target': {'id': 'Early-onset Alzheimer disease in families with late-onset Alzheimer disease: a potential important subtype of familial Alzheimer disease', 'type': 'Publication', 'properties': {}}, 'type': 'AUTHORED', 'properties': {}}, {'source': {'id': 'Steinbart EJ', 'type': 'Person', 'properties': {}}, 'target': {'id': 'Early-onset Alzheimer disease in families with late-onset Alzheimer disease: a potential important subtype of familial Alzheimer disease', 'type': 'Publication', 'properties': {}}, 'type': 'CO_AUTHORED', 'properties': {}}, {'source': {'id': 'Rumbaugh M', 'type': 'Person', 'properties': {}}, 'target': {'id': 'Early-onset Alzheimer disease in families with late-onset Alzheimer disease: a potential important subtype of familial Alzheimer disease', 'type': 'Publication', 'properties': {}}, 'type': 'CO_AUTHORED', 'properties': {}}, {'source': {'id': 'Payami H', 'type': 'Person', 'properties': {}}, 'target': {'id': 'Early-onset Alzheimer disease in families with late-onset Alzheimer disease: a potential important subtype of familial Alzheimer disease', 'type': 'Publication', 'properties': {}}, 'type': 'CO_AUTHORED', 'properties': {}}, {'source': {'id': 'Borenstein AR', 'type': 'Person', 'properties': {}}, 'target': {'id': 'Early-life risk factors for Alzheimer disease', 'type': 'Publication', 'properties': {}}, 'type': 'AUTHORED', 'properties': {}}, {'source': {'id': 'Copenhaver CI', 'type': 'Person', 'properties': {}}, 'target': {'id': 'Early-life risk factors for Alzheimer disease', 'type': 'Publication', 'properties': {}}, 'type': 'CO_AUTHORED', 'properties': {}}, {'source': {'id': 'Mortimer JA', 'type': 'Person', 'properties': {}}, 'target': {'id': 'Early-life risk factors for Alzheimer disease', 'type': 'Publication', 'properties': {}}, 'type': 'CO_AUTHORED', 'properties': {}}, {'source': {'id': 'Gatz M', 'type': 'Person', 'properties': {}}, 'target': {'id': 'Publication', 'type': 'Reynolds CA', 'properties': {}}, 'type': 'AUTHORED', 'properties': {}}, {'source': {'id': 'Gatz M', 'type': 'Person', 'properties': {}}, 'target': {'id': 'Publication', 'type': 'Fr', 'properties': {}}, 'type': 'CO_AUTHORED', 'properties': {}}], 'source': {'id': None, 'metadata': {}, 'page_content': '4. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta\\nNeuropathol (Berl) 1991;82:239–259.\\n5. National Institute on Aging-Reagan Working Group. Consensus recommenda-\\ntions for the postmortem diagnosis of Alzheimer’s disease. Neurobiol Aging 1997;\\n18(suppl 4):S1–S2.\\n6. Popescu A, Lippa CF, Lee VM, Trojanowski JQ. Lewy bodies in the amygdala:\\nincrease of alpha-synuclein aggregates in neurodegenerative diseases with tau-\\nbased inclusions. Arch Neurol 2004;61:1915–1919.\\n7. Rogan S, Lippa CF. Alzheimer’s disease and other dementias: a review. Am J Alz-\\nheimers Dis Other Demen 2002;17:11–17.\\n8. Kukull WA, Higdon R, Bowen JD, McCormick WC, et al. Dementia and Alzheimer\\ndisease incidence: a prospective cohort study. Arch Neurol 2002;59:1737–1746.\\n9. Rocca WA, Hofman A, Brayne C, Breteler MM, et al. Frequency and distribu-\\ntion of Alzheimer’s disease in Europe: a collaborative study of 1980–1990\\nprevalence findings. The EURODEM-Prevalence Research Group. Ann Neurol\\n1991;30:381–390.\\n10. Campion D, Dumanchin C, Hannequin D, Dubois B, et al. Early-onset autosomal\\ndominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation\\nspectrum. Am J Hum Genet 1999;65:664–670.\\n11. Brickell KL, Steinbart EJ, Rumbaugh M, Payami H, et al. Early-onset Alzheimer\\ndisease in families with late-onset Alzheimer disease: a potential important subtype\\nof familial Alzheimer disease. Arch Neurol 2006;63:1307–1311.\\n12. Borenstein AR, Copenhaver CI, Mortimer JA. Early-life risk factors for Alzheimer\\ndisease. Alzheimer Dis Assoc Disord 2006;20:63–72.\\n13. Gatz M, Reynolds CA, Fr', 'type': 'Document'}}, {'nodes': [{'id': 'Cognitive impairment in adults with Down’s syndrome: similarities to early cognitive changes in Alzheimer’s disease', 'type': 'Publication', 'properties': {}}, {'id': 'Specificity of the fivefold increase in AD in mothers of adults with Down syndrome', 'type': 'Publication', 'properties': {}}, {'id': 'Molecular mapping of Alzheimer-type dementia in Down’s syndrome', 'type': 'Publication', 'properties': {}}, {'id': 'Haupt M', 'type': 'Person', 'properties': {}}, {'id': 'Brugge KL', 'type': 'Person', 'properties': {}}, {'id': 'Comparison of the severity of neuropathologic changes in familial and sporadic Alzheimer’s disease', 'type': 'Publication', 'properties': {}}, {'id': 'Leverenz JB', 'type': 'Person', 'properties': {}}, {'id': 'Influence of the amyloid precursor protein locus on dementia in Down syndrome', 'type': 'Publication', 'properties': {}}, {'id': 'The molecular and genetic basis of AD: the end of the beginning: the 2000 Wartenberg lecture', 'type': 'Publication', 'properties': {}}, {'id': 'Rosenberg RN', 'type': 'Person', 'properties': {}}, {'id': 'Early amyloid deposition in the medial temporal lobe of young Down syndrome patients: a regional quantitative analysis', 'type': 'Publication', 'properties': {}}, {'id': 'Alzheimer’s disease: identical phenotype of familial and non-familial cases', 'type': 'Publication', 'properties': {}}, {'id': 'Prasher VP', 'type': 'Person', 'properties': {}}, {'id': 'Lai F', 'type': 'Person', 'properties': {}}, {'id': 'Nochlin D', 'type': 'Person', 'properties': {}}, {'id': 'Role of genes and environments for explaining Alzheimer disease', 'type': 'Publication', 'properties': {}}, {'id': 'Margallo-Lana M', 'type': 'Person', 'properties': {}}, {'id': 'Gatz M', 'type': 'Person', 'properties': {}}, {'id': 'APOE genotype and gender effects on Alzheimer disease in 100 adults with Down syndrome', 'type': 'Publication', 'properties': {}}, {'id': 'Schupf N', 'type': 'Person', 'properties': {}}], 'relationships': [{'source': {'id': 'Gatz M', 'type': 'Person', 'properties': {}}, 'target': {'id': 'Role of genes and environments for explaining Alzheimer disease', 'type': 'Publication', 'properties': {}}, 'type': 'AUTHORED', 'properties': {}}, {'source': {'id': 'Brugge KL', 'type': 'Person', 'properties': {}}, 'target': {'id': 'Cognitive impairment in adults with Down’s syndrome: similarities to early cognitive changes in Alzheimer’s disease', 'type': 'Publication', 'properties': {}}, 'type': 'AUTHORED', 'properties': {}}, {'source': {'id': 'Leverenz JB', 'type': 'Person', 'properties': {}}, 'target': {'id': 'Early amyloid deposition in the medial temporal lobe of young Down syndrome patients: a regional quantitative analysis', 'type': 'Publication', 'properties': {}}, 'type': 'AUTHORED', 'properties': {}}, {'source': {'id': 'Prasher VP', 'type': 'Person', 'properties': {}}, 'target': {'id': 'Molecular mapping of Alzheimer-type dementia in Down’s syndrome', 'type': 'Publication', 'properties': {}}, 'type': 'AUTHORED', 'properties': {}}, {'source': {'id': 'Lai F', 'type': 'Person', 'properties': {}}, 'target': {'id': 'APOE genotype and gender effects on Alzheimer disease in 100 adults with Down syndrome', 'type': 'Publication', 'properties': {}}, 'type': 'AUTHORED', 'properties': {}}, {'source': {'id': 'Margallo-Lana M', 'type': 'Person', 'properties': {}}, 'target': {'id': 'Influence of the amyloid precursor protein locus on dementia in Down syndrome', 'type': 'Publication', 'properties': {}}, 'type': 'AUTHORED', 'properties': {}}, {'source': {'id': 'Schupf N', 'type': 'Person', 'properties': {}}, 'target': {'id': 'Specificity of the fivefold increase in AD in mothers of adults with Down syndrome', 'type': 'Publication', 'properties': {}}, 'type': 'AUTHORED', 'properties': {}}, {'source': {'id': 'Haupt M', 'type': 'Person', 'properties': {}}, 'target': {'id': 'Alzheimer’s disease: identical phenotype of familial and non-familial cases', 'type': 'Publication', 'properties': {}}, 'type': 'AUTHORED', 'properties': {}}, {'source': {'id': 'Nochlin D', 'type': 'Person', 'properties': {}}, 'target': {'id': 'Comparison of the severity of neuropathologic changes in familial and sporadic Alzheimer’s disease', 'type': 'Publication', 'properties': {}}, 'type': 'AUTHORED', 'properties': {}}, {'source': {'id': 'Rosenberg RN', 'type': 'Person', 'properties': {}}, 'target': {'id': 'The molecular and genetic basis of AD: the end of the beginning: the 2000 Wartenberg lecture', 'type': 'Publication', 'properties': {}}, 'type': 'AUTHORED', 'properties': {}}], 'source': {'id': None, 'metadata': {}, 'page_content': ' Dis Assoc Disord 2006;20:63–72.\\n13. Gatz M, Reynolds CA, Fratiglioni L, Johansson B, et al. Role of genes and environ-\\nments for explaining Alzheimer disease. Arch Gen Psychiatry 2006;63:168–174.\\n14. Brugge KL, Nichols SL, Salmon DP, Hill LR, et al. Cognitive impairment in adults\\nwith Down’s syndrome: similarities to early cognitive changes in Alzheimer’s dis-\\nease. Neurology 1994;44:232–238.\\n15. Leverenz JB, Raskind MA. Early amyloid deposition in the medial temporal lobe of\\nyoung Down syndrome patients: a regional quantitative analysis. Exp Neurol 1998;\\n150:296–304.\\n16. Prasher VP, Farrer MJ, Kessling AM, Fisher EM, et al. Molecular mapping of\\nAlzheimer-type dementia in Down’s syndrome. Ann Neurol 1998;43:380–383.\\n17. Lai F, Kammann E, Rebeck GW, Anderson A, et al. APOE genotype and gender\\neffects on Alzheimer disease in 100 adults with Down syndrome. Neurology 1999;\\n53:331–336.\\n18. Margallo-Lana M, Morris CM, Gibson AM, Tan AL, et al. Influence of the amyloid\\nprecursor protein locus on dementia in Down syndrome. Neurology 2004;62:\\n1996–1998.\\n19. Schupf N, Kapell D, Nightingale B, Lee JH, et al. Specificity of the fivefold increase\\nin AD in mothers of adults with Down syndrome. Neurology 2001;57:979–984.\\n20. Haupt M, Kurz A, Pollmann S, Romero B. Alzheimer’s disease: identical phenotype\\nof familial and non-familial cases. J Neurol 1992;239:248–250.\\n21. Nochlin D, van Belle G, Bird TD, Sumi SM. Comparison of the severity of neuro-\\npathologic changes in familial and sporadic Alzheimer’s disease. Alzheimer Dis\\nAssoc Disord 1993;7:212–222.\\n22. Rosenberg RN. The molecular and genetic basis of AD: the end of the beginning:\\nthe 2000 Wartenberg lecture. Neurology 2000;54:', 'type': 'Document'}}, {'nodes': [{'id': 'Bertram L, McQueen MB, Mullin K, Blacker D', 'type': 'Researcher', 'properties': {}}, {'id': 'Meyer MR, Tschanz JT, Norton MC, Welsh-Bohmer KA', 'type': 'Researcher', 'properties': {}}, {'id': 'Nussbaum RL, Ellis CE', 'type': 'Researcher', 'properties': {}}, {'id': 'Rogaeva E, Meng Y, Lee JH, Gu Y', 'type': 'Researcher', 'properties': {}}, {'id': 'Sleegers K, van Duijn CM', 'type': 'Researcher', 'properties': {}}, {'id': \"Alzheimer's disease\", 'type': 'Disease', 'properties': {}}, {'id': 'Bertram L, Tanzi RE', 'type': 'Researcher', 'properties': {}}, {'id': 'Serretti A, Artioli P, Quartesan R, De Ronchi D', 'type': 'Researcher', 'properties': {}}, {'id': 'Khachaturian AS, Corcoran CD, Mayer LS, Zandi PP', 'type': 'Researcher', 'properties': {}}], 'relationships': [{'source': {'id': \"Alzheimer's disease\", 'type': 'Disease', 'properties': {}}, 'target': {'id': 'Sleegers K, van Duijn CM', 'type': 'Researcher', 'properties': {}}, 'type': 'GENES', 'properties': {}}, {'source': {'id': \"Alzheimer's disease\", 'type': 'Disease', 'properties': {}}, 'target': {'id': 'Nussbaum RL, Ellis CE', 'type': 'Researcher', 'properties': {}}, 'type': 'GENES', 'properties': {}}, {'source': {'id': \"Alzheimer's disease\", 'type': 'Disease', 'properties': {}}, 'target': {'id': 'Bertram L, Tanzi RE', 'type': 'Researcher', 'properties': {}}, 'type': 'GENES', 'properties': {}}, {'source': {'id': \"Alzheimer's disease\", 'type': 'Disease', 'properties': {}}, 'target': {'id': 'Serretti A, Artioli P, Quartesan R, De Ronchi D', 'type': 'Researcher', 'properties': {}}, 'type': 'GENES', 'properties': {}}, {'source': {'id': \"Alzheimer's disease\", 'type': 'Disease', 'properties': {}}, 'target': {'id': 'Bertram L, McQueen MB, Mullin K, Blacker D', 'type': 'Researcher', 'properties': {}}, 'type': 'GENES', 'properties': {}}, {'source': {'id': \"Alzheimer's disease\", 'type': 'Disease', 'properties': {}}, 'target': {'id': 'Meyer MR, Tschanz JT, Norton MC, Welsh-Bohmer KA', 'type': 'Researcher', 'properties': {}}, 'type': 'GENES', 'properties': {}}, {'source': {'id': \"Alzheimer's disease\", 'type': 'Disease', 'properties': {}}, 'target': {'id': 'Khachaturian AS, Corcoran CD, Mayer LS, Zandi PP', 'type': 'Researcher', 'properties': {}}, 'type': 'GENES', 'properties': {}}, {'source': {'id': \"Alzheimer's disease\", 'type': 'Disease', 'properties': {}}, 'target': {'id': 'Rogaeva E, Meng Y, Lee JH, Gu Y', 'type': 'Researcher', 'properties': {}}, 'type': 'GENES', 'properties': {}}], 'source': {'id': None, 'metadata': {}, 'page_content': ' basis of AD: the end of the beginning:\\nthe 2000 Wartenberg lecture. Neurology 2000;54:2045–2054.\\n23. Sleegers K, van Duijn CM. Alzheimer’s disease: genes, pathogenesis and risk pre-\\ndiction Community Genet 2001;4:197–203.\\n24. Nussbaum RL, Ellis CE. Alzheimer’s disease and Parkinson’s disease. N Engl J Med\\n2003;348:1356–1364.\\n25. Goedert M, Spillantini MG. A century of Alzheimer’s disease. Science 2006;314:\\n777–781.\\n26. Roses AD, Saunders AM. Perspective on a pathogenesis and treatment of Alzhei-\\nmer’s disease. Alz Dem 2006;2:59–70.\\n27. Kamboh MI. Molecular genetics of late-onset Alzheimer’s disease. Ann Hum Genet\\n2004;68:381–404.\\n28. Bertram L, Tanzi RE. The current status of Alzheimer’s disease genetics: what do we\\ntell the patients? Pharmacol Res 2004;50:385–396.\\n29. Serretti A, Artioli P, Quartesan R, De Ronchi D. Genes involved in Alzheimer’s\\ndisease, a survey of possible candidates. J Alzheimers Dis 2005;7:331–353.\\n30. Bertram L, McQueen MB, Mullin K, Blacker D, et al. Systematic meta-analyses of\\nAlzheimer disease genetic association studies: the AlzGene database. Nat Genet\\n2007;39:17–23.\\n31. Meyer MR, Tschanz JT, Norton MC, Welsh-Bohmer KA, et al. APOE genotype\\npredicts when–not whether–one is predisposed to develop Alzheimer disease. Nat\\nGenet 1998;19:321–322.\\n32. Khachaturian AS, Corcoran CD, Mayer LS, Zandi PP, et al. Apolipoprotein E\\nepsilon4 count affects age at onset of Alzheimer disease, but not lifetime suscepti-\\nbility: The Cache County Study. Arch Gen Psychiatry 2004;61:518–524.\\n33. Rogaeva E, Meng Y, Lee JH, Gu Y, et', 'type': 'Document'}}, {'nodes': [{'id': 'Alpha2 macroglobulin', 'type': 'Protein', 'properties': {}}, {'id': 'APOE varepsilon4', 'type': 'Gene', 'properties': {}}, {'id': 'Alzheimer’s disease', 'type': 'Disease', 'properties': {}}, {'id': 'GAB2', 'type': 'Gene', 'properties': {}}, {'id': 'Alpha2-macroglobulin', 'type': 'Protein', 'properties': {}}, {'id': 'Alzheimer’s risk', 'type': 'Risk', 'properties': {}}, {'id': 'Alpha-2 macroglobulin', 'type': 'Protein', 'properties': {}}, {'id': 'SORL1', 'type': 'Gene', 'properties': {}}, {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, {'id': 'Glutathione S-transferase omega-1', 'type': 'Protein', 'properties': {}}], 'relationships': [{'source': {'id': 'SORL1', 'type': 'Gene', 'properties': {}}, 'target': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'type': 'GENETIC_ASSOCIATION', 'properties': {}}, {'source': {'id': 'Alpha-2 macroglobulin', 'type': 'Protein', 'properties': {}}, 'target': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'type': 'GENETIC_ASSOCIATION', 'properties': {}}, {'source': {'id': 'Alpha2 macroglobulin', 'type': 'Protein', 'properties': {}}, 'target': {'id': 'Alzheimer’s disease', 'type': 'Disease', 'properties': {}}, 'type': 'RISK_FACTOR_FOR', 'properties': {}}, {'source': {'id': 'Alpha2-macroglobulin', 'type': 'Protein', 'properties': {}}, 'target': {'id': 'Alzheimer’s disease', 'type': 'Disease', 'properties': {}}, 'type': 'RISK_FACTOR_FOR', 'properties': {}}, {'source': {'id': 'Glutathione S-transferase omega-1', 'type': 'Protein', 'properties': {}}, 'target': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'type': 'MODIFIES_AGE_AT_ONSET', 'properties': {}}, {'source': {'id': 'GAB2', 'type': 'Gene', 'properties': {}}, 'target': {'id': 'Alzheimer’s risk', 'type': 'Risk', 'properties': {}}, 'type': 'MODIFIES_RISK_IN', 'properties': {}}, {'source': {'id': 'APOE varepsilon4', 'type': 'Gene', 'properties': {}}, 'target': {'id': 'Alzheimer’s risk', 'type': 'Risk', 'properties': {}}, 'type': 'MODIFIES_RISK_IN', 'properties': {}}], 'source': {'id': None, 'metadata': {}, 'page_content': ':518–524.\\n33. Rogaeva E, Meng Y, Lee JH, Gu Y, et al. The neuronal sortilin-related receptor SORL1\\nis genetically associated with Alzheimer disease. Nat Genet 2007;39:168–177.34. Blacker D, Wilcox MA, Laird NM, Rodes L, et al. Alpha-2 macroglobulin is genet-\\nically associated with Alzheimer disease. Nat Genet 1998;19:357–360.\\n35. Dodel RC, Du Y, Bales KR, Gao F, et al. Alpha2 macroglobulin and the risk of\\nAlzheimer’s disease. Neurology 2000;54:438–442.\\n36. Gibson AM, Singleton AB, Smith G, Woodward R, et al. Lack of association of the\\nalpha2-macroglobulin locus on chromosome 12 in AD. Neurology 2000;54:433–438.\\n37. Depboylu C, Lohmuller F, Du Y, Riemenschneider M, et al. Alpha2-macroglobu-\\nlin, lipoprotein receptor-related protein and lipoprotein receptor-associated pro-\\ntein and the genetic risk for developing Alzheimer’s disease. Neurosci Lett 2006;400:\\n187–190.\\n38. Li YJ, Oliveira SA, Xu P, Martin ER, et al. Glutathione S-transferase omega-1\\nmodifiesage-at-onset of Alzheimer disease and Parkinson disease. Hum Mol Genet\\n2003;12:3259–3267.\\n39. Reiman EM, Webster JA, Myers AJ, Hardy J, et al. GAB2 alleles modify Alzheimer’s\\nrisk in APOE varepsilon4 carriers. Neuron 2007;54:713–720.\\n40. Pericak-Vance MA, Bass MP, Yamaoka LH, Gaskell PC, et al. Complete genomic\\nscreen in late-onset familial Alzheimer disease. Evidence for a new locus on chro-\\nmosome 12. JAMA 1997;278:1237–1241.\\n41. Rogaeva E, Premkumar S, Song Y, Sorbi S, et al. Evidence for an Alzheimer disease\\nsusceptibility locus on chromosome 12 and for', 'type': 'Document'}}, {'nodes': [{'id': 'chromosome 12', 'type': 'Chromosome', 'properties': {}}, {'id': 'chromosome 10', 'type': 'Chromosome', 'properties': {}}, {'id': 'Alzheimer’s disease', 'type': 'Disease', 'properties': {}}, {'id': 'plasminogen activator urokinase (PLAU)', 'type': 'Protein', 'properties': {}}, {'id': 'chromosome 10q', 'type': 'Chromosome', 'properties': {}}, {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, {'id': 'plasma Abeta42', 'type': 'Substance', 'properties': {}}], 'relationships': [{'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'chromosome 12', 'type': 'Chromosome', 'properties': {}}, 'type': 'LOCATED_ON', 'properties': {}}, {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'chromosome 10q', 'type': 'Chromosome', 'properties': {}}, 'type': 'LOCATED_ON', 'properties': {}}, {'source': {'id': 'plasma Abeta42', 'type': 'Substance', 'properties': {}}, 'target': {'id': 'chromosome 10', 'type': 'Chromosome', 'properties': {}}, 'type': 'LOCATED_ON', 'properties': {}}, {'source': {'id': 'plasminogen activator urokinase (PLAU)', 'type': 'Protein', 'properties': {}}, 'target': {'id': 'Alzheimer’s disease', 'type': 'Disease', 'properties': {}}, 'type': 'ASSOCIATED_WITH', 'properties': {}}], 'source': {'id': None, 'metadata': {}, 'page_content': ' Sorbi S, et al. Evidence for an Alzheimer disease\\nsusceptibility locus on chromosome 12 and for further locus heterogeneity. JAMA\\n1998;280:614–618.\\n42. Wu WS, Holmans P, Wavrant-DeVrieze F, Shears S, et al. Genetic studies on\\nchromosome 12 in late-onset Alzheimer disease. JAMA 1998;280:619–622.\\n43. D’Introno A, Solfrizzi V, Colacicco AM, Capurso C, et al. Current knowledge of\\nchromosome 12 susceptibility genes for late-onset Alzheimer’s disease. Neurobiol\\nAging 2006;27:1537–1553.\\n44. Bertram L, Blacker D, Mullin K, Keeney D, et al. Evidence for genetic linkage of\\nAlzheimer’s disease to chromosome 10q. Science 2000;290:2302–2303.\\n45. Ertekin-Taner N, Graff-Radford N, Younkin LH, Eckman C, et al. Linkage of\\nplasma Abeta42 to a quantitative locus on chromosome 10 in late-onset Alzhei-\\nmer’s disease pedigrees. Science 2000;290:2303–2304.\\n46. Myers A, Holmans P, Marshall H, Kwon J, et al. Susceptibility locus for Alzheimer’s\\ndisease on chromosome 10. Science 2000;290:2304–2305.\\n47. Grupe A, Li Y, Rowland C, Nowotny P, et al. A scan of chromosome 10 identifies a\\nnovel locus showing strong association with late-onset Alzheimer disease. Am J\\nHum Genet 2006;78:78–88.\\n48. Riemenschneider M, Konta L, Friedrich P, Schwarz S, et al. A functional polymor-\\nphism within plasminogen activator urokinase (PLAU) is associated with Alzhei-\\nmer’s disease. Hum Mol Genet 2006;15:2446–2456.\\n49. Scott WK, Hauser ER, Schmechel DE, Welsh-Bohmer KA, et al. Ordered-subsets\\nlinkage analysis detects', 'type': 'Document'}}, {'nodes': [{'id': 'UBQLN1', 'type': 'Gene', 'properties': {}}, {'id': 'Ubiquilin gene', 'type': 'Gene', 'properties': {}}, {'id': 'Genomewide screen', 'type': 'Study', 'properties': {}}, {'id': 'Dutch population', 'type': 'Population', 'properties': {}}, {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, {'id': 'chromosome 19p13.2', 'type': 'Chromosome', 'properties': {}}, {'id': 'Ubiquilin 1 polymorphisms', 'type': 'Gene', 'properties': {}}, {'id': '7q36', 'type': 'Chromosome', 'properties': {}}, {'id': 'late-onset Alzheimer’s disease', 'type': 'Disease', 'properties': {}}, {'id': 'DAPK1 variants', 'type': 'Gene', 'properties': {}}, {'id': 'late-onset Alzheimer disease locus', 'type': 'Disease', 'properties': {}}, {'id': 'Alzheimer’s disease', 'type': 'Disease', 'properties': {}}, {'id': 'ubiquilin', 'type': 'Protein', 'properties': {}}, {'id': 'chromosomes 2q34', 'type': 'Chromosome', 'properties': {}}], 'relationships': [{'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'chromosomes 2q34', 'type': 'Chromosome', 'properties': {}}, 'type': 'LOCATED_ON', 'properties': {}}, {'source': {'id': 'DAPK1 variants', 'type': 'Gene', 'properties': {}}, 'target': {'id': 'Alzheimer’s disease', 'type': 'Disease', 'properties': {}}, 'type': 'ASSOCIATED_WITH', 'properties': {}}, {'source': {'id': 'late-onset Alzheimer disease locus', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'chromosome 19p13.2', 'type': 'Chromosome', 'properties': {}}, 'type': 'LOCATED_ON', 'properties': {}}, {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'target': {'id': '7q36', 'type': 'Chromosome', 'properties': {}}, 'type': 'LOCATED_ON', 'properties': {}}, {'source': {'id': 'Alzheimer’s disease', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'UBQLN1', 'type': 'Gene', 'properties': {}}, 'type': 'ASSOCIATED_WITH', 'properties': {}}, {'source': {'id': 'Ubiquilin gene', 'type': 'Gene', 'properties': {}}, 'target': {'id': 'Alzheimer’s disease', 'type': 'Disease', 'properties': {}}, 'type': 'ASSOCIATED_WITH', 'properties': {}}, {'source': {'id': 'ubiquilin', 'type': 'Protein', 'properties': {}}, 'target': {'id': 'Alzheimer’s disease', 'type': 'Disease', 'properties': {}}, 'type': 'ASSOCIATED_WITH', 'properties': {}}, {'source': {'id': 'Ubiquilin 1 polymorphisms', 'type': 'Gene', 'properties': {}}, 'target': {'id': 'late-onset Alzheimer’s disease', 'type': 'Disease', 'properties': {}}, 'type': 'NOT_ASSOCIATED_WITH', 'properties': {}}, {'source': {'id': 'Genomewide screen', 'type': 'Study', 'properties': {}}, 'target': {'id': 'Dutch population', 'type': 'Population', 'properties': {}}, 'type': 'CONDUCTED_ON', 'properties': {}}], 'source': {'id': None, 'metadata': {}, 'page_content': 'hel DE, Welsh-Bohmer KA, et al. Ordered-subsets\\nlinkage analysis detects novel Alzheimer disease Loci on chromosomes 2q34 and\\n15q22. Am J Hum Genet 2003;73:1041–1051.\\n50. Li Y, Grupe A, Rowland C, Nowotny P, et al. DAPK1 variants are associated with\\nAlzheimer’s disease and allele-specific expression. Hum Mol Genet 2006;15:2560–\\n2568.\\n51. Wijsman EM, Daw EW, Yu CE, Payami H, et al. Evidence for a novel late-onset\\nAlzheimer disease locus on chromosome 19p13.2. Am J Hum Genet 2004;75:398–\\n409.\\n52. Rademakers R, Cruts M, Sleegers K, Dermaut B, et al. Linkage and association\\nstudies identify a novel locus for Alzheimer disease at 7q36 in a Dutch population-\\nbased sample. Am J Hum Genet 2005;77:643–652.\\n53. Bertram L, Hiltunen M, Parkinson M, Ingelsson M, et al. Family-based association\\nbetween Alzheimer’s disease and variants in UBQLN1. N Engl J Med 2005;352:\\n884–894.\\n54. Bensemain F, Chapuis J, Tian J, Shi J, et al. Association study of the Ubiquilin gene\\nwith Alzheimer’s disease. Neurobiol Dis 2006;22:691–693.\\n55. Kamboh MI, Minster RL, Feingold E, DeKosky ST. Genetic association of ubiquilin\\nwith Alzheimer’s disease and related quantitative measures. Mol Psychiatry 2006;\\n11:273–279.\\n56. Smemo S, Nowotny P, Hinrichs AL, Kauwe JS, et al. Ubiquilin 1 polymor-\\nphisms are not associated with late-onset Alzheimer’s disease. Ann Neurol\\n2006;59:21–26.\\n57. Liu F, Arias-Vasquez A, Sleegers K, Aulchnko YS, et al. A Genomewide screen for\\nlate-onset Alzheimer disease in a genetically isolated Dutch population. Am', 'type': 'Document'}}, {'nodes': [{'id': 'genetically isolated Dutch population', 'type': 'Population', 'properties': {}}, {'id': 'late-onset Alzheimer disease', 'type': 'Disease', 'properties': {}}, {'id': 'mutations of the presenilin-1 gene', 'type': 'Gene', 'properties': {}}, {'id': 'large kindred', 'type': 'Family', 'properties': {}}, {'id': 'presenilin-1 gene', 'type': 'Gene', 'properties': {}}, {'id': 'chromosome 14-linked familial Alzheimer’s disease', 'type': 'Disease', 'properties': {}}, {'id': 'Alzheimer’s disease', 'type': 'Disease', 'properties': {}}, {'id': 'familial cohort', 'type': 'Population', 'properties': {}}, {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}], 'relationships': [{'source': {'id': 'late-onset Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'genetically isolated Dutch population', 'type': 'Population', 'properties': {}}, 'type': 'GENOMEWIDE_SCREEN', 'properties': {}}, {'source': {'id': 'chromosome 14-linked familial Alzheimer’s disease', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'large kindred', 'type': 'Family', 'properties': {}}, 'type': 'PHENOTYPE_OF', 'properties': {}}, {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'familial cohort', 'type': 'Population', 'properties': {}}, 'type': 'NATURAL_HISTORY', 'properties': {}}, {'source': {'id': 'Alzheimer’s disease', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'mutations of the presenilin-1 gene', 'type': 'Gene', 'properties': {}}, 'type': 'CLINICAL_PHENOTYPIC_HETEROGENEITY', 'properties': {}}, {'source': {'id': 'Alzheimer’s disease', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'presenilin-1 gene', 'type': 'Gene', 'properties': {}}, 'type': 'ASSOCIATED_WITH', 'properties': {}}], 'source': {'id': None, 'metadata': {}, 'page_content': ' et al. A Genomewide screen for\\nlate-onset Alzheimer disease in a genetically isolated Dutch population. Am J Hum\\nGenet 2007;81:17–31.\\n58. Lampe TH, Bird TD, Nochlin D, Nemens E, et al. Phenotype of chromosome\\n14-linked familial Alzheimer’s disease in a large kindred. Ann Neurol 1994;36:368–\\n378.\\n59. Godbolt AK, Cipolotti L, Watt H, Fox NC, et al. The natural history of Alzheimer\\ndisease: a longitudinal presymptomatic and symptomatic study of a familial co-\\nhort. Arch Neurol 2004;61:1743–1748.\\n60. Larner AJ, Doran M. Clinical phenotypic heterogeneity of Alzheimer’s disease\\nassociated with mutations of the presenilin-1 gene. J Neurol 2006;253:139–158.\\n61. Sherrington R, Froelich S, Sorbi S, Campion D, et al. Alzheimer’s disease associatedBird\\n238 Genetics INMedicine', 'type': 'Document'}}, {'nodes': [{'id': 'presenilin-1', 'type': 'Gene', 'properties': {}}, {'id': 'apolipoprotein-E genotyping', 'type': 'Gene', 'properties': {}}, {'id': 'presenilin-2', 'type': 'Gene', 'properties': {}}, {'id': \"sporadic Alzheimer's disease\", 'type': 'Disease', 'properties': {}}, {'id': 'presenilin 2', 'type': 'Gene', 'properties': {}}, {'id': \"Alzheimer's disease\", 'type': 'Disease', 'properties': {}}, {'id': 'cognitive decline', 'type': 'Characteristic', 'properties': {}}, {'id': 'apolipoprotein E', 'type': 'Gene', 'properties': {}}, {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, {'id': 'APOE alleles', 'type': 'Gene', 'properties': {}}, {'id': 'presenile Alzheimer disease', 'type': 'Disease', 'properties': {}}], 'relationships': [{'source': {'id': 'presenilin 2', 'type': 'Gene', 'properties': {}}, 'target': {'id': \"Alzheimer's disease\", 'type': 'Disease', 'properties': {}}, 'type': 'MUTATED_IN', 'properties': {}}, {'source': {'id': 'presenilin-1', 'type': 'Gene', 'properties': {}}, 'target': {'id': 'presenile Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'type': 'CONTRIBUTES_TO', 'properties': {}}, {'source': {'id': 'presenilin-2', 'type': 'Gene', 'properties': {}}, 'target': {'id': 'presenile Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'type': 'CONTRIBUTES_TO', 'properties': {}}, {'source': {'id': 'apolipoprotein E', 'type': 'Gene', 'properties': {}}, 'target': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'type': 'INFLUENCES', 'properties': {}}, {'source': {'id': 'APOE alleles', 'type': 'Gene', 'properties': {}}, 'target': {'id': 'cognitive decline', 'type': 'Characteristic', 'properties': {}}, 'type': 'PREDICTS', 'properties': {}}, {'source': {'id': 'apolipoprotein-E genotyping', 'type': 'Gene', 'properties': {}}, 'target': {'id': \"sporadic Alzheimer's disease\", 'type': 'Disease', 'properties': {}}, 'type': 'PREDICTS', 'properties': {}}], 'source': {'id': None, 'metadata': {}, 'page_content': 'with mutations in presenilin 2 is rare and variably penetrant. Hum Mol Genet\\n1996;5:985–988.\\n62. Janssen JC, Beck JA, Campbell TA, Dickinson A, et al. Early onset familial Alzhei-\\nmer’s disease: mutation frequency in 31 families. Neurology 2003;60:235–239.\\n63. Raux G, Guyant-Marechal L, Martin C, Bou J, et al. Molecular diagnosis of auto-\\nsomal dominant early onset Alzheimer’s disease: an update. J Med Genet 2005;42:\\n793–795.\\n64. Cruts M, van Duijn CM, Backhovens H, van den Broeck M, et al. Estimation of the\\ngenetic contribution of presenilin-1 and -2 mutations in a population-based study\\nof presenile Alzheimer disease. Hum Mol Genet 1998;7:43–51.\\n65. Cummings JL, Vinters HV, Cole GM, Khachaturian ZS. Alzheimer’s disease: eti-\\nologies, pathophysiology, cognitive reserve and treatment opportunities. Neurol-\\nogy1998;51:2–17.\\n66. Jarvik G, Larson EB, Goddard K, Schellenberg GD, et al. Influence of apolipopro-\\ntein E genotype on the transmission of Alzheimer disease in a community-based\\nsample. Am J Hum Genet 1996;58:191–200.\\n67. Martins CA, Oulhaj A, de Jager CA, Williams JH. APOE alleles predict the rate of\\ncognitive decline in Alzheimer disease: a nonlinear model. Neurology 2005; 65:\\n1888–1893.\\n68. Saunders AM, Hulette O, Welsh-Bohmer KA, Schmechel DE, et al. Specificity,\\nsensitivity, and predictive value of apolipoprotein-E genotyping for sporadic Alz-\\nheimer’s disease. Lancet 1996;348:90–93.\\n69. Green RC, Cupples LA, Go R, Benke KS, et al. Risk of dementia among white and\\nAfrican American relatives of patients with Alzheimer disease. JAMA 2002;287:\\n329–336.\\n70. Romas SN, Santana V, Williamson J, Cia', 'type': 'Document'}}, {'nodes': [{'id': 'Patients', 'type': 'Person', 'properties': {}}, {'id': 'sporadic and familial cases of Alzheimer’s disease', 'type': 'Condition', 'properties': {}}, {'id': 'Familial Alzheimer disease', 'type': 'Disease', 'properties': {}}, {'id': 'Genetic risk', 'type': 'Risk', 'properties': {}}, {'id': 'Caribbean Hispanics', 'type': 'Ethnicity', 'properties': {}}, {'id': 'Genetic testing', 'type': 'Procedure', 'properties': {}}, {'id': 'First-degree relatives', 'type': 'Relationship', 'properties': {}}, {'id': 'genetic risk for Alzheimer’s disease', 'type': 'Risk', 'properties': {}}, {'id': 'age when prevalence of AD increases, then declines', 'type': 'Phenomenon', 'properties': {}}, {'id': 'Apolipoprotein E', 'type': 'Protein', 'properties': {}}, {'id': 'Genetic factors', 'type': 'Factor', 'properties': {}}, {'id': 'diagnosis of Alzheimer disease', 'type': 'Procedure', 'properties': {}}, {'id': 'Alzheimer’s disease', 'type': 'Disease', 'properties': {}}, {'id': 'neuropathological series', 'type': 'Study', 'properties': {}}, {'id': 'APOE', 'type': 'Gene', 'properties': {}}], 'relationships': [{'source': {'id': 'Caribbean Hispanics', 'type': 'Ethnicity', 'properties': {}}, 'target': {'id': 'Familial Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'type': 'ASSOCIATED_WITH', 'properties': {}}, {'source': {'id': 'APOE', 'type': 'Gene', 'properties': {}}, 'target': {'id': 'age when prevalence of AD increases, then declines', 'type': 'Phenomenon', 'properties': {}}, 'type': 'PREDICTS', 'properties': {}}, {'source': {'id': 'Apolipoprotein E', 'type': 'Protein', 'properties': {}}, 'target': {'id': 'Alzheimer’s disease', 'type': 'Disease', 'properties': {}}, 'type': 'GENOTYPING_IN', 'properties': {}}, {'source': {'id': 'Apolipoprotein E', 'type': 'Protein', 'properties': {}}, 'target': {'id': 'neuropathological series', 'type': 'Study', 'properties': {}}, 'type': 'GENOTYPES_IN', 'properties': {}}, {'source': {'id': 'Apolipoprotein E', 'type': 'Protein', 'properties': {}}, 'target': {'id': 'diagnosis of Alzheimer disease', 'type': 'Procedure', 'properties': {}}, 'type': 'GENOTYPING_IN', 'properties': {}}, {'source': {'id': 'Genetic factors', 'type': 'Factor', 'properties': {}}, 'target': {'id': 'Alzheimer’s disease', 'type': 'Disease', 'properties': {}}, 'type': 'REVIEWED_IN', 'properties': {}}, {'source': {'id': 'Genetic testing', 'type': 'Procedure', 'properties': {}}, 'target': {'id': 'sporadic and familial cases of Alzheimer’s disease', 'type': 'Condition', 'properties': {}}, 'type': 'NOT_RECOMMENDED_FOR', 'properties': {}}, {'source': {'id': 'Genetic risk', 'type': 'Risk', 'properties': {}}, 'target': {'id': 'Alzheimer’s disease', 'type': 'Disease', 'properties': {}}, 'type': 'ASSESSED_FOR', 'properties': {}}, {'source': {'id': 'First-degree relatives', 'type': 'Relationship', 'properties': {}}, 'target': {'id': 'genetic risk for Alzheimer’s disease', 'type': 'Risk', 'properties': {}}, 'type': 'ASSESSED_FOR', 'properties': {}}, {'source': {'id': 'First-degree relatives', 'type': 'Relationship', 'properties': {}}, 'target': {'id': 'Alzheimer’s disease', 'type': 'Disease', 'properties': {}}, 'type': 'AT_RISK_FOR', 'properties': {}}, {'source': {'id': 'Patients', 'type': 'Person', 'properties': {}}, 'target': {'id': 'Alzheimer’s disease', 'type': 'Disease', 'properties': {}}, 'type': 'WITH_RELATIVES', 'properties': {}}], 'source': {'id': None, 'metadata': {}, 'page_content': ' 2002;287:\\n329–336.\\n70. Romas SN, Santana V, Williamson J, Ciappa A, et al. Familial Alzheimer disease\\namong Caribbean Hispanics: a reexamination of its association with APOE. Arch\\nNeurol 2002;59:87–91.\\n71. Breitner JC, Wyse BW, Anthony JC, Welsh-Bohmer KA, et al. APOE-epsilon4\\ncount predicts age when prevalence of AD increases, then declines: the Cache\\nCounty Study. Neurology 1999;53:321–331.\\n72. National Institute on Aging/Alzheimer’s Association Working Group. Apoli-\\npoprotein E genotyping in Alzheimer’s disease. Lancet 1996;347:1091–1095.\\n73. Welsh-Bohmer KA, Gearing M, Saunders AM, Roses AD, et al. Apolipoprotein E\\ngenotypes in a neuropathological series from the Consortium to Establish a Regis-\\ntry for Alzheimer’s Disease. Ann Neurol 1997;42:319–325.\\n74. Tsuang D, Larson EB, Bowen J, McCormick W, et al. The utility of apolipoprotein\\nE genotyping in the diagnosis of Alzheimer disease in a community-based case\\nseries. Arch Neurol 1999;56:1489–1495.\\n75. Levy-Lahad E, Bird TD. Genetic factors in Alzheimer’s disease: a review of recent\\nadvances. Ann Neurol 1996;40:829–840.\\n76. van der Cammen TJ, Croes EA, Dermaut B, de Jager MC. Genetic testing has no\\nplace as a routine diagnostic test in sporadic and familial cases of Alzheimer’s\\ndisease. J Am Geriatr Soc 2004;52:2110–2113.\\n77. Farrer LA, O’Sullivan DM, Cupples LA, Growdon JH, et al. Assessment of genetic risk\\nfor Alzheimer’s disease among first-degree relatives. Ann Neurol 1989;25:485–493.\\n78. Silverman JM, Li G, Zaccario ML, Smith CJ, et al. Patterns of risk in first-degree\\nrelatives of patients with Alzheimer’s disease. Arch Gen Psychiatry 1994;51:577–\\n586', 'type': 'Document'}}, {'nodes': [{'id': 'woman', 'type': 'Person', 'properties': {}}, {'id': 'parents', 'type': 'Person', 'properties': {}}, {'id': 'adult children', 'type': 'Person', 'properties': {}}, {'id': 'children', 'type': 'Person', 'properties': {}}, {'id': 'first-degree relatives', 'type': 'Person', 'properties': {}}, {'id': 'patients', 'type': 'Person', 'properties': {}}, {'id': 'Alzheimer’s disease', 'type': 'Disease', 'properties': {}}], 'relationships': [{'source': {'id': 'Alzheimer’s disease', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'patients', 'type': 'Person', 'properties': {}}, 'type': 'HAS_RELATIVE', 'properties': {}}, {'source': {'id': 'Alzheimer’s disease', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'first-degree relatives', 'type': 'Person', 'properties': {}}, 'type': 'HAS_RELATIVE', 'properties': {}}, {'source': {'id': 'Alzheimer’s disease', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'children', 'type': 'Person', 'properties': {}}, 'type': 'HAS_RELATIVE', 'properties': {}}, {'source': {'id': 'Alzheimer’s disease', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'parents', 'type': 'Person', 'properties': {}}, 'type': 'HAS_PARENT', 'properties': {}}, {'source': {'id': 'Alzheimer’s disease', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'children', 'type': 'Person', 'properties': {}}, 'type': 'HAS_CHILD', 'properties': {}}, {'source': {'id': 'Alzheimer’s disease', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'adult children', 'type': 'Person', 'properties': {}}, 'type': 'HAS_CHILD', 'properties': {}}, {'source': {'id': 'Alzheimer’s disease', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'woman', 'type': 'Person', 'properties': {}}, 'type': 'HAS_CHILD', 'properties': {}}], 'source': {'id': None, 'metadata': {}, 'page_content': 'degree\\nrelatives of patients with Alzheimer’s disease. Arch Gen Psychiatry 1994;51:577–\\n586.\\n79. Green RC. Risk assessment for Alzheimer’s disease with genetic susceptibility test-\\ning: has the moment arrived? Alz’s Care Quarterly 2002;3:208–214.\\n80. Cupples LA, Farrer LA, Sadovnick AD, Relkin N, et al. Estimating risk curves for\\nfirst-degree relatives of patients with Alzheimer’s disease: the REVEAL study. Genet\\nMed 2004;6:192–196.\\n81. Heston LL, Mastri AR, Anderson VE, White J. Dementia of the Alzheimer type.\\nClinical genetics, natural history, and associated conditions. Arch Gen Psychiatry\\n1981;38:1085–1090.\\n82. Jayadev S, Steinbart EJ, Chi Y-Y, Kukull WA, et al. Conjugal Alzheimer disease: risk\\nin children when both parents have Alzheimer disease. Arch Neurol In press.\\n83. Breitner JC. APOE genotyping and Alzheimer’s disease. Lancet 1996;347:\\n1184–1185.\\n84. Roberts JS, Cupples LA, Relkin NR, Whitehouse PJ, et al. Genetic risk assessment\\nfor adult children of people with Alzheimer’s disease: the Risk Evaluation and\\nEducation for Alzheimer’s Disease (REVEAL) study. J Geriatr Psychiatry Neurol\\n2005;18:250–255.\\n85. Steinbart EJ, Smith CO, Poorkaj P, Bird TD. Impact of DNA testing for early-onset\\nfamilial Alzheimer disease and frontotemporal dementia. Arch Neurol 2001;58:\\n1828–1831.\\n86. Quaid KA, Murrell JR, Hake AM, Farlow MR. Presymptomatic genetic testing with\\nan APP mutation. J Genet Couns 2000;9:327–345.\\n87. Towner D, Loewy RS. Ethics of preimplantation diagnosis for a woman destined to\\ndevelop early-onset Alzheimer disease. JAMA 2002;287:1038–1040.88. Verlinsky Y, Rechitsky S, Verlinsky O, Masciangelo C, et al. Preimplantation diag-\\nnosis', 'type': 'Document'}}, {'nodes': [{'id': 'Best Talent', 'type': 'Award', 'properties': {}}, {'id': 'accessible offline', 'type': 'Characteristic', 'properties': {}}, {'id': 'lightweight app', 'type': 'Characteristic', 'properties': {}}, {'id': 'Adam', 'type': 'Person', 'properties': {}}, {'id': 'Microsoft', 'type': 'Company', 'properties': {}}, {'id': 'Microsoft Word', 'type': 'Product', 'properties': {}}], 'relationships': [{'source': {'id': 'Adam', 'type': 'Person', 'properties': {}}, 'target': {'id': 'Microsoft', 'type': 'Company', 'properties': {}}, 'type': 'WORKS_FOR', 'properties': {}}, {'source': {'id': 'Adam', 'type': 'Person', 'properties': {}}, 'target': {'id': 'Best Talent', 'type': 'Award', 'properties': {}}, 'type': 'HAS_AWARD', 'properties': {}}, {'source': {'id': 'Microsoft Word', 'type': 'Product', 'properties': {}}, 'target': {'id': 'Microsoft', 'type': 'Company', 'properties': {}}, 'type': 'PRODUCED_BY', 'properties': {}}, {'source': {'id': 'Microsoft Word', 'type': 'Product', 'properties': {}}, 'target': {'id': 'lightweight app', 'type': 'Characteristic', 'properties': {}}, 'type': 'HAS_CHARACTERISTIC', 'properties': {}}, {'source': {'id': 'Microsoft Word', 'type': 'Product', 'properties': {}}, 'target': {'id': 'accessible offline', 'type': 'Characteristic', 'properties': {}}, 'type': 'HAS_CHARACTERISTIC', 'properties': {}}], 'source': {'id': None, 'metadata': {}, 'page_content': ' S, Verlinsky O, Masciangelo C, et al. Preimplantation diag-\\nnosis for early-onset Alzheimer disease caused by V717L mutation. JAMA 2002;\\n287:1018–1021.\\n89. Feldman H, Gauthier S, Hecker J, Vellas B, et al. Economic evaluation of donepezil\\nin moderate to severe Alzheimer disease. Neurology 2004;63:644–650.\\n90. Seltzer B, Zolnouni P, Nunez M, Goldman R, et al. Efficacy of donepezil in early-\\nstage Alzheimer disease: a randomized placebo-controlled trial. Arch Neurol 2004;\\n61:1852–1856.\\n91. Petersen RC, Thomas RG, Grundman M, Bennett D, et al. Vitamin E and donepezil\\nfor the treatment of mild cognitive impairment. N Engl J Med 2005;352:2379–\\n2388.\\n92. Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with\\nAlzheimer’s disease: results of a US Multicentre, Randomized, Double-Blind, Pla-\\ncebo-Controlled Trial. The Donepezil Study Group. Dementia 1996;7:293–303.\\n93. Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: A 6-month\\nrandomized, placebo-controlled trial with a 6-month extension. The Galantamine\\nUSA-1 Study Group. Neurology 2000;54:2261–2268.\\n94. Tariot PN, Solomon PR, Morris JC, Kershaw P, et al. A 5-month, randomized,\\nplacebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study\\nGroup. Neurology 2000;54:2269–2276.\\n95. Mega MS, Dinov ID, Porter V, Chow G, et al. Metabolic patterns associated with\\nthe clinical response to galantamine therapy: a fludeoxyglucose f 18 positron emis-\\nsion tomographic study. Arch Neurol 2005;62:721–728.\\n96. Reisberg B, Doody R, Stoffler A, Schmitt F, et al. Memantine', 'type': 'Document'}}, {'nodes': [{'id': '3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors', 'type': 'Drug', 'properties': {}}, {'id': 'Memantine', 'type': 'Drug', 'properties': {}}, {'id': 'Donepezil', 'type': 'Drug', 'properties': {}}, {'id': 'Cognition', 'type': 'Process', 'properties': {}}, {'id': \"Alzheimer's disease\", 'type': 'Disease', 'properties': {}}, {'id': 'Zinc', 'type': 'Substance', 'properties': {}}, {'id': 'Copper', 'type': 'Substance', 'properties': {}}, {'id': 'Antioxidants', 'type': 'Substance', 'properties': {}}], 'relationships': [{'source': {'id': 'Memantine', 'type': 'Drug', 'properties': {}}, 'target': {'id': \"Alzheimer's disease\", 'type': 'Disease', 'properties': {}}, 'type': 'USED_FOR', 'properties': {}}, {'source': {'id': 'Memantine', 'type': 'Drug', 'properties': {}}, 'target': {'id': \"Alzheimer's disease\", 'type': 'Disease', 'properties': {}}, 'type': 'EXTENSION_STUDY', 'properties': {}}, {'source': {'id': 'Memantine', 'type': 'Drug', 'properties': {}}, 'target': {'id': \"Alzheimer's disease\", 'type': 'Disease', 'properties': {}}, 'type': 'SAFETY_STUDY', 'properties': {}}, {'source': {'id': 'Memantine', 'type': 'Drug', 'properties': {}}, 'target': {'id': \"Alzheimer's disease\", 'type': 'Disease', 'properties': {}}, 'type': 'TREATMENT_IN_PATIENTS', 'properties': {}}, {'source': {'id': 'Donepezil', 'type': 'Drug', 'properties': {}}, 'target': {'id': 'Memantine', 'type': 'Drug', 'properties': {}}, 'type': 'RECEIVING', 'properties': {}}, {'source': {'id': 'Antioxidants', 'type': 'Substance', 'properties': {}}, 'target': {'id': 'Cognition', 'type': 'Process', 'properties': {}}, 'type': 'IMPACT_ON', 'properties': {}}, {'source': {'id': 'Zinc', 'type': 'Substance', 'properties': {}}, 'target': {'id': 'Cognition', 'type': 'Process', 'properties': {}}, 'type': 'IMPACT_ON', 'properties': {}}, {'source': {'id': 'Copper', 'type': 'Substance', 'properties': {}}, 'target': {'id': 'Cognition', 'type': 'Process', 'properties': {}}, 'type': 'IMPACT_ON', 'properties': {}}, {'source': {'id': '3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors', 'type': 'Drug', 'properties': {}}, 'target': {'id': \"Alzheimer's disease\", 'type': 'Disease', 'properties': {}}, 'type': 'DECREASED_PREVALENCE_OF', 'properties': {}}], 'source': {'id': None, 'metadata': {}, 'page_content': ' Reisberg B, Doody R, Stoffler A, Schmitt F, et al. Memantine in moderate-to-severe\\nAlzheimer’s disease. N Engl J Med 2003;348:1333–1341.\\n97. Tariot PN, Farlow MR, Grossberg GT, Graham SM, et al. Memantine treatment in\\npatients with moderate to severe Alzheimer disease already receiving donepezil: a\\nrandomized controlled trial. JAMA 2004;291:317–324.\\n98. Reisberg B, Doody R, Stoffler A, Schmitt F, et al. A 24-week open-label extension\\nstudy of memantine in moderate to severe Alzheimer disease. Arch Neurol 2006;\\n63:49–54.\\n99. Ott BR, Blake LM, Kagan E, Resnick M. for the Memantine MEM-MD-11AB Study\\nGroup. Open label, multicenter, 28-week extension study of the safety and tolera-\\nbility of memantine in patients with mild to moderate Alzheimer’s disease. J Neurol\\n2007;254:351–358.\\n100. Overshott R, Burns A. Treatment of dementia. J Neurol Neurosurg Psychiatry 2005;\\n5(suppl 76):v53–v59.\\n101. Klafki HW, Staufenbiel M, Kornhuber J, Wiltfang J. Therapeutic approaches to\\nAlzheimer’s disease. Brain 2006;129:2840–2855.\\n102. Masters CL, Beyreuther K. Alzheimer’s centennial legacy: prospects for rational\\ntherapeutic intervention targeting the Abeta amyloid pathway. Brain 2006;129:\\n2823–2839.\\n103. Yaffe K, Clemons TE, McBee WL, Lindblad AS. Impact of antioxidants, zinc, and\\ncopper on cognition in the elderly: a randomized, controlled trial. Neurology 2004;\\n63:1705–1707.\\n104. Wolozin B, Kellman W, Ruosseau P, Celesia GG, et al. Decreased prevalence of\\nAlzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reduc-\\ntase inhibitors. Arch Neurol 2000;57:1439', 'type': 'Document'}}, {'nodes': [{'id': 'Statins', 'type': 'Product', 'properties': {}}, {'id': 'treatment of mild to moderate Alzheimer disease', 'type': 'Condition', 'properties': {}}, {'id': 'Statin therapy', 'type': 'Treatment', 'properties': {}}, {'id': 'reduced neuropathologic changes of Alzheimer disease', 'type': 'Characteristic', 'properties': {}}, {'id': 'glutaryl coenzyme A reductase inhibitors', 'type': 'Product', 'properties': {}}, {'id': 'Estrogen replacement therapy', 'type': 'Treatment', 'properties': {}}, {'id': 'Alzheimer-disease-like pathology', 'type': 'Characteristic', 'properties': {}}, {'id': 'Immunization with amyloid-beta', 'type': 'Treatment', 'properties': {}}], 'relationships': [{'source': {'id': 'glutaryl coenzyme A reductase inhibitors', 'type': 'Product', 'properties': {}}, 'target': {'id': 'Statins', 'type': 'Product', 'properties': {}}, 'type': 'IS_A', 'properties': {}}, {'source': {'id': 'Statin therapy', 'type': 'Treatment', 'properties': {}}, 'target': {'id': 'reduced neuropathologic changes of Alzheimer disease', 'type': 'Characteristic', 'properties': {}}, 'type': 'ASSOCIATED_WITH', 'properties': {}}, {'source': {'id': 'Immunization with amyloid-beta', 'type': 'Treatment', 'properties': {}}, 'target': {'id': 'Alzheimer-disease-like pathology', 'type': 'Characteristic', 'properties': {}}, 'type': 'ATTENUATES', 'properties': {}}, {'source': {'id': 'Estrogen replacement therapy', 'type': 'Treatment', 'properties': {}}, 'target': {'id': 'treatment of mild to moderate Alzheimer disease', 'type': 'Condition', 'properties': {}}, 'type': 'USED_FOR', 'properties': {}}], 'source': {'id': None, 'metadata': {}, 'page_content': 'glutaryl coenzyme A reduc-\\ntase inhibitors. Arch Neurol 2000;57:1439–1443.\\n105. Li G, Higdon R, Kukull WA, Peskind E, et al. Statin therapy and risk of dementia in\\nthe elderly: a community-based prospective cohort study. Neurology 2004;63:\\n1624–1628.\\n106. Li G, Larson EB, Sonnen JA, Shofer JB, et al. Statin therapy is associated with\\nreduced neuropathologic changes of Alzheimer disease. Neurology 2007;69:878–\\n885.\\n107. Schenk D, Barbour R, Dunn W, Gordon G, et al. Immunization with amyloid-beta\\nattenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;\\n400:173–177.\\n108. Check E. Nerve inflammation halts trial for Alzheimer drug. Nature 2002;415:462.\\n109. Ferrer I, Boada Rovira M, Sanchez Guerra ML, Rey MJ, et al. Neuropathology and\\npathogenesis of encephalitis following amyloid-beta immunization in Alzheimer’s\\ndisease. Brain Pathol 2004;14:11–20.\\n110. Gilman S, Koller M, Black RS, Jenkins L, et al., AN1792(QS-21)-201 Study Team.\\nClinical effects of Abeta immunization (AN1792) in patients with AD in an inter-\\nrupted trial. Neurology 2005;64:1553–1562.\\n111. Qu B, Boyer PJ, Johnston SA, Hynan LS, et al. Abeta42 gene vaccination reduces\\nbrain amyloid plaque burden in transgenic mice. J Neurol Sci 2006;244:151–\\n158.\\n112. Mulnard RA, Cotman CW, Kawas C, van Dyck CH, et al. Estrogen replacement\\ntherapy for treatment of mild to moderate Alzheimer disease: a randomized con-\\ntrolled trial. Alzheimer’s Disease Cooperative Study. JAMA 2000;283:1007–1015.\\n113. Wang PN, Liao SQ, Liu RS, Liu CY, et al. Effects of estrogen on cognition, mood,\\nand cerebral blood flow in AD: a controlled study. Neurology 2000;54', 'type': 'Document'}}, {'nodes': [{'id': 'cerebral blood flow', 'type': 'Physiological Function', 'properties': {}}, {'id': 'Genetic aspects', 'type': 'Genetic Factor', 'properties': {}}, {'id': 'estrogen', 'type': 'Hormone', 'properties': {}}, {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, {'id': 'cognition', 'type': 'Cognitive Function', 'properties': {}}, {'id': 'mood', 'type': 'Emotional State', 'properties': {}}], 'relationships': [{'source': {'id': 'estrogen', 'type': 'Hormone', 'properties': {}}, 'target': {'id': 'cognition', 'type': 'Cognitive Function', 'properties': {}}, 'type': 'AFFECTS', 'properties': {}}, {'source': {'id': 'estrogen', 'type': 'Hormone', 'properties': {}}, 'target': {'id': 'mood', 'type': 'Emotional State', 'properties': {}}, 'type': 'AFFECTS', 'properties': {}}, {'source': {'id': 'estrogen', 'type': 'Hormone', 'properties': {}}, 'target': {'id': 'cerebral blood flow', 'type': 'Physiological Function', 'properties': {}}, 'type': 'AFFECTS', 'properties': {}}, {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}, 'target': {'id': 'Genetic aspects', 'type': 'Genetic Factor', 'properties': {}}, 'type': 'HAS_GENETIC_ASPECTS', 'properties': {}}], 'source': {'id': None, 'metadata': {}, 'page_content': ' of estrogen on cognition, mood,\\nand cerebral blood flow in AD: a controlled study. Neurology 2000;54:2061–2066.Genetic aspects of Alzheimer disease\\nApril 2008 /H18528Vol. 10 /H18528No. 4 239', 'type': 'Document'}}]\n"
          ]
        }
      ],
      "source": [
        "file_path = '/content/graph_documents.txt'  # Adjust this path if the file is located elsewhere\n",
        "\n",
        "# Read the file content\n",
        "with open(file_path, 'r') as file:\n",
        "    graph_documents_json = file.read()\n",
        "import json\n",
        "\n",
        "# Convert JSON string back to a Python object (list of graph documents)\n",
        "graph_documents = json.loads(graph_documents_json)\n",
        "\n",
        "# Check the loaded graph documents\n",
        "print(graph_documents)\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "cJu1mp0FUvbm",
        "outputId": "e4435912-bdc8-4d2a-ab87-783087417ac8"
      },
      "outputs": [
        {
          "data": {
            "text/plain": [
              "[{'nodes': [{'id': 'tau containing neurofibrillary tangles',\n",
              "    'type': 'Finding',\n",
              "    'properties': {}},\n",
              "   {'id': 'age at onset of Alzheimer disease',\n",
              "    'type': 'Characteristic',\n",
              "    'properties': {}},\n",
              "   {'id': 'amyloid plaques', 'type': 'Finding', 'properties': {}},\n",
              "   {'id': 'dementia', 'type': 'Condition', 'properties': {}},\n",
              "   {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "   {'id': 'Apo lipoprotein E', 'type': 'Gene', 'properties': {}}],\n",
              "  'relationships': [{'source': {'id': 'Alzheimer disease',\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'dementia', 'type': 'Condition', 'properties': {}},\n",
              "    'type': 'IS_CAUSE_OF',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'amyloid plaques', 'type': 'Finding', 'properties': {}},\n",
              "    'type': 'HAS_PATHOLOGIC_FINDINGS',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'tau containing neurofibrillary tangles',\n",
              "     'type': 'Finding',\n",
              "     'properties': {}},\n",
              "    'type': 'HAS_PATHOLOGIC_FINDINGS',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'Apo lipoprotein E', 'type': 'Gene', 'properties': {}},\n",
              "    'type': 'HAS_GENETIC_RISK_FACTOR',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Apo lipoprotein E', 'type': 'Gene', 'properties': {}},\n",
              "    'target': {'id': 'age at onset of Alzheimer disease',\n",
              "     'type': 'Characteristic',\n",
              "     'properties': {}},\n",
              "    'type': 'INFLUENCES',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Apo lipoprotein E', 'type': 'Gene', 'properties': {}},\n",
              "    'target': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "    'type': 'INFLUENCES',\n",
              "    'properties': {}}],\n",
              "  'source': {'id': None,\n",
              "   'metadata': {},\n",
              "   'page_content': 'Genetic aspects of Alzheimer disease\\nThomas D. Bird, MD\\nAlzheimer disease is the most common cause of dementia and represents a major public health problem. The\\nneuropathologic findings of amyloid- /H9252plaques and tau containing neurofibrillary tangles represent important\\nmolecular clues to the underlying pathogenesis. Genetic factors are well recognized, but complicated. Three rare\\nforms of autosomal-dominant early-onset familial Alzheimer disease have been identified and are associated with\\nmutations in amyloid precursor protein, presenilin 1, and presenilin 2 genes. The more common late-onset form\\nof Alzheimer disease is assumed to be polygenic/multifactorial. However, thus far the only clearly identified genetic\\nrisk factor for Alzheimer disease is Apo lipoprotein E. The /H92804 allele of Apo lipoprotein E influences age at onset of\\nAlzheimer disease, but is neither necessary nor sufficient for the disease. The search continues for the discovery\\nof additional genetic influences. Genet Med 2008:10(4):231–239.\\nKey Words: Alzheimer, dementia, amyloid, neurogenetics\\nTable of Contents\\nOverview ................................................................................................................. 231\\nClinical manifestations of Alzheimer disease ............................................... 231\\nEstablishing the diagnosis of Alzheimer disease ......................................... 231\\nDifferential diagnosis of Alzheimer disease .................................................. 232\\nPrevalence of Alzheimer disease .................................................................... 232\\nCauses .................................................................................................................... 232\\nEnvironmental causes ...................................................................................... 233\\nHeritable causes ................................................................................................ .233\\nChromosomal ................................................................................................. 233\\nDown syndrome ......................................................................................... 233\\nSingle gene ................................................................................................ 233\\nLate-onset familial Alzheimer disease ................................................... 233\\nEarly onset familial Alzheimer disease ...................................................... 233\\nUnknown cause ................................................................................................. 234\\nEvaluation Strategy ............................................................................................... 234\\nFamily history ..................................................................................................... 234\\nMolecular genetic testing ................................................................................ 234\\nLate-onset familial AD .................................................................................. 234\\nEarly-onset familial AD ................................................................................. 235\\nGenetic Counseling ............................................................................................... 235\\nMode of inheritance .......................................................................................... 235\\nRisk to family members–late-onset nonfamilial Alzheimer disease .......... 235Risk to family members–early-onset familial Alzheimer disease .............. 235\\nRelated genetic counseling issue ................................................................... 235\\nUse of APOE genotyp',\n",
              "   'type': 'Document'}},\n",
              " {'nodes': [{'id': 'dementia', 'type': 'Symptom', 'properties': {}},\n",
              "   {'id': 'hallucinations', 'type': 'Symptom', 'properties': {}},\n",
              "   {'id': 'memory failure', 'type': 'Symptom', 'properties': {}},\n",
              "   {'id': 'withdrawal', 'type': 'Symptom', 'properties': {}},\n",
              "   {'id': 'language disturbance', 'type': 'Symptom', 'properties': {}},\n",
              "   {'id': 'seizures', 'type': 'Symptom', 'properties': {}},\n",
              "   {'id': 'confusion', 'type': 'Symptom', 'properties': {}},\n",
              "   {'id': 'Parkinsonian features', 'type': 'Symptom', 'properties': {}},\n",
              "   {'id': 'poor judgment', 'type': 'Symptom', 'properties': {}},\n",
              "   {'id': 'agitation', 'type': 'Symptom', 'properties': {}},\n",
              "   {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}],\n",
              "  'relationships': [{'source': {'id': 'Alzheimer disease',\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'dementia', 'type': 'Symptom', 'properties': {}},\n",
              "    'type': 'HAS_MANIFESTATION',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'memory failure', 'type': 'Symptom', 'properties': {}},\n",
              "    'type': 'HAS_MANIFESTATION',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'confusion', 'type': 'Symptom', 'properties': {}},\n",
              "    'type': 'HAS_MANIFESTATION',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'poor judgment', 'type': 'Symptom', 'properties': {}},\n",
              "    'type': 'HAS_MANIFESTATION',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'language disturbance',\n",
              "     'type': 'Symptom',\n",
              "     'properties': {}},\n",
              "    'type': 'HAS_MANIFESTATION',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'agitation', 'type': 'Symptom', 'properties': {}},\n",
              "    'type': 'HAS_MANIFESTATION',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'withdrawal', 'type': 'Symptom', 'properties': {}},\n",
              "    'type': 'HAS_MANIFESTATION',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'hallucinations', 'type': 'Symptom', 'properties': {}},\n",
              "    'type': 'HAS_MANIFESTATION',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'seizures', 'type': 'Symptom', 'properties': {}},\n",
              "    'type': 'HAS_MANIFESTATION',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'Parkinsonian features',\n",
              "     'type': 'Symptom',\n",
              "     'properties': {}},\n",
              "    'type': 'HAS_MANIFESTATION',\n",
              "    'properties': {}}],\n",
              "  'source': {'id': None,\n",
              "   'metadata': {},\n",
              "   'page_content': '-onset familial Alzheimer disease .............. 235\\nRelated genetic counseling issue ................................................................... 235\\nUse of APOE genotyping for predictive testing ......................................... 235\\nDown syndrome ............................................................................................. 236\\nTesting of at-risk asymptomatic EOAD family members ............................. 236\\nTesting of at-risk asymptomatic adults ...................................................... 236\\nTesting of at-risk individuals during childhood ......................................... 236\\nPrenatal testing ................................................................................................. 236\\nPreimplantation genetic diagnosis ................................................................. 236\\nManagement .......................................................................................................... 236\\nTreatment of manifestations ........................................................................... 236\\nTherapies under investigation ......................................................................... 236\\nOther ................................................................................................................... 236\\nGenetics clinics ............................................................................................. 236\\nSupport groups .............................................................................................. 236\\nSummary ................................................................................................................. .237\\nDisease characteristics .................................................................................... 237\\nDiagnosis/testing ............................................................................................. 237\\nManagement ...................................................................................................... 237\\nGenetic counseling ........................................................................................... 237\\nResources .............................................................................................................. 237\\nClinical manifestations of Alzheimer disease\\nThe clinical manifestation of Alzheimer disease (AD) is de-\\nmentia that typically begins with subtle and poorly recognized\\nfailure of memory and slowly becomes more severe and, even-\\ntually, incapacitating. Other common findings include confu-\\nsion, poor judgment, language disturbance, agitation, with-\\ndrawal, and hallucinations. Occasionally, seizures, Parkinsonianfeatures, increased muscle tone, myoclonus, incontinence, and\\nmutism occur.1\\nDeath usually results from general inanition, malnutrition,\\nand pneumonia. The typical clinical duration of the disease is\\n8–10 years, with a range from 1 to 25 years.\\nEstablishing the diagnosis of Alzheimer disease\\nEstablishing the diagnosis of Alzheimer disease relies on\\nclinical-neuropathologic assessment.1Neuropathologic find-\\nings on autopsy examination remain the gold standard for di-\\nagnosis of AD. The clinical diagnosis of AD (before autopsy\\nconfirmation) is correct about 80–90% of the time.2\\n●Clinical signs: slowly progressive dementia\\n●Neuroimaging: gross cerebral cortical atrophy3\\n●Neuropathologic findings: microscopic extracellular amy-\\nloid-/H9252(A/H9252)-amyloid neuritic plaques, intraneuronal neu-From the University of Washington',\n",
              "   'type': 'Document'}},\n",
              " {'nodes': [{'id': 'Thomas D. Bird', 'type': 'Person', 'properties': {}},\n",
              "   {'id': 'VA Puget Sound Health Care System',\n",
              "    'type': 'Organization',\n",
              "    'properties': {}},\n",
              "   {'id': 'University of Washington',\n",
              "    'type': 'Organization',\n",
              "    'properties': {}},\n",
              "   {'id': 'Athena Diagnostics, Inc.', 'type': 'Company', 'properties': {}}],\n",
              "  'relationships': [{'source': {'id': 'Thomas D. Bird',\n",
              "     'type': 'Person',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'University of Washington',\n",
              "     'type': 'Organization',\n",
              "     'properties': {}},\n",
              "    'type': 'WORKS_FOR',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Thomas D. Bird', 'type': 'Person', 'properties': {}},\n",
              "    'target': {'id': 'VA Puget Sound Health Care System',\n",
              "     'type': 'Organization',\n",
              "     'properties': {}},\n",
              "    'type': 'WORKS_FOR',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Thomas D. Bird', 'type': 'Person', 'properties': {}},\n",
              "    'target': {'id': 'Athena Diagnostics, Inc.',\n",
              "     'type': 'Company',\n",
              "     'properties': {}},\n",
              "    'type': 'RECEIVES',\n",
              "    'properties': {}}],\n",
              "  'source': {'id': None,\n",
              "   'metadata': {},\n",
              "   'page_content': 'H9252)-amyloid neuritic plaques, intraneuronal neu-From the University of Washington, Geriatric Research Education and Clinical Center, VA\\nPuget Sound Health Care System, Seattle, Washington.\\nThomas D. Bird, MD, University of Washington, Geriatric Research Education and Clinical\\nCenter, VA Puget Sound Health Care System, Seattle, Washington. E-mail: tomnroz@\\nu.washington.edu.\\nDisclosure: Dr. Bird receives licensing fees from Athena Diagnostics, Inc.\\nSubmitted for publication January 11, 2008.\\nAccepted for publication January 29, 2008.\\nDOI: 10.1097/GIM.0b013e31816b64dcApril 2008 /H18528Vol. 10 /H18528No. 4\\nGenetics inMedicine\\ncollaborative review\\nGenetics INMedicine 231',\n",
              "   'type': 'Document'}},\n",
              " {'nodes': [{'id': 'United States', 'type': 'Country', 'properties': {}},\n",
              "   {'id': 'frontotemporal dementia', 'type': 'Disease', 'properties': {}},\n",
              "   {'id': 'North America', 'type': 'Region', 'properties': {}},\n",
              "   {'id': 'Parkinson disease', 'type': 'Disease', 'properties': {}},\n",
              "   {'id': 'diffuse Lewy body disease', 'type': 'Disease', 'properties': {}},\n",
              "   {'id': 'depression', 'type': 'Condition', 'properties': {}},\n",
              "   {'id': 'rofibrillary tangles',\n",
              "    'type': 'Pathological Feature',\n",
              "    'properties': {}},\n",
              "   {'id': 'Creutzfeldt-Jakob disease', 'type': 'Disease', 'properties': {}},\n",
              "   {'id': 'chronic drug intoxication', 'type': 'Condition', 'properties': {}},\n",
              "   {'id': 'thyroid disease', 'type': 'Condition', 'properties': {}},\n",
              "   {'id': 'CADASIL', 'type': 'Disease', 'properties': {}},\n",
              "   {'id': 'normal-pressure hydrocephalus',\n",
              "    'type': 'Condition',\n",
              "    'properties': {}},\n",
              "   {'id': 'Europe', 'type': 'Region', 'properties': {}},\n",
              "   {'id': 'Picks disease', 'type': 'Disease', 'properties': {}},\n",
              "   {'id': 'central nervous system angitis',\n",
              "    'type': 'Condition',\n",
              "    'properties': {}},\n",
              "   {'id': 'amyloid angiopathy',\n",
              "    'type': 'Pathological Feature',\n",
              "    'properties': {}},\n",
              "   {'id': 'vitamin deficiencies', 'type': 'Condition', 'properties': {}},\n",
              "   {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}],\n",
              "  'relationships': [{'source': {'id': 'Alzheimer disease',\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'rofibrillary tangles',\n",
              "     'type': 'Pathological Feature',\n",
              "     'properties': {}},\n",
              "    'type': 'ASSOCIATED_WITH',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'amyloid angiopathy',\n",
              "     'type': 'Pathological Feature',\n",
              "     'properties': {}},\n",
              "    'type': 'ASSOCIATED_WITH',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'depression', 'type': 'Condition', 'properties': {}},\n",
              "    'type': 'DIFFERENTIAL_DIAGNOSIS',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'chronic drug intoxication',\n",
              "     'type': 'Condition',\n",
              "     'properties': {}},\n",
              "    'type': 'DIFFERENTIAL_DIAGNOSIS',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'thyroid disease', 'type': 'Condition', 'properties': {}},\n",
              "    'type': 'DIFFERENTIAL_DIAGNOSIS',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'vitamin deficiencies',\n",
              "     'type': 'Condition',\n",
              "     'properties': {}},\n",
              "    'type': 'DIFFERENTIAL_DIAGNOSIS',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'central nervous system angitis',\n",
              "     'type': 'Condition',\n",
              "     'properties': {}},\n",
              "    'type': 'DIFFERENTIAL_DIAGNOSIS',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'normal-pressure hydrocephalus',\n",
              "     'type': 'Condition',\n",
              "     'properties': {}},\n",
              "    'type': 'DIFFERENTIAL_DIAGNOSIS',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'frontotemporal dementia',\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'type': 'DIFFERENTIAL_DIAGNOSIS',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'Picks disease', 'type': 'Disease', 'properties': {}},\n",
              "    'type': 'DIFFERENTIAL_DIAGNOSIS',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'Parkinson disease', 'type': 'Disease', 'properties': {}},\n",
              "    'type': 'DIFFERENTIAL_DIAGNOSIS',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'diffuse Lewy body disease',\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'type': 'DIFFERENTIAL_DIAGNOSIS',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'Creutzfeldt-Jakob disease',\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'type': 'DIFFERENTIAL_DIAGNOSIS',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'CADASIL', 'type': 'Disease', 'properties': {}},\n",
              "    'type': 'DIFFERENTIAL_DIAGNOSIS',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'North America', 'type': 'Region', 'properties': {}},\n",
              "    'type': 'PREVALENCE',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'Europe', 'type': 'Region', 'properties': {}},\n",
              "    'type': 'PREVALENCE',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'United States', 'type': 'Country', 'properties': {}},\n",
              "    'type': 'PREVALENCE',\n",
              "    'properties': {}}],\n",
              "  'source': {'id': None,\n",
              "   'metadata': {},\n",
              "   'page_content': 'rofibrillary tangles, and amyloid angiopathy at postmor-\\ntem examination (Figs. 1 and 2). The plaques should stain\\npositively with A /H9252-amyloid antibodies and negative for\\nprion antibodies, which are diagnostic of prion diseases.\\nThe numbers of plaques and tangles must exceed those\\nfound in age-matched controls without dementia. Guide-\\nlines for the quantitative assessment of these changes ex-ist.4,5Aggregation of alpha-synuclein in the form of Lewy\\nbodies may also be found in neurons in the amygdala.6\\nDifferential diagnosis of Alzheimer disease\\nDifferential diagnosis of AD includes other causes of de-\\nmentia, especially treatable forms of cognitive decline, such as\\ndepression, chronic drug intoxication, chronic central nervous\\nsystem infection, thyroid disease, vitamin deficiencies (espe-\\ncially B12 and thiamine), central nervous system angitis, and\\nnormal-pressure hydrocephalus.1\\nOther degenerative disorders associated with dementia, such as\\nfrontotemporal dementia, including frontotemporal dementia\\nwith parkinsonism-17, Picks disease, Parkinson disease, diffuse\\nLewy body disease, Creutzfeldt-Jakob disease, and cerebral auto-\\nsomal dominant arteriopathy with subcortical infarcts and leu-\\nkoencephalopathy (CADASIL), may also be confused with AD.7\\nComputerized tomography and magnetic resonance imag-\\ning are valuable for identifying some of these other causes of\\ndementia, including neoplasms, normal-pressure hydroceph-\\nalus, frontotemporal dementia, and cerebral vascular disease.\\nPrevalence of Alzheimer disease\\nAD is the most common cause of dementia in North Amer-\\nica and Europe, with an estimate of 4 million affected individ-\\nuals in the United States.\\nThe prevalence of AD increases with age. Mild memory loss\\nis often called mild cognitive impairment. In many persons\\nmild cognitive impairment is considered an early stage of AD.\\nThe incidence of AD rises from 2.8 per 1000 person years in\\nthe 65–69 years age group to 56.1 per 1000 person years in the\\nolder than 90-year age group.8Approximately 10% of persons\\nolder than 70 years have significant memory loss and more\\nthan half of these individuals have AD',\n",
              "   'type': 'Document'}},\n",
              " {'nodes': [{'id': 'Unknown (includes genetic/environment interactions)',\n",
              "    'type': 'Cause',\n",
              "    'properties': {}},\n",
              "   {'id': 'late-onset familial AD', 'type': 'Condition', 'properties': {}},\n",
              "   {'id': 'Early-onset familial AD (AD1, AD3, AD4)',\n",
              "    'type': 'Cause',\n",
              "    'properties': {}},\n",
              "   {'id': 'Alzheimer disease', 'type': 'Condition', 'properties': {}},\n",
              "   {'id': 'Alzheimer brain', 'type': 'Condition', 'properties': {}},\n",
              "   {'id': 'marked diffuse cortical atrophy',\n",
              "    'type': 'Characteristic',\n",
              "    'properties': {}},\n",
              "   {'id': 'early-onset AD', 'type': 'Condition', 'properties': {}},\n",
              "   {'id': 'Late-onset familial (AD2)', 'type': 'Cause', 'properties': {}},\n",
              "   {'id': 'persons older than 85 years', 'type': 'Person', 'properties': {}},\n",
              "   {'id': 'AD', 'type': 'Condition', 'properties': {}},\n",
              "   {'id': 'persons older than 70 years', 'type': 'Person', 'properties': {}},\n",
              "   {'id': 'familial', 'type': 'Characteristic', 'properties': {}},\n",
              "   {'id': 'onset before age 60-65 years',\n",
              "    'type': 'Characteristic',\n",
              "    'properties': {}},\n",
              "   {'id': 'autosomal-dominant manner',\n",
              "    'type': 'Characteristic',\n",
              "    'properties': {}},\n",
              "   {'id': 'significant memory loss', 'type': 'Condition', 'properties': {}},\n",
              "   {'id': 'Familial', 'type': 'Cause', 'properties': {}},\n",
              "   {'id': 'early onset', 'type': 'Characteristic', 'properties': {}},\n",
              "   {'id': 'neuritic plaque', 'type': 'Characteristic', 'properties': {}},\n",
              "   {'id': 'onset after age 60-65 years',\n",
              "    'type': 'Characteristic',\n",
              "    'properties': {}},\n",
              "   {'id': 'dementia', 'type': 'Condition', 'properties': {}},\n",
              "   {'id': 'ventricular enlargement',\n",
              "    'type': 'Characteristic',\n",
              "    'properties': {}},\n",
              "   {'id': 'neurofibrillary tangles',\n",
              "    'type': 'Characteristic',\n",
              "    'properties': {}},\n",
              "   {'id': 'early-onset familial AD', 'type': 'Condition', 'properties': {}},\n",
              "   {'id': 'Chromosomal (Down syndrome)', 'type': 'Cause', 'properties': {}}],\n",
              "  'relationships': [{'source': {'id': 'persons older than 70 years',\n",
              "     'type': 'Person',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'significant memory loss',\n",
              "     'type': 'Condition',\n",
              "     'properties': {}},\n",
              "    'type': 'HAS',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'persons older than 70 years',\n",
              "     'type': 'Person',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'AD', 'type': 'Condition', 'properties': {}},\n",
              "    'type': 'HAS',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'persons older than 85 years',\n",
              "     'type': 'Person',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'dementia', 'type': 'Condition', 'properties': {}},\n",
              "    'type': 'HAS',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'AD', 'type': 'Condition', 'properties': {}},\n",
              "    'target': {'id': 'early onset',\n",
              "     'type': 'Characteristic',\n",
              "     'properties': {}},\n",
              "    'type': 'IS',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'early-onset AD', 'type': 'Condition', 'properties': {}},\n",
              "    'target': {'id': 'familial', 'type': 'Characteristic', 'properties': {}},\n",
              "    'type': 'IS',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'early-onset AD', 'type': 'Condition', 'properties': {}},\n",
              "    'target': {'id': 'autosomal-dominant manner',\n",
              "     'type': 'Characteristic',\n",
              "     'properties': {}},\n",
              "    'type': 'IS',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'early-onset familial AD',\n",
              "     'type': 'Condition',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'onset before age 60-65 years',\n",
              "     'type': 'Characteristic',\n",
              "     'properties': {}},\n",
              "    'type': 'IS',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'late-onset familial AD',\n",
              "     'type': 'Condition',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'onset after age 60-65 years',\n",
              "     'type': 'Characteristic',\n",
              "     'properties': {}},\n",
              "    'type': 'IS',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alzheimer brain', 'type': 'Condition', 'properties': {}},\n",
              "    'target': {'id': 'marked diffuse cortical atrophy',\n",
              "     'type': 'Characteristic',\n",
              "     'properties': {}},\n",
              "    'type': 'SHOWS',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alzheimer brain', 'type': 'Condition', 'properties': {}},\n",
              "    'target': {'id': 'ventricular enlargement',\n",
              "     'type': 'Characteristic',\n",
              "     'properties': {}},\n",
              "    'type': 'SHOWS',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alzheimer disease',\n",
              "     'type': 'Condition',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'neuritic plaque',\n",
              "     'type': 'Characteristic',\n",
              "     'properties': {}},\n",
              "    'type': 'SHOWS',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alzheimer disease',\n",
              "     'type': 'Condition',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'neurofibrillary tangles',\n",
              "     'type': 'Characteristic',\n",
              "     'properties': {}},\n",
              "    'type': 'SHOWS',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alzheimer disease',\n",
              "     'type': 'Condition',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'Chromosomal (Down syndrome)',\n",
              "     'type': 'Cause',\n",
              "     'properties': {}},\n",
              "    'type': 'CAUSED_BY',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alzheimer disease',\n",
              "     'type': 'Condition',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'Familial', 'type': 'Cause', 'properties': {}},\n",
              "    'type': 'CAUSED_BY',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alzheimer disease',\n",
              "     'type': 'Condition',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'Late-onset familial (AD2)',\n",
              "     'type': 'Cause',\n",
              "     'properties': {}},\n",
              "    'type': 'CAUSED_BY',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alzheimer disease',\n",
              "     'type': 'Condition',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'Early-onset familial AD (AD1, AD3, AD4)',\n",
              "     'type': 'Cause',\n",
              "     'properties': {}},\n",
              "    'type': 'CAUSED_BY',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alzheimer disease',\n",
              "     'type': 'Condition',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'Unknown (includes genetic/environment interactions)',\n",
              "     'type': 'Cause',\n",
              "     'properties': {}},\n",
              "    'type': 'CAUSED_BY',\n",
              "    'properties': {}}],\n",
              "  'source': {'id': None,\n",
              "   'metadata': {},\n",
              "   'page_content': 'roximately 10% of persons\\nolder than 70 years have significant memory loss and more\\nthan half of these individuals have AD. An estimated 25–45%\\nof persons older than 85 years have dementia.\\nCAUSES\\nAbout 1–6% of all AD is early onset (before age 60–65\\nyears) and about 60% of early-onset AD is familial, with 13%\\nseeming to be inherited in an autosomal-dominant manner\\n(Table 1).9,10\\nThe distinction between early-onset familial AD (EOFAD,\\nonset before age 60–65 years) and late-onset familial AD (on-\\nset after age 60–65 years) is somewhat arbitrary. Early-onset\\ncases can occur in families with generally late-onset disease.11\\nFig. 1. Normal adult brain (top) compared with Alzheimer brain (bottom) showing\\nmarked diffuse cortical atrophy and ventricular enlargement.\\nFig. 2. Microscopic neuropathology of Alzheimer disease showing a neuritic plaque\\n(lower left hand corner) and neurofibrillary tangles (upper right hand corner).Table 1\\nCauses of Alzheimer disease\\nCause % of cases\\nChromosomal (Down syndrome) /H110211\\nFamilial /H1101125\\nLate-onset familial (AD2) 15–25\\nEarly-onset familial AD (AD1, AD3, AD4) /H110212\\nUnknown (includes genetic/environment interactions) /H1101175Bird\\n232 Genetics INMedicine',\n",
              "   'type': 'Document'}},\n",
              " {'nodes': [{'id': 'Familial cases', 'type': 'Cases', 'properties': {}},\n",
              "   {'id': 'persons with Down syndrome',\n",
              "    'type': 'Individuals',\n",
              "    'properties': {}},\n",
              "   {'id': 'polymorphism in the APP gene',\n",
              "    'type': 'Polymorphism',\n",
              "    'properties': {}},\n",
              "   {'id': 'pathogenesis of AD', 'type': 'Disease', 'properties': {}},\n",
              "   {'id': 'familial', 'type': 'Type', 'properties': {}},\n",
              "   {'id': 'brain', 'type': 'Organ', 'properties': {}},\n",
              "   {'id': 'Apo E genotype', 'type': 'Genotype', 'properties': {}},\n",
              "   {'id': '25% of AD', 'type': 'Percentage', 'properties': {}},\n",
              "   {'id': 'APP gene', 'type': 'Gene', 'properties': {}},\n",
              "   {'id': 'Twin studies', 'type': 'Study', 'properties': {}},\n",
              "   {'id': 'AD', 'type': 'Disease', 'properties': {}},\n",
              "   {'id': 'Aβ deposition', 'type': 'Deposition', 'properties': {}},\n",
              "   {'id': 'unknown environmental factors', 'type': 'Factor', 'properties': {}},\n",
              "   {'id': 'environmental agents', 'type': 'Agent', 'properties': {}},\n",
              "   {'id': 'research on the molecular and genetic basis of AD',\n",
              "    'type': 'Research',\n",
              "    'properties': {}},\n",
              "   {'id': 'genes and environment', 'type': 'Factor', 'properties': {}},\n",
              "   {'id': 'mothers younger than 35 years',\n",
              "    'type': 'Mothers',\n",
              "    'properties': {}},\n",
              "   {'id': 'Down syndrome', 'type': 'Chromosomal Condition', 'properties': {}},\n",
              "   {'id': 'age of onset of dementia', 'type': 'Onset Age', 'properties': {}},\n",
              "   {'id': 'chromosome 21', 'type': 'Chromosome', 'properties': {}},\n",
              "   {'id': 'clinical evidence of cognitive decline',\n",
              "    'type': 'Evidence',\n",
              "    'properties': {}},\n",
              "   {'id': '78-year-old woman', 'type': 'Individual', 'properties': {}},\n",
              "   {'id': 'onset age', 'type': 'Onset Age', 'properties': {}},\n",
              "   {'id': 'Rosenberg, Sleegers, van Duijn, Nussbaum, Ellis, Goedert, Spillantini, Roses, Saunders',\n",
              "    'type': 'Researchers',\n",
              "    'properties': {}},\n",
              "   {'id': 'unexplained increased risk for AD',\n",
              "    'type': 'Risk',\n",
              "    'properties': {}},\n",
              "   {'id': 'neuropathologic hallmarks of AD',\n",
              "    'type': 'Hallmarks',\n",
              "    'properties': {}},\n",
              "   {'id': 'predisposing genetic background',\n",
              "    'type': 'Background',\n",
              "    'properties': {}},\n",
              "   {'id': 'family history or by molecular genetic testing',\n",
              "    'type': 'Criteria',\n",
              "    'properties': {}}],\n",
              "  'relationships': [{'source': {'id': 'environmental agents',\n",
              "     'type': 'Agent',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'pathogenesis of AD',\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'type': 'INVOLVED_IN',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'unknown environmental factors',\n",
              "     'type': 'Factor',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'predisposing genetic background',\n",
              "     'type': 'Background',\n",
              "     'properties': {}},\n",
              "    'type': 'ACTING_ON',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Twin studies', 'type': 'Study', 'properties': {}},\n",
              "    'target': {'id': 'genes and environment',\n",
              "     'type': 'Factor',\n",
              "     'properties': {}},\n",
              "    'type': 'IMPLICATED',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Down syndrome',\n",
              "     'type': 'Chromosomal Condition',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'neuropathologic hallmarks of AD',\n",
              "     'type': 'Hallmarks',\n",
              "     'properties': {}},\n",
              "    'type': 'DEVELOP',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'persons with Down syndrome',\n",
              "     'type': 'Individuals',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'clinical evidence of cognitive decline',\n",
              "     'type': 'Evidence',\n",
              "     'properties': {}},\n",
              "    'type': 'SHOW',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'APP gene', 'type': 'Gene', 'properties': {}},\n",
              "    'target': {'id': 'chromosome 21', 'type': 'Chromosome', 'properties': {}},\n",
              "    'type': 'OVEREXPRESSION_ON',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Aβ deposition', 'type': 'Deposition', 'properties': {}},\n",
              "    'target': {'id': 'brain', 'type': 'Organ', 'properties': {}},\n",
              "    'type': 'BEGIN_IN',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': '78-year-old woman',\n",
              "     'type': 'Individual',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'AD', 'type': 'Disease', 'properties': {}},\n",
              "    'type': 'NOTED',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Apo E genotype', 'type': 'Genotype', 'properties': {}},\n",
              "    'target': {'id': 'age of onset of dementia',\n",
              "     'type': 'Onset Age',\n",
              "     'properties': {}},\n",
              "    'type': 'ASSOCIATED_WITH',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'polymorphism in the APP gene',\n",
              "     'type': 'Polymorphism',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'onset age', 'type': 'Onset Age', 'properties': {}},\n",
              "    'type': 'ASSOCIATED_WITH',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'mothers younger than 35 years',\n",
              "     'type': 'Mothers',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'unexplained increased risk for AD',\n",
              "     'type': 'Risk',\n",
              "     'properties': {}},\n",
              "    'type': 'FOUND',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': '25% of AD', 'type': 'Percentage', 'properties': {}},\n",
              "    'target': {'id': 'familial', 'type': 'Type', 'properties': {}},\n",
              "    'type': 'IS',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Familial cases', 'type': 'Cases', 'properties': {}},\n",
              "    'target': {'id': 'family history or by molecular genetic testing',\n",
              "     'type': 'Criteria',\n",
              "     'properties': {}},\n",
              "    'type': 'DISTINGUISHED_BY',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'research on the molecular and genetic basis of AD',\n",
              "     'type': 'Research',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'Rosenberg, Sleegers, van Duijn, Nussbaum, Ellis, Goedert, Spillantini, Roses, Saunders',\n",
              "     'type': 'Researchers',\n",
              "     'properties': {}},\n",
              "    'type': 'SUMMARIZED_BY',\n",
              "    'properties': {}}],\n",
              "  'source': {'id': None,\n",
              "   'metadata': {},\n",
              "   'page_content': 'Environmental causes\\nNo environmental agents (e.g., head trauma, viruses, toxins,\\nlow education level) have been proven to be directly involved\\nin the pathogenesis of AD. It is often speculated that late-onset\\nAD is the result of unknown environmental factors acting on a\\npredisposing genetic background.12Twin studies have impli-\\ncated both genes and environment.13\\nHeritable causes\\nChromosomal\\nDown syndrome. Essentially, all persons with Down syndrome\\n(DS) (trisomy 21) develop the neuropathologic hallmarks of\\nAD after 40 years. More than half of individuals with DS also\\nshow, if carefully observed or tested, clinical evidence of cog-\\nnitive decline.14The presumed reason for this association is the\\nlifelong overexpression of the APP gene on chromosome 21\\nencoding the amyloid precursor protein and the resultant\\noverproduction of /H9252-amyloid in the brains of persons who are\\ntrisomic for this gene.\\nThe A /H9252deposition in the brain may begin in the first decade\\nof life in persons with DS.15AD was not noted clinically or\\npathologically in a 78-year-old woman with partial trisomy 21,\\nwho did not have an extra copy of the APP gene.16Two studies\\nhave found no association of Apo E genotype with age of onset\\nof dementia in DS,17,18but one study did find an association of\\nonset age with a polymorphism in the APP gene.18Schupf et\\nal.19found an unexplained increased risk for AD in mothers\\nyounger than 35 years, who gave birth to children with DS.\\nSingle gene. About 25% of AD is familial (i.e., two or more\\nfamily members have AD). Familial cases seem to have the\\nsame clinical and pathologic phenotypes as nonfamilial cases\\n(i.e., an individual with AD and no known family history of\\nAD)20,21and are thus distinguished only by family history or by\\nmolecular genetic testing. A large volume of research on the\\nmolecular and genetic basis of AD has been summarized by\\nRosenberg,22Sleegers and van Duijn,23Nussbaum and Ellis,24\\nGoedert and Spillantini,25and Roses and Saunders.26\\nLate-onset familial Alzheimer disease',\n",
              "   'type': 'Document'}},\n",
              " {'nodes': [{'id': 'amyloid precursor protein (APP) trafficking',\n",
              "    'type': 'Process',\n",
              "    'properties': {}},\n",
              "   {'id': 'late-onset AD', 'type': 'Disease', 'properties': {}},\n",
              "   {'id': 'markers', 'type': 'Marker', 'properties': {}},\n",
              "   {'id': 'families', 'type': 'Group', 'properties': {}},\n",
              "   {'id': 'multiple susceptibility genes', 'type': 'Gene', 'properties': {}},\n",
              "   {'id': 'GST02', 'type': 'Gene', 'properties': {}},\n",
              "   {'id': 'chromosome 12', 'type': 'Chromosome', 'properties': {}},\n",
              "   {'id': 'chromosome 10', 'type': 'Chromosome', 'properties': {}},\n",
              "   {'id': 'GAB2', 'type': 'Gene', 'properties': {}},\n",
              "   {'id': 'age of onset', 'type': 'Characteristic', 'properties': {}},\n",
              "   {'id': 'EOFAD', 'type': 'Disease', 'properties': {}},\n",
              "   {'id': 'before age 65 years', 'type': 'Age', 'properties': {}},\n",
              "   {'id': 'A2M', 'type': 'Gene', 'properties': {}},\n",
              "   {'id': 'usually in the 40s or early 50s', 'type': 'Age', 'properties': {}},\n",
              "   {'id': 'late-onset familial Alzheimer disease',\n",
              "    'type': 'Disease',\n",
              "    'properties': {}},\n",
              "   {'id': 'SORL1', 'type': 'Gene', 'properties': {}},\n",
              "   {'id': 'GST01', 'type': 'Gene', 'properties': {}},\n",
              "   {'id': 'APOE e4 allele', 'type': 'Gene', 'properties': {}}],\n",
              "  'relationships': [{'source': {'id': 'late-onset familial Alzheimer disease',\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'multiple susceptibility genes',\n",
              "     'type': 'Gene',\n",
              "     'properties': {}},\n",
              "    'type': 'INVOLVES',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'APOE e4 allele', 'type': 'Gene', 'properties': {}},\n",
              "    'target': {'id': 'age of onset',\n",
              "     'type': 'Characteristic',\n",
              "     'properties': {}},\n",
              "    'type': 'AFFECTS',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'SORL1', 'type': 'Gene', 'properties': {}},\n",
              "    'target': {'id': 'amyloid precursor protein (APP) trafficking',\n",
              "     'type': 'Process',\n",
              "     'properties': {}},\n",
              "    'type': 'INVOLVED_WITH',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'A2M', 'type': 'Gene', 'properties': {}},\n",
              "    'target': {'id': 'chromosome 12', 'type': 'Chromosome', 'properties': {}},\n",
              "    'type': 'LOCATED_ON',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'GST01', 'type': 'Gene', 'properties': {}},\n",
              "    'target': {'id': 'chromosome 10', 'type': 'Chromosome', 'properties': {}},\n",
              "    'type': 'LOCATED_ON',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'GST02', 'type': 'Gene', 'properties': {}},\n",
              "    'target': {'id': 'chromosome 10', 'type': 'Chromosome', 'properties': {}},\n",
              "    'type': 'LOCATED_ON',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'GAB2', 'type': 'Gene', 'properties': {}},\n",
              "    'target': {'id': 'APOE e4 allele', 'type': 'Gene', 'properties': {}},\n",
              "    'type': 'INTERACTS_WITH',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'late-onset AD', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'markers', 'type': 'Marker', 'properties': {}},\n",
              "    'type': 'LINKED_TO',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'EOFAD', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'families', 'type': 'Group', 'properties': {}},\n",
              "    'type': 'REFERS_TO',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'EOFAD', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'families', 'type': 'Group', 'properties': {}},\n",
              "    'type': 'OCCURS_IN',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'EOFAD', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'before age 65 years', 'type': 'Age', 'properties': {}},\n",
              "    'type': 'HAS_MEAN_AGE_OF_ONSET',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'EOFAD', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'usually in the 40s or early 50s',\n",
              "     'type': 'Age',\n",
              "     'properties': {}},\n",
              "    'type': 'HAS_MEAN_AGE_OF_ONSET',\n",
              "    'properties': {}}],\n",
              "  'source': {'id': None,\n",
              "   'metadata': {},\n",
              "   'page_content': 'Goedert and Spillantini,25and Roses and Saunders.26\\nLate-onset familial Alzheimer disease. Many families have mul-\\ntiple affected members, most or all of whom have onset of\\ndementia after age 60 or 65 years (Table 2). Disease duration is\\ntypically 8–10 years, but ranges from 2 to 25 years. Investiga-\\ntions have supported the concept that late-onset AD is a com-\\nplex disorder that may involve multiple susceptibility genes\\n(reviewed and summarized by Kamboh,27Bertram and\\nTanzi,28Serretti et al.,29and Roses and Saunders26). Bertram et\\nal.30have performed a meta-analysis on these data. The follow-\\ning information are currently available:●Well-documented association of late-onset familial AD\\n(FAD) with the APOE e4 allele. The APOE e4 allele, by\\nunknown mechanisms, seems to affect age of onset by\\nshifting the onset toward an earlier age.31,32\\n●Several other potential genes are under investigation:\\n●SORL1 on chromosome 11q23, a protein involved with\\namyloid precursor protein (APP) trafficking33\\n●A2M on chromosome 1234–37\\n●GST01 andGST02 on chromosome 1038\\n●GAB2 on chromosome 11q14 interacting with the\\nAPOE e4 allele39\\n●Several other potential loci are under investigation on the\\nfollowing chromosomes:\\n●1240–43\\n●1044–48\\n●2q, 9p, and 15q49,50\\n●19p1351\\n●7q3652\\n●9q22 ( UBQLN1 )53–56\\n●Studies of late-onset AD in a genetically isolated Dutch\\npopulation have suggested linkage of AD to markers on\\nchromosome 1q22, 3q23, 10q22, and 11q25.57\\nEarly -onset familial Alzheimer disease\\n●Clinical features: EOFAD refers to families in which mul-\\ntiple cases of AD occur with the mean age of onset usually\\nbefore age 65 years, although some studies have used age\\n60 or 70 years. Age of onset is usually in the 40s or early\\n50s, although onset in the 30s and early 60s has been re-\\nported. Campion et al.10',\n",
              "   'type': 'Document'}},\n",
              " {'nodes': [{'id': '19q13.2', 'type': 'Genomic Locus', 'properties': {}},\n",
              "   {'id': 'APP', 'type': 'Gene', 'properties': {}},\n",
              "   {'id': 'nonfamilial AD', 'type': 'Disease', 'properties': {}},\n",
              "   {'id': 'Presenilin 2 (PS2)', 'type': 'Gene', 'properties': {}},\n",
              "   {'id': 'alpha- and gamma-secretases', 'type': 'Enzyme', 'properties': {}},\n",
              "   {'id': 'gamma-secretase complex',\n",
              "    'type': 'Protein Complex',\n",
              "    'properties': {}},\n",
              "   {'id': 'early-onset AD', 'type': 'Disease', 'properties': {}},\n",
              "   {'id': '41.2 per 100,000 persons', 'type': 'Statistic', 'properties': {}},\n",
              "   {'id': 'autosomal-dominant inheritance',\n",
              "    'type': 'Characteristic',\n",
              "    'properties': {}},\n",
              "   {'id': 'positive family history',\n",
              "    'type': 'Characteristic',\n",
              "    'properties': {}},\n",
              "   {'id': 'Apolipoprotein E', 'type': 'Protein', 'properties': {}},\n",
              "   {'id': 'APP, Presenilin 1 (PS1), Presenilin 2 (PS2)',\n",
              "    'type': 'Gene',\n",
              "    'properties': {}},\n",
              "   {'id': 'Presenilin 1 (PS1)', 'type': 'Gene', 'properties': {}},\n",
              "   {'id': 'AD1, AD3, and AD4', 'type': 'Subtype', 'properties': {}},\n",
              "   {'id': 'extracellular amyloid plaque',\n",
              "    'type': 'Structure',\n",
              "    'properties': {}},\n",
              "   {'id': 'EOFAD', 'type': 'Disease', 'properties': {}},\n",
              "   {'id': 'A beta-peptide', 'type': 'Protein', 'properties': {}},\n",
              "   {'id': 'APOE', 'type': 'Gene', 'properties': {}}],\n",
              "  'relationships': [{'source': {'id': 'early-onset AD',\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'target': {'id': '41.2 per 100,000 persons',\n",
              "     'type': 'Statistic',\n",
              "     'properties': {}},\n",
              "    'type': 'HAS_PREVALENCE',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'early-onset AD', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'positive family history',\n",
              "     'type': 'Characteristic',\n",
              "     'properties': {}},\n",
              "    'type': 'HAS_FAMILY_HISTORY',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'early-onset AD', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'autosomal-dominant inheritance',\n",
              "     'type': 'Characteristic',\n",
              "     'properties': {}},\n",
              "    'type': 'HAS_INHERITANCE_CRITERIA',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'EOFAD', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'nonfamilial AD', 'type': 'Disease', 'properties': {}},\n",
              "    'type': 'SIMILAR_TO',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'EOFAD', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'AD1, AD3, and AD4', 'type': 'Subtype', 'properties': {}},\n",
              "    'type': 'HAS_GENETIC_SUBTYPES',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'EOFAD', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'APP, Presenilin 1 (PS1), Presenilin 2 (PS2)',\n",
              "     'type': 'Gene',\n",
              "     'properties': {}},\n",
              "    'type': 'HAS_CAUSATIVE_GENES',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'APP', 'type': 'Gene', 'properties': {}},\n",
              "    'target': {'id': 'alpha- and gamma-secretases',\n",
              "     'type': 'Enzyme',\n",
              "     'properties': {}},\n",
              "    'type': 'CLEAVED_BY',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'APP', 'type': 'Gene', 'properties': {}},\n",
              "    'target': {'id': 'A beta-peptide', 'type': 'Protein', 'properties': {}},\n",
              "    'type': 'FORMS',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'A beta-peptide', 'type': 'Protein', 'properties': {}},\n",
              "    'target': {'id': 'extracellular amyloid plaque',\n",
              "     'type': 'Structure',\n",
              "     'properties': {}},\n",
              "    'type': 'PRIMARY_COMPONENT_OF',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Presenilin 1 (PS1)', 'type': 'Gene', 'properties': {}},\n",
              "    'target': {'id': 'gamma-secretase complex',\n",
              "     'type': 'Protein Complex',\n",
              "     'properties': {}},\n",
              "    'type': 'PART_OF',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Presenilin 2 (PS2)', 'type': 'Gene', 'properties': {}},\n",
              "    'target': {'id': 'Presenilin 1 (PS1)', 'type': 'Gene', 'properties': {}},\n",
              "    'type': 'CLOSE_HOMOLOG_OF',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'APOE', 'type': 'Gene', 'properties': {}},\n",
              "    'target': {'id': '19q13.2', 'type': 'Genomic Locus', 'properties': {}},\n",
              "    'type': 'LOCATED_AT',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'APOE', 'type': 'Gene', 'properties': {}},\n",
              "    'target': {'id': 'Apolipoprotein E', 'type': 'Protein', 'properties': {}},\n",
              "    'type': 'ENCODES',\n",
              "    'properties': {}}],\n",
              "  'source': {'id': None,\n",
              "   'metadata': {},\n",
              "   'page_content': ', although onset in the 30s and early 60s has been re-\\nported. Campion et al.10found a prevalence of early-onset\\nAD in the general population of 41.2 per 100,000 persons\\nat risk (ages 40–59 years). Sixty-one percent of these in-\\ndividuals with early-onset AD had a positive family history,\\nand 13% met stringent criteria for autosomal-dominant in-\\nheritance (i.e., affected individuals in three generations).\\nEOFAD cannot be clinically distinguished from nonfamilial\\nAD except on the basis of family history and age of onset. The\\ndementia phenotype is similar to that of late-onset AD,\\nsometimes with a long prodrome.58–60\\n●Molecular genetics: At least three subtypes of EOFAD (AD1,\\nAD3, and AD4) have been identified based on the causative\\ngene. The relative proportion of each subtype and the caus-\\native genes are summarized in Table 3.10,61–63 The APP is\\ncleaved by alpha- and gamma-secretases to form the A beta-\\npeptide, which is the primary component of the extracellular\\namyloid plaque deposited in AD (Fig. 3). Presenilin 1 (PS1)\\nis part of the gamma-secretase complex (and PS2 is a close\\nhomolog of PS1). Thus, the three primary genes associated\\nwith EOFAD are all related to APP and A beta-amyloid mo-\\nlecular biology. It is likely that other genes will be identified as\\na cause of EOFAD because kindreds with autosomal-domi-\\nnant FAD with no known mutations in presenilin 1\\n(PSEN1 ),PSEN2 ,o rAPPhave been described.63,64Table 2\\nLate-onset familial Alzheimer’s disease: molecular genetics\\nLocus\\nnameGene\\nsymbolChromosomal\\nlocusProtein\\nnameTest\\navailability\\nAD2 APOE 19q13.2 ApolipoproteinE ClinicalGenetic aspects of Alzheimer disease\\nApril 2008 /H18528Vol. 10 /H18528No. 4 233',\n",
              "   'type': 'Document'}},\n",
              " {'nodes': [{'id': 'late-onset FAD', 'type': 'Disease', 'properties': {}},\n",
              "   {'id': 'head trauma', 'type': 'Factor', 'properties': {}},\n",
              "   {'id': 'late-onset AD', 'type': 'Disease', 'properties': {}},\n",
              "   {'id': 'late-onset familial AD', 'type': 'Disease', 'properties': {}},\n",
              "   {'id': 'APOE allele e4', 'type': 'Gene', 'properties': {}},\n",
              "   {'id': 'EOFAD', 'type': 'Disease', 'properties': {}},\n",
              "   {'id': 'viruses', 'type': 'Factor', 'properties': {}},\n",
              "   {'id': 'aging', 'type': 'Factor', 'properties': {}},\n",
              "   {'id': 'nonfamilial AD', 'type': 'Disease', 'properties': {}},\n",
              "   {'id': 'after age 60–65 years', 'type': 'Characteristic', 'properties': {}},\n",
              "   {'id': 'e4/e4 genotype', 'type': 'Genotype', 'properties': {}},\n",
              "   {'id': 'AD', 'type': 'Disease', 'properties': {}},\n",
              "   {'id': 'genetic predisposition', 'type': 'Factor', 'properties': {}},\n",
              "   {'id': 'multiple cases of AD', 'type': 'Disease', 'properties': {}},\n",
              "   {'id': 'APOE e4', 'type': 'Gene', 'properties': {}},\n",
              "   {'id': 'positive family history of dementia',\n",
              "    'type': 'Factor',\n",
              "    'properties': {}},\n",
              "   {'id': 'APOE e4 allele', 'type': 'Gene', 'properties': {}},\n",
              "   {'id': 'toxins', 'type': 'Factor', 'properties': {}},\n",
              "   {'id': 'exposure to environmental agents',\n",
              "    'type': 'Factor',\n",
              "    'properties': {}},\n",
              "   {'id': 'before age 60–65 years',\n",
              "    'type': 'Characteristic',\n",
              "    'properties': {}}],\n",
              "  'relationships': [{'source': {'id': 'nonfamilial AD',\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'AD', 'type': 'Disease', 'properties': {}},\n",
              "    'type': 'MEETS_DIAGNOSTIC_CRITERIA',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'nonfamilial AD', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'aging', 'type': 'Factor', 'properties': {}},\n",
              "    'type': 'RESULTS_FROM',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'nonfamilial AD', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'genetic predisposition',\n",
              "     'type': 'Factor',\n",
              "     'properties': {}},\n",
              "    'type': 'RESULTS_FROM',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'nonfamilial AD', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'exposure to environmental agents',\n",
              "     'type': 'Factor',\n",
              "     'properties': {}},\n",
              "    'type': 'RESULTS_FROM',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'nonfamilial AD', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'head trauma', 'type': 'Factor', 'properties': {}},\n",
              "    'type': 'RESULTS_FROM',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'nonfamilial AD', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'viruses', 'type': 'Factor', 'properties': {}},\n",
              "    'type': 'RESULTS_FROM',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'nonfamilial AD', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'toxins', 'type': 'Factor', 'properties': {}},\n",
              "    'type': 'RESULTS_FROM',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'EOFAD', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'multiple cases of AD',\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'type': 'DIAGNOSED_IN_FAMILIES_WITH',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'EOFAD', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'before age 60–65 years',\n",
              "     'type': 'Characteristic',\n",
              "     'properties': {}},\n",
              "    'type': 'MEAN_AGE_OF_ONSET',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'late-onset FAD', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'multiple cases of AD',\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'type': 'DIAGNOSED_IN_FAMILIES_WITH',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'late-onset FAD', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'after age 60–65 years',\n",
              "     'type': 'Characteristic',\n",
              "     'properties': {}},\n",
              "    'type': 'MEAN_AGE_OF_ONSET',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'APOE allele e4', 'type': 'Gene', 'properties': {}},\n",
              "    'target': {'id': 'late-onset AD', 'type': 'Disease', 'properties': {}},\n",
              "    'type': 'ASSOCIATED_WITH',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'APOE e4', 'type': 'Gene', 'properties': {}},\n",
              "    'target': {'id': 'late-onset AD', 'type': 'Disease', 'properties': {}},\n",
              "    'type': 'ASSOCIATED_WITH',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'APOE e4', 'type': 'Gene', 'properties': {}},\n",
              "    'target': {'id': 'positive family history of dementia',\n",
              "     'type': 'Factor',\n",
              "     'properties': {}},\n",
              "    'type': 'ASSOCIATED_WITH',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'APOE e4 allele', 'type': 'Gene', 'properties': {}},\n",
              "    'target': {'id': 'late-onset familial AD',\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'type': 'ASSOCIATED_WITH',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'APOE e4 allele', 'type': 'Gene', 'properties': {}},\n",
              "    'target': {'id': 'e4/e4 genotype', 'type': 'Genotype', 'properties': {}},\n",
              "    'type': 'ASSOCIATED_WITH',\n",
              "    'properties': {}}],\n",
              "  'source': {'id': None,\n",
              "   'metadata': {},\n",
              "   'page_content': 'Unknown causes\\nIndividuals with nonfamilial AD meet the diagnostic criteria\\nfor AD and have a negative family history. Onset can be any-\\ntime in adulthood. The exact pathogenesis of the disease is\\nunknown. A common hypothesis is that nonfamilial AD is\\nmultifactorial and results from a combination of aging, genetic\\npredisposition, and exposure to one or more environmental\\nagents, such as head trauma, viruses, and/or toxins65although\\nno environmental agents have been proven to be directly in-\\nvolved in the pathogenesis of AD.EVALUATION STRATEGY\\nFamily history\\nA three-generation family history with close attention to the\\nhistory of individuals with dementia should be obtained. For each\\naffected individual, the age of onset of dementia should be noted.\\nGenerally, individuals with onset before age 65 years are consid-\\nered to have early-onset AD and those with onset after age 65 years\\nare considered to have late-onset AD. Medical records of affected\\nfamily members, including reports of neuroimaging studies and\\nautopsy examinations, should be obtained.\\n●The diagnosis of EOFAD is made in families with multiple\\ncases of AD in which the mean age of onset is before age\\n60–65 years.\\n●The diagnosis of late-onset FAD is made in families with\\nmultiple cases of AD in which the mean age of onset is\\nafter age 60–65 years.\\nMolecular genetic testing\\nLate-onset familial AD\\nThe association of one or two copies of the APOE allele e4\\n(i.e., genotypes e2/e4, e3/e4, e4/e4) with late-onset AD is well\\ndocumented (Table 4).32,66,67\\n●The association between APOE e4 and AD is greatest\\nwhen the individual has a positive family history of de-\\nmentia. The last column of Table 4 largely represents late-\\nonset familial AD.\\n●The strongest association between the APOE e4 allele and\\nAD, relative to the normal control population, is with the\\ne4/e4 genotype. That genotype occurs in about 1% of the\\nnormal control population and in nearly 19% of the fa-\\nmilial AD population.\\n●In individuals who have the clinical diagnosis of AD, the\\nprobability that AD is the correct diagnosis is increased',\n",
              "   'type': 'Document'}},\n",
              " {'nodes': [{'id': 'APOE e4/e4 genotype',\n",
              "    'type': 'Genotype',\n",
              "    'properties': {}},\n",
              "   {'id': 'Individuals with AD', 'type': 'Population', 'properties': {}},\n",
              "   {'id': 'APP', 'type': 'Protein', 'properties': {}},\n",
              "   {'id': 'PSEN2', 'type': 'Gene', 'properties': {}},\n",
              "   {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "   {'id': 'Individuals with AD and positive family history of dementia',\n",
              "    'type': 'Population',\n",
              "    'properties': {}},\n",
              "   {'id': 'APOE e4 allele', 'type': 'Genotype', 'properties': {}},\n",
              "   {'id': 'Early-onset familial Alzheimer disease (EOFAD)',\n",
              "    'type': 'Disease',\n",
              "    'properties': {}},\n",
              "   {'id': 'APP gene', 'type': 'Gene', 'properties': {}},\n",
              "   {'id': 'AD', 'type': 'Disease', 'properties': {}},\n",
              "   {'id': 'APOE genotype', 'type': 'Genotype', 'properties': {}},\n",
              "   {'id': 'Rare Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "   {'id': '1q31-q42', 'type': 'Chromosomal locus', 'properties': {}},\n",
              "   {'id': 'Normal controls', 'type': 'Population', 'properties': {}},\n",
              "   {'id': 'Caribbean Hispanics', 'type': 'Ethnicity', 'properties': {}},\n",
              "   {'id': '14q24.3', 'type': 'Chromosomal locus', 'properties': {}},\n",
              "   {'id': 'Breitner et al.', 'type': 'Person', 'properties': {}},\n",
              "   {'id': 'PSEN1', 'type': 'Gene', 'properties': {}},\n",
              "   {'id': 'Amyloid beta A4 protein', 'type': 'Protein', 'properties': {}},\n",
              "   {'id': 'African-Americans', 'type': 'Ethnicity', 'properties': {}},\n",
              "   {'id': '21q21', 'type': 'Chromosomal locus', 'properties': {}},\n",
              "   {'id': 'lifetime risks for developing AD',\n",
              "    'type': 'Disease',\n",
              "    'properties': {}}],\n",
              "  'relationships': [{'source': {'id': 'AD',\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'APOE e4/e4 genotype',\n",
              "     'type': 'Genotype',\n",
              "     'properties': {}},\n",
              "    'type': 'ASSOCIATED_WITH',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'APOE e4 allele', 'type': 'Genotype', 'properties': {}},\n",
              "    'type': 'ASSOCIATED_WITH',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'APOE e4 allele', 'type': 'Genotype', 'properties': {}},\n",
              "    'target': {'id': 'AD', 'type': 'Disease', 'properties': {}},\n",
              "    'type': 'NOT_SPECIFIC_FOR',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'APOE e4 allele', 'type': 'Genotype', 'properties': {}},\n",
              "    'target': {'id': 'AD', 'type': 'Disease', 'properties': {}},\n",
              "    'type': 'NOT_RULE_OUT',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Breitner et al.', 'type': 'Person', 'properties': {}},\n",
              "    'target': {'id': 'lifetime risks for developing AD',\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'type': 'ESTIMATED',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'APOE genotype', 'type': 'Genotype', 'properties': {}},\n",
              "    'target': {'id': 'African-Americans',\n",
              "     'type': 'Ethnicity',\n",
              "     'properties': {}},\n",
              "    'type': 'FOUND_IN',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'APOE genotype', 'type': 'Genotype', 'properties': {}},\n",
              "    'target': {'id': 'Caribbean Hispanics',\n",
              "     'type': 'Ethnicity',\n",
              "     'properties': {}},\n",
              "    'type': 'FOUND_IN',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'APP gene', 'type': 'Gene', 'properties': {}},\n",
              "    'target': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "    'type': 'INVOLVED_IN',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'PSEN1', 'type': 'Gene', 'properties': {}},\n",
              "    'target': {'id': 'Early-onset familial Alzheimer disease (EOFAD)',\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'type': 'CAUSES',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'APP', 'type': 'Protein', 'properties': {}},\n",
              "    'target': {'id': 'Amyloid beta A4 protein',\n",
              "     'type': 'Protein',\n",
              "     'properties': {}},\n",
              "    'type': 'PRODUCES',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'PSEN1', 'type': 'Gene', 'properties': {}},\n",
              "    'target': {'id': '14q24.3', 'type': 'Chromosomal locus', 'properties': {}},\n",
              "    'type': 'LOCATED_AT',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'APP', 'type': 'Protein', 'properties': {}},\n",
              "    'target': {'id': '21q21', 'type': 'Chromosomal locus', 'properties': {}},\n",
              "    'type': 'LOCATED_AT',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'PSEN2', 'type': 'Gene', 'properties': {}},\n",
              "    'target': {'id': 'Rare Alzheimer disease',\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'type': 'CAUSES',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'PSEN2', 'type': 'Gene', 'properties': {}},\n",
              "    'target': {'id': '1q31-q42',\n",
              "     'type': 'Chromosomal locus',\n",
              "     'properties': {}},\n",
              "    'type': 'LOCATED_AT',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'APOE genotype', 'type': 'Genotype', 'properties': {}},\n",
              "    'target': {'id': 'Normal controls',\n",
              "     'type': 'Population',\n",
              "     'properties': {}},\n",
              "    'type': 'FOUND_IN',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'APOE genotype', 'type': 'Genotype', 'properties': {}},\n",
              "    'target': {'id': 'Individuals with AD',\n",
              "     'type': 'Population',\n",
              "     'properties': {}},\n",
              "    'type': 'FOUND_IN',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'APOE genotype', 'type': 'Genotype', 'properties': {}},\n",
              "    'target': {'id': 'Individuals with AD and positive family history of dementia',\n",
              "     'type': 'Population',\n",
              "     'properties': {}},\n",
              "    'type': 'FOUND_IN',\n",
              "    'properties': {}}],\n",
              "  'source': {'id': None,\n",
              "   'metadata': {},\n",
              "   'page_content': '●In individuals who have the clinical diagnosis of AD, the\\nprobability that AD is the correct diagnosis is increased to\\nabout 97% in the presence of the APOE e4/e4 genotype.68\\n●The increased risk of AD associated with one APOE e4\\nallele or two APOE e4 alleles is also found in African-\\nAmericans69and Caribbean Hispanics.70\\n●Approximately 42% of persons with AD do not have an\\nAPOE e4 allele. Thus, APOE genotyping is not specific for\\nAD. The absence of an APOE e4 allele does not rule out\\nthe diagnosis of AD2.\\n●Breitner et al.71have estimated lifetime risks for devel-\\noping AD based on gender and APOE genotype (see\\nTesting of At-risk Asymptomatic Individuals under\\nGenetic Counseling).\\nFig. 3. Molecular aspects of the APP gene and protein showing the sites of cleavage by\\n/H9251,/H9252, and /H9253secretases, production of the A /H9252peptide (upper right), and sites of several\\ndisease causing mutations (bottom line).Table 3\\nEarly-onset familial Alzheimer disease (EOFAD): molecular genetics\\nLocus name Proportion of EOFAD Gene symbol Chromosomal locus Protein name Test availability\\nAD3 20–70% PSEN1 14q24.3 Presenilin-1 Clinical\\nAD1 10–15% APP 21q21 Amyloid beta A4 protein Clinical\\nAD4 Rare PSEN2 1q31-q42 Presenilin-2 Clinical\\nTable 4\\nPercent of APOE genotypes in controls and individuals with AD\\nAPOE\\ngenotypeNormal controls\\n(n/H11005304)All individuals\\nwith AD\\n(n/H11005233)Individuals with AD\\nand positive family\\nhistory of dementiaa\\n(n/H1100585)\\ne2/e2 1.3% 0% 0%\\ne2/e3 12.5% 3.4% 3.5%\\ne2/e4 4.9% 4.3% 8.2%\\ne3/e3 59.9% 38.2% 23.5%\\ne3/e4 20.7% 41.2% 45.9%\\ne4/',\n",
              "   'type': 'Document'}},\n",
              " {'nodes': [{'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "   {'id': 'e4', 'type': 'Genotype', 'properties': {}},\n",
              "   {'id': 'e3', 'type': 'Genotype', 'properties': {}}],\n",
              "  'relationships': [{'source': {'id': 'e3',\n",
              "     'type': 'Genotype',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "    'type': 'TRANSMISSION',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'e4', 'type': 'Genotype', 'properties': {}},\n",
              "    'target': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "    'type': 'TRANSMISSION',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'e4', 'type': 'Genotype', 'properties': {}},\n",
              "    'target': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "    'type': 'TRANSMISSION',\n",
              "    'properties': {}}],\n",
              "  'source': {'id': None,\n",
              "   'metadata': {},\n",
              "   'page_content': '5%\\ne3/e4 20.7% 41.2% 45.9%\\ne4/e4 0.7% 12.9% 18.8%\\nModified from Jarvik G, Larson EB, Goddard K, Schellenberg GD, et al. Influ-\\nence of apolipoprotein E genotype on the transmission of Alzheimer disease in\\na community-based sample. Am J Hum Genet 1996;58:191–200.\\naMost families would be considered to have late-onset familial AD.Bird\\n234 Genetics INMedicine',\n",
              "   'type': 'Document'}},\n",
              " {'nodes': [{'id': 'autosomal-dominant manner',\n",
              "    'type': 'Concept',\n",
              "    'properties': {}},\n",
              "   {'id': 'EOFAD', 'type': 'Concept', 'properties': {}},\n",
              "   {'id': 'APOE e4 allele', 'type': 'Concept', 'properties': {}},\n",
              "   {'id': 'diagnosis of AD', 'type': 'Concept', 'properties': {}},\n",
              "   {'id': 'APOE genotyping', 'type': 'Concept', 'properties': {}},\n",
              "   {'id': 'molecular genetic testing', 'type': 'Concept', 'properties': {}},\n",
              "   {'id': 'APOE e2 allele', 'type': 'Concept', 'properties': {}},\n",
              "   {'id': 'AD3', 'type': 'Concept', 'properties': {}},\n",
              "   {'id': 'significant diagnostic use in identifying AD',\n",
              "    'type': 'Concept',\n",
              "    'properties': {}},\n",
              "   {'id': 'neuropathologic confirmation of AD',\n",
              "    'type': 'Concept',\n",
              "    'properties': {}},\n",
              "   {'id': 'AD1', 'type': 'Concept', 'properties': {}},\n",
              "   {'id': 'AD474', 'type': 'Concept', 'properties': {}},\n",
              "   {'id': 'AD', 'type': 'Concept', 'properties': {}},\n",
              "   {'id': 'risk for AD', 'type': 'Concept', 'properties': {}}],\n",
              "  'relationships': [{'source': {'id': 'APOE genotyping',\n",
              "     'type': 'Concept',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'diagnosis of AD', 'type': 'Concept', 'properties': {}},\n",
              "    'type': 'HAS_ADJUNCT_ROLE_IN',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'APOE e4 allele', 'type': 'Concept', 'properties': {}},\n",
              "    'target': {'id': 'neuropathologic confirmation of AD',\n",
              "     'type': 'Concept',\n",
              "     'properties': {}},\n",
              "    'type': 'IS_ASSOCIATED_WITH',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'APOE genotyping', 'type': 'Concept', 'properties': {}},\n",
              "    'target': {'id': 'significant diagnostic use in identifying AD',\n",
              "     'type': 'Concept',\n",
              "     'properties': {}},\n",
              "    'type': 'NOT_FOUND_TO_BE',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'APOE e2 allele', 'type': 'Concept', 'properties': {}},\n",
              "    'target': {'id': 'risk for AD', 'type': 'Concept', 'properties': {}},\n",
              "    'type': 'HAS_PROTECTIVE_EFFECT_IN',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'APOE e4 allele', 'type': 'Concept', 'properties': {}},\n",
              "    'target': {'id': 'risk for AD', 'type': 'Concept', 'properties': {}},\n",
              "    'type': 'IS_ASSOCIATED_WITH',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'EOFAD', 'type': 'Concept', 'properties': {}},\n",
              "    'target': {'id': 'AD3', 'type': 'Concept', 'properties': {}},\n",
              "    'type': 'HAS_SUBTYPES',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'EOFAD', 'type': 'Concept', 'properties': {}},\n",
              "    'target': {'id': 'AD1', 'type': 'Concept', 'properties': {}},\n",
              "    'type': 'HAS_SUBTYPES',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'EOFAD', 'type': 'Concept', 'properties': {}},\n",
              "    'target': {'id': 'AD474', 'type': 'Concept', 'properties': {}},\n",
              "    'type': 'HAS_SUBTYPES',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'EOFAD', 'type': 'Concept', 'properties': {}},\n",
              "    'target': {'id': 'molecular genetic testing',\n",
              "     'type': 'Concept',\n",
              "     'properties': {}},\n",
              "    'type': 'CAN_BE_DISTINGUISHED_BY',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'EOFAD', 'type': 'Concept', 'properties': {}},\n",
              "    'target': {'id': 'autosomal-dominant manner',\n",
              "     'type': 'Concept',\n",
              "     'properties': {}},\n",
              "    'type': 'IS_INHERITED_IN',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'AD', 'type': 'Concept', 'properties': {}},\n",
              "    'target': {'id': 'AD', 'type': 'Concept', 'properties': {}},\n",
              "    'type': 'IS_CONSIDERED_POLYGENIC_AND_MULTIFACTORIAL',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'EOFAD', 'type': 'Concept', 'properties': {}},\n",
              "    'target': {'id': 'autosomal-dominant manner',\n",
              "     'type': 'Concept',\n",
              "     'properties': {}},\n",
              "    'type': 'IS_INHERITED_IN',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'AD', 'type': 'Concept', 'properties': {}},\n",
              "    'target': {'id': 'AD', 'type': 'Concept', 'properties': {}},\n",
              "    'type': 'IS_CONSIDERED_POLYGENIC_AND_MULTIFACTORIAL',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'AD', 'type': 'Concept', 'properties': {}},\n",
              "    'target': {'id': 'AD', 'type': 'Concept', 'properties': {}},\n",
              "    'type': 'IS_GENETICALLY_HETEROGENEOUS',\n",
              "    'properties': {}}],\n",
              "  'source': {'id': None,\n",
              "   'metadata': {},\n",
              "   'page_content': 'The usefulness of APOE genotyping in clinical diagnosis and\\nrisk assessment remains unclear (Statements and Policies Re-\\ngarding Genetic Testing).\\n●Although the presence of one APOE e4 allele or two APOE\\ne4 alleles is neither necessary nor sufficient to establish a\\ndiagnosis of AD, APOE genotyping may have an adjunct\\nrole in the diagnosis of AD because a large proportion of\\nindividuals with one APOE e4 allele or two APOE e4 al-\\nleles who are demented have been found to have neuro-\\npathologic confirmation of AD at autopsy.2,66,72,73\\n●In contrast, APOE genotyping was not found to be of\\nsignificant diagnostic use in identifying AD in a commu-\\nnity-based sample with late-onset dementia.74\\nThere is some evidence that the APOE e2 allele may have a\\nprotective effect in regard to risk for AD (Table 4).\\nAnother way to look at this association between AD and an\\nAPOE e4 allele is with APOE e4 allele frequencies (Table 5).\\nEarly-onset familial AD\\nThe three known subtypes of EOFAD, called AD3, AD1, and\\nAD474,75can only be distinguished by molecular genetic testing\\n(Table 3). Genetic testing of individuals who are simplex cases\\n(i.e., a single occurrence of early-onset AD in a family) is con-\\ntroversial and should be undertaken in the context of formal\\ngenetic counseling.76A small proportion ( /H110215%) of such cases\\nwill have a mutation in PS1.\\nGENETIC COUNSELING\\nMode of inheritance\\nBecause AD is genetically heterogeneous, genetic counseling\\nof persons with AD and their family members must be tailored\\nto the information available for that family. AD is usually con-\\nsidered polygenic and multifactorial. EOFAD is inherited in an\\nautosomal-dominant manner.\\nRisk to family members—late-onset nonfamilial Alzheimer disease\\nGenetic counseling for people with nonfamilial AD and\\ntheir family members must be empiric and relatively nonspe-\\ncific. It should be pointed out that AD is common and that theoverall lifetime risk to any individual of developing dementia is\\napproximately 10–12%.\\nFirst-degree relatives of a person with AD have a cumulative\\n',\n",
              "   'type': 'Document'}},\n",
              " {'nodes': [{'id': 'family members', 'type': 'Person', 'properties': {}},\n",
              "   {'id': 'parents', 'type': 'Person', 'properties': {}},\n",
              "   {'id': 'offspring', 'type': 'Person', 'properties': {}},\n",
              "   {'id': 'sibs', 'type': 'Person', 'properties': {}},\n",
              "   {'id': 'individuals', 'type': 'Person', 'properties': {}},\n",
              "   {'id': \"proband's parents\", 'type': 'Person', 'properties': {}},\n",
              "   {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}],\n",
              "  'relationships': [{'source': {'id': 'Alzheimer disease',\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'individuals', 'type': 'Person', 'properties': {}},\n",
              "    'type': 'AFFECTS',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'family members', 'type': 'Person', 'properties': {}},\n",
              "    'type': 'AFFECTS',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'parents', 'type': 'Person', 'properties': {}},\n",
              "    'type': 'AFFECTS',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'offspring', 'type': 'Person', 'properties': {}},\n",
              "    'type': 'AFFECTS',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'individuals', 'type': 'Person', 'properties': {}},\n",
              "    'type': 'AFFECTS',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'family members', 'type': 'Person', 'properties': {}},\n",
              "    'type': 'AFFECTS',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'parents', 'type': 'Person', 'properties': {}},\n",
              "    'type': 'AFFECTS',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'offspring', 'type': 'Person', 'properties': {}},\n",
              "    'type': 'AFFECTS',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'family members', 'type': 'Person', 'properties': {}},\n",
              "    'type': 'AFFECTS',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'sibs', 'type': 'Person', 'properties': {}},\n",
              "    'type': 'AFFECTS',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': \"proband's parents\", 'type': 'Person', 'properties': {}},\n",
              "    'type': 'AFFECTS',\n",
              "    'properties': {}}],\n",
              "  'source': {'id': None,\n",
              "   'metadata': {},\n",
              "   'page_content': ' of developing dementia is\\napproximately 10–12%.\\nFirst-degree relatives of a person with AD have a cumulative\\nlifetime risk of developing AD of about 15–30%, which is typ-\\nically reported as a 20–25% risk.77,78This risk is about 2.5 times\\nthat of the background risk ( /H1101127% vs. 10.4%).79,80\\nDisagreement exists as to whether the age of onset of the\\naffected person changes the risk to first-degree relatives. One\\nstudy found that early-onset AD increased the risk,78whereas\\nanother study did not.77\\nThe number of additional affected family members proba-\\nbly increases the risk to close relatives, but the magnitude of\\nthat increase is unclear unless the pattern in the family is char-\\nacteristic of autosomal-dominant inheritance. Having two,\\nthree, or more affected family members probably raises the risk\\nto other first-degree relatives in excess of that noted above for\\nnonfamilial cases, although the exact magnitude of the risk is\\nnot clear. Heston et al.81found a 35–45% risk of dementia in\\nindividuals who had a parent with AD and a sib with onset of\\nAD before age 70 years. Jayadev et al.82also report data sug-\\ngesting that offspring of parents with conjugal AD (i.e., both\\nparents affected) had an increased risk of dementia.\\nRisk to family members—early-onset familial Alzheimer disease\\nMany individuals diagnosed as having early-onset AD have\\nanother affected family member, although family history is\\nnegative 40% of the time.10Family history may be “negative”\\nbecause of early death of a parent, failure to recognize the dis-\\norder in family members, or, rarely, a de novo mutation. The\\nrisk to sibs depends upon the genetic status of the affected\\nproband’s parent. If one of the proband’s parents has a mutant\\nallele, then the risk to the sibs of inheriting the mutant allele is\\n50%. Individuals with EOFAD (and a mutation in APP,PS1,o r\\nPS2) have a 50% chance of transmitting the mutant allele to\\neach child. The risk to other family members depends upon the\\nstatus of the proband’s parents. If a parent',\n",
              "   'type': 'Document'}},\n",
              " {'nodes': [{'id': 'APOE testing', 'type': 'Test', 'properties': {}},\n",
              "   {'id': 'developing AD', 'type': 'Event', 'properties': {}},\n",
              "   {'id': 'predictive testing', 'type': 'Purpose', 'properties': {}},\n",
              "   {'id': 'APOE e4/e4 genotype', 'type': 'Genotype', 'properties': {}},\n",
              "   {'id': 'developing AD by age 73 years', 'type': 'Event', 'properties': {}},\n",
              "   {'id': 'APOE e4 allele', 'type': 'Allele', 'properties': {}},\n",
              "   {'id': 'risk', 'type': 'Characteristic', 'properties': {}},\n",
              "   {'id': 'age of onset', 'type': 'Characteristic', 'properties': {}},\n",
              "   {'id': 'men', 'type': 'Person', 'properties': {}},\n",
              "   {'id': 'AD', 'type': 'Disease', 'properties': {}},\n",
              "   {'id': 'adjunct diagnostic test', 'type': 'Purpose', 'properties': {}},\n",
              "   {'id': 'women with an APOE e4/e4 genotype',\n",
              "    'type': 'Population',\n",
              "    'properties': {}},\n",
              "   {'id': 'APOE', 'type': 'Gene', 'properties': {}}],\n",
              "  'relationships': [{'source': {'id': 'APOE',\n",
              "     'type': 'Gene',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'AD', 'type': 'Disease', 'properties': {}},\n",
              "    'type': 'PREDICTS',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'APOE e4/e4 genotype',\n",
              "     'type': 'Genotype',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'developing AD', 'type': 'Event', 'properties': {}},\n",
              "    'type': 'PREDICTS_RISK',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'women with an APOE e4/e4 genotype',\n",
              "     'type': 'Population',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'developing AD by age 73 years',\n",
              "     'type': 'Event',\n",
              "     'properties': {}},\n",
              "    'type': 'HAVE_PROBABILITY',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'men', 'type': 'Person', 'properties': {}},\n",
              "    'target': {'id': 'developing AD', 'type': 'Event', 'properties': {}},\n",
              "    'type': 'HAVE_RISK',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'APOE e4 allele', 'type': 'Allele', 'properties': {}},\n",
              "    'target': {'id': 'risk', 'type': 'Characteristic', 'properties': {}},\n",
              "    'type': 'AFFECTS',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'APOE e4 allele', 'type': 'Allele', 'properties': {}},\n",
              "    'target': {'id': 'age of onset',\n",
              "     'type': 'Characteristic',\n",
              "     'properties': {}},\n",
              "    'type': 'AFFECTS',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'APOE testing', 'type': 'Test', 'properties': {}},\n",
              "    'target': {'id': 'predictive testing',\n",
              "     'type': 'Purpose',\n",
              "     'properties': {}},\n",
              "    'type': 'USED_FOR',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'APOE testing', 'type': 'Test', 'properties': {}},\n",
              "    'target': {'id': 'adjunct diagnostic test',\n",
              "     'type': 'Purpose',\n",
              "     'properties': {}},\n",
              "    'type': 'USED_AS',\n",
              "    'properties': {}}],\n",
              "  'source': {'id': None,\n",
              "   'metadata': {},\n",
              "   'page_content': '. The risk to other family members depends upon the\\nstatus of the proband’s parents. If a parent is found to be af-\\nfected, his or her family members are at risk.\\nRelated genetic counseling issues\\nUse of APOE genotyping for predictive testing\\nIn contrast to the use of APOE testing as an adjunct diagnos-\\ntic test in individuals with dementia, there is general agreement\\nthatAPOE testing has limited value used for predictive testing\\nfor AD in asymptomatic persons. Data suggest that a young\\nasymptomatic person with the APOE e4/e4 genotype may have\\nan approximately 30% lifetime risk of developing AD.83Fur-\\nther refinement of this risk reveals that women with an APOE\\ne4/e4 genotype have a 45% probability of developing AD by\\nage 73 years, whereas men have a 25% risk.71These risks are\\nlower—and the likely age of onset later—for persons with only\\noneAPOE e4 allele (peak age 87 years) or no APOE e4 allele\\n(peak age 95 years). These estimates are not generally consid-\\nered clinically useful; however, a research study to assess the\\npotential use of APOE testing in relatives of individuals with\\nlate-onset AD is under way.79,84Table 5\\nAPOE allele frequencies in controls and individuals with AD\\nAPOE\\nalleleNormal\\ncontrols\\n(n/H11005304)All individuals\\nwith AD\\n(n/H11005233)Individuals with AD\\nand positive family\\nhistory of dementiaa\\n(n/H1100585)\\ne2 9.0% 3.9% 5.9%\\ne3 76.5% 60.5% 48.2%\\ne4 13.7% 35.6% 45.9%\\nModified from Jarvik G, Larson EB, Goddard K, Schellenberg GD, et al. Influ-\\nence of apolipoprotein E genotype on the transmission of Alzheimer disease in\\na community-based sample. Am J Hum Genet 1996;58:191–200.\\naMost families would be considered to have late-onset familial AD.Genetic aspects of Alzheimer disease\\nApril 2008 /H18528Vol. 10 /H18528No. 4 235',\n",
              "   'type': 'Document'}},\n",
              " {'nodes': [{'id': 'mutations in the PSEN1 gene',\n",
              "    'type': 'Genetic Mutation',\n",
              "    'properties': {}},\n",
              "   {'id': 'prenatal diagnosis', 'type': 'Medical Procedure', 'properties': {}},\n",
              "   {'id': 'prenatal testing', 'type': 'Medical Procedure', 'properties': {}},\n",
              "   {'id': 'increased risk for EOFAD', 'type': 'Condition', 'properties': {}},\n",
              "   {'id': 'fetal cells obtained by amniocentesis',\n",
              "    'type': 'Biological Sample',\n",
              "    'properties': {}},\n",
              "   {'id': 'chorionic villus sampling',\n",
              "    'type': 'Medical Procedure',\n",
              "    'properties': {}},\n",
              "   {'id': 'Down syndrome', 'type': 'Disease', 'properties': {}},\n",
              "   {'id': 'increased risk for AD', 'type': 'Condition', 'properties': {}}],\n",
              "  'relationships': [{'source': {'id': 'Down syndrome',\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'increased risk for AD',\n",
              "     'type': 'Condition',\n",
              "     'properties': {}},\n",
              "    'type': 'CAUSES',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'mutations in the PSEN1 gene',\n",
              "     'type': 'Genetic Mutation',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'increased risk for EOFAD',\n",
              "     'type': 'Condition',\n",
              "     'properties': {}},\n",
              "    'type': 'CAUSES',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'mutations in the PSEN1 gene',\n",
              "     'type': 'Genetic Mutation',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'prenatal diagnosis',\n",
              "     'type': 'Medical Procedure',\n",
              "     'properties': {}},\n",
              "    'type': 'CAUSES',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'mutations in the PSEN1 gene',\n",
              "     'type': 'Genetic Mutation',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'prenatal testing',\n",
              "     'type': 'Medical Procedure',\n",
              "     'properties': {}},\n",
              "    'type': 'CAUSES',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'mutations in the PSEN1 gene',\n",
              "     'type': 'Genetic Mutation',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'fetal cells obtained by amniocentesis',\n",
              "     'type': 'Biological Sample',\n",
              "     'properties': {}},\n",
              "    'type': 'CAUSES',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'mutations in the PSEN1 gene',\n",
              "     'type': 'Genetic Mutation',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'chorionic villus sampling',\n",
              "     'type': 'Medical Procedure',\n",
              "     'properties': {}},\n",
              "    'type': 'CAUSES',\n",
              "    'properties': {}}],\n",
              "  'source': {'id': None,\n",
              "   'metadata': {},\n",
              "   'page_content': 'Down syndrome\\nFamily members of persons with DS are not at increased risk\\nfor AD.\\nTesting of at-risk asymptomatic EOAD family members\\nTesting of at-risk asymptomatic adults\\nTesting of asymptomatic adults at risk for EOFAD caused by\\nmutations in the PSEN1 ,PSEN2 ,o rAPP gene is available clin-\\nically. Testing results for at-risk asymptomatic adults can only\\nbe interpreted after an affected family member’s disease-caus-\\ning mutation has been identified. It should be remembered\\nthat testing of asymptomatic at-risk individuals with nonspe-\\ncific or equivocal symptoms is predictive testing, not diagnos-\\ntic testing.\\nPreliminary results have shown that although relatively few\\nfamily members choose such testing, they usually cope well\\nwith the results, which can affect personal relationships and\\nemotional well-being.85However, significant depression after\\nsuch testing has been reported.86\\nTesting of at-risk individuals during childhood\\nConsensus holds that individuals at risk for adult-onset dis-\\norders should not have testing during childhood in the absence\\nof symptoms. The principal arguments against testing asymp-\\ntomatic individuals during childhood are that it removes their\\nchoice to know or not know this information, it raises the\\npossibility of stigmatization within the family and in other so-\\ncial settings, and it could have serious educational and career\\nimplications.\\nPrenatal testing\\nPrenatal diagnosis for pregnancies at increased risk for mu-\\ntations in the PSEN1 gene is possible by analysis of DNA ex-\\ntracted from fetal cells obtained by amniocentesis usually per-\\nformed at about 15–18 weeks’ gestation or chorionic villus\\nsampling at about 10 to 12 weeks’ gestation. The disease-caus-\\ning allele of an affected family member must be identified be-\\nfore prenatal testing can be performed.\\nNo laboratories offering molecular genetic testing for pre-\\nnatal diagnosis of EOFAD caused by APP orPSEN2 mutations\\nare listed in the GeneTests Laboratory Directory. However,\\nprenatal testing may be available for families in which the dis-\\nease-causing mutation has been identified.\\nRequests for prenatal diagnosis of adult-onset diseases are\\nuncommon. Differences in perspective may exist among med-\\nical',\n",
              "   'type': 'Document'}},\n",
              " {'nodes': [{'id': 'beta-site cleaving enzyme (BACE) inhibitors',\n",
              "    'type': 'Drug',\n",
              "    'properties': {}},\n",
              "   {'id': 'pregnancy termination',\n",
              "    'type': 'Medical Procedure',\n",
              "    'properties': {}},\n",
              "   {'id': 'anti-inflammatory agents', 'type': 'Drug', 'properties': {}},\n",
              "   {'id': 'individuals', 'type': 'Person', 'properties': {}},\n",
              "   {'id': 'behavioral benefit', 'type': 'Medical Benefit', 'properties': {}},\n",
              "   {'id': 'Preimplantation genetic diagnosis',\n",
              "    'type': 'Medical Procedure',\n",
              "    'properties': {}},\n",
              "   {'id': 'statins', 'type': 'Drug', 'properties': {}},\n",
              "   {'id': 'cognitive benefit', 'type': 'Medical Benefit', 'properties': {}},\n",
              "   {'id': 'centers', 'type': 'Facility', 'properties': {}},\n",
              "   {'id': 'treatment', 'type': 'Medical Procedure', 'properties': {}},\n",
              "   {'id': 'families', 'type': 'Group', 'properties': {}},\n",
              "   {'id': 'Aricept®', 'type': 'Drug', 'properties': {}},\n",
              "   {'id': 'parents', 'type': 'Person', 'properties': {}},\n",
              "   {'id': 'over-the-counter medications',\n",
              "    'type': 'Medication',\n",
              "    'properties': {}},\n",
              "   {'id': 'Memantine', 'type': 'Drug', 'properties': {}},\n",
              "   {'id': 'ginkgo biloba', 'type': 'Herbal Supplement', 'properties': {}},\n",
              "   {'id': 'disease-causing mutation',\n",
              "    'type': 'Medical Condition',\n",
              "    'properties': {}},\n",
              "   {'id': 'moderate to severe AD',\n",
              "    'type': 'Medical Condition',\n",
              "    'properties': {}},\n",
              "   {'id': 'acetylcholinesterase',\n",
              "    'type': 'Biological Molecule',\n",
              "    'properties': {}},\n",
              "   {'id': 'estrogens', 'type': 'Drug', 'properties': {}},\n",
              "   {'id': 'Vitamins', 'type': 'Supplement', 'properties': {}},\n",
              "   {'id': 'Drugs', 'type': 'Medical Treatment', 'properties': {}},\n",
              "   {'id': 'tacrine', 'type': 'Drug', 'properties': {}},\n",
              "   {'id': 'brain cholinergic system',\n",
              "    'type': 'Biological System',\n",
              "    'properties': {}},\n",
              "   {'id': 'adult-onset diseases',\n",
              "    'type': 'Medical Condition',\n",
              "    'properties': {}},\n",
              "   {'id': 'Exelon®', 'type': 'Drug', 'properties': {}},\n",
              "   {'id': 'antioxidants', 'type': 'Drug', 'properties': {}},\n",
              "   {'id': 'care', 'type': 'Service', 'properties': {}},\n",
              "   {'id': 'galantamine', 'type': 'Drug', 'properties': {}},\n",
              "   {'id': 'cholinergic activity',\n",
              "    'type': 'Biological Activity',\n",
              "    'properties': {}},\n",
              "   {'id': 'assisted living arrangements', 'type': 'Service', 'properties': {}},\n",
              "   {'id': 'neurotransmitters',\n",
              "    'type': 'Biological Molecule',\n",
              "    'properties': {}},\n",
              "   {'id': 'nerve growth factors',\n",
              "    'type': 'Biological Molecule',\n",
              "    'properties': {}},\n",
              "   {'id': 'manifestations', 'type': 'Medical Condition', 'properties': {}},\n",
              "   {'id': 'depression', 'type': 'Medical Condition', 'properties': {}},\n",
              "   {'id': 'prenatal diagnosis', 'type': 'Medical Procedure', 'properties': {}},\n",
              "   {'id': 'Treatment trials', 'type': 'Medical Study', 'properties': {}},\n",
              "   {'id': 'biochemical basis', 'type': 'Medical Concept', 'properties': {}},\n",
              "   {'id': 'prenatal testing', 'type': 'Medical Procedure', 'properties': {}},\n",
              "   {'id': 'APP mutation', 'type': 'Medical Condition', 'properties': {}},\n",
              "   {'id': 'Antidepressant medication', 'type': 'Drug', 'properties': {}},\n",
              "   {'id': 'mother', 'type': 'Person', 'properties': {}}],\n",
              "  'relationships': [{'source': {'id': 'prenatal diagnosis',\n",
              "     'type': 'Medical Procedure',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'adult-onset diseases',\n",
              "     'type': 'Medical Condition',\n",
              "     'properties': {}},\n",
              "    'type': 'USED_FOR',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'prenatal testing',\n",
              "     'type': 'Medical Procedure',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'pregnancy termination',\n",
              "     'type': 'Medical Procedure',\n",
              "     'properties': {}},\n",
              "    'type': 'USED_FOR',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'centers', 'type': 'Facility', 'properties': {}},\n",
              "    'target': {'id': 'prenatal testing',\n",
              "     'type': 'Medical Procedure',\n",
              "     'properties': {}},\n",
              "    'type': 'PROVIDE_SERVICE',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'parents', 'type': 'Person', 'properties': {}},\n",
              "    'target': {'id': 'prenatal testing',\n",
              "     'type': 'Medical Procedure',\n",
              "     'properties': {}},\n",
              "    'type': 'MAKE_DECISION',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Preimplantation genetic diagnosis',\n",
              "     'type': 'Medical Procedure',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'families', 'type': 'Group', 'properties': {}},\n",
              "    'type': 'AVAILABLE_FOR',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Preimplantation genetic diagnosis',\n",
              "     'type': 'Medical Procedure',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'disease-causing mutation',\n",
              "     'type': 'Medical Condition',\n",
              "     'properties': {}},\n",
              "    'type': 'AVAILABLE_FOR',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Preimplantation genetic diagnosis',\n",
              "     'type': 'Medical Procedure',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'mother', 'type': 'Person', 'properties': {}},\n",
              "    'type': 'AVAILABLE_FOR',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Preimplantation genetic diagnosis',\n",
              "     'type': 'Medical Procedure',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'APP mutation',\n",
              "     'type': 'Medical Condition',\n",
              "     'properties': {}},\n",
              "    'type': 'AVAILABLE_FOR',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'treatment',\n",
              "     'type': 'Medical Procedure',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'manifestations',\n",
              "     'type': 'Medical Condition',\n",
              "     'properties': {}},\n",
              "    'type': 'USED_FOR',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'individuals', 'type': 'Person', 'properties': {}},\n",
              "    'target': {'id': 'assisted living arrangements',\n",
              "     'type': 'Service',\n",
              "     'properties': {}},\n",
              "    'type': 'REQUIRE',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'individuals', 'type': 'Person', 'properties': {}},\n",
              "    'target': {'id': 'care', 'type': 'Service', 'properties': {}},\n",
              "    'type': 'REQUIRE',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'biochemical basis',\n",
              "     'type': 'Medical Concept',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'brain cholinergic system',\n",
              "     'type': 'Biological System',\n",
              "     'properties': {}},\n",
              "    'type': 'RELATED_TO',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'biochemical basis',\n",
              "     'type': 'Medical Concept',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'neurotransmitters',\n",
              "     'type': 'Biological Molecule',\n",
              "     'properties': {}},\n",
              "    'type': 'RELATED_TO',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Drugs', 'type': 'Medical Treatment', 'properties': {}},\n",
              "    'target': {'id': 'cholinergic activity',\n",
              "     'type': 'Biological Activity',\n",
              "     'properties': {}},\n",
              "    'type': 'INCREASE',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Drugs', 'type': 'Medical Treatment', 'properties': {}},\n",
              "    'target': {'id': 'acetylcholinesterase',\n",
              "     'type': 'Biological Molecule',\n",
              "     'properties': {}},\n",
              "    'type': 'INHIBIT',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Drugs', 'type': 'Medical Treatment', 'properties': {}},\n",
              "    'target': {'id': 'behavioral benefit',\n",
              "     'type': 'Medical Benefit',\n",
              "     'properties': {}},\n",
              "    'type': 'PRODUCE',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Drugs', 'type': 'Medical Treatment', 'properties': {}},\n",
              "    'target': {'id': 'cognitive benefit',\n",
              "     'type': 'Medical Benefit',\n",
              "     'properties': {}},\n",
              "    'type': 'PRODUCE',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'tacrine', 'type': 'Drug', 'properties': {}},\n",
              "    'target': {'id': 'Aricept®', 'type': 'Drug', 'properties': {}},\n",
              "    'type': 'SIMILAR_TO',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'tacrine', 'type': 'Drug', 'properties': {}},\n",
              "    'target': {'id': 'Exelon®', 'type': 'Drug', 'properties': {}},\n",
              "    'type': 'SIMILAR_TO',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'tacrine', 'type': 'Drug', 'properties': {}},\n",
              "    'target': {'id': 'galantamine', 'type': 'Drug', 'properties': {}},\n",
              "    'type': 'SIMILAR_TO',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Memantine', 'type': 'Drug', 'properties': {}},\n",
              "    'target': {'id': 'moderate to severe AD',\n",
              "     'type': 'Medical Condition',\n",
              "     'properties': {}},\n",
              "    'type': 'TREAT',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Antidepressant medication',\n",
              "     'type': 'Drug',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'depression',\n",
              "     'type': 'Medical Condition',\n",
              "     'properties': {}},\n",
              "    'type': 'IMPROVE',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Treatment trials',\n",
              "     'type': 'Medical Study',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'anti-inflammatory agents',\n",
              "     'type': 'Drug',\n",
              "     'properties': {}},\n",
              "    'type': 'EVALUATE',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Treatment trials',\n",
              "     'type': 'Medical Study',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'estrogens', 'type': 'Drug', 'properties': {}},\n",
              "    'type': 'EVALUATE',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Treatment trials',\n",
              "     'type': 'Medical Study',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'nerve growth factors',\n",
              "     'type': 'Biological Molecule',\n",
              "     'properties': {}},\n",
              "    'type': 'EVALUATE',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Treatment trials',\n",
              "     'type': 'Medical Study',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'ginkgo biloba',\n",
              "     'type': 'Herbal Supplement',\n",
              "     'properties': {}},\n",
              "    'type': 'EVALUATE',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Treatment trials',\n",
              "     'type': 'Medical Study',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'statins', 'type': 'Drug', 'properties': {}},\n",
              "    'type': 'EVALUATE',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Treatment trials',\n",
              "     'type': 'Medical Study',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'beta-site cleaving enzyme (BACE) inhibitors',\n",
              "     'type': 'Drug',\n",
              "     'properties': {}},\n",
              "    'type': 'EVALUATE',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Treatment trials',\n",
              "     'type': 'Medical Study',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'antioxidants', 'type': 'Drug', 'properties': {}},\n",
              "    'type': 'EVALUATE',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Vitamins', 'type': 'Supplement', 'properties': {}},\n",
              "    'target': {'id': 'treatment',\n",
              "     'type': 'Medical Procedure',\n",
              "     'properties': {}},\n",
              "    'type': 'USED_IN',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'over-the-counter medications',\n",
              "     'type': 'Medication',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'treatment',\n",
              "     'type': 'Medical Procedure',\n",
              "     'properties': {}},\n",
              "    'type': 'USED_IN',\n",
              "    'properties': {}}],\n",
              "  'source': {'id': None,\n",
              "   'metadata': {},\n",
              "   'page_content': ' for prenatal diagnosis of adult-onset diseases are\\nuncommon. Differences in perspective may exist among med-\\nical professionals and within families regarding the use of pre-\\nnatal testing, particularly if the testing is being considered for\\nthe purpose of pregnancy termination. Although most centers\\nwould consider decisions about prenatal testing to be the\\nchoice of the parents, careful discussion of these issues is ap-\\npropriate.\\nPreimplantation genetic diagnosis\\nPreimplantation genetic diagnosis may be available for fam-\\nilies in which the disease-causing mutation has been identified.Preimplantation diagnosis has been reported in a mother with\\nanAPP mutation.87,88\\nMANAGEMENT\\nTreatment of manifestations\\nThe mainstay of treatment for AD is necessarily supportive\\nand each symptom is managed on an individual basis.1In gen-\\neral, affected individuals eventually require assisted living ar-\\nrangements or care in a nursing home.\\nAlthough the exact biochemical basis of AD is not well un-\\nderstood, it is known that deficiencies of the brain cholinergic\\nsystem and of other neurotransmitters are present. Drugs that\\nincrease cholinergic activity by inhibiting acetylcholinesterase\\nproduce a modest but useful behavioral or cognitive benefit in\\nsome affected individuals. The first such drug was tacrine;\\nhowever, this agent is also hepatotoxic. Newer such drugs with\\nsimilar pharmacologic action, such as Aricept® (donepezil),89–91\\nExelon® (rivastigmine),92and galantamine,93–95 are not hepato-\\ntoxic.\\nMemantine, an NMDA receptor antagonist, has shown some\\neffectiveness in the treatment of moderate to severe AD.96–99\\nAntidepressant medication may improve associated de-\\npression.\\nTherapies under investigation\\nTreatment trials evaluating use of anti-inflammatory agents\\n(NSAIDs), estrogens, nerve growth factors, ginkgo biloba, st-\\natins, beta-site cleaving enzyme (BACE) inhibitors, and anti-\\noxidants are under way or recently reviewed.100–102\\nOther\\nVitamins and other over-the-counter medications have\\nbeen used in the treatment of AD.103\\nSome, but not all, reports suggest that affected individuals\\ntaking 3-hydroxy-3-methylglutaryl (HMG)-coen',\n",
              "   'type': 'Document'}},\n",
              " {'nodes': [{'id': 'search for possible vaccination approach',\n",
              "    'type': 'Activity',\n",
              "    'properties': {}},\n",
              "   {'id': 'H9252-amyloid', 'type': 'Substance', 'properties': {}},\n",
              "   {'id': 'human trial', 'type': 'Clinical Trial', 'properties': {}},\n",
              "   {'id': 'AD mouse model', 'type': 'Animal Model', 'properties': {}},\n",
              "   {'id': 'Genetics clinics', 'type': 'Facility', 'properties': {}},\n",
              "   {'id': 'individuals and families', 'type': 'Group', 'properties': {}},\n",
              "   {'id': 'information', 'type': 'Activity', 'properties': {}},\n",
              "   {'id': 'few subjects', 'type': 'Person', 'properties': {}},\n",
              "   {'id': 'support', 'type': 'Activity', 'properties': {}},\n",
              "   {'id': 'individuals', 'type': 'Person', 'properties': {}},\n",
              "   {'id': 'symptomatic AD', 'type': 'Condition', 'properties': {}},\n",
              "   {'id': 'Support groups', 'type': 'Organization', 'properties': {}},\n",
              "   {'id': 'dementia', 'type': 'Condition', 'properties': {}},\n",
              "   {'id': 'treatment', 'type': 'Therapy', 'properties': {}},\n",
              "   {'id': 'AD pathology', 'type': 'Condition', 'properties': {}},\n",
              "   {'id': 'encephalitis', 'type': 'Condition', 'properties': {}},\n",
              "   {'id': '3-hydroxy-3-methylglutaryl (HMG)-coenzyme A reductase inhibitors',\n",
              "    'type': 'Medication',\n",
              "    'properties': {}}],\n",
              "  'relationships': [{'source': {'id': 'individuals',\n",
              "     'type': 'Person',\n",
              "     'properties': {}},\n",
              "    'target': {'id': '3-hydroxy-3-methylglutaryl (HMG)-coenzyme A reductase inhibitors',\n",
              "     'type': 'Medication',\n",
              "     'properties': {}},\n",
              "    'type': 'AFFECTED_BY',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'individuals', 'type': 'Person', 'properties': {}},\n",
              "    'target': {'id': 'dementia', 'type': 'Condition', 'properties': {}},\n",
              "    'type': 'HAVE',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'AD mouse model',\n",
              "     'type': 'Animal Model',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'H9252-amyloid', 'type': 'Substance', 'properties': {}},\n",
              "    'type': 'IMMUNIZED_WITH',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'AD mouse model',\n",
              "     'type': 'Animal Model',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'AD pathology', 'type': 'Condition', 'properties': {}},\n",
              "    'type': 'ATTENUATED',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'AD mouse model',\n",
              "     'type': 'Animal Model',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'search for possible vaccination approach',\n",
              "     'type': 'Activity',\n",
              "     'properties': {}},\n",
              "    'type': 'STIMULATED',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'human trial',\n",
              "     'type': 'Clinical Trial',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'encephalitis', 'type': 'Condition', 'properties': {}},\n",
              "    'type': 'HALTED',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'human trial',\n",
              "     'type': 'Clinical Trial',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'few subjects', 'type': 'Person', 'properties': {}},\n",
              "    'type': 'HALTED',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'treatment', 'type': 'Therapy', 'properties': {}},\n",
              "    'target': {'id': 'symptomatic AD', 'type': 'Condition', 'properties': {}},\n",
              "    'type': 'NOT_PROVEN_BENEFICIAL_FOR',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Genetics clinics', 'type': 'Facility', 'properties': {}},\n",
              "    'target': {'id': 'information', 'type': 'Activity', 'properties': {}},\n",
              "    'type': 'PROVIDE',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Genetics clinics', 'type': 'Facility', 'properties': {}},\n",
              "    'target': {'id': 'support', 'type': 'Activity', 'properties': {}},\n",
              "    'type': 'PROVIDE',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Support groups',\n",
              "     'type': 'Organization',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'individuals and families',\n",
              "     'type': 'Group',\n",
              "     'properties': {}},\n",
              "    'type': 'ESTABLISHED_FOR',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Support groups',\n",
              "     'type': 'Organization',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'information', 'type': 'Activity', 'properties': {}},\n",
              "    'type': 'PROVIDE',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Support groups',\n",
              "     'type': 'Organization',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'support', 'type': 'Activity', 'properties': {}},\n",
              "    'type': 'PROVIDE',\n",
              "    'properties': {}}],\n",
              "  'source': {'id': None,\n",
              "   'metadata': {},\n",
              "   'page_content': ' reports suggest that affected individuals\\ntaking 3-hydroxy-3-methylglutaryl (HMG)-coenzyme A re-\\nductase inhibitors for hypercholesteralemia have a reduced in-\\ncidence of dementia.104–106\\nImmunization of an AD mouse model with /H9252-amyloid has\\nattenuated the AD pathology and stimulated the search for a\\npossible vaccination approach to the treatment of human\\nAD.107A human trial of this approach was halted because of\\nencephalitis in a few subjects.108–110 Alternative approaches to\\nimmunization therapy have been proposed.111\\nThus far, treatment of symptomatic AD with estrogens has\\nnot proven beneficial.112,113\\nGenetics clinics\\nGenetics clinics are a source of information for individuals\\nand families regarding the natural history, treatment, mode of\\ninheritance, and genetic risks to other family members as well\\nas information about available consumer-oriented resources.\\nSupport groups\\nSupport groups have been established for individuals and\\nfamilies to provide information, support, and contact withBird\\n236 Genetics INMedicine',\n",
              "   'type': 'Document'}},\n",
              " {'nodes': [{'id': 'hallucinations',\n",
              "    'type': 'Characteristic',\n",
              "    'properties': {}},\n",
              "   {'id': 'withdrawal', 'type': 'Characteristic', 'properties': {}},\n",
              "   {'id': 'language disturbance', 'type': 'Characteristic', 'properties': {}},\n",
              "   {'id': 'Neuropathologic findings',\n",
              "    'type': 'Assessment Method',\n",
              "    'properties': {}},\n",
              "   {'id': 'symptom management', 'type': 'Approach', 'properties': {}},\n",
              "   {'id': 'mutations', 'type': 'Cause', 'properties': {}},\n",
              "   {'id': 'familial', 'type': 'Genetic Component', 'properties': {}},\n",
              "   {'id': 'APOE genotyping', 'type': 'Assessment Method', 'properties': {}},\n",
              "   {'id': 'late-onset', 'type': 'Genetic Component', 'properties': {}},\n",
              "   {'id': 'clinical diagnosis', 'type': 'Assessment Method', 'properties': {}},\n",
              "   {'id': 'poor judgment', 'type': 'Characteristic', 'properties': {}},\n",
              "   {'id': 'drug therapy', 'type': 'Management', 'properties': {}},\n",
              "   {'id': 'PSEN2', 'type': 'Gene', 'properties': {}},\n",
              "   {'id': 'three genes', 'type': 'Genes', 'properties': {}},\n",
              "   {'id': 'mutism', 'type': 'Characteristic', 'properties': {}},\n",
              "   {'id': 'Molecular genetic testing',\n",
              "    'type': 'Testing Method',\n",
              "    'properties': {}},\n",
              "   {'id': '1 to 25 years', 'type': 'Duration', 'properties': {}},\n",
              "   {'id': 'Assisted living arrangements',\n",
              "    'type': 'Approach',\n",
              "    'properties': {}},\n",
              "   {'id': 'AD', 'type': 'Disease', 'properties': {}},\n",
              "   {'id': 'myoclonus', 'type': 'Characteristic', 'properties': {}},\n",
              "   {'id': 'early-onset', 'type': 'Genetic Component', 'properties': {}},\n",
              "   {'id': 'care in a nursing home', 'type': 'Approach', 'properties': {}},\n",
              "   {'id': 'death', 'type': 'Outcome', 'properties': {}},\n",
              "   {'id': 'dementia', 'type': 'Characteristic', 'properties': {}},\n",
              "   {'id': '8 to 10 years', 'type': 'Duration', 'properties': {}},\n",
              "   {'id': 'APP', 'type': 'Gene', 'properties': {}},\n",
              "   {'id': 'behavioral or cognitive benefit',\n",
              "    'type': 'Benefit',\n",
              "    'properties': {}},\n",
              "   {'id': 'seizures', 'type': 'Characteristic', 'properties': {}},\n",
              "   {'id': 'EOFAD', 'type': 'Form', 'properties': {}},\n",
              "   {'id': 'individual symptom management',\n",
              "    'type': 'Approach',\n",
              "    'properties': {}},\n",
              "   {'id': 'clinical laboratories', 'type': 'Facility', 'properties': {}},\n",
              "   {'id': 'cholinergic activity inhibitors', 'type': 'Drug', 'properties': {}},\n",
              "   {'id': 'clinical-neuropathologic assessment',\n",
              "    'type': 'Assessment Method',\n",
              "    'properties': {}},\n",
              "   {'id': 'Parkinsonian features', 'type': 'Characteristic', 'properties': {}},\n",
              "   {'id': 'PSEN1', 'type': 'Gene', 'properties': {}},\n",
              "   {'id': 'increased muscle tone', 'type': 'Characteristic', 'properties': {}},\n",
              "   {'id': 'agitation', 'type': 'Characteristic', 'properties': {}},\n",
              "   {'id': 'confusion', 'type': 'Characteristic', 'properties': {}},\n",
              "   {'id': 'APOE e4 allele', 'type': 'Assessment Method', 'properties': {}},\n",
              "   {'id': 'incontinence', 'type': 'Characteristic', 'properties': {}},\n",
              "   {'id': 'supportive treatment', 'type': 'Management', 'properties': {}},\n",
              "   {'id': 'drug therapy', 'type': 'Approach', 'properties': {}}],\n",
              "  'relationships': [{'source': {'id': 'AD',\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'dementia', 'type': 'Characteristic', 'properties': {}},\n",
              "    'type': 'CHARACTERIZED_BY',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'confusion', 'type': 'Characteristic', 'properties': {}},\n",
              "    'type': 'CHARACTERIZED_BY',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'poor judgment',\n",
              "     'type': 'Characteristic',\n",
              "     'properties': {}},\n",
              "    'type': 'CHARACTERIZED_BY',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'language disturbance',\n",
              "     'type': 'Characteristic',\n",
              "     'properties': {}},\n",
              "    'type': 'CHARACTERIZED_BY',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'agitation', 'type': 'Characteristic', 'properties': {}},\n",
              "    'type': 'CHARACTERIZED_BY',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'withdrawal', 'type': 'Characteristic', 'properties': {}},\n",
              "    'type': 'CHARACTERIZED_BY',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'hallucinations',\n",
              "     'type': 'Characteristic',\n",
              "     'properties': {}},\n",
              "    'type': 'CHARACTERIZED_BY',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'seizures', 'type': 'Characteristic', 'properties': {}},\n",
              "    'type': 'CHARACTERIZED_BY',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'Parkinsonian features',\n",
              "     'type': 'Characteristic',\n",
              "     'properties': {}},\n",
              "    'type': 'CHARACTERIZED_BY',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'increased muscle tone',\n",
              "     'type': 'Characteristic',\n",
              "     'properties': {}},\n",
              "    'type': 'CHARACTERIZED_BY',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'myoclonus', 'type': 'Characteristic', 'properties': {}},\n",
              "    'type': 'CHARACTERIZED_BY',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'incontinence',\n",
              "     'type': 'Characteristic',\n",
              "     'properties': {}},\n",
              "    'type': 'CHARACTERIZED_BY',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'mutism', 'type': 'Characteristic', 'properties': {}},\n",
              "    'type': 'CHARACTERIZED_BY',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'death', 'type': 'Outcome', 'properties': {}},\n",
              "    'type': 'RESULTS_IN',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': '8 to 10 years', 'type': 'Duration', 'properties': {}},\n",
              "    'type': 'HAS_DURATION',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': '1 to 25 years', 'type': 'Duration', 'properties': {}},\n",
              "    'type': 'HAS_DURATION',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'familial',\n",
              "     'type': 'Genetic Component',\n",
              "     'properties': {}},\n",
              "    'type': 'HAS_GENETIC_COMPONENT',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'late-onset',\n",
              "     'type': 'Genetic Component',\n",
              "     'properties': {}},\n",
              "    'type': 'HAS_GENETIC_COMPONENT',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'early-onset',\n",
              "     'type': 'Genetic Component',\n",
              "     'properties': {}},\n",
              "    'type': 'HAS_GENETIC_COMPONENT',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'clinical-neuropathologic assessment',\n",
              "     'type': 'Assessment Method',\n",
              "     'properties': {}},\n",
              "    'type': 'RELIANT_ON',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'Neuropathologic findings',\n",
              "     'type': 'Assessment Method',\n",
              "     'properties': {}},\n",
              "    'type': 'RELIANT_ON',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'clinical diagnosis',\n",
              "     'type': 'Assessment Method',\n",
              "     'properties': {}},\n",
              "    'type': 'RELIANT_ON',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'APOE e4 allele',\n",
              "     'type': 'Assessment Method',\n",
              "     'properties': {}},\n",
              "    'type': 'RELIANT_ON',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'APOE genotyping',\n",
              "     'type': 'Assessment Method',\n",
              "     'properties': {}},\n",
              "    'type': 'RELIANT_ON',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'EOFAD', 'type': 'Form', 'properties': {}},\n",
              "    'type': 'RECOGNIZES',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'EOFAD', 'type': 'Form', 'properties': {}},\n",
              "    'target': {'id': 'mutations', 'type': 'Cause', 'properties': {}},\n",
              "    'type': 'CAUSED_BY',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'EOFAD', 'type': 'Form', 'properties': {}},\n",
              "    'target': {'id': 'APP', 'type': 'Gene', 'properties': {}},\n",
              "    'type': 'CAUSED_BY',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'EOFAD', 'type': 'Form', 'properties': {}},\n",
              "    'target': {'id': 'PSEN1', 'type': 'Gene', 'properties': {}},\n",
              "    'type': 'CAUSED_BY',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'EOFAD', 'type': 'Form', 'properties': {}},\n",
              "    'target': {'id': 'PSEN2', 'type': 'Gene', 'properties': {}},\n",
              "    'type': 'CAUSED_BY',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'EOFAD', 'type': 'Form', 'properties': {}},\n",
              "    'target': {'id': 'three genes', 'type': 'Genes', 'properties': {}},\n",
              "    'type': 'RECOGNIZES',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'three genes', 'type': 'Genes', 'properties': {}},\n",
              "    'target': {'id': 'Molecular genetic testing',\n",
              "     'type': 'Testing Method',\n",
              "     'properties': {}},\n",
              "    'type': 'TESTED_BY',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Molecular genetic testing',\n",
              "     'type': 'Testing Method',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'clinical laboratories',\n",
              "     'type': 'Facility',\n",
              "     'properties': {}},\n",
              "    'type': 'AVAILABLE_IN',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'supportive treatment',\n",
              "     'type': 'Management',\n",
              "     'properties': {}},\n",
              "    'type': 'MANAGED_BY',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'supportive treatment',\n",
              "     'type': 'Management',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'symptom management',\n",
              "     'type': 'Approach',\n",
              "     'properties': {}},\n",
              "    'type': 'INVOLVES',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'supportive treatment',\n",
              "     'type': 'Management',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'individual symptom management',\n",
              "     'type': 'Approach',\n",
              "     'properties': {}},\n",
              "    'type': 'INVOLVES',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'supportive treatment',\n",
              "     'type': 'Management',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'Assisted living arrangements',\n",
              "     'type': 'Approach',\n",
              "     'properties': {}},\n",
              "    'type': 'INVOLVES',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'supportive treatment',\n",
              "     'type': 'Management',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'care in a nursing home',\n",
              "     'type': 'Approach',\n",
              "     'properties': {}},\n",
              "    'type': 'INVOLVES',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'supportive treatment',\n",
              "     'type': 'Management',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'drug therapy', 'type': 'Approach', 'properties': {}},\n",
              "    'type': 'INVOLVES',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'drug therapy', 'type': 'Management', 'properties': {}},\n",
              "    'target': {'id': 'cholinergic activity inhibitors',\n",
              "     'type': 'Drug',\n",
              "     'properties': {}},\n",
              "    'type': 'UTILIZES',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'cholinergic activity inhibitors',\n",
              "     'type': 'Drug',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'behavioral or cognitive benefit',\n",
              "     'type': 'Benefit',\n",
              "     'properties': {}},\n",
              "    'type': 'PRODUCES',\n",
              "    'properties': {}}],\n",
              "  'source': {'id': None,\n",
              "   'metadata': {},\n",
              "   'page_content': 'other affected individuals. The Resources section may include\\ndisease-specific and/or umbrella support organizations.\\nSUMMARY\\nDisease characteristics\\nAD is characterized by dementia that typically begins with\\nsubtle and poorly recognized failure of memory and slowly\\nbecomes more severe and, eventually, incapacitating. Other\\ncommon findings include confusion, poor judgment, lan-\\nguage disturbance, agitation, withdrawal, and hallucinations.\\nOccasionally, seizures, Parkinsonian features, increased mus-\\ncle tone, myoclonus, incontinence, and mutism occur. Death\\nusually results from general inanition, malnutrition, and\\npneumonia. The typical clinical duration of the disease is 8 to\\n10 years, with a range from 1 to 25 years. About 25% of all AD\\nis familial (i.e., two or more persons in a family have AD) of\\nwhich about 95% is late-onset (after age 60–65 years) and 5%\\nis early-onset (before age 65 years).\\nDiagnosis/testing\\nEstablishing the diagnosis of AD relies upon clinical-neuro-\\npathologic assessment. Neuropathologic findings of extracel-\\nlular /H9252-amyloid plaques and intraneuronal neurofibrillary\\ntangles remain the gold standard for diagnosis. The clinical\\ndiagnosis of AD, based on signs of slowly progressive dementia\\nand findings of gross cerebral cortical atrophy on neuroimag-\\ning, is correct about 80–90% of the time. The association of the\\nAPOE e4 allele with AD is significant; however, APOE geno-\\ntyping is neither fully specific nor sensitive. APOE genotyping\\nmay have an adjunct role in the diagnosis of AD in symptom-\\natic individuals and a limited role at this time in predictive\\ntesting of asymptomatic individuals. Three forms of EOFAD\\ncaused by mutations in one of three genes ( APP,PSEN1 , and\\nPSEN2 ) are recognized. Molecular genetic testing of the three\\ngenes is available in clinical laboratories.\\nManagement\\nTreatment is supportive. Each symptom is managed on an\\nindividual basis. Assisted living arrangements or care in a nurs-\\ning home is usually necessary. Drugs that increase cholinergic\\nactivity by inhibiting acetylcholinesterase produce a modest\\nbut useful behavioral or cognitive benefit in some',\n",
              "   'type': 'Document'}},\n",
              " {'nodes': [{'id': 'family members', 'type': 'Person', 'properties': {}},\n",
              "   {'id': 'Alzheimer Disease', 'type': 'Resource', 'properties': {}},\n",
              "   {'id': 'depression', 'type': 'Condition', 'properties': {}},\n",
              "   {'id': 'genetic counseling', 'type': 'Service', 'properties': {}},\n",
              "   {'id': 'AD', 'type': 'Disease', 'properties': {}},\n",
              "   {'id': 'activity', 'type': 'Activity', 'properties': {}},\n",
              "   {'id': 'EOFAD', 'type': 'Disease', 'properties': {}},\n",
              "   {'id': 'persons with AD', 'type': 'Person', 'properties': {}},\n",
              "   {'id': 'dementia', 'type': 'Condition', 'properties': {}},\n",
              "   {'id': 'acetylcholinesterase', 'type': 'Protein', 'properties': {}},\n",
              "   {'id': 'Antidepressant medication', 'type': 'Medication', 'properties': {}},\n",
              "   {'id': 'autosomal-dominant manner',\n",
              "    'type': 'Characteristic',\n",
              "    'properties': {}}],\n",
              "  'relationships': [{'source': {'id': 'acetylcholinesterase',\n",
              "     'type': 'Protein',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'activity', 'type': 'Activity', 'properties': {}},\n",
              "    'type': 'INHIBITS',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Antidepressant medication',\n",
              "     'type': 'Medication',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'depression', 'type': 'Condition', 'properties': {}},\n",
              "    'type': 'IMPROVES',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'genetic counseling',\n",
              "     'type': 'Service',\n",
              "     'properties': {}},\n",
              "    'type': 'GENETICALLY_HETEROGENEOUS',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'persons with AD', 'type': 'Person', 'properties': {}},\n",
              "    'type': 'GENETICALLY_HETEROGENEOUS',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'family members', 'type': 'Person', 'properties': {}},\n",
              "    'type': 'GENETICALLY_HETEROGENEOUS',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'dementia', 'type': 'Condition', 'properties': {}},\n",
              "    'type': 'GENETICALLY_HETEROGENEOUS',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'AD', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'Alzheimer Disease',\n",
              "     'type': 'Resource',\n",
              "     'properties': {}},\n",
              "    'type': 'GENETICALLY_HETEROGENEOUS',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'EOFAD', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'autosomal-dominant manner',\n",
              "     'type': 'Characteristic',\n",
              "     'properties': {}},\n",
              "    'type': 'INHERITED_IN',\n",
              "    'properties': {}}],\n",
              "  'source': {'id': None,\n",
              "   'metadata': {},\n",
              "   'page_content': '\\nactivity by inhibiting acetylcholinesterase produce a modest\\nbut useful behavioral or cognitive benefit in some affected in-\\ndividuals. Antidepressant medication may improve associated\\ndepression. An NMDA receptor antagonist is also FDA ap-\\nproved.\\nGenetic counseling\\nBecause AD is genetically heterogeneous, genetic counseling\\nof persons with AD and their family members must be tailored\\nto the information available for that family. It should be\\npointed out that AD is common and that the overall lifetime\\nrisk for any individual of developing dementia is approxi-\\nmately 10–12%. Genetic counseling for people with nonfamil-\\nial AD and their family members must be empiric and rela-\\ntively nonspecific. First-degree relatives of a simplex case of AD(i.e., single occurrence in a family) have a cumulative lifetime\\nrisk of developing AD of about 15–30%, which is typically re-\\nported as a 20–25% risk. This risk is about 2.5 times that of the\\nbackground risk ( /H1101127% vs. 10.4%). In contrast, EOFAD with\\nmutations in APP,PS1orPS2is inherited in an autosomal-\\ndominant manner.\\nRESOURCES\\nAlzheimer’s Association National Headquarters, 225 North\\nMichigan Avenue Fl 17, Chicago, IL 60601-7633, Phone:\\n800-272-3900, 312-335-8700, Fax: 312-335-1110, E-mail:\\ninfo@alz.org, www.alz.org.\\nAlzheimer’s Disease Education and Referral Center, PO Box 8250,\\nSilver Spring, MD 20907-8250, Phone: 800-438-4380; 301-495-\\n3334, Fax: 301-495-3334, E-mail: adear@ alzheimers.org,\\nwww. alzheimers.org.\\nNational Library of Medicine Genetics Home Reference,\\nAlzheimer Disease.\\nNCBI Genes and Disease, Alzheimer Disease.\\nNational Institute on Aging, Building 31, Room 5C27, 31\\nCenter Drive MSC 2292, Bethesda, MD 20892, Phone:\\n301-496-1752, E-mail: karpf@nia.nih.gov, www.nia.nih',\n",
              "   'type': 'Document'}},\n",
              " {'nodes': [{'id': 'ApoE and Alzheimer’s Disease',\n",
              "    'type': 'Topic',\n",
              "    'properties': {}},\n",
              "   {'id': 'Diagnostic challenges in dementia',\n",
              "    'type': 'Topic',\n",
              "    'properties': {}},\n",
              "   {'id': 'Alzheimer’s disease and primary dementias',\n",
              "    'type': 'Publication',\n",
              "    'properties': {}},\n",
              "   {'id': 'Kaye JA', 'type': 'Person', 'properties': {}},\n",
              "   {'id': 'National Institute on Aging/Alzheimer’s Association Working Group',\n",
              "    'type': 'Organization',\n",
              "    'properties': {}},\n",
              "   {'id': 'Post SG, Whitehouse PJ, Binstock RH, Bird TD',\n",
              "    'type': 'Person',\n",
              "    'properties': {}},\n",
              "   {'id': 'ethical, legal, and psychosocial implications of genetic testing in children and adolescents',\n",
              "    'type': 'Topic',\n",
              "    'properties': {}},\n",
              "   {'id': 'Apolipoprotein E genotyping in Alzheimer’s disease',\n",
              "    'type': 'Topic',\n",
              "    'properties': {}},\n",
              "   {'id': 'National Society of Genetic Counselors',\n",
              "    'type': 'Organization',\n",
              "    'properties': {}},\n",
              "   {'id': 'Veterans Affairs Research Funds and NIA/NIH Grant P50 AG 005136-22',\n",
              "    'type': 'Funding Source',\n",
              "    'properties': {}},\n",
              "   {'id': 'Mayeux R, Saunders AM, Shea S, Mirra S',\n",
              "    'type': 'Person',\n",
              "    'properties': {}},\n",
              "   {'id': 'Resolution on prenatal and childhood testing for adult-onset disorders',\n",
              "    'type': 'Policy',\n",
              "    'properties': {}},\n",
              "   {'id': 'This work', 'type': 'Work', 'properties': {}},\n",
              "   {'id': 'American College of Medical Genetics/American Society of Human Genetics Working Group',\n",
              "    'type': 'Organization',\n",
              "    'properties': {}},\n",
              "   {'id': 'Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer’s disease',\n",
              "    'type': 'Publication',\n",
              "    'properties': {}},\n",
              "   {'id': 'American Society of Human Genetics',\n",
              "    'type': 'Organization',\n",
              "    'properties': {}},\n",
              "   {'id': 'The clinical introduction of genetic testing for Alzheimer’s disease: an ethical perspective',\n",
              "    'type': 'Publication',\n",
              "    'properties': {}},\n",
              "   {'id': 'Bird TD, Miller BL', 'type': 'Person', 'properties': {}}],\n",
              "  'relationships': [{'source': {'id': 'American College of Medical Genetics/American Society of Human Genetics Working Group',\n",
              "     'type': 'Organization',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'ApoE and Alzheimer’s Disease',\n",
              "     'type': 'Topic',\n",
              "     'properties': {}},\n",
              "    'type': 'WORKED_ON',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'American Society of Human Genetics',\n",
              "     'type': 'Organization',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'ethical, legal, and psychosocial implications of genetic testing in children and adolescents',\n",
              "     'type': 'Topic',\n",
              "     'properties': {}},\n",
              "    'type': 'WORKED_ON',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'National Institute on Aging/Alzheimer’s Association Working Group',\n",
              "     'type': 'Organization',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'Apolipoprotein E genotyping in Alzheimer’s disease',\n",
              "     'type': 'Topic',\n",
              "     'properties': {}},\n",
              "    'type': 'WORKED_ON',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'National Society of Genetic Counselors',\n",
              "     'type': 'Organization',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'Resolution on prenatal and childhood testing for adult-onset disorders',\n",
              "     'type': 'Policy',\n",
              "     'properties': {}},\n",
              "    'type': 'ISSUED',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Post SG, Whitehouse PJ, Binstock RH, Bird TD',\n",
              "     'type': 'Person',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'The clinical introduction of genetic testing for Alzheimer’s disease: an ethical perspective',\n",
              "     'type': 'Publication',\n",
              "     'properties': {}},\n",
              "    'type': 'WROTE',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Veterans Affairs Research Funds and NIA/NIH Grant P50 AG 005136-22',\n",
              "     'type': 'Funding Source',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'This work', 'type': 'Work', 'properties': {}},\n",
              "    'type': 'SUPPORTED',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Bird TD, Miller BL', 'type': 'Person', 'properties': {}},\n",
              "    'target': {'id': 'Alzheimer’s disease and primary dementias',\n",
              "     'type': 'Publication',\n",
              "     'properties': {}},\n",
              "    'type': 'WROTE',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Mayeux R, Saunders AM, Shea S, Mirra S',\n",
              "     'type': 'Person',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer’s disease',\n",
              "     'type': 'Publication',\n",
              "     'properties': {}},\n",
              "    'type': 'MENTIONED_IN',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Kaye JA', 'type': 'Person', 'properties': {}},\n",
              "    'target': {'id': 'Diagnostic challenges in dementia',\n",
              "     'type': 'Topic',\n",
              "     'properties': {}},\n",
              "    'type': 'DISCUSSED',\n",
              "    'properties': {}}],\n",
              "  'source': {'id': None,\n",
              "   'metadata': {},\n",
              "   'page_content': '496-1752, E-mail: karpf@nia.nih.gov, www.nia.nih.\\ngov.\\nPUBLISHED STATEMENTS AND POLICIES REGARDING GENETIC\\nTESTING\\n●American College of Medical Genetics/American Society of\\nHuman Genetics Working Group on ApoE and Alzheimer’s Dis-\\nease. Statement on use of apolipoprotein E testing for Alzhei-\\nmer’s disease. 1995.\\n●American Society of Human Genetics and American College of\\nMedical Genetics. Points to consider: ethical, legal, and psycho-\\nsocial implications of genetic testing in children and adolescents.\\n1995.\\n●National Institute on Aging/Alzheimer’s Association Working\\nGroup. Apolipoprotein E genotyping in Alzheimer’s disease.\\nLancet 1996;347:1091–1095.\\n●National Society of Genetic Counselors. Resolution on prenatal\\nand childhood testing for adult-onset disorders. 1995.\\n●Post SG, Whitehouse PJ, Binstock RH, Bird TD, et al. The clinical\\nintroduction of genetic testing for Alzheimer’s disease: an ethical\\nperspective. JAMA 1997;277:832–836.\\nACKNOWLEDGMENTS\\nThis work was supported by funding from Veterans Affairs\\nResearch Funds and NIA/NIH Grant P50 AG 005136-22.\\nReferences\\n1. Bird TD, Miller BL. Alzheimer’s disease and primary dementias. In: Kasper D,\\nFauci A, Branwald E, Longo DL, et al., editors. Harrison’s principles of internal\\nmedicine, 16th ed. New York: McGraw-Hill, 2005:2393–2406.\\n2. Mayeux R, Saunders AM, Shea S, Mirra S, et al. Utility of the apolipoprotein E\\ngenotype in the diagnosis of Alzheimer’s disease. Alzheimer’s Disease Centers Con-\\nsortium on Apolipoprotein E and Alzheimer’s Disease. N Engl J Med 1998;338:\\n506–511.\\n3. Kaye JA. Diagnostic challenges in dementia. Neurology 1998;51:45–52.Genetic aspects of Alzheimer disease\\nApril 2008 /H18528Vol. 10 /H18528No. 4 237',\n",
              "   'type': 'Document'}},\n",
              " {'nodes': [{'id': 'Rumbaugh M', 'type': 'Person', 'properties': {}},\n",
              "   {'id': 'Borenstein AR', 'type': 'Person', 'properties': {}},\n",
              "   {'id': 'Brayne C', 'type': 'Person', 'properties': {}},\n",
              "   {'id': 'Braak E', 'type': 'Person', 'properties': {}},\n",
              "   {'id': 'Publication', 'type': 'Reynolds CA', 'properties': {}},\n",
              "   {'id': 'Early-onset Alzheimer disease in families with late-onset Alzheimer disease: a potential important subtype of familial Alzheimer disease',\n",
              "    'type': 'Publication',\n",
              "    'properties': {}},\n",
              "   {'id': 'Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum',\n",
              "    'type': 'Publication',\n",
              "    'properties': {}},\n",
              "   {'id': 'Neuropathological staging of Alzheimer-related changes',\n",
              "    'type': 'Publication',\n",
              "    'properties': {}},\n",
              "   {'id': 'Alzheimer’s disease and other dementias: a review',\n",
              "    'type': 'Publication',\n",
              "    'properties': {}},\n",
              "   {'id': 'Payami H', 'type': 'Person', 'properties': {}},\n",
              "   {'id': 'Dementia and Alzheimer disease incidence: a prospective cohort study',\n",
              "    'type': 'Publication',\n",
              "    'properties': {}},\n",
              "   {'id': 'Campion D', 'type': 'Person', 'properties': {}},\n",
              "   {'id': 'Hofman A', 'type': 'Person', 'properties': {}},\n",
              "   {'id': 'Early-life risk factors for Alzheimer disease',\n",
              "    'type': 'Publication',\n",
              "    'properties': {}},\n",
              "   {'id': 'National Institute on Aging-Reagan Working Group',\n",
              "    'type': 'Organization',\n",
              "    'properties': {}},\n",
              "   {'id': 'Braak H', 'type': 'Person', 'properties': {}},\n",
              "   {'id': 'Lee VM', 'type': 'Person', 'properties': {}},\n",
              "   {'id': 'Brickell KL', 'type': 'Person', 'properties': {}},\n",
              "   {'id': 'Lippa CF', 'type': 'Person', 'properties': {}},\n",
              "   {'id': 'Consensus recommendations for the postmortem diagnosis of Alzheimer’s disease',\n",
              "    'type': 'Publication',\n",
              "    'properties': {}},\n",
              "   {'id': 'Hannequin D', 'type': 'Person', 'properties': {}},\n",
              "   {'id': 'Publication', 'type': 'Fr', 'properties': {}},\n",
              "   {'id': 'Higdon R', 'type': 'Person', 'properties': {}},\n",
              "   {'id': 'Mortimer JA', 'type': 'Person', 'properties': {}},\n",
              "   {'id': 'Popescu A', 'type': 'Person', 'properties': {}},\n",
              "   {'id': 'Breteler MM', 'type': 'Person', 'properties': {}},\n",
              "   {'id': 'Steinbart EJ', 'type': 'Person', 'properties': {}},\n",
              "   {'id': 'Rogan S', 'type': 'Person', 'properties': {}},\n",
              "   {'id': 'McCormick WC', 'type': 'Person', 'properties': {}},\n",
              "   {'id': 'Frequency and distribution of Alzheimer’s disease in Europe: a collaborative study of 1980–1990 prevalence findings',\n",
              "    'type': 'Publication',\n",
              "    'properties': {}},\n",
              "   {'id': 'Copenhaver CI', 'type': 'Person', 'properties': {}},\n",
              "   {'id': 'Kukull WA', 'type': 'Person', 'properties': {}},\n",
              "   {'id': 'Dumanchin C', 'type': 'Person', 'properties': {}},\n",
              "   {'id': 'Rocca WA', 'type': 'Person', 'properties': {}},\n",
              "   {'id': 'Gatz M', 'type': 'Person', 'properties': {}},\n",
              "   {'id': 'Bowen JD', 'type': 'Person', 'properties': {}},\n",
              "   {'id': 'Trojanowski JQ', 'type': 'Person', 'properties': {}},\n",
              "   {'id': 'Dubois B', 'type': 'Person', 'properties': {}},\n",
              "   {'id': 'Lewy bodies in the amygdala: increase of alpha-synuclein aggregates in neurodegenerative diseases with tau-based inclusions',\n",
              "    'type': 'Publication',\n",
              "    'properties': {}}],\n",
              "  'relationships': [{'source': {'id': 'Braak H',\n",
              "     'type': 'Person',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'Neuropathological staging of Alzheimer-related changes',\n",
              "     'type': 'Publication',\n",
              "     'properties': {}},\n",
              "    'type': 'AUTHORED',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Braak E', 'type': 'Person', 'properties': {}},\n",
              "    'target': {'id': 'Neuropathological staging of Alzheimer-related changes',\n",
              "     'type': 'Publication',\n",
              "     'properties': {}},\n",
              "    'type': 'AUTHORED',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'National Institute on Aging-Reagan Working Group',\n",
              "     'type': 'Organization',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'Consensus recommendations for the postmortem diagnosis of Alzheimer’s disease',\n",
              "     'type': 'Publication',\n",
              "     'properties': {}},\n",
              "    'type': 'PUBLISHED',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Popescu A', 'type': 'Person', 'properties': {}},\n",
              "    'target': {'id': 'Lewy bodies in the amygdala: increase of alpha-synuclein aggregates in neurodegenerative diseases with tau-based inclusions',\n",
              "     'type': 'Publication',\n",
              "     'properties': {}},\n",
              "    'type': 'AUTHORED',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Lippa CF', 'type': 'Person', 'properties': {}},\n",
              "    'target': {'id': 'Lewy bodies in the amygdala: increase of alpha-synuclein aggregates in neurodegenerative diseases with tau-based inclusions',\n",
              "     'type': 'Publication',\n",
              "     'properties': {}},\n",
              "    'type': 'CO_AUTHORED',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Lee VM', 'type': 'Person', 'properties': {}},\n",
              "    'target': {'id': 'Lewy bodies in the amygdala: increase of alpha-synuclein aggregates in neurodegenerative diseases with tau-based inclusions',\n",
              "     'type': 'Publication',\n",
              "     'properties': {}},\n",
              "    'type': 'CO_AUTHORED',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Trojanowski JQ', 'type': 'Person', 'properties': {}},\n",
              "    'target': {'id': 'Lewy bodies in the amygdala: increase of alpha-synuclein aggregates in neurodegenerative diseases with tau-based inclusions',\n",
              "     'type': 'Publication',\n",
              "     'properties': {}},\n",
              "    'type': 'CO_AUTHORED',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Rogan S', 'type': 'Person', 'properties': {}},\n",
              "    'target': {'id': 'Alzheimer’s disease and other dementias: a review',\n",
              "     'type': 'Publication',\n",
              "     'properties': {}},\n",
              "    'type': 'AUTHORED',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Lippa CF', 'type': 'Person', 'properties': {}},\n",
              "    'target': {'id': 'Alzheimer’s disease and other dementias: a review',\n",
              "     'type': 'Publication',\n",
              "     'properties': {}},\n",
              "    'type': 'CO_AUTHORED',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Kukull WA', 'type': 'Person', 'properties': {}},\n",
              "    'target': {'id': 'Dementia and Alzheimer disease incidence: a prospective cohort study',\n",
              "     'type': 'Publication',\n",
              "     'properties': {}},\n",
              "    'type': 'AUTHORED',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Higdon R', 'type': 'Person', 'properties': {}},\n",
              "    'target': {'id': 'Dementia and Alzheimer disease incidence: a prospective cohort study',\n",
              "     'type': 'Publication',\n",
              "     'properties': {}},\n",
              "    'type': 'CO_AUTHORED',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Bowen JD', 'type': 'Person', 'properties': {}},\n",
              "    'target': {'id': 'Dementia and Alzheimer disease incidence: a prospective cohort study',\n",
              "     'type': 'Publication',\n",
              "     'properties': {}},\n",
              "    'type': 'CO_AUTHORED',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'McCormick WC', 'type': 'Person', 'properties': {}},\n",
              "    'target': {'id': 'Dementia and Alzheimer disease incidence: a prospective cohort study',\n",
              "     'type': 'Publication',\n",
              "     'properties': {}},\n",
              "    'type': 'CO_AUTHORED',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Rocca WA', 'type': 'Person', 'properties': {}},\n",
              "    'target': {'id': 'Frequency and distribution of Alzheimer’s disease in Europe: a collaborative study of 1980–1990 prevalence findings',\n",
              "     'type': 'Publication',\n",
              "     'properties': {}},\n",
              "    'type': 'AUTHORED',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Hofman A', 'type': 'Person', 'properties': {}},\n",
              "    'target': {'id': 'Frequency and distribution of Alzheimer’s disease in Europe: a collaborative study of 1980–1990 prevalence findings',\n",
              "     'type': 'Publication',\n",
              "     'properties': {}},\n",
              "    'type': 'CO_AUTHORED',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Brayne C', 'type': 'Person', 'properties': {}},\n",
              "    'target': {'id': 'Frequency and distribution of Alzheimer’s disease in Europe: a collaborative study of 1980–1990 prevalence findings',\n",
              "     'type': 'Publication',\n",
              "     'properties': {}},\n",
              "    'type': 'CO_AUTHORED',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Breteler MM', 'type': 'Person', 'properties': {}},\n",
              "    'target': {'id': 'Frequency and distribution of Alzheimer’s disease in Europe: a collaborative study of 1980–1990 prevalence findings',\n",
              "     'type': 'Publication',\n",
              "     'properties': {}},\n",
              "    'type': 'CO_AUTHORED',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Campion D', 'type': 'Person', 'properties': {}},\n",
              "    'target': {'id': 'Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum',\n",
              "     'type': 'Publication',\n",
              "     'properties': {}},\n",
              "    'type': 'AUTHORED',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Dumanchin C', 'type': 'Person', 'properties': {}},\n",
              "    'target': {'id': 'Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum',\n",
              "     'type': 'Publication',\n",
              "     'properties': {}},\n",
              "    'type': 'CO_AUTHORED',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Hannequin D', 'type': 'Person', 'properties': {}},\n",
              "    'target': {'id': 'Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum',\n",
              "     'type': 'Publication',\n",
              "     'properties': {}},\n",
              "    'type': 'CO_AUTHORED',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Dubois B', 'type': 'Person', 'properties': {}},\n",
              "    'target': {'id': 'Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum',\n",
              "     'type': 'Publication',\n",
              "     'properties': {}},\n",
              "    'type': 'CO_AUTHORED',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Brickell KL', 'type': 'Person', 'properties': {}},\n",
              "    'target': {'id': 'Early-onset Alzheimer disease in families with late-onset Alzheimer disease: a potential important subtype of familial Alzheimer disease',\n",
              "     'type': 'Publication',\n",
              "     'properties': {}},\n",
              "    'type': 'AUTHORED',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Steinbart EJ', 'type': 'Person', 'properties': {}},\n",
              "    'target': {'id': 'Early-onset Alzheimer disease in families with late-onset Alzheimer disease: a potential important subtype of familial Alzheimer disease',\n",
              "     'type': 'Publication',\n",
              "     'properties': {}},\n",
              "    'type': 'CO_AUTHORED',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Rumbaugh M', 'type': 'Person', 'properties': {}},\n",
              "    'target': {'id': 'Early-onset Alzheimer disease in families with late-onset Alzheimer disease: a potential important subtype of familial Alzheimer disease',\n",
              "     'type': 'Publication',\n",
              "     'properties': {}},\n",
              "    'type': 'CO_AUTHORED',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Payami H', 'type': 'Person', 'properties': {}},\n",
              "    'target': {'id': 'Early-onset Alzheimer disease in families with late-onset Alzheimer disease: a potential important subtype of familial Alzheimer disease',\n",
              "     'type': 'Publication',\n",
              "     'properties': {}},\n",
              "    'type': 'CO_AUTHORED',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Borenstein AR', 'type': 'Person', 'properties': {}},\n",
              "    'target': {'id': 'Early-life risk factors for Alzheimer disease',\n",
              "     'type': 'Publication',\n",
              "     'properties': {}},\n",
              "    'type': 'AUTHORED',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Copenhaver CI', 'type': 'Person', 'properties': {}},\n",
              "    'target': {'id': 'Early-life risk factors for Alzheimer disease',\n",
              "     'type': 'Publication',\n",
              "     'properties': {}},\n",
              "    'type': 'CO_AUTHORED',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Mortimer JA', 'type': 'Person', 'properties': {}},\n",
              "    'target': {'id': 'Early-life risk factors for Alzheimer disease',\n",
              "     'type': 'Publication',\n",
              "     'properties': {}},\n",
              "    'type': 'CO_AUTHORED',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Gatz M', 'type': 'Person', 'properties': {}},\n",
              "    'target': {'id': 'Publication', 'type': 'Reynolds CA', 'properties': {}},\n",
              "    'type': 'AUTHORED',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Gatz M', 'type': 'Person', 'properties': {}},\n",
              "    'target': {'id': 'Publication', 'type': 'Fr', 'properties': {}},\n",
              "    'type': 'CO_AUTHORED',\n",
              "    'properties': {}}],\n",
              "  'source': {'id': None,\n",
              "   'metadata': {},\n",
              "   'page_content': '4. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta\\nNeuropathol (Berl) 1991;82:239–259.\\n5. National Institute on Aging-Reagan Working Group. Consensus recommenda-\\ntions for the postmortem diagnosis of Alzheimer’s disease. Neurobiol Aging 1997;\\n18(suppl 4):S1–S2.\\n6. Popescu A, Lippa CF, Lee VM, Trojanowski JQ. Lewy bodies in the amygdala:\\nincrease of alpha-synuclein aggregates in neurodegenerative diseases with tau-\\nbased inclusions. Arch Neurol 2004;61:1915–1919.\\n7. Rogan S, Lippa CF. Alzheimer’s disease and other dementias: a review. Am J Alz-\\nheimers Dis Other Demen 2002;17:11–17.\\n8. Kukull WA, Higdon R, Bowen JD, McCormick WC, et al. Dementia and Alzheimer\\ndisease incidence: a prospective cohort study. Arch Neurol 2002;59:1737–1746.\\n9. Rocca WA, Hofman A, Brayne C, Breteler MM, et al. Frequency and distribu-\\ntion of Alzheimer’s disease in Europe: a collaborative study of 1980–1990\\nprevalence findings. The EURODEM-Prevalence Research Group. Ann Neurol\\n1991;30:381–390.\\n10. Campion D, Dumanchin C, Hannequin D, Dubois B, et al. Early-onset autosomal\\ndominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation\\nspectrum. Am J Hum Genet 1999;65:664–670.\\n11. Brickell KL, Steinbart EJ, Rumbaugh M, Payami H, et al. Early-onset Alzheimer\\ndisease in families with late-onset Alzheimer disease: a potential important subtype\\nof familial Alzheimer disease. Arch Neurol 2006;63:1307–1311.\\n12. Borenstein AR, Copenhaver CI, Mortimer JA. Early-life risk factors for Alzheimer\\ndisease. Alzheimer Dis Assoc Disord 2006;20:63–72.\\n13. Gatz M, Reynolds CA, Fr',\n",
              "   'type': 'Document'}},\n",
              " {'nodes': [{'id': 'Cognitive impairment in adults with Down’s syndrome: similarities to early cognitive changes in Alzheimer’s disease',\n",
              "    'type': 'Publication',\n",
              "    'properties': {}},\n",
              "   {'id': 'Specificity of the fivefold increase in AD in mothers of adults with Down syndrome',\n",
              "    'type': 'Publication',\n",
              "    'properties': {}},\n",
              "   {'id': 'Molecular mapping of Alzheimer-type dementia in Down’s syndrome',\n",
              "    'type': 'Publication',\n",
              "    'properties': {}},\n",
              "   {'id': 'Haupt M', 'type': 'Person', 'properties': {}},\n",
              "   {'id': 'Brugge KL', 'type': 'Person', 'properties': {}},\n",
              "   {'id': 'Comparison of the severity of neuropathologic changes in familial and sporadic Alzheimer’s disease',\n",
              "    'type': 'Publication',\n",
              "    'properties': {}},\n",
              "   {'id': 'Leverenz JB', 'type': 'Person', 'properties': {}},\n",
              "   {'id': 'Influence of the amyloid precursor protein locus on dementia in Down syndrome',\n",
              "    'type': 'Publication',\n",
              "    'properties': {}},\n",
              "   {'id': 'The molecular and genetic basis of AD: the end of the beginning: the 2000 Wartenberg lecture',\n",
              "    'type': 'Publication',\n",
              "    'properties': {}},\n",
              "   {'id': 'Rosenberg RN', 'type': 'Person', 'properties': {}},\n",
              "   {'id': 'Early amyloid deposition in the medial temporal lobe of young Down syndrome patients: a regional quantitative analysis',\n",
              "    'type': 'Publication',\n",
              "    'properties': {}},\n",
              "   {'id': 'Alzheimer’s disease: identical phenotype of familial and non-familial cases',\n",
              "    'type': 'Publication',\n",
              "    'properties': {}},\n",
              "   {'id': 'Prasher VP', 'type': 'Person', 'properties': {}},\n",
              "   {'id': 'Lai F', 'type': 'Person', 'properties': {}},\n",
              "   {'id': 'Nochlin D', 'type': 'Person', 'properties': {}},\n",
              "   {'id': 'Role of genes and environments for explaining Alzheimer disease',\n",
              "    'type': 'Publication',\n",
              "    'properties': {}},\n",
              "   {'id': 'Margallo-Lana M', 'type': 'Person', 'properties': {}},\n",
              "   {'id': 'Gatz M', 'type': 'Person', 'properties': {}},\n",
              "   {'id': 'APOE genotype and gender effects on Alzheimer disease in 100 adults with Down syndrome',\n",
              "    'type': 'Publication',\n",
              "    'properties': {}},\n",
              "   {'id': 'Schupf N', 'type': 'Person', 'properties': {}}],\n",
              "  'relationships': [{'source': {'id': 'Gatz M',\n",
              "     'type': 'Person',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'Role of genes and environments for explaining Alzheimer disease',\n",
              "     'type': 'Publication',\n",
              "     'properties': {}},\n",
              "    'type': 'AUTHORED',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Brugge KL', 'type': 'Person', 'properties': {}},\n",
              "    'target': {'id': 'Cognitive impairment in adults with Down’s syndrome: similarities to early cognitive changes in Alzheimer’s disease',\n",
              "     'type': 'Publication',\n",
              "     'properties': {}},\n",
              "    'type': 'AUTHORED',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Leverenz JB', 'type': 'Person', 'properties': {}},\n",
              "    'target': {'id': 'Early amyloid deposition in the medial temporal lobe of young Down syndrome patients: a regional quantitative analysis',\n",
              "     'type': 'Publication',\n",
              "     'properties': {}},\n",
              "    'type': 'AUTHORED',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Prasher VP', 'type': 'Person', 'properties': {}},\n",
              "    'target': {'id': 'Molecular mapping of Alzheimer-type dementia in Down’s syndrome',\n",
              "     'type': 'Publication',\n",
              "     'properties': {}},\n",
              "    'type': 'AUTHORED',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Lai F', 'type': 'Person', 'properties': {}},\n",
              "    'target': {'id': 'APOE genotype and gender effects on Alzheimer disease in 100 adults with Down syndrome',\n",
              "     'type': 'Publication',\n",
              "     'properties': {}},\n",
              "    'type': 'AUTHORED',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Margallo-Lana M', 'type': 'Person', 'properties': {}},\n",
              "    'target': {'id': 'Influence of the amyloid precursor protein locus on dementia in Down syndrome',\n",
              "     'type': 'Publication',\n",
              "     'properties': {}},\n",
              "    'type': 'AUTHORED',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Schupf N', 'type': 'Person', 'properties': {}},\n",
              "    'target': {'id': 'Specificity of the fivefold increase in AD in mothers of adults with Down syndrome',\n",
              "     'type': 'Publication',\n",
              "     'properties': {}},\n",
              "    'type': 'AUTHORED',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Haupt M', 'type': 'Person', 'properties': {}},\n",
              "    'target': {'id': 'Alzheimer’s disease: identical phenotype of familial and non-familial cases',\n",
              "     'type': 'Publication',\n",
              "     'properties': {}},\n",
              "    'type': 'AUTHORED',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Nochlin D', 'type': 'Person', 'properties': {}},\n",
              "    'target': {'id': 'Comparison of the severity of neuropathologic changes in familial and sporadic Alzheimer’s disease',\n",
              "     'type': 'Publication',\n",
              "     'properties': {}},\n",
              "    'type': 'AUTHORED',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Rosenberg RN', 'type': 'Person', 'properties': {}},\n",
              "    'target': {'id': 'The molecular and genetic basis of AD: the end of the beginning: the 2000 Wartenberg lecture',\n",
              "     'type': 'Publication',\n",
              "     'properties': {}},\n",
              "    'type': 'AUTHORED',\n",
              "    'properties': {}}],\n",
              "  'source': {'id': None,\n",
              "   'metadata': {},\n",
              "   'page_content': ' Dis Assoc Disord 2006;20:63–72.\\n13. Gatz M, Reynolds CA, Fratiglioni L, Johansson B, et al. Role of genes and environ-\\nments for explaining Alzheimer disease. Arch Gen Psychiatry 2006;63:168–174.\\n14. Brugge KL, Nichols SL, Salmon DP, Hill LR, et al. Cognitive impairment in adults\\nwith Down’s syndrome: similarities to early cognitive changes in Alzheimer’s dis-\\nease. Neurology 1994;44:232–238.\\n15. Leverenz JB, Raskind MA. Early amyloid deposition in the medial temporal lobe of\\nyoung Down syndrome patients: a regional quantitative analysis. Exp Neurol 1998;\\n150:296–304.\\n16. Prasher VP, Farrer MJ, Kessling AM, Fisher EM, et al. Molecular mapping of\\nAlzheimer-type dementia in Down’s syndrome. Ann Neurol 1998;43:380–383.\\n17. Lai F, Kammann E, Rebeck GW, Anderson A, et al. APOE genotype and gender\\neffects on Alzheimer disease in 100 adults with Down syndrome. Neurology 1999;\\n53:331–336.\\n18. Margallo-Lana M, Morris CM, Gibson AM, Tan AL, et al. Influence of the amyloid\\nprecursor protein locus on dementia in Down syndrome. Neurology 2004;62:\\n1996–1998.\\n19. Schupf N, Kapell D, Nightingale B, Lee JH, et al. Specificity of the fivefold increase\\nin AD in mothers of adults with Down syndrome. Neurology 2001;57:979–984.\\n20. Haupt M, Kurz A, Pollmann S, Romero B. Alzheimer’s disease: identical phenotype\\nof familial and non-familial cases. J Neurol 1992;239:248–250.\\n21. Nochlin D, van Belle G, Bird TD, Sumi SM. Comparison of the severity of neuro-\\npathologic changes in familial and sporadic Alzheimer’s disease. Alzheimer Dis\\nAssoc Disord 1993;7:212–222.\\n22. Rosenberg RN. The molecular and genetic basis of AD: the end of the beginning:\\nthe 2000 Wartenberg lecture. Neurology 2000;54:',\n",
              "   'type': 'Document'}},\n",
              " {'nodes': [{'id': 'Bertram L, McQueen MB, Mullin K, Blacker D',\n",
              "    'type': 'Researcher',\n",
              "    'properties': {}},\n",
              "   {'id': 'Meyer MR, Tschanz JT, Norton MC, Welsh-Bohmer KA',\n",
              "    'type': 'Researcher',\n",
              "    'properties': {}},\n",
              "   {'id': 'Nussbaum RL, Ellis CE', 'type': 'Researcher', 'properties': {}},\n",
              "   {'id': 'Rogaeva E, Meng Y, Lee JH, Gu Y',\n",
              "    'type': 'Researcher',\n",
              "    'properties': {}},\n",
              "   {'id': 'Sleegers K, van Duijn CM', 'type': 'Researcher', 'properties': {}},\n",
              "   {'id': \"Alzheimer's disease\", 'type': 'Disease', 'properties': {}},\n",
              "   {'id': 'Bertram L, Tanzi RE', 'type': 'Researcher', 'properties': {}},\n",
              "   {'id': 'Serretti A, Artioli P, Quartesan R, De Ronchi D',\n",
              "    'type': 'Researcher',\n",
              "    'properties': {}},\n",
              "   {'id': 'Khachaturian AS, Corcoran CD, Mayer LS, Zandi PP',\n",
              "    'type': 'Researcher',\n",
              "    'properties': {}}],\n",
              "  'relationships': [{'source': {'id': \"Alzheimer's disease\",\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'Sleegers K, van Duijn CM',\n",
              "     'type': 'Researcher',\n",
              "     'properties': {}},\n",
              "    'type': 'GENES',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': \"Alzheimer's disease\",\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'Nussbaum RL, Ellis CE',\n",
              "     'type': 'Researcher',\n",
              "     'properties': {}},\n",
              "    'type': 'GENES',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': \"Alzheimer's disease\",\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'Bertram L, Tanzi RE',\n",
              "     'type': 'Researcher',\n",
              "     'properties': {}},\n",
              "    'type': 'GENES',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': \"Alzheimer's disease\",\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'Serretti A, Artioli P, Quartesan R, De Ronchi D',\n",
              "     'type': 'Researcher',\n",
              "     'properties': {}},\n",
              "    'type': 'GENES',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': \"Alzheimer's disease\",\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'Bertram L, McQueen MB, Mullin K, Blacker D',\n",
              "     'type': 'Researcher',\n",
              "     'properties': {}},\n",
              "    'type': 'GENES',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': \"Alzheimer's disease\",\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'Meyer MR, Tschanz JT, Norton MC, Welsh-Bohmer KA',\n",
              "     'type': 'Researcher',\n",
              "     'properties': {}},\n",
              "    'type': 'GENES',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': \"Alzheimer's disease\",\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'Khachaturian AS, Corcoran CD, Mayer LS, Zandi PP',\n",
              "     'type': 'Researcher',\n",
              "     'properties': {}},\n",
              "    'type': 'GENES',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': \"Alzheimer's disease\",\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'Rogaeva E, Meng Y, Lee JH, Gu Y',\n",
              "     'type': 'Researcher',\n",
              "     'properties': {}},\n",
              "    'type': 'GENES',\n",
              "    'properties': {}}],\n",
              "  'source': {'id': None,\n",
              "   'metadata': {},\n",
              "   'page_content': ' basis of AD: the end of the beginning:\\nthe 2000 Wartenberg lecture. Neurology 2000;54:2045–2054.\\n23. Sleegers K, van Duijn CM. Alzheimer’s disease: genes, pathogenesis and risk pre-\\ndiction Community Genet 2001;4:197–203.\\n24. Nussbaum RL, Ellis CE. Alzheimer’s disease and Parkinson’s disease. N Engl J Med\\n2003;348:1356–1364.\\n25. Goedert M, Spillantini MG. A century of Alzheimer’s disease. Science 2006;314:\\n777–781.\\n26. Roses AD, Saunders AM. Perspective on a pathogenesis and treatment of Alzhei-\\nmer’s disease. Alz Dem 2006;2:59–70.\\n27. Kamboh MI. Molecular genetics of late-onset Alzheimer’s disease. Ann Hum Genet\\n2004;68:381–404.\\n28. Bertram L, Tanzi RE. The current status of Alzheimer’s disease genetics: what do we\\ntell the patients? Pharmacol Res 2004;50:385–396.\\n29. Serretti A, Artioli P, Quartesan R, De Ronchi D. Genes involved in Alzheimer’s\\ndisease, a survey of possible candidates. J Alzheimers Dis 2005;7:331–353.\\n30. Bertram L, McQueen MB, Mullin K, Blacker D, et al. Systematic meta-analyses of\\nAlzheimer disease genetic association studies: the AlzGene database. Nat Genet\\n2007;39:17–23.\\n31. Meyer MR, Tschanz JT, Norton MC, Welsh-Bohmer KA, et al. APOE genotype\\npredicts when–not whether–one is predisposed to develop Alzheimer disease. Nat\\nGenet 1998;19:321–322.\\n32. Khachaturian AS, Corcoran CD, Mayer LS, Zandi PP, et al. Apolipoprotein E\\nepsilon4 count affects age at onset of Alzheimer disease, but not lifetime suscepti-\\nbility: The Cache County Study. Arch Gen Psychiatry 2004;61:518–524.\\n33. Rogaeva E, Meng Y, Lee JH, Gu Y, et',\n",
              "   'type': 'Document'}},\n",
              " {'nodes': [{'id': 'Alpha2 macroglobulin',\n",
              "    'type': 'Protein',\n",
              "    'properties': {}},\n",
              "   {'id': 'APOE varepsilon4', 'type': 'Gene', 'properties': {}},\n",
              "   {'id': 'Alzheimer’s disease', 'type': 'Disease', 'properties': {}},\n",
              "   {'id': 'GAB2', 'type': 'Gene', 'properties': {}},\n",
              "   {'id': 'Alpha2-macroglobulin', 'type': 'Protein', 'properties': {}},\n",
              "   {'id': 'Alzheimer’s risk', 'type': 'Risk', 'properties': {}},\n",
              "   {'id': 'Alpha-2 macroglobulin', 'type': 'Protein', 'properties': {}},\n",
              "   {'id': 'SORL1', 'type': 'Gene', 'properties': {}},\n",
              "   {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "   {'id': 'Glutathione S-transferase omega-1',\n",
              "    'type': 'Protein',\n",
              "    'properties': {}}],\n",
              "  'relationships': [{'source': {'id': 'SORL1',\n",
              "     'type': 'Gene',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "    'type': 'GENETIC_ASSOCIATION',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alpha-2 macroglobulin',\n",
              "     'type': 'Protein',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "    'type': 'GENETIC_ASSOCIATION',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alpha2 macroglobulin',\n",
              "     'type': 'Protein',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'Alzheimer’s disease',\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'type': 'RISK_FACTOR_FOR',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alpha2-macroglobulin',\n",
              "     'type': 'Protein',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'Alzheimer’s disease',\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'type': 'RISK_FACTOR_FOR',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Glutathione S-transferase omega-1',\n",
              "     'type': 'Protein',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "    'type': 'MODIFIES_AGE_AT_ONSET',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'GAB2', 'type': 'Gene', 'properties': {}},\n",
              "    'target': {'id': 'Alzheimer’s risk', 'type': 'Risk', 'properties': {}},\n",
              "    'type': 'MODIFIES_RISK_IN',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'APOE varepsilon4', 'type': 'Gene', 'properties': {}},\n",
              "    'target': {'id': 'Alzheimer’s risk', 'type': 'Risk', 'properties': {}},\n",
              "    'type': 'MODIFIES_RISK_IN',\n",
              "    'properties': {}}],\n",
              "  'source': {'id': None,\n",
              "   'metadata': {},\n",
              "   'page_content': ':518–524.\\n33. Rogaeva E, Meng Y, Lee JH, Gu Y, et al. The neuronal sortilin-related receptor SORL1\\nis genetically associated with Alzheimer disease. Nat Genet 2007;39:168–177.34. Blacker D, Wilcox MA, Laird NM, Rodes L, et al. Alpha-2 macroglobulin is genet-\\nically associated with Alzheimer disease. Nat Genet 1998;19:357–360.\\n35. Dodel RC, Du Y, Bales KR, Gao F, et al. Alpha2 macroglobulin and the risk of\\nAlzheimer’s disease. Neurology 2000;54:438–442.\\n36. Gibson AM, Singleton AB, Smith G, Woodward R, et al. Lack of association of the\\nalpha2-macroglobulin locus on chromosome 12 in AD. Neurology 2000;54:433–438.\\n37. Depboylu C, Lohmuller F, Du Y, Riemenschneider M, et al. Alpha2-macroglobu-\\nlin, lipoprotein receptor-related protein and lipoprotein receptor-associated pro-\\ntein and the genetic risk for developing Alzheimer’s disease. Neurosci Lett 2006;400:\\n187–190.\\n38. Li YJ, Oliveira SA, Xu P, Martin ER, et al. Glutathione S-transferase omega-1\\nmodifiesage-at-onset of Alzheimer disease and Parkinson disease. Hum Mol Genet\\n2003;12:3259–3267.\\n39. Reiman EM, Webster JA, Myers AJ, Hardy J, et al. GAB2 alleles modify Alzheimer’s\\nrisk in APOE varepsilon4 carriers. Neuron 2007;54:713–720.\\n40. Pericak-Vance MA, Bass MP, Yamaoka LH, Gaskell PC, et al. Complete genomic\\nscreen in late-onset familial Alzheimer disease. Evidence for a new locus on chro-\\nmosome 12. JAMA 1997;278:1237–1241.\\n41. Rogaeva E, Premkumar S, Song Y, Sorbi S, et al. Evidence for an Alzheimer disease\\nsusceptibility locus on chromosome 12 and for',\n",
              "   'type': 'Document'}},\n",
              " {'nodes': [{'id': 'chromosome 12', 'type': 'Chromosome', 'properties': {}},\n",
              "   {'id': 'chromosome 10', 'type': 'Chromosome', 'properties': {}},\n",
              "   {'id': 'Alzheimer’s disease', 'type': 'Disease', 'properties': {}},\n",
              "   {'id': 'plasminogen activator urokinase (PLAU)',\n",
              "    'type': 'Protein',\n",
              "    'properties': {}},\n",
              "   {'id': 'chromosome 10q', 'type': 'Chromosome', 'properties': {}},\n",
              "   {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "   {'id': 'plasma Abeta42', 'type': 'Substance', 'properties': {}}],\n",
              "  'relationships': [{'source': {'id': 'Alzheimer disease',\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'chromosome 12', 'type': 'Chromosome', 'properties': {}},\n",
              "    'type': 'LOCATED_ON',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'chromosome 10q', 'type': 'Chromosome', 'properties': {}},\n",
              "    'type': 'LOCATED_ON',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'plasma Abeta42', 'type': 'Substance', 'properties': {}},\n",
              "    'target': {'id': 'chromosome 10', 'type': 'Chromosome', 'properties': {}},\n",
              "    'type': 'LOCATED_ON',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'plasminogen activator urokinase (PLAU)',\n",
              "     'type': 'Protein',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'Alzheimer’s disease',\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'type': 'ASSOCIATED_WITH',\n",
              "    'properties': {}}],\n",
              "  'source': {'id': None,\n",
              "   'metadata': {},\n",
              "   'page_content': ' Sorbi S, et al. Evidence for an Alzheimer disease\\nsusceptibility locus on chromosome 12 and for further locus heterogeneity. JAMA\\n1998;280:614–618.\\n42. Wu WS, Holmans P, Wavrant-DeVrieze F, Shears S, et al. Genetic studies on\\nchromosome 12 in late-onset Alzheimer disease. JAMA 1998;280:619–622.\\n43. D’Introno A, Solfrizzi V, Colacicco AM, Capurso C, et al. Current knowledge of\\nchromosome 12 susceptibility genes for late-onset Alzheimer’s disease. Neurobiol\\nAging 2006;27:1537–1553.\\n44. Bertram L, Blacker D, Mullin K, Keeney D, et al. Evidence for genetic linkage of\\nAlzheimer’s disease to chromosome 10q. Science 2000;290:2302–2303.\\n45. Ertekin-Taner N, Graff-Radford N, Younkin LH, Eckman C, et al. Linkage of\\nplasma Abeta42 to a quantitative locus on chromosome 10 in late-onset Alzhei-\\nmer’s disease pedigrees. Science 2000;290:2303–2304.\\n46. Myers A, Holmans P, Marshall H, Kwon J, et al. Susceptibility locus for Alzheimer’s\\ndisease on chromosome 10. Science 2000;290:2304–2305.\\n47. Grupe A, Li Y, Rowland C, Nowotny P, et al. A scan of chromosome 10 identifies a\\nnovel locus showing strong association with late-onset Alzheimer disease. Am J\\nHum Genet 2006;78:78–88.\\n48. Riemenschneider M, Konta L, Friedrich P, Schwarz S, et al. A functional polymor-\\nphism within plasminogen activator urokinase (PLAU) is associated with Alzhei-\\nmer’s disease. Hum Mol Genet 2006;15:2446–2456.\\n49. Scott WK, Hauser ER, Schmechel DE, Welsh-Bohmer KA, et al. Ordered-subsets\\nlinkage analysis detects',\n",
              "   'type': 'Document'}},\n",
              " {'nodes': [{'id': 'UBQLN1', 'type': 'Gene', 'properties': {}},\n",
              "   {'id': 'Ubiquilin gene', 'type': 'Gene', 'properties': {}},\n",
              "   {'id': 'Genomewide screen', 'type': 'Study', 'properties': {}},\n",
              "   {'id': 'Dutch population', 'type': 'Population', 'properties': {}},\n",
              "   {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "   {'id': 'chromosome 19p13.2', 'type': 'Chromosome', 'properties': {}},\n",
              "   {'id': 'Ubiquilin 1 polymorphisms', 'type': 'Gene', 'properties': {}},\n",
              "   {'id': '7q36', 'type': 'Chromosome', 'properties': {}},\n",
              "   {'id': 'late-onset Alzheimer’s disease',\n",
              "    'type': 'Disease',\n",
              "    'properties': {}},\n",
              "   {'id': 'DAPK1 variants', 'type': 'Gene', 'properties': {}},\n",
              "   {'id': 'late-onset Alzheimer disease locus',\n",
              "    'type': 'Disease',\n",
              "    'properties': {}},\n",
              "   {'id': 'Alzheimer’s disease', 'type': 'Disease', 'properties': {}},\n",
              "   {'id': 'ubiquilin', 'type': 'Protein', 'properties': {}},\n",
              "   {'id': 'chromosomes 2q34', 'type': 'Chromosome', 'properties': {}}],\n",
              "  'relationships': [{'source': {'id': 'Alzheimer disease',\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'chromosomes 2q34',\n",
              "     'type': 'Chromosome',\n",
              "     'properties': {}},\n",
              "    'type': 'LOCATED_ON',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'DAPK1 variants', 'type': 'Gene', 'properties': {}},\n",
              "    'target': {'id': 'Alzheimer’s disease',\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'type': 'ASSOCIATED_WITH',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'late-onset Alzheimer disease locus',\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'chromosome 19p13.2',\n",
              "     'type': 'Chromosome',\n",
              "     'properties': {}},\n",
              "    'type': 'LOCATED_ON',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': '7q36', 'type': 'Chromosome', 'properties': {}},\n",
              "    'type': 'LOCATED_ON',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alzheimer’s disease',\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'UBQLN1', 'type': 'Gene', 'properties': {}},\n",
              "    'type': 'ASSOCIATED_WITH',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Ubiquilin gene', 'type': 'Gene', 'properties': {}},\n",
              "    'target': {'id': 'Alzheimer’s disease',\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'type': 'ASSOCIATED_WITH',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'ubiquilin', 'type': 'Protein', 'properties': {}},\n",
              "    'target': {'id': 'Alzheimer’s disease',\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'type': 'ASSOCIATED_WITH',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Ubiquilin 1 polymorphisms',\n",
              "     'type': 'Gene',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'late-onset Alzheimer’s disease',\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'type': 'NOT_ASSOCIATED_WITH',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Genomewide screen', 'type': 'Study', 'properties': {}},\n",
              "    'target': {'id': 'Dutch population',\n",
              "     'type': 'Population',\n",
              "     'properties': {}},\n",
              "    'type': 'CONDUCTED_ON',\n",
              "    'properties': {}}],\n",
              "  'source': {'id': None,\n",
              "   'metadata': {},\n",
              "   'page_content': 'hel DE, Welsh-Bohmer KA, et al. Ordered-subsets\\nlinkage analysis detects novel Alzheimer disease Loci on chromosomes 2q34 and\\n15q22. Am J Hum Genet 2003;73:1041–1051.\\n50. Li Y, Grupe A, Rowland C, Nowotny P, et al. DAPK1 variants are associated with\\nAlzheimer’s disease and allele-specific expression. Hum Mol Genet 2006;15:2560–\\n2568.\\n51. Wijsman EM, Daw EW, Yu CE, Payami H, et al. Evidence for a novel late-onset\\nAlzheimer disease locus on chromosome 19p13.2. Am J Hum Genet 2004;75:398–\\n409.\\n52. Rademakers R, Cruts M, Sleegers K, Dermaut B, et al. Linkage and association\\nstudies identify a novel locus for Alzheimer disease at 7q36 in a Dutch population-\\nbased sample. Am J Hum Genet 2005;77:643–652.\\n53. Bertram L, Hiltunen M, Parkinson M, Ingelsson M, et al. Family-based association\\nbetween Alzheimer’s disease and variants in UBQLN1. N Engl J Med 2005;352:\\n884–894.\\n54. Bensemain F, Chapuis J, Tian J, Shi J, et al. Association study of the Ubiquilin gene\\nwith Alzheimer’s disease. Neurobiol Dis 2006;22:691–693.\\n55. Kamboh MI, Minster RL, Feingold E, DeKosky ST. Genetic association of ubiquilin\\nwith Alzheimer’s disease and related quantitative measures. Mol Psychiatry 2006;\\n11:273–279.\\n56. Smemo S, Nowotny P, Hinrichs AL, Kauwe JS, et al. Ubiquilin 1 polymor-\\nphisms are not associated with late-onset Alzheimer’s disease. Ann Neurol\\n2006;59:21–26.\\n57. Liu F, Arias-Vasquez A, Sleegers K, Aulchnko YS, et al. A Genomewide screen for\\nlate-onset Alzheimer disease in a genetically isolated Dutch population. Am',\n",
              "   'type': 'Document'}},\n",
              " {'nodes': [{'id': 'genetically isolated Dutch population',\n",
              "    'type': 'Population',\n",
              "    'properties': {}},\n",
              "   {'id': 'late-onset Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "   {'id': 'mutations of the presenilin-1 gene',\n",
              "    'type': 'Gene',\n",
              "    'properties': {}},\n",
              "   {'id': 'large kindred', 'type': 'Family', 'properties': {}},\n",
              "   {'id': 'presenilin-1 gene', 'type': 'Gene', 'properties': {}},\n",
              "   {'id': 'chromosome 14-linked familial Alzheimer’s disease',\n",
              "    'type': 'Disease',\n",
              "    'properties': {}},\n",
              "   {'id': 'Alzheimer’s disease', 'type': 'Disease', 'properties': {}},\n",
              "   {'id': 'familial cohort', 'type': 'Population', 'properties': {}},\n",
              "   {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}}],\n",
              "  'relationships': [{'source': {'id': 'late-onset Alzheimer disease',\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'genetically isolated Dutch population',\n",
              "     'type': 'Population',\n",
              "     'properties': {}},\n",
              "    'type': 'GENOMEWIDE_SCREEN',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'chromosome 14-linked familial Alzheimer’s disease',\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'large kindred', 'type': 'Family', 'properties': {}},\n",
              "    'type': 'PHENOTYPE_OF',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'familial cohort',\n",
              "     'type': 'Population',\n",
              "     'properties': {}},\n",
              "    'type': 'NATURAL_HISTORY',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alzheimer’s disease',\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'mutations of the presenilin-1 gene',\n",
              "     'type': 'Gene',\n",
              "     'properties': {}},\n",
              "    'type': 'CLINICAL_PHENOTYPIC_HETEROGENEITY',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alzheimer’s disease',\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'presenilin-1 gene', 'type': 'Gene', 'properties': {}},\n",
              "    'type': 'ASSOCIATED_WITH',\n",
              "    'properties': {}}],\n",
              "  'source': {'id': None,\n",
              "   'metadata': {},\n",
              "   'page_content': ' et al. A Genomewide screen for\\nlate-onset Alzheimer disease in a genetically isolated Dutch population. Am J Hum\\nGenet 2007;81:17–31.\\n58. Lampe TH, Bird TD, Nochlin D, Nemens E, et al. Phenotype of chromosome\\n14-linked familial Alzheimer’s disease in a large kindred. Ann Neurol 1994;36:368–\\n378.\\n59. Godbolt AK, Cipolotti L, Watt H, Fox NC, et al. The natural history of Alzheimer\\ndisease: a longitudinal presymptomatic and symptomatic study of a familial co-\\nhort. Arch Neurol 2004;61:1743–1748.\\n60. Larner AJ, Doran M. Clinical phenotypic heterogeneity of Alzheimer’s disease\\nassociated with mutations of the presenilin-1 gene. J Neurol 2006;253:139–158.\\n61. Sherrington R, Froelich S, Sorbi S, Campion D, et al. Alzheimer’s disease associatedBird\\n238 Genetics INMedicine',\n",
              "   'type': 'Document'}},\n",
              " {'nodes': [{'id': 'presenilin-1', 'type': 'Gene', 'properties': {}},\n",
              "   {'id': 'apolipoprotein-E genotyping', 'type': 'Gene', 'properties': {}},\n",
              "   {'id': 'presenilin-2', 'type': 'Gene', 'properties': {}},\n",
              "   {'id': \"sporadic Alzheimer's disease\", 'type': 'Disease', 'properties': {}},\n",
              "   {'id': 'presenilin 2', 'type': 'Gene', 'properties': {}},\n",
              "   {'id': \"Alzheimer's disease\", 'type': 'Disease', 'properties': {}},\n",
              "   {'id': 'cognitive decline', 'type': 'Characteristic', 'properties': {}},\n",
              "   {'id': 'apolipoprotein E', 'type': 'Gene', 'properties': {}},\n",
              "   {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "   {'id': 'APOE alleles', 'type': 'Gene', 'properties': {}},\n",
              "   {'id': 'presenile Alzheimer disease', 'type': 'Disease', 'properties': {}}],\n",
              "  'relationships': [{'source': {'id': 'presenilin 2',\n",
              "     'type': 'Gene',\n",
              "     'properties': {}},\n",
              "    'target': {'id': \"Alzheimer's disease\",\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'type': 'MUTATED_IN',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'presenilin-1', 'type': 'Gene', 'properties': {}},\n",
              "    'target': {'id': 'presenile Alzheimer disease',\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'type': 'CONTRIBUTES_TO',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'presenilin-2', 'type': 'Gene', 'properties': {}},\n",
              "    'target': {'id': 'presenile Alzheimer disease',\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'type': 'CONTRIBUTES_TO',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'apolipoprotein E', 'type': 'Gene', 'properties': {}},\n",
              "    'target': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "    'type': 'INFLUENCES',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'APOE alleles', 'type': 'Gene', 'properties': {}},\n",
              "    'target': {'id': 'cognitive decline',\n",
              "     'type': 'Characteristic',\n",
              "     'properties': {}},\n",
              "    'type': 'PREDICTS',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'apolipoprotein-E genotyping',\n",
              "     'type': 'Gene',\n",
              "     'properties': {}},\n",
              "    'target': {'id': \"sporadic Alzheimer's disease\",\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'type': 'PREDICTS',\n",
              "    'properties': {}}],\n",
              "  'source': {'id': None,\n",
              "   'metadata': {},\n",
              "   'page_content': 'with mutations in presenilin 2 is rare and variably penetrant. Hum Mol Genet\\n1996;5:985–988.\\n62. Janssen JC, Beck JA, Campbell TA, Dickinson A, et al. Early onset familial Alzhei-\\nmer’s disease: mutation frequency in 31 families. Neurology 2003;60:235–239.\\n63. Raux G, Guyant-Marechal L, Martin C, Bou J, et al. Molecular diagnosis of auto-\\nsomal dominant early onset Alzheimer’s disease: an update. J Med Genet 2005;42:\\n793–795.\\n64. Cruts M, van Duijn CM, Backhovens H, van den Broeck M, et al. Estimation of the\\ngenetic contribution of presenilin-1 and -2 mutations in a population-based study\\nof presenile Alzheimer disease. Hum Mol Genet 1998;7:43–51.\\n65. Cummings JL, Vinters HV, Cole GM, Khachaturian ZS. Alzheimer’s disease: eti-\\nologies, pathophysiology, cognitive reserve and treatment opportunities. Neurol-\\nogy1998;51:2–17.\\n66. Jarvik G, Larson EB, Goddard K, Schellenberg GD, et al. Influence of apolipopro-\\ntein E genotype on the transmission of Alzheimer disease in a community-based\\nsample. Am J Hum Genet 1996;58:191–200.\\n67. Martins CA, Oulhaj A, de Jager CA, Williams JH. APOE alleles predict the rate of\\ncognitive decline in Alzheimer disease: a nonlinear model. Neurology 2005; 65:\\n1888–1893.\\n68. Saunders AM, Hulette O, Welsh-Bohmer KA, Schmechel DE, et al. Specificity,\\nsensitivity, and predictive value of apolipoprotein-E genotyping for sporadic Alz-\\nheimer’s disease. Lancet 1996;348:90–93.\\n69. Green RC, Cupples LA, Go R, Benke KS, et al. Risk of dementia among white and\\nAfrican American relatives of patients with Alzheimer disease. JAMA 2002;287:\\n329–336.\\n70. Romas SN, Santana V, Williamson J, Cia',\n",
              "   'type': 'Document'}},\n",
              " {'nodes': [{'id': 'Patients', 'type': 'Person', 'properties': {}},\n",
              "   {'id': 'sporadic and familial cases of Alzheimer’s disease',\n",
              "    'type': 'Condition',\n",
              "    'properties': {}},\n",
              "   {'id': 'Familial Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "   {'id': 'Genetic risk', 'type': 'Risk', 'properties': {}},\n",
              "   {'id': 'Caribbean Hispanics', 'type': 'Ethnicity', 'properties': {}},\n",
              "   {'id': 'Genetic testing', 'type': 'Procedure', 'properties': {}},\n",
              "   {'id': 'First-degree relatives', 'type': 'Relationship', 'properties': {}},\n",
              "   {'id': 'genetic risk for Alzheimer’s disease',\n",
              "    'type': 'Risk',\n",
              "    'properties': {}},\n",
              "   {'id': 'age when prevalence of AD increases, then declines',\n",
              "    'type': 'Phenomenon',\n",
              "    'properties': {}},\n",
              "   {'id': 'Apolipoprotein E', 'type': 'Protein', 'properties': {}},\n",
              "   {'id': 'Genetic factors', 'type': 'Factor', 'properties': {}},\n",
              "   {'id': 'diagnosis of Alzheimer disease',\n",
              "    'type': 'Procedure',\n",
              "    'properties': {}},\n",
              "   {'id': 'Alzheimer’s disease', 'type': 'Disease', 'properties': {}},\n",
              "   {'id': 'neuropathological series', 'type': 'Study', 'properties': {}},\n",
              "   {'id': 'APOE', 'type': 'Gene', 'properties': {}}],\n",
              "  'relationships': [{'source': {'id': 'Caribbean Hispanics',\n",
              "     'type': 'Ethnicity',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'Familial Alzheimer disease',\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'type': 'ASSOCIATED_WITH',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'APOE', 'type': 'Gene', 'properties': {}},\n",
              "    'target': {'id': 'age when prevalence of AD increases, then declines',\n",
              "     'type': 'Phenomenon',\n",
              "     'properties': {}},\n",
              "    'type': 'PREDICTS',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Apolipoprotein E', 'type': 'Protein', 'properties': {}},\n",
              "    'target': {'id': 'Alzheimer’s disease',\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'type': 'GENOTYPING_IN',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Apolipoprotein E', 'type': 'Protein', 'properties': {}},\n",
              "    'target': {'id': 'neuropathological series',\n",
              "     'type': 'Study',\n",
              "     'properties': {}},\n",
              "    'type': 'GENOTYPES_IN',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Apolipoprotein E', 'type': 'Protein', 'properties': {}},\n",
              "    'target': {'id': 'diagnosis of Alzheimer disease',\n",
              "     'type': 'Procedure',\n",
              "     'properties': {}},\n",
              "    'type': 'GENOTYPING_IN',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Genetic factors', 'type': 'Factor', 'properties': {}},\n",
              "    'target': {'id': 'Alzheimer’s disease',\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'type': 'REVIEWED_IN',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Genetic testing', 'type': 'Procedure', 'properties': {}},\n",
              "    'target': {'id': 'sporadic and familial cases of Alzheimer’s disease',\n",
              "     'type': 'Condition',\n",
              "     'properties': {}},\n",
              "    'type': 'NOT_RECOMMENDED_FOR',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Genetic risk', 'type': 'Risk', 'properties': {}},\n",
              "    'target': {'id': 'Alzheimer’s disease',\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'type': 'ASSESSED_FOR',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'First-degree relatives',\n",
              "     'type': 'Relationship',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'genetic risk for Alzheimer’s disease',\n",
              "     'type': 'Risk',\n",
              "     'properties': {}},\n",
              "    'type': 'ASSESSED_FOR',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'First-degree relatives',\n",
              "     'type': 'Relationship',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'Alzheimer’s disease',\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'type': 'AT_RISK_FOR',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Patients', 'type': 'Person', 'properties': {}},\n",
              "    'target': {'id': 'Alzheimer’s disease',\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'type': 'WITH_RELATIVES',\n",
              "    'properties': {}}],\n",
              "  'source': {'id': None,\n",
              "   'metadata': {},\n",
              "   'page_content': ' 2002;287:\\n329–336.\\n70. Romas SN, Santana V, Williamson J, Ciappa A, et al. Familial Alzheimer disease\\namong Caribbean Hispanics: a reexamination of its association with APOE. Arch\\nNeurol 2002;59:87–91.\\n71. Breitner JC, Wyse BW, Anthony JC, Welsh-Bohmer KA, et al. APOE-epsilon4\\ncount predicts age when prevalence of AD increases, then declines: the Cache\\nCounty Study. Neurology 1999;53:321–331.\\n72. National Institute on Aging/Alzheimer’s Association Working Group. Apoli-\\npoprotein E genotyping in Alzheimer’s disease. Lancet 1996;347:1091–1095.\\n73. Welsh-Bohmer KA, Gearing M, Saunders AM, Roses AD, et al. Apolipoprotein E\\ngenotypes in a neuropathological series from the Consortium to Establish a Regis-\\ntry for Alzheimer’s Disease. Ann Neurol 1997;42:319–325.\\n74. Tsuang D, Larson EB, Bowen J, McCormick W, et al. The utility of apolipoprotein\\nE genotyping in the diagnosis of Alzheimer disease in a community-based case\\nseries. Arch Neurol 1999;56:1489–1495.\\n75. Levy-Lahad E, Bird TD. Genetic factors in Alzheimer’s disease: a review of recent\\nadvances. Ann Neurol 1996;40:829–840.\\n76. van der Cammen TJ, Croes EA, Dermaut B, de Jager MC. Genetic testing has no\\nplace as a routine diagnostic test in sporadic and familial cases of Alzheimer’s\\ndisease. J Am Geriatr Soc 2004;52:2110–2113.\\n77. Farrer LA, O’Sullivan DM, Cupples LA, Growdon JH, et al. Assessment of genetic risk\\nfor Alzheimer’s disease among first-degree relatives. Ann Neurol 1989;25:485–493.\\n78. Silverman JM, Li G, Zaccario ML, Smith CJ, et al. Patterns of risk in first-degree\\nrelatives of patients with Alzheimer’s disease. Arch Gen Psychiatry 1994;51:577–\\n586',\n",
              "   'type': 'Document'}},\n",
              " {'nodes': [{'id': 'woman', 'type': 'Person', 'properties': {}},\n",
              "   {'id': 'parents', 'type': 'Person', 'properties': {}},\n",
              "   {'id': 'adult children', 'type': 'Person', 'properties': {}},\n",
              "   {'id': 'children', 'type': 'Person', 'properties': {}},\n",
              "   {'id': 'first-degree relatives', 'type': 'Person', 'properties': {}},\n",
              "   {'id': 'patients', 'type': 'Person', 'properties': {}},\n",
              "   {'id': 'Alzheimer’s disease', 'type': 'Disease', 'properties': {}}],\n",
              "  'relationships': [{'source': {'id': 'Alzheimer’s disease',\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'patients', 'type': 'Person', 'properties': {}},\n",
              "    'type': 'HAS_RELATIVE',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alzheimer’s disease',\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'first-degree relatives',\n",
              "     'type': 'Person',\n",
              "     'properties': {}},\n",
              "    'type': 'HAS_RELATIVE',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alzheimer’s disease',\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'children', 'type': 'Person', 'properties': {}},\n",
              "    'type': 'HAS_RELATIVE',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alzheimer’s disease',\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'parents', 'type': 'Person', 'properties': {}},\n",
              "    'type': 'HAS_PARENT',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alzheimer’s disease',\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'children', 'type': 'Person', 'properties': {}},\n",
              "    'type': 'HAS_CHILD',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alzheimer’s disease',\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'adult children', 'type': 'Person', 'properties': {}},\n",
              "    'type': 'HAS_CHILD',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alzheimer’s disease',\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'woman', 'type': 'Person', 'properties': {}},\n",
              "    'type': 'HAS_CHILD',\n",
              "    'properties': {}}],\n",
              "  'source': {'id': None,\n",
              "   'metadata': {},\n",
              "   'page_content': 'degree\\nrelatives of patients with Alzheimer’s disease. Arch Gen Psychiatry 1994;51:577–\\n586.\\n79. Green RC. Risk assessment for Alzheimer’s disease with genetic susceptibility test-\\ning: has the moment arrived? Alz’s Care Quarterly 2002;3:208–214.\\n80. Cupples LA, Farrer LA, Sadovnick AD, Relkin N, et al. Estimating risk curves for\\nfirst-degree relatives of patients with Alzheimer’s disease: the REVEAL study. Genet\\nMed 2004;6:192–196.\\n81. Heston LL, Mastri AR, Anderson VE, White J. Dementia of the Alzheimer type.\\nClinical genetics, natural history, and associated conditions. Arch Gen Psychiatry\\n1981;38:1085–1090.\\n82. Jayadev S, Steinbart EJ, Chi Y-Y, Kukull WA, et al. Conjugal Alzheimer disease: risk\\nin children when both parents have Alzheimer disease. Arch Neurol In press.\\n83. Breitner JC. APOE genotyping and Alzheimer’s disease. Lancet 1996;347:\\n1184–1185.\\n84. Roberts JS, Cupples LA, Relkin NR, Whitehouse PJ, et al. Genetic risk assessment\\nfor adult children of people with Alzheimer’s disease: the Risk Evaluation and\\nEducation for Alzheimer’s Disease (REVEAL) study. J Geriatr Psychiatry Neurol\\n2005;18:250–255.\\n85. Steinbart EJ, Smith CO, Poorkaj P, Bird TD. Impact of DNA testing for early-onset\\nfamilial Alzheimer disease and frontotemporal dementia. Arch Neurol 2001;58:\\n1828–1831.\\n86. Quaid KA, Murrell JR, Hake AM, Farlow MR. Presymptomatic genetic testing with\\nan APP mutation. J Genet Couns 2000;9:327–345.\\n87. Towner D, Loewy RS. Ethics of preimplantation diagnosis for a woman destined to\\ndevelop early-onset Alzheimer disease. JAMA 2002;287:1038–1040.88. Verlinsky Y, Rechitsky S, Verlinsky O, Masciangelo C, et al. Preimplantation diag-\\nnosis',\n",
              "   'type': 'Document'}},\n",
              " {'nodes': [{'id': 'Best Talent', 'type': 'Award', 'properties': {}},\n",
              "   {'id': 'accessible offline', 'type': 'Characteristic', 'properties': {}},\n",
              "   {'id': 'lightweight app', 'type': 'Characteristic', 'properties': {}},\n",
              "   {'id': 'Adam', 'type': 'Person', 'properties': {}},\n",
              "   {'id': 'Microsoft', 'type': 'Company', 'properties': {}},\n",
              "   {'id': 'Microsoft Word', 'type': 'Product', 'properties': {}}],\n",
              "  'relationships': [{'source': {'id': 'Adam',\n",
              "     'type': 'Person',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'Microsoft', 'type': 'Company', 'properties': {}},\n",
              "    'type': 'WORKS_FOR',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Adam', 'type': 'Person', 'properties': {}},\n",
              "    'target': {'id': 'Best Talent', 'type': 'Award', 'properties': {}},\n",
              "    'type': 'HAS_AWARD',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Microsoft Word', 'type': 'Product', 'properties': {}},\n",
              "    'target': {'id': 'Microsoft', 'type': 'Company', 'properties': {}},\n",
              "    'type': 'PRODUCED_BY',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Microsoft Word', 'type': 'Product', 'properties': {}},\n",
              "    'target': {'id': 'lightweight app',\n",
              "     'type': 'Characteristic',\n",
              "     'properties': {}},\n",
              "    'type': 'HAS_CHARACTERISTIC',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Microsoft Word', 'type': 'Product', 'properties': {}},\n",
              "    'target': {'id': 'accessible offline',\n",
              "     'type': 'Characteristic',\n",
              "     'properties': {}},\n",
              "    'type': 'HAS_CHARACTERISTIC',\n",
              "    'properties': {}}],\n",
              "  'source': {'id': None,\n",
              "   'metadata': {},\n",
              "   'page_content': ' S, Verlinsky O, Masciangelo C, et al. Preimplantation diag-\\nnosis for early-onset Alzheimer disease caused by V717L mutation. JAMA 2002;\\n287:1018–1021.\\n89. Feldman H, Gauthier S, Hecker J, Vellas B, et al. Economic evaluation of donepezil\\nin moderate to severe Alzheimer disease. Neurology 2004;63:644–650.\\n90. Seltzer B, Zolnouni P, Nunez M, Goldman R, et al. Efficacy of donepezil in early-\\nstage Alzheimer disease: a randomized placebo-controlled trial. Arch Neurol 2004;\\n61:1852–1856.\\n91. Petersen RC, Thomas RG, Grundman M, Bennett D, et al. Vitamin E and donepezil\\nfor the treatment of mild cognitive impairment. N Engl J Med 2005;352:2379–\\n2388.\\n92. Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with\\nAlzheimer’s disease: results of a US Multicentre, Randomized, Double-Blind, Pla-\\ncebo-Controlled Trial. The Donepezil Study Group. Dementia 1996;7:293–303.\\n93. Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: A 6-month\\nrandomized, placebo-controlled trial with a 6-month extension. The Galantamine\\nUSA-1 Study Group. Neurology 2000;54:2261–2268.\\n94. Tariot PN, Solomon PR, Morris JC, Kershaw P, et al. A 5-month, randomized,\\nplacebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study\\nGroup. Neurology 2000;54:2269–2276.\\n95. Mega MS, Dinov ID, Porter V, Chow G, et al. Metabolic patterns associated with\\nthe clinical response to galantamine therapy: a fludeoxyglucose f 18 positron emis-\\nsion tomographic study. Arch Neurol 2005;62:721–728.\\n96. Reisberg B, Doody R, Stoffler A, Schmitt F, et al. Memantine',\n",
              "   'type': 'Document'}},\n",
              " {'nodes': [{'id': '3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors',\n",
              "    'type': 'Drug',\n",
              "    'properties': {}},\n",
              "   {'id': 'Memantine', 'type': 'Drug', 'properties': {}},\n",
              "   {'id': 'Donepezil', 'type': 'Drug', 'properties': {}},\n",
              "   {'id': 'Cognition', 'type': 'Process', 'properties': {}},\n",
              "   {'id': \"Alzheimer's disease\", 'type': 'Disease', 'properties': {}},\n",
              "   {'id': 'Zinc', 'type': 'Substance', 'properties': {}},\n",
              "   {'id': 'Copper', 'type': 'Substance', 'properties': {}},\n",
              "   {'id': 'Antioxidants', 'type': 'Substance', 'properties': {}}],\n",
              "  'relationships': [{'source': {'id': 'Memantine',\n",
              "     'type': 'Drug',\n",
              "     'properties': {}},\n",
              "    'target': {'id': \"Alzheimer's disease\",\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'type': 'USED_FOR',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Memantine', 'type': 'Drug', 'properties': {}},\n",
              "    'target': {'id': \"Alzheimer's disease\",\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'type': 'EXTENSION_STUDY',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Memantine', 'type': 'Drug', 'properties': {}},\n",
              "    'target': {'id': \"Alzheimer's disease\",\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'type': 'SAFETY_STUDY',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Memantine', 'type': 'Drug', 'properties': {}},\n",
              "    'target': {'id': \"Alzheimer's disease\",\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'type': 'TREATMENT_IN_PATIENTS',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Donepezil', 'type': 'Drug', 'properties': {}},\n",
              "    'target': {'id': 'Memantine', 'type': 'Drug', 'properties': {}},\n",
              "    'type': 'RECEIVING',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Antioxidants', 'type': 'Substance', 'properties': {}},\n",
              "    'target': {'id': 'Cognition', 'type': 'Process', 'properties': {}},\n",
              "    'type': 'IMPACT_ON',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Zinc', 'type': 'Substance', 'properties': {}},\n",
              "    'target': {'id': 'Cognition', 'type': 'Process', 'properties': {}},\n",
              "    'type': 'IMPACT_ON',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Copper', 'type': 'Substance', 'properties': {}},\n",
              "    'target': {'id': 'Cognition', 'type': 'Process', 'properties': {}},\n",
              "    'type': 'IMPACT_ON',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': '3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors',\n",
              "     'type': 'Drug',\n",
              "     'properties': {}},\n",
              "    'target': {'id': \"Alzheimer's disease\",\n",
              "     'type': 'Disease',\n",
              "     'properties': {}},\n",
              "    'type': 'DECREASED_PREVALENCE_OF',\n",
              "    'properties': {}}],\n",
              "  'source': {'id': None,\n",
              "   'metadata': {},\n",
              "   'page_content': ' Reisberg B, Doody R, Stoffler A, Schmitt F, et al. Memantine in moderate-to-severe\\nAlzheimer’s disease. N Engl J Med 2003;348:1333–1341.\\n97. Tariot PN, Farlow MR, Grossberg GT, Graham SM, et al. Memantine treatment in\\npatients with moderate to severe Alzheimer disease already receiving donepezil: a\\nrandomized controlled trial. JAMA 2004;291:317–324.\\n98. Reisberg B, Doody R, Stoffler A, Schmitt F, et al. A 24-week open-label extension\\nstudy of memantine in moderate to severe Alzheimer disease. Arch Neurol 2006;\\n63:49–54.\\n99. Ott BR, Blake LM, Kagan E, Resnick M. for the Memantine MEM-MD-11AB Study\\nGroup. Open label, multicenter, 28-week extension study of the safety and tolera-\\nbility of memantine in patients with mild to moderate Alzheimer’s disease. J Neurol\\n2007;254:351–358.\\n100. Overshott R, Burns A. Treatment of dementia. J Neurol Neurosurg Psychiatry 2005;\\n5(suppl 76):v53–v59.\\n101. Klafki HW, Staufenbiel M, Kornhuber J, Wiltfang J. Therapeutic approaches to\\nAlzheimer’s disease. Brain 2006;129:2840–2855.\\n102. Masters CL, Beyreuther K. Alzheimer’s centennial legacy: prospects for rational\\ntherapeutic intervention targeting the Abeta amyloid pathway. Brain 2006;129:\\n2823–2839.\\n103. Yaffe K, Clemons TE, McBee WL, Lindblad AS. Impact of antioxidants, zinc, and\\ncopper on cognition in the elderly: a randomized, controlled trial. Neurology 2004;\\n63:1705–1707.\\n104. Wolozin B, Kellman W, Ruosseau P, Celesia GG, et al. Decreased prevalence of\\nAlzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reduc-\\ntase inhibitors. Arch Neurol 2000;57:1439',\n",
              "   'type': 'Document'}},\n",
              " {'nodes': [{'id': 'Statins', 'type': 'Product', 'properties': {}},\n",
              "   {'id': 'treatment of mild to moderate Alzheimer disease',\n",
              "    'type': 'Condition',\n",
              "    'properties': {}},\n",
              "   {'id': 'Statin therapy', 'type': 'Treatment', 'properties': {}},\n",
              "   {'id': 'reduced neuropathologic changes of Alzheimer disease',\n",
              "    'type': 'Characteristic',\n",
              "    'properties': {}},\n",
              "   {'id': 'glutaryl coenzyme A reductase inhibitors',\n",
              "    'type': 'Product',\n",
              "    'properties': {}},\n",
              "   {'id': 'Estrogen replacement therapy',\n",
              "    'type': 'Treatment',\n",
              "    'properties': {}},\n",
              "   {'id': 'Alzheimer-disease-like pathology',\n",
              "    'type': 'Characteristic',\n",
              "    'properties': {}},\n",
              "   {'id': 'Immunization with amyloid-beta',\n",
              "    'type': 'Treatment',\n",
              "    'properties': {}}],\n",
              "  'relationships': [{'source': {'id': 'glutaryl coenzyme A reductase inhibitors',\n",
              "     'type': 'Product',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'Statins', 'type': 'Product', 'properties': {}},\n",
              "    'type': 'IS_A',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Statin therapy', 'type': 'Treatment', 'properties': {}},\n",
              "    'target': {'id': 'reduced neuropathologic changes of Alzheimer disease',\n",
              "     'type': 'Characteristic',\n",
              "     'properties': {}},\n",
              "    'type': 'ASSOCIATED_WITH',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Immunization with amyloid-beta',\n",
              "     'type': 'Treatment',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'Alzheimer-disease-like pathology',\n",
              "     'type': 'Characteristic',\n",
              "     'properties': {}},\n",
              "    'type': 'ATTENUATES',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Estrogen replacement therapy',\n",
              "     'type': 'Treatment',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'treatment of mild to moderate Alzheimer disease',\n",
              "     'type': 'Condition',\n",
              "     'properties': {}},\n",
              "    'type': 'USED_FOR',\n",
              "    'properties': {}}],\n",
              "  'source': {'id': None,\n",
              "   'metadata': {},\n",
              "   'page_content': 'glutaryl coenzyme A reduc-\\ntase inhibitors. Arch Neurol 2000;57:1439–1443.\\n105. Li G, Higdon R, Kukull WA, Peskind E, et al. Statin therapy and risk of dementia in\\nthe elderly: a community-based prospective cohort study. Neurology 2004;63:\\n1624–1628.\\n106. Li G, Larson EB, Sonnen JA, Shofer JB, et al. Statin therapy is associated with\\nreduced neuropathologic changes of Alzheimer disease. Neurology 2007;69:878–\\n885.\\n107. Schenk D, Barbour R, Dunn W, Gordon G, et al. Immunization with amyloid-beta\\nattenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;\\n400:173–177.\\n108. Check E. Nerve inflammation halts trial for Alzheimer drug. Nature 2002;415:462.\\n109. Ferrer I, Boada Rovira M, Sanchez Guerra ML, Rey MJ, et al. Neuropathology and\\npathogenesis of encephalitis following amyloid-beta immunization in Alzheimer’s\\ndisease. Brain Pathol 2004;14:11–20.\\n110. Gilman S, Koller M, Black RS, Jenkins L, et al., AN1792(QS-21)-201 Study Team.\\nClinical effects of Abeta immunization (AN1792) in patients with AD in an inter-\\nrupted trial. Neurology 2005;64:1553–1562.\\n111. Qu B, Boyer PJ, Johnston SA, Hynan LS, et al. Abeta42 gene vaccination reduces\\nbrain amyloid plaque burden in transgenic mice. J Neurol Sci 2006;244:151–\\n158.\\n112. Mulnard RA, Cotman CW, Kawas C, van Dyck CH, et al. Estrogen replacement\\ntherapy for treatment of mild to moderate Alzheimer disease: a randomized con-\\ntrolled trial. Alzheimer’s Disease Cooperative Study. JAMA 2000;283:1007–1015.\\n113. Wang PN, Liao SQ, Liu RS, Liu CY, et al. Effects of estrogen on cognition, mood,\\nand cerebral blood flow in AD: a controlled study. Neurology 2000;54',\n",
              "   'type': 'Document'}},\n",
              " {'nodes': [{'id': 'cerebral blood flow',\n",
              "    'type': 'Physiological Function',\n",
              "    'properties': {}},\n",
              "   {'id': 'Genetic aspects', 'type': 'Genetic Factor', 'properties': {}},\n",
              "   {'id': 'estrogen', 'type': 'Hormone', 'properties': {}},\n",
              "   {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "   {'id': 'cognition', 'type': 'Cognitive Function', 'properties': {}},\n",
              "   {'id': 'mood', 'type': 'Emotional State', 'properties': {}}],\n",
              "  'relationships': [{'source': {'id': 'estrogen',\n",
              "     'type': 'Hormone',\n",
              "     'properties': {}},\n",
              "    'target': {'id': 'cognition',\n",
              "     'type': 'Cognitive Function',\n",
              "     'properties': {}},\n",
              "    'type': 'AFFECTS',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'estrogen', 'type': 'Hormone', 'properties': {}},\n",
              "    'target': {'id': 'mood', 'type': 'Emotional State', 'properties': {}},\n",
              "    'type': 'AFFECTS',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'estrogen', 'type': 'Hormone', 'properties': {}},\n",
              "    'target': {'id': 'cerebral blood flow',\n",
              "     'type': 'Physiological Function',\n",
              "     'properties': {}},\n",
              "    'type': 'AFFECTS',\n",
              "    'properties': {}},\n",
              "   {'source': {'id': 'Alzheimer disease', 'type': 'Disease', 'properties': {}},\n",
              "    'target': {'id': 'Genetic aspects',\n",
              "     'type': 'Genetic Factor',\n",
              "     'properties': {}},\n",
              "    'type': 'HAS_GENETIC_ASPECTS',\n",
              "    'properties': {}}],\n",
              "  'source': {'id': None,\n",
              "   'metadata': {},\n",
              "   'page_content': ' of estrogen on cognition, mood,\\nand cerebral blood flow in AD: a controlled study. Neurology 2000;54:2061–2066.Genetic aspects of Alzheimer disease\\nApril 2008 /H18528Vol. 10 /H18528No. 4 239',\n",
              "   'type': 'Document'}}]"
            ]
          },
          "execution_count": 16,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "graph_documents"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "wVh1eikiIbTa",
        "outputId": "92d9d947-140e-4b42-a711-6163c2176ba7"
      },
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "Graph documents saved successfully to 'graph_documents.txt'\n"
          ]
        }
      ],
      "source": [
        "import json\n",
        "\n",
        "# Assuming `graph_documents` is the output you want to save\n",
        "# Convert graph_documents to JSON string for better readability\n",
        "#graph_documents_json = json.dumps([doc.dict() for doc in graph_documents], indent=4)\n",
        "\n",
        "# Save to a .txt file\n",
        "#with open('graph_documents.txt', 'w') as file:\n",
        "#    file.write(graph_documents_json)\n",
        "\n",
        "#print(\"Graph documents saved successfully to 'graph_documents.txt'\")\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "ATq57FATVRDm",
        "outputId": "4bfd3cac-c982-437d-fbdc-5229f4db691a"
      },
      "outputs": [
        {
          "name": "stderr",
          "output_type": "stream",
          "text": [
            "<ipython-input-17-9d53ef4eeb8e>:8: LangChainDeprecationWarning: The class `OpenAIEmbeddings` was deprecated in LangChain 0.0.9 and will be removed in 1.0. An updated version of the class exists in the langchain-openai package and should be used instead. To use it run `pip install -U langchain-openai` and import as `from langchain_openai import OpenAIEmbeddings`.\n",
            "  embeddings = OpenAIEmbeddings()\n"
          ]
        }
      ],
      "source": [
        "graph = Neo4jGraph(\n",
        "    url=\"neo4j+s://##############.databases.neo4j.io:7687\",\n",
        "    username=\"neo4j\",\n",
        "    password=\"#######################\"\n",
        ")\n",
        "\n",
        "# Initialize the OpenAI embeddings\n",
        "embeddings = OpenAIEmbeddings()\n",
        "\n",
        "# Create the vector index from the existing graph\n",
        "vector_index = Neo4jVector.from_existing_graph(\n",
        "    embedding=embeddings,\n",
        "    graph=graph,\n",
        "    index_name='vector_index',\n",
        "    node_label=\"Embeddable\",\n",
        "    text_node_properties=['definition', 'term', 'clause'],\n",
        "    embedding_node_property='embedding',\n",
        ")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "OfSQoYIqVTul"
      },
      "outputs": [],
      "source": [
        "# Set up the LLM (Language Model)\n",
        "llm = ChatOpenAI(temperature=0.0, model_name=\"gpt-3.5-turbo-16k\")\n",
        "\n",
        "# Create a retrieval-based QA chain using the vector index\n",
        "qa_chain = RetrievalQA.from_chain_type(\n",
        "    llm=llm,\n",
        "    chain_type=\"stuff\",\n",
        "    retriever=vector_index.as_retriever(search_type=\"similarity\"),\n",
        "    return_source_documents=True\n",
        ")\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "gXXrqiUbXvXu"
      },
      "outputs": [],
      "source": [
        "# Define the chatbot function\n",
        "def alzheimers_chatbot(query):\n",
        "    result = qa_chain({\"query\": query})\n",
        "    answer = result[\"result\"]\n",
        "    source_docs = result[\"source_documents\"]\n",
        "    return answer, source_docs"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "eMsyif94YMmc",
        "outputId": "68c0ddaf-32ef-4c58-bb1e-4f8ed932352a"
      },
      "outputs": [
        {
          "name": "stderr",
          "output_type": "stream",
          "text": [
            "<ipython-input-31-b44b81f55b6c>:3: LangChainDeprecationWarning: The method `Chain.__call__` was deprecated in langchain 0.1.0 and will be removed in 1.0. Use invoke instead.\n",
            "  result = qa_chain({\"query\": query})\n"
          ]
        },
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "Response: The risk factors for Alzheimer's disease include age, family history, genetics, certain medical conditions (such as high blood pressure, diabetes, and heart disease), head injuries, and lifestyle factors (such as smoking, lack of physical exercise, and poor diet).\n",
            "\n",
            "Sources:\n"
          ]
        }
      ],
      "source": [
        "# Example usage\n",
        "user_query = \"What are the risk factors for Alzheimer's disease?\"\n",
        "response, sources = alzheimers_chatbot(user_query)\n",
        "\n",
        "print(\"Response:\", response)\n",
        "print(\"\\nSources:\")\n",
        "for doc in sources:\n",
        "    print(f\"- {doc.metadata['source']}\")\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "B8ZDtZW2MY6-",
        "outputId": "227b23e4-f084-4a84-c271-1d9e7e321561"
      },
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "Requirement already satisfied: streamlit in /usr/local/lib/python3.10/dist-packages (1.38.0)\n",
            "Requirement already satisfied: altair<6,>=4.0 in /usr/local/lib/python3.10/dist-packages (from streamlit) (4.2.2)\n",
            "Requirement already satisfied: blinker<2,>=1.0.0 in /usr/lib/python3/dist-packages (from streamlit) (1.4)\n",
            "Requirement already satisfied: cachetools<6,>=4.0 in /usr/local/lib/python3.10/dist-packages (from streamlit) (5.5.0)\n",
            "Requirement already satisfied: click<9,>=7.0 in /usr/local/lib/python3.10/dist-packages (from streamlit) (8.1.7)\n",
            "Requirement already satisfied: numpy<3,>=1.20 in /usr/local/lib/python3.10/dist-packages (from streamlit) (1.26.4)\n",
            "Requirement already satisfied: packaging<25,>=20 in /usr/local/lib/python3.10/dist-packages (from streamlit) (24.1)\n",
            "Requirement already satisfied: pandas<3,>=1.3.0 in /usr/local/lib/python3.10/dist-packages (from streamlit) (2.1.4)\n",
            "Requirement already satisfied: pillow<11,>=7.1.0 in /usr/local/lib/python3.10/dist-packages (from streamlit) (9.4.0)\n",
            "Requirement already satisfied: protobuf<6,>=3.20 in /usr/local/lib/python3.10/dist-packages (from streamlit) (3.20.3)\n",
            "Requirement already satisfied: pyarrow>=7.0 in /usr/local/lib/python3.10/dist-packages (from streamlit) (14.0.2)\n",
            "Requirement already satisfied: requests<3,>=2.27 in /usr/local/lib/python3.10/dist-packages (from streamlit) (2.32.3)\n",
            "Requirement already satisfied: rich<14,>=10.14.0 in /usr/local/lib/python3.10/dist-packages (from streamlit) (13.8.0)\n",
            "Requirement already satisfied: tenacity<9,>=8.1.0 in /usr/local/lib/python3.10/dist-packages (from streamlit) (8.5.0)\n",
            "Requirement already satisfied: toml<2,>=0.10.1 in /usr/local/lib/python3.10/dist-packages (from streamlit) (0.10.2)\n",
            "Requirement already satisfied: typing-extensions<5,>=4.3.0 in /usr/local/lib/python3.10/dist-packages (from streamlit) (4.12.2)\n",
            "Requirement already satisfied: gitpython!=3.1.19,<4,>=3.0.7 in /usr/local/lib/python3.10/dist-packages (from streamlit) (3.1.43)\n",
            "Requirement already satisfied: pydeck<1,>=0.8.0b4 in /usr/local/lib/python3.10/dist-packages (from streamlit) (0.9.1)\n",
            "Requirement already satisfied: tornado<7,>=6.0.3 in /usr/local/lib/python3.10/dist-packages (from streamlit) (6.3.3)\n",
            "Requirement already satisfied: watchdog<5,>=2.1.5 in /usr/local/lib/python3.10/dist-packages (from streamlit) (4.0.2)\n",
            "Requirement already satisfied: entrypoints in /usr/local/lib/python3.10/dist-packages (from altair<6,>=4.0->streamlit) (0.4)\n",
            "Requirement already satisfied: jinja2 in /usr/local/lib/python3.10/dist-packages (from altair<6,>=4.0->streamlit) (3.1.4)\n",
            "Requirement already satisfied: jsonschema>=3.0 in /usr/local/lib/python3.10/dist-packages (from altair<6,>=4.0->streamlit) (4.23.0)\n",
            "Requirement already satisfied: toolz in /usr/local/lib/python3.10/dist-packages (from altair<6,>=4.0->streamlit) (0.12.1)\n",
            "Requirement already satisfied: gitdb<5,>=4.0.1 in /usr/local/lib/python3.10/dist-packages (from gitpython!=3.1.19,<4,>=3.0.7->streamlit) (4.0.11)\n",
            "Requirement already satisfied: python-dateutil>=2.8.2 in /usr/local/lib/python3.10/dist-packages (from pandas<3,>=1.3.0->streamlit) (2.8.2)\n",
            "Requirement already satisfied: pytz>=2020.1 in /usr/local/lib/python3.10/dist-packages (from pandas<3,>=1.3.0->streamlit) (2024.1)\n",
            "Requirement already satisfied: tzdata>=2022.1 in /usr/local/lib/python3.10/dist-packages (from pandas<3,>=1.3.0->streamlit) (2024.1)\n",
            "Requirement already satisfied: charset-normalizer<4,>=2 in /usr/local/lib/python3.10/dist-packages (from requests<3,>=2.27->streamlit) (3.3.2)\n",
            "Requirement already satisfied: idna<4,>=2.5 in /usr/local/lib/python3.10/dist-packages (from requests<3,>=2.27->streamlit) (3.8)\n",
            "Requirement already satisfied: urllib3<3,>=1.21.1 in /usr/local/lib/python3.10/dist-packages (from requests<3,>=2.27->streamlit) (2.0.7)\n",
            "Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.10/dist-packages (from requests<3,>=2.27->streamlit) (2024.8.30)\n",
            "Requirement already satisfied: markdown-it-py>=2.2.0 in /usr/local/lib/python3.10/dist-packages (from rich<14,>=10.14.0->streamlit) (3.0.0)\n",
            "Requirement already satisfied: pygments<3.0.0,>=2.13.0 in /usr/local/lib/python3.10/dist-packages (from rich<14,>=10.14.0->streamlit) (2.16.1)\n",
            "Requirement already satisfied: smmap<6,>=3.0.1 in /usr/local/lib/python3.10/dist-packages (from gitdb<5,>=4.0.1->gitpython!=3.1.19,<4,>=3.0.7->streamlit) (5.0.1)\n",
            "Requirement already satisfied: MarkupSafe>=2.0 in /usr/local/lib/python3.10/dist-packages (from jinja2->altair<6,>=4.0->streamlit) (2.1.5)\n",
            "Requirement already satisfied: attrs>=22.2.0 in /usr/local/lib/python3.10/dist-packages (from jsonschema>=3.0->altair<6,>=4.0->streamlit) (24.2.0)\n",
            "Requirement already satisfied: jsonschema-specifications>=2023.03.6 in /usr/local/lib/python3.10/dist-packages (from jsonschema>=3.0->altair<6,>=4.0->streamlit) (2023.12.1)\n",
            "Requirement already satisfied: referencing>=0.28.4 in /usr/local/lib/python3.10/dist-packages (from jsonschema>=3.0->altair<6,>=4.0->streamlit) (0.35.1)\n",
            "Requirement already satisfied: rpds-py>=0.7.1 in /usr/local/lib/python3.10/dist-packages (from jsonschema>=3.0->altair<6,>=4.0->streamlit) (0.20.0)\n",
            "Requirement already satisfied: mdurl~=0.1 in /usr/local/lib/python3.10/dist-packages (from markdown-it-py>=2.2.0->rich<14,>=10.14.0->streamlit) (0.1.2)\n",
            "Requirement already satisfied: six>=1.5 in /usr/local/lib/python3.10/dist-packages (from python-dateutil>=2.8.2->pandas<3,>=1.3.0->streamlit) (1.16.0)\n",
            "Collecting pyngrok\n",
            "  Downloading pyngrok-7.2.0-py3-none-any.whl.metadata (7.4 kB)\n",
            "Requirement already satisfied: PyYAML>=5.1 in /usr/local/lib/python3.10/dist-packages (from pyngrok) (6.0.2)\n",
            "Downloading pyngrok-7.2.0-py3-none-any.whl (22 kB)\n",
            "Installing collected packages: pyngrok\n",
            "Successfully installed pyngrok-7.2.0\n"
          ]
        }
      ],
      "source": [
        "!pip install streamlit\n",
        "!pip install pyngrok\n",
        "import streamlit as st"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "qUaePJA5MGQc"
      },
      "outputs": [],
      "source": [
        "\n",
        "# Function to initialize vector index and QA chain\n",
        "def initialize_qa_chain():\n",
        "    # Initialize the OpenAI embeddings\n",
        "    embeddings = OpenAIEmbeddings()\n",
        "\n",
        "    # Create the vector index from the existing graph\n",
        "    vector_index = Neo4jVector.from_existing_graph(\n",
        "        embedding=embeddings,\n",
        "        graph=graph,\n",
        "        index_name='vector_index',\n",
        "        node_label=\"Embeddable\",\n",
        "        text_node_properties=['definition', 'term', 'clause'],\n",
        "        embedding_node_property='embedding',\n",
        "    )\n",
        "\n",
        "    # Set up the LLM (Language Model)\n",
        "    llm = ChatOpenAI(temperature=0.0, model_name=\"gpt-3.5-turbo-16k\")\n",
        "\n",
        "    # Create a retrieval-based QA chain using the vector index\n",
        "    qa_chain = RetrievalQA.from_chain_type(\n",
        "        llm=llm,\n",
        "        chain_type=\"stuff\",\n",
        "        retriever=vector_index.as_retriever(search_type=\"similarity\"),\n",
        "        return_source_documents=True\n",
        "    )\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "weMilizmYTgx"
      },
      "outputs": [],
      "source": [
        "qa_chain = initialize_qa_chain()\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "mjgH_aJ1YWH0",
        "outputId": "0f1600f6-e407-42d7-dd8e-1cfa987b53d1"
      },
      "outputs": [
        {
          "name": "stderr",
          "output_type": "stream",
          "text": [
            "2024-09-10 04:31:04.790 WARNING streamlit.runtime.scriptrunner_utils.script_run_context: Thread 'MainThread': missing ScriptRunContext! This warning can be ignored when running in bare mode.\n",
            "2024-09-10 04:31:04.939 \n",
            "  \u001b[33m\u001b[1mWarning:\u001b[0m to view this Streamlit app on a browser, run it with the following\n",
            "  command:\n",
            "\n",
            "    streamlit run /usr/local/lib/python3.10/dist-packages/colab_kernel_launcher.py [ARGUMENTS]\n",
            "2024-09-10 04:31:04.955 Thread 'MainThread': missing ScriptRunContext! This warning can be ignored when running in bare mode.\n"
          ]
        },
        {
          "data": {
            "text/plain": [
              "DeltaGenerator()"
            ]
          },
          "execution_count": 41,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "# Streamlit UI\n",
        "st.title(\"Alzheimer's Disease Chatbot\")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "eCR0j5bTYcYu",
        "outputId": "0bf2fb75-e6ac-4d20-a8fc-5917e152ea86"
      },
      "outputs": [
        {
          "name": "stderr",
          "output_type": "stream",
          "text": [
            "2024-09-10 04:31:15.975 Thread 'MainThread': missing ScriptRunContext! This warning can be ignored when running in bare mode.\n",
            "2024-09-10 04:31:15.978 Thread 'MainThread': missing ScriptRunContext! This warning can be ignored when running in bare mode.\n",
            "2024-09-10 04:31:15.980 Thread 'MainThread': missing ScriptRunContext! This warning can be ignored when running in bare mode.\n",
            "2024-09-10 04:31:15.982 Session state does not function when running a script without `streamlit run`\n",
            "2024-09-10 04:31:15.984 Thread 'MainThread': missing ScriptRunContext! This warning can be ignored when running in bare mode.\n",
            "2024-09-10 04:31:15.986 Thread 'MainThread': missing ScriptRunContext! This warning can be ignored when running in bare mode.\n"
          ]
        }
      ],
      "source": [
        "# User input for the query\n",
        "user_query = st.text_input(\"Enter your question about Alzheimer's disease:\")\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "la-95FgWZb2a"
      },
      "outputs": [],
      "source": [
        "if user_query:\n",
        "    with st.spinner(\"Retrieving answer...\"):\n",
        "        # Call the chatbot function\n",
        "        response, sources = qa_chain({\"query\": user_query})\n",
        "\n",
        "        # Display the response\n",
        "        st.subheader(\"Response:\")\n",
        "        st.write(response['result'])\n",
        "\n",
        "        # Display the sources\n",
        "        st.subheader(\"Source Documents:\")\n",
        "        for doc in response['source_documents']:\n",
        "            st.write(f\"- {doc.metadata['source']}\")\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "YOh4Aj9Fxs3F",
        "outputId": "931c09ab-119a-4dca-814d-d474916ea28e"
      },
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "Requirement already satisfied: pyngrok in /usr/local/lib/python3.10/dist-packages (7.2.0)\n",
            "Requirement already satisfied: PyYAML>=5.1 in /usr/local/lib/python3.10/dist-packages (from pyngrok) (6.0.2)\n",
            "Authtoken saved to configuration file: /root/.config/ngrok/ngrok.yml\n"
          ]
        }
      ],
      "source": [
        "!pip install pyngrok\n",
        "from pyngrok import ngrok\n",
        "\n",
        "# Replace \"your_authtoken\" with the actual token from ngrok dashboard\n",
        "!ngrok authtoken ##############\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "fKz3wc97ZcAq",
        "outputId": "9015113d-f53a-47f7-ea65-a612849be801"
      },
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "Overwriting app.py\n"
          ]
        }
      ],
      "source": [
        "%%writefile app.py\n",
        "import streamlit as st\n",
        "\n",
        "st.title(\"Alzheimer's RAG Chatbot\")\n",
        "\n",
        "query = st.text_input(\"Enter your question:\")\n",
        "\n",
        "if st.button(\"Submit\"):\n",
        "    if query:\n",
        "        response, sources = alzheimers_chatbot(query)  # Replace with your chatbot function\n",
        "        st.write(\"Response:\", response)\n",
        "        st.write(\"\\nSources:\")\n",
        "        for doc in sources:\n",
        "            st.write(f\"- {doc.metadata['source']}\")\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "background_save": true,
          "base_uri": "https://localhost:8080/"
        },
        "id": "CnX38Pew5kc9",
        "outputId": "0270fea9-29b0-4ae1-d60a-166017e3649b"
      },
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "Authtoken saved to configuration file: /root/.config/ngrok/ngrok.yml\n",
            "Public URL for your Streamlit app: NgrokTunnel: \"https://25cf-34-173-233-29.ngrok-free.app\" -> \"http://localhost:8501\"\n",
            "\n",
            "Collecting usage statistics. To deactivate, set browser.gatherUsageStats to false.\n",
            "\u001b[0m\n",
            "\u001b[0m\n",
            "\u001b[34m\u001b[1m  You can now view your Streamlit app in your browser.\u001b[0m\n",
            "\u001b[0m\n",
            "\u001b[34m  Local URL: \u001b[0m\u001b[1mhttp://localhost:8501\u001b[0m\n",
            "\u001b[34m  Network URL: \u001b[0m\u001b[1mhttp://172.28.0.12:8501\u001b[0m\n",
            "\u001b[34m  External URL: \u001b[0m\u001b[1mhttp://34.173.233.29:8501\u001b[0m\n",
            "\u001b[0m\n",
            "2024-09-10 05:20:07.637 Uncaught app exception\n",
            "Traceback (most recent call last):\n",
            "  File \"/usr/local/lib/python3.10/dist-packages/streamlit/runtime/scriptrunner/exec_code.py\", line 88, in exec_func_with_error_handling\n",
            "    result = func()\n",
            "  File \"/usr/local/lib/python3.10/dist-packages/streamlit/runtime/scriptrunner/script_runner.py\", line 590, in code_to_exec\n",
            "    exec(code, module.__dict__)\n",
            "  File \"/content/app.py\", line 9, in <module>\n",
            "    response, sources = alzheimers_chatbot(query)  # Replace with your chatbot function\n",
            "NameError: name 'alzheimers_chatbot' is not defined\n"
          ]
        }
      ],
      "source": [
        "#from pyngrok import ngrok\n",
        "\n",
        "# Create the Streamlit tunnel\n",
        "#public_url = ngrok.connect(port='8501', proto='http')\n",
        "\n",
        "# Run the Streamlit app\n",
        "#!streamlit run app.py &\n",
        "\n",
        "# Output the public URL\n",
        "#print(f\"Public URL for your Streamlit app: {public_url}\")\n",
        "\n",
        "from pyngrok import ngrok\n",
        "\n",
        "# Authenticate your ngrok account\n",
        "!ngrok authtoken ######################################\n",
        "\n",
        "# Create an HTTP tunnel for Streamlit on port 8501\n",
        "public_url = ngrok.connect(8501, \"http\")\n",
        "\n",
        "# Print the public URL to access the Streamlit app\n",
        "print(f\"Public URL for your Streamlit app: {public_url}\")\n",
        "\n",
        "# Run the Streamlit app in the background\n",
        "!streamlit run app.py &\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "6XRtHkOL7UoD",
        "outputId": "3d5dcc02-d095-49b2-f456-782e8fef780d"
      },
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "Writing app.py\n"
          ]
        }
      ],
      "source": [
        "%%writefile app.py\n",
        "import streamlit as st\n",
        "from neo4j import GraphDatabase\n",
        "from langchain_community.graphs import Neo4jGraph\n",
        "from langchain.embeddings.openai import OpenAIEmbeddings\n",
        "from langchain.chains import RetrievalQA\n",
        "from langchain.chat_models import ChatOpenAI\n",
        "from langchain.vectorstores.neo4j_vector import Neo4jVector\n",
        "\n",
        "# Define the Neo4j graph connection\n",
        "graph = Neo4jGraph(\n",
        "    url=\"neo4j+s://###c0.databases.neo4j.io:7687\",\n",
        "    username=\"neo4j\",\n",
        "    password=\"jc###################\n",
        ")\n",
        "\n",
        "# Function to initialize vector index and QA chain\n",
        "def initialize_qa_chain():\n",
        "    # Initialize the OpenAI embeddings\n",
        "    embeddings = OpenAIEmbeddings()\n",
        "\n",
        "    # Create the vector index from the existing graph\n",
        "    vector_index = Neo4jVector.from_existing_graph(\n",
        "        embedding=embeddings,\n",
        "        graph=graph,\n",
        "        index_name='vector_index',\n",
        "        node_label=\"Embeddable\",\n",
        "        text_node_properties=['definition', 'term', 'clause'],\n",
        "        embedding_node_property='embedding',\n",
        "    )\n",
        "\n",
        "    # Set up the LLM (Language Model)\n",
        "    llm = ChatOpenAI(temperature=0.0, model_name=\"gpt-3.5-turbo-16k\")\n",
        "\n",
        "    # Create a retrieval-based QA chain using the vector index\n",
        "    qa_chain = RetrievalQA.from_chain_type(\n",
        "        llm=llm,\n",
        "        chain_type=\"stuff\",\n",
        "        retriever=vector_index.as_retriever(search_type=\"similarity\"),\n",
        "        return_source_documents=True\n",
        "    )\n",
        "\n",
        "    return qa_chain\n",
        "\n",
        "# Initialize the QA chain once\n",
        "qa_chain = initialize_qa_chain()\n",
        "\n",
        "# Define the chatbot function\n",
        "def alzheimers_chatbot(query):\n",
        "    result = qa_chain({\"query\": query})\n",
        "    answer = result[\"result\"]\n",
        "    source_docs = result[\"source_documents\"]\n",
        "    return answer, source_docs\n",
        "\n",
        "#######################################################################################################\n",
        "# Streamlit UI\n",
        "#st.title(\"Alzheimer's Disease RAG Chatbot\")\n",
        "\n",
        "# User input for the query\n",
        "#query = st.text_input(\"Enter your question about Alzheimer's disease:\")\n",
        "\n",
        "# Run the chatbot when the user submits a query\n",
        "#if st.button(\"Submit\"):\n",
        " #   if query:\n",
        "  #      response, sources = alzheimers_chatbot(query)\n",
        "\n",
        "        # Display the response\n",
        " #       st.subheader(\"Response:\")\n",
        "#        st.write(response)\n",
        "\n",
        "        # Display the sources\n",
        "#        st.subheader(\"Source Documents:\")\n",
        " #       for doc in sources:\n",
        " #           st.write(f\"- {doc.metadata['source']}\")\n",
        "########################################################################################################\n",
        "\n",
        "# Streamlit UI\n",
        "st.title(\"Alzheimer's Disease RAG Chatbot\")\n",
        "\n",
        "# Initialize the session state to store the chat history\n",
        "if \"chat_history\" not in st.session_state:\n",
        "    st.session_state[\"chat_history\"] = []\n",
        "\n",
        "# User input for the query\n",
        "query = st.text_input(\"Ask your question about Alzheimer's disease:\")\n",
        "\n",
        "# Run the chatbot when the user submits a query\n",
        "if st.button(\"Submit\"):\n",
        "    if query:\n",
        "        # Call the chatbot function and get the response\n",
        "        response, sources = alzheimers_chatbot(query)\n",
        "\n",
        "        # Add the user's question and the model's response to the chat history\n",
        "        st.session_state[\"chat_history\"].append({\"query\": query, \"response\": response})\n",
        "\n",
        "# Display the conversation history\n",
        "st.subheader(\"Conversation:\")\n",
        "for chat in st.session_state[\"chat_history\"]:\n",
        "    st.write(f\"**You:** {chat['query']}\")\n",
        "    st.write(f\"**Chatbot:** {chat['response']}\")\n",
        "\n",
        "# Optionally, display sources\n",
        "if st.checkbox(\"Show Sources\"):\n",
        "    st.subheader(\"Source Documents:\")\n",
        "    for doc in sources:\n",
        "        st.write(f\"- {doc.metadata['source']}\")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "XC5U5ads5kfw",
        "outputId": "0427dc6e-164a-4e14-e97a-5c9f6b4e6d3a"
      },
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "Collecting streamlit\n",
            "  Downloading streamlit-1.38.0-py2.py3-none-any.whl.metadata (8.5 kB)\n",
            "Collecting pyngrok\n",
            "  Downloading pyngrok-7.2.0-py3-none-any.whl.metadata (7.4 kB)\n",
            "Collecting neo4j\n",
            "  Downloading neo4j-5.24.0-py3-none-any.whl.metadata (5.7 kB)\n",
            "Collecting openai\n",
            "  Downloading openai-1.44.1-py3-none-any.whl.metadata (22 kB)\n",
            "Requirement already satisfied: altair<6,>=4.0 in /usr/local/lib/python3.10/dist-packages (from streamlit) (4.2.2)\n",
            "Requirement already satisfied: blinker<2,>=1.0.0 in /usr/lib/python3/dist-packages (from streamlit) (1.4)\n",
            "Requirement already satisfied: cachetools<6,>=4.0 in /usr/local/lib/python3.10/dist-packages (from streamlit) (5.5.0)\n",
            "Requirement already satisfied: click<9,>=7.0 in /usr/local/lib/python3.10/dist-packages (from streamlit) (8.1.7)\n",
            "Requirement already satisfied: numpy<3,>=1.20 in /usr/local/lib/python3.10/dist-packages (from streamlit) (1.26.4)\n",
            "Requirement already satisfied: packaging<25,>=20 in /usr/local/lib/python3.10/dist-packages (from streamlit) (24.1)\n",
            "Requirement already satisfied: pandas<3,>=1.3.0 in /usr/local/lib/python3.10/dist-packages (from streamlit) (2.1.4)\n",
            "Requirement already satisfied: pillow<11,>=7.1.0 in /usr/local/lib/python3.10/dist-packages (from streamlit) (9.4.0)\n",
            "Requirement already satisfied: protobuf<6,>=3.20 in /usr/local/lib/python3.10/dist-packages (from streamlit) (3.20.3)\n",
            "Requirement already satisfied: pyarrow>=7.0 in /usr/local/lib/python3.10/dist-packages (from streamlit) (14.0.2)\n",
            "Requirement already satisfied: requests<3,>=2.27 in /usr/local/lib/python3.10/dist-packages (from streamlit) (2.32.3)\n",
            "Requirement already satisfied: rich<14,>=10.14.0 in /usr/local/lib/python3.10/dist-packages (from streamlit) (13.8.0)\n",
            "Collecting tenacity<9,>=8.1.0 (from streamlit)\n",
            "  Downloading tenacity-8.5.0-py3-none-any.whl.metadata (1.2 kB)\n",
            "Requirement already satisfied: toml<2,>=0.10.1 in /usr/local/lib/python3.10/dist-packages (from streamlit) (0.10.2)\n",
            "Requirement already satisfied: typing-extensions<5,>=4.3.0 in /usr/local/lib/python3.10/dist-packages (from streamlit) (4.12.2)\n",
            "Collecting gitpython!=3.1.19,<4,>=3.0.7 (from streamlit)\n",
            "  Downloading GitPython-3.1.43-py3-none-any.whl.metadata (13 kB)\n",
            "Collecting pydeck<1,>=0.8.0b4 (from streamlit)\n",
            "  Downloading pydeck-0.9.1-py2.py3-none-any.whl.metadata (4.1 kB)\n",
            "Requirement already satisfied: tornado<7,>=6.0.3 in /usr/local/lib/python3.10/dist-packages (from streamlit) (6.3.3)\n",
            "Collecting watchdog<5,>=2.1.5 (from streamlit)\n",
            "  Downloading watchdog-4.0.2-py3-none-manylinux2014_x86_64.whl.metadata (38 kB)\n",
            "Requirement already satisfied: PyYAML>=5.1 in /usr/local/lib/python3.10/dist-packages (from pyngrok) (6.0.2)\n",
            "Requirement already satisfied: pytz in /usr/local/lib/python3.10/dist-packages (from neo4j) (2024.1)\n",
            "Requirement already satisfied: anyio<5,>=3.5.0 in /usr/local/lib/python3.10/dist-packages (from openai) (3.7.1)\n",
            "Requirement already satisfied: distro<2,>=1.7.0 in /usr/lib/python3/dist-packages (from openai) (1.7.0)\n",
            "Collecting httpx<1,>=0.23.0 (from openai)\n",
            "  Downloading httpx-0.27.2-py3-none-any.whl.metadata (7.1 kB)\n",
            "Collecting jiter<1,>=0.4.0 (from openai)\n",
            "  Downloading jiter-0.5.0-cp310-cp310-manylinux_2_17_x86_64.manylinux2014_x86_64.whl.metadata (3.6 kB)\n",
            "Requirement already satisfied: pydantic<3,>=1.9.0 in /usr/local/lib/python3.10/dist-packages (from openai) (2.8.2)\n",
            "Requirement already satisfied: sniffio in /usr/local/lib/python3.10/dist-packages (from openai) (1.3.1)\n",
            "Requirement already satisfied: tqdm>4 in /usr/local/lib/python3.10/dist-packages (from openai) (4.66.5)\n",
            "Requirement already satisfied: entrypoints in /usr/local/lib/python3.10/dist-packages (from altair<6,>=4.0->streamlit) (0.4)\n",
            "Requirement already satisfied: jinja2 in /usr/local/lib/python3.10/dist-packages (from altair<6,>=4.0->streamlit) (3.1.4)\n",
            "Requirement already satisfied: jsonschema>=3.0 in /usr/local/lib/python3.10/dist-packages (from altair<6,>=4.0->streamlit) (4.23.0)\n",
            "Requirement already satisfied: toolz in /usr/local/lib/python3.10/dist-packages (from altair<6,>=4.0->streamlit) (0.12.1)\n",
            "Requirement already satisfied: idna>=2.8 in /usr/local/lib/python3.10/dist-packages (from anyio<5,>=3.5.0->openai) (3.8)\n",
            "Requirement already satisfied: exceptiongroup in /usr/local/lib/python3.10/dist-packages (from anyio<5,>=3.5.0->openai) (1.2.2)\n",
            "Collecting gitdb<5,>=4.0.1 (from gitpython!=3.1.19,<4,>=3.0.7->streamlit)\n",
            "  Downloading gitdb-4.0.11-py3-none-any.whl.metadata (1.2 kB)\n",
            "Requirement already satisfied: certifi in /usr/local/lib/python3.10/dist-packages (from httpx<1,>=0.23.0->openai) (2024.8.30)\n",
            "Collecting httpcore==1.* (from httpx<1,>=0.23.0->openai)\n",
            "  Downloading httpcore-1.0.5-py3-none-any.whl.metadata (20 kB)\n",
            "Collecting h11<0.15,>=0.13 (from httpcore==1.*->httpx<1,>=0.23.0->openai)\n",
            "  Downloading h11-0.14.0-py3-none-any.whl.metadata (8.2 kB)\n",
            "Requirement already satisfied: python-dateutil>=2.8.2 in /usr/local/lib/python3.10/dist-packages (from pandas<3,>=1.3.0->streamlit) (2.8.2)\n",
            "Requirement already satisfied: tzdata>=2022.1 in /usr/local/lib/python3.10/dist-packages (from pandas<3,>=1.3.0->streamlit) (2024.1)\n",
            "Requirement already satisfied: annotated-types>=0.4.0 in /usr/local/lib/python3.10/dist-packages (from pydantic<3,>=1.9.0->openai) (0.7.0)\n",
            "Requirement already satisfied: pydantic-core==2.20.1 in /usr/local/lib/python3.10/dist-packages (from pydantic<3,>=1.9.0->openai) (2.20.1)\n",
            "Requirement already satisfied: charset-normalizer<4,>=2 in /usr/local/lib/python3.10/dist-packages (from requests<3,>=2.27->streamlit) (3.3.2)\n",
            "Requirement already satisfied: urllib3<3,>=1.21.1 in /usr/local/lib/python3.10/dist-packages (from requests<3,>=2.27->streamlit) (2.0.7)\n",
            "Requirement already satisfied: markdown-it-py>=2.2.0 in /usr/local/lib/python3.10/dist-packages (from rich<14,>=10.14.0->streamlit) (3.0.0)\n",
            "Requirement already satisfied: pygments<3.0.0,>=2.13.0 in /usr/local/lib/python3.10/dist-packages (from rich<14,>=10.14.0->streamlit) (2.16.1)\n",
            "Collecting smmap<6,>=3.0.1 (from gitdb<5,>=4.0.1->gitpython!=3.1.19,<4,>=3.0.7->streamlit)\n",
            "  Downloading smmap-5.0.1-py3-none-any.whl.metadata (4.3 kB)\n",
            "Requirement already satisfied: MarkupSafe>=2.0 in /usr/local/lib/python3.10/dist-packages (from jinja2->altair<6,>=4.0->streamlit) (2.1.5)\n",
            "Requirement already satisfied: attrs>=22.2.0 in /usr/local/lib/python3.10/dist-packages (from jsonschema>=3.0->altair<6,>=4.0->streamlit) (24.2.0)\n",
            "Requirement already satisfied: jsonschema-specifications>=2023.03.6 in /usr/local/lib/python3.10/dist-packages (from jsonschema>=3.0->altair<6,>=4.0->streamlit) (2023.12.1)\n",
            "Requirement already satisfied: referencing>=0.28.4 in /usr/local/lib/python3.10/dist-packages (from jsonschema>=3.0->altair<6,>=4.0->streamlit) (0.35.1)\n",
            "Requirement already satisfied: rpds-py>=0.7.1 in /usr/local/lib/python3.10/dist-packages (from jsonschema>=3.0->altair<6,>=4.0->streamlit) (0.20.0)\n",
            "Requirement already satisfied: mdurl~=0.1 in /usr/local/lib/python3.10/dist-packages (from markdown-it-py>=2.2.0->rich<14,>=10.14.0->streamlit) (0.1.2)\n",
            "Requirement already satisfied: six>=1.5 in /usr/local/lib/python3.10/dist-packages (from python-dateutil>=2.8.2->pandas<3,>=1.3.0->streamlit) (1.16.0)\n",
            "Downloading streamlit-1.38.0-py2.py3-none-any.whl (8.7 MB)\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m8.7/8.7 MB\u001b[0m \u001b[31m34.5 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading pyngrok-7.2.0-py3-none-any.whl (22 kB)\n",
            "Downloading neo4j-5.24.0-py3-none-any.whl (294 kB)\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m294.6/294.6 kB\u001b[0m \u001b[31m11.2 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading openai-1.44.1-py3-none-any.whl (373 kB)\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m373.5/373.5 kB\u001b[0m \u001b[31m12.2 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading GitPython-3.1.43-py3-none-any.whl (207 kB)\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m207.3/207.3 kB\u001b[0m \u001b[31m6.9 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading httpx-0.27.2-py3-none-any.whl (76 kB)\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m76.4/76.4 kB\u001b[0m \u001b[31m3.7 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading httpcore-1.0.5-py3-none-any.whl (77 kB)\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m77.9/77.9 kB\u001b[0m \u001b[31m3.7 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading jiter-0.5.0-cp310-cp310-manylinux_2_17_x86_64.manylinux2014_x86_64.whl (318 kB)\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m318.9/318.9 kB\u001b[0m \u001b[31m9.1 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading pydeck-0.9.1-py2.py3-none-any.whl (6.9 MB)\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m6.9/6.9 MB\u001b[0m \u001b[31m44.2 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading tenacity-8.5.0-py3-none-any.whl (28 kB)\n",
            "Downloading watchdog-4.0.2-py3-none-manylinux2014_x86_64.whl (82 kB)\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m82.9/82.9 kB\u001b[0m \u001b[31m4.6 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading gitdb-4.0.11-py3-none-any.whl (62 kB)\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m62.7/62.7 kB\u001b[0m \u001b[31m2.7 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading h11-0.14.0-py3-none-any.whl (58 kB)\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m58.3/58.3 kB\u001b[0m \u001b[31m1.9 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading smmap-5.0.1-py3-none-any.whl (24 kB)\n",
            "Installing collected packages: watchdog, tenacity, smmap, pyngrok, neo4j, jiter, h11, pydeck, httpcore, gitdb, httpx, gitpython, openai, streamlit\n",
            "  Attempting uninstall: tenacity\n",
            "    Found existing installation: tenacity 9.0.0\n",
            "    Uninstalling tenacity-9.0.0:\n",
            "      Successfully uninstalled tenacity-9.0.0\n",
            "Successfully installed gitdb-4.0.11 gitpython-3.1.43 h11-0.14.0 httpcore-1.0.5 httpx-0.27.2 jiter-0.5.0 neo4j-5.24.0 openai-1.44.1 pydeck-0.9.1 pyngrok-7.2.0 smmap-5.0.1 streamlit-1.38.0 tenacity-8.5.0 watchdog-4.0.2\n",
            "Authtoken saved to configuration file: /root/.config/ngrok/ngrok.yml\n"
          ]
        }
      ],
      "source": [
        "!pip install streamlit pyngrok neo4j openai\n",
        "!ngrok authtoken ##################################\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "background_save": true,
          "base_uri": "https://localhost:8080/"
        },
        "id": "Kfs_mZMl5kib",
        "outputId": "8a74ad11-9699-4f49-ffa2-215d6d97686a"
      },
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "\n",
            "Collecting usage statistics. To deactivate, set browser.gatherUsageStats to false.\n",
            "\u001b[0m\n",
            "\u001b[0m\n",
            "\u001b[34m\u001b[1m  You can now view your Streamlit app in your browser.\u001b[0m\n",
            "\u001b[0m\n",
            "\u001b[34m  Local URL: \u001b[0m\u001b[1mhttp://localhost:8501\u001b[0m\n",
            "\u001b[34m  Network URL: \u001b[0m\u001b[1mhttp://172.28.0.12:8501\u001b[0m\n",
            "\u001b[34m  External URL: \u001b[0m\u001b[1mhttp://34.138.41.254:8501\u001b[0m\n",
            "\u001b[0m\n"
          ]
        }
      ],
      "source": [
        "!streamlit run app.py &\n",
        "from pyngrok import ngrok\n",
        "public_url = ngrok.connect(8501)\n",
        "print(f\"Public URL for your Streamlit app: {public_url}\")\n"
      ]
    }
  ],
  "metadata": {
    "colab": {
      "provenance": []
    },
    "kernelspec": {
      "display_name": "Python 3",
      "name": "python3"
    },
    "language_info": {
      "name": "python"
    }
  },
  "nbformat": 4,
  "nbformat_minor": 0
}
